Small interfering RNA for the modification of HFE2 expression

Abstract

Aspects of the application provide siRNAs that target and reduce the expression of hemochromatosis type 2 (HFE2), compositions and methods of using the same to reduce serum hepcidin concentration and treat anemias of inflammation, iron-restricted anemias and / or conditions associated with anemia.

Description

Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO SMALL INTERFERING RNA FOR THE MODIFICATION OF HFE2 EXPRESSION RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No.63 / 738,643, filed December 24, 2024, the disclosure of which is incorporated herein by reference in its entirety.SEQUENCE LISTING

[0002] This application contains an electronic Sequence Listing which has been submitted in XML file format with this application, the content of which is incorporated by reference herein in its entirety. The Sequence Listing XML file submitted with this application is entitled “14874-001 -228_SEQ_LISTING. xml”, was created on December 10, 2025, and is 1,322,146 bytes in size.FIELD

[0003] Provided herein are small interfering ribonucleic acid (siRNA) targeting hemochromatosis type 2 (HFE2) mRNA, and compositions and methods for their use, for example, to reduce HFE2 expression and / or hepcidin levels, and to treat disorders related to iron homeostasis.BACKGROUND

[0004] Iron is important for biological processes such as oxygen transport, DNA synthesis, and cellular respiration. Dysregulation of iron homeostasis leads to various pathological conditions such as anemia, hemochromatosis, and iron overload disorders.

[0005] Hepcidin is a peptide hormone made in the liver that negatively controls intestinal iron absorption in the duodenum, sequesters iron in tissues and lowers serum iron levels. Lack of functional hepcidin in humans causes juvenile hemochromatosis, a particularly severe form of iron overload disorder. Inappropriate increased hepcidin expression causes severe iron deficiency anemia in humans. Hemochromatosis type 2 protein (HFE2), also known as repulsive guidance molecule c (RGMc) and hemojuvelin (HJV), is a positive regulator of hepcidin.NAI-5008944785v1 Page 1 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO

[0006] Anemia of inflammation (Al), previously known as anemia of chronic diseases, is associated with high hepcidin levels. Al occurs in several common disorders, including chronic infections, autoimmune diseases, chronic kidney disease, anemia of the elderly, advanced cancer, graft versus host disease, congestive heart failure, and chronic obstructive pulmonary disease. Al is one of the most common anemias worldwide and the most frequent anemia in hospitalized patients.

[0007] There remains a need for effective interventions to treat disorders associated with high hepcidin levels. For instance, treatment of Al with oral iron is ineffective since the high hepcidin levels counteract its intestinal absorption. Chronic treatment with red blood cells transfusions is not recommended because of transient effect and adverse reactions; it is limited to severe refractory anemia. Targeted RNA-based therapies, such as small interfering RNAs (siRNAs) that downregulate the expression of genes implicated in disease have been approved by the United States Food and Drug Administration targeting, inter alia, hepatic lactate dehydrogenase (nedosiran) and proprotein convertase subtilisin / kexin type-9 (PCSK9) (inclisiran), none, however, address disorders related to iron homeostasis.

[0008] There is a need for novel siRNAs that specifically reduce the expression of genes such as HFE involved in the regulation of hepcidin and iron homeostasis which can provide a therapeutic approach for disorders associated with high hepcidin levels such as, e.g., anemia.SUMMARY

[0009] In one aspect, provided herein is an isolated small interfering RNA (siRNA) for reducing HFE2 expression and / or inhibiting HFE2 function in a cell or mammal.

[0010] In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 2 and modified versions thereof. In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 2.NAI-5008944785v1 Page 2 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO

[0011] In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 3 and modified versions thereof. In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 3.

[0012] In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 4.

[0013] In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of BD-11900, BD-11984, BD-12044, BD-12212, BD-12296, BD-12380, BD-12572 and BD-12596. In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of BD-12044, BD-12212, BD-12296 and BD-12596. In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of BD-12296 and BD-12044.

[0014] In one aspect, provided herein is a pharmaceutical composition comprising an siRNA and a pharmaceutically acceptable excipient, carrier or delivery vehicle.

[0015] In some embodiments of the pharmaceutical composition provided herein, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 2.

[0016] In some embodiments of the pharmaceutical composition provided herein, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 3.

[0017] In some embodiments of the pharmaceutical composition provided herein, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 4.

[0018] In some embodiments of the pharmaceutical composition provided herein, the siRNA is a duplex selected from the group consisting of duplexes BD-11900, BD-11984,NAI-5008944785v1 Page 3 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO BD-12044, BD-12212, BD-12296, BD-12380, BD-12572 and BD-12596. In some embodiments of the pharmaceutical composition provided herein, the siRNA is a duplex selected from the group consisting of duplexes BD-12044, BD-12212, BD-12296 and BD-12596. In some embodiments of the pharmaceutical composition provided herein, the siRNA is BD-12044 and BD-12296.

[0019] In one aspect, provided herein is a pharmaceutical composition comprising siRNA BD-12296 and a pharmaceutically acceptable excipient, carrier or delivery vehicle.

[0020] In one aspect, provided herein is a pharmaceutical composition comprising siRNA BD-12044 and a pharmaceutically acceptable excipient, carrier or delivery vehicle.

[0021] In some embodiments of the pharmaceutical composition provided herein, the pharmaceutical composition is in the form of a lipid nanoparticle.

[0022] In one aspect, provided herein is a method of reducing expression of HFE2 in a cell comprising administeringto the subject an siRNA as provided in the instant disclosure. In one aspect, provided herein is a method of reducing expression of HFE2 in a cell comprising contacting the cell with an siRNA as provided in the instant disclosure. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 2. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 3. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 4. In one embodiment, the siRNA is a duplex selected from the group consisting of BD-11900, BD-11984, BD-12044, BD-12212, BD-12296, BD-12380, BD-12572 and BD-12596. In one embodiment, the siRNA is a duplex selected from the group consisting of BD-12044, BD-12212, BD-12296 and BD-12596. In one embodiment, the siRNA is BD-12296. In one aspect, the siRNA is BD-12044.

[0023] In one aspect, provided herein is a method of reducing hepcidin serum concentration in a subject comprising administering to the subject a therapeutically effective amount of an siRNA as provided in the instant disclosure. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 2. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexesNAI-5008944785v1 Page 4 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO listed in TABLE 3. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 4. In one embodiment, the siRNA is a duplex selected from the group consisting of BD-11900, BD-11984, BD-12044, BD-12212, BD-12296, BD-12380, BD-12572 and BD-12596. In one embodiment, the siRNA is a duplex selected from the group consisting of BD-12044, BD-12212, BD-12296 and BD-12596. In one aspect, the siRNA is BD-12296. In one aspect, the siRNA is BD-12044. In one aspect, provided herein is a method to boost erythropoiesis in a subject having an anemia, the method comprising administering to the subject a therapeutically effective amount of an siRNA as provided in the instant disclosure. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 2. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 3. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 4. In one embodiment, the siRNA duplex is selected from the group consistingof BD-11900, BD-11984, BD-12044, BD-12212, BD-12296, BD-12380, BD-12572 and BD-12596. In one embodiment, the siRNA duplex is selected from the group consisting of BD-12044, BD-12212, BD-12296 and BD-12596. In one aspect, the siRNA duplex is BD-12296. In one embodiment, the siRNA duplex is BD-12044. In one aspect, provided herein is a method of treating a disorder associated with elevated serum hepcidin concentration in a subject, comprising administering to the subjectwith a disorder associated with elevated serum hepcidin concentration a therapeutically effective amount of an siRNA as provided in the instant disclosure. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 2. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 3. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 4. In one embodiment, the siRNA duplex is selected from the group consisting of BD-11900, BD-11984, BD-12044, BD-12212, BD-12296, BD-12380, BD-12572 and BD-12596. In one embodiment, the siRNA duplex is selected from the group consisting of BD-12044, BD-12212, BD-12296 and BD-12596. In one aspect, the siRNA duplex is BD-12296.NAI-5008944785v1 Page 5 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO In one aspect, the siRNA duplex is BD-12044. In one aspect, provided herein is a method of treating a disease, disorder or condition selected from:(i) an anemia associated with elevated hepcidin;(ii) an iron refractory iron deficiency anemia;(iii) a hepcidin-producing adenoma; and(iv) an anemia of inflammation (“Al”)in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of an siRNA as provided in the instant disclosure. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 2. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 3. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 4. In one embodiment, the siRNA duplex is selected from the group consisting of BD-11900, BD-11984, BD-12044, BD-12212, BD-12296, BD-12380, BD-12572 and BD-12596. In one embodiment, the siRNA duplex is selected from the group consisting of BD-12044, BD-12212, BD-12296 and BD-12596. In one embodiment, the siRNA is BD-12296. In one embodiment, the siRNA BD.12044.

[0024] In certain embodiments, the method further comprises administering a therapeutically effective amount of a second therapeutic agent useful in the treatment of the disease, disorder or condition.

[0025] In some embodiments, a method of treating Al is provided wherein the Al is associated with, or caused by, an underlying condition or disease. For example, in some embodiments, the subject has a chronic infection, an autoimmune disease, chronic kidney disease, an anemia of the elderly, an advanced cancer, graft versus host disease, congestive heart failure, myelofibrosis, irritable bowel syndrome, rheumatoid arthritis, sepsis, or chronic obstructive pulmonary disease.

[0026] In one aspect, provided herein is an siRNA of the instant disclosure for use in a method of treating a cancer or a tumor in a subject. In one aspect, provided herein is anNAI-5008944785v1 Page 6 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO siRNA of the instant disclosure for use in a method of reducing expression of HFE2 in a cell. In one aspect, provided herein is an siRNA of the instant disclosure for use in a method of reducing hepcidin serum concentration in a subject. In one aspect, provided herein is an siRNA of the instant disclosure for use in a method to boost erythropoiesis in a subject having an anemia. In one aspect, provided herein is an siRNA of the instant disclosure for use in a method of treating a disease, disorder or condition selected from:(i) an anemia associated with elevated hepcidin;(ii) an iron refractory iron deficiency anemia;(iii) a hepcidin-producing adenoma; and(iv) an anemia of inflammation (“Al”)in a subject.

[0027] In one aspect, provided herein is use of an siRNA of the instant disclosure in the manufacture of a medicament for treating a cancer or a tumor. In one aspect, provided herein is use of an siRNA of the instant disclosure in the manufacture of a medicament for use in reducing expression of HFE2 in a cell. In one aspect, provided herein is use of an siRNA of the instant disclosure in the manufacture of a medicament for reducing hepcidin serum concentration in a subjectin one aspect, provided herein is use of an siRNA of the instant disclosure in the manufacture of a medicament for boosting erythropoiesis in a subject having an anemia. In one aspect, provided herein is use of an siRNA of the instant disclosure in the manufacture of a medicament for treating a disease, disorder or condition selected from:(i) an anemia associated with elevated hepcidin;(ii) an iron refractory iron deficiency anemia;(iii) a hepcidin-producing adenoma; and(iv) an anemia of inflammation (“Al”).BRIEF DESCRIPTION OF DRAWINGS

[0028] FIGURE 1 shows HFE2 knockdown 28-days after HFE2-siRNA treatment with BD-12296.NAI-5008944785v1 Page 7 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO

[0029] FIGURE 2 shows HAMP knockdown 28-days after HFE2-siRNA treatment BD-12296.DETAILED DESCRIPTION

[0030] In one aspect, the disclosure provides siRNAs effective for reducing HFE2 expression and / or inhibiting HFE2 function in a cell or mammal. In some embodiments, the siRNA effects the RNA-induced silencing complex (RlSC)-mediated cleavage of RNA transcripts of a HFE2 gene.

[0031] In one aspect, provided herein are compositions and methods for treating a pathological condition or disease in a mammal caused by the expression of HFE2.

[0032] Certain aspects of this disclosure relate to an observation that HFE2 is a regulator of hepcidin synthesis.

[0033] In one aspect, the disclosure provides compositions and methods for reducing hepcidin levels and / or modulating iron homeostasis for treatment of a pathological condition or disease, or symptom or complication thereof, associated with elevated hepcidin levels.Terminology

[0034] The terms “treat,” “treating,” and “treatment” as used herein mean to relieve or alleviate one or more symptoms associated with a disease or condition; or to delay or prevent the worsening or progression of the disease or condition or symptom thereof; or to reduce severity of a disease or condition or symptom thereof.

[0035] As used herein, the phrase “effective amount” refers to an amount of each active agent (e.g., siRNA) that will elicit a biological or medical response of a tissue, system or subject that is being sought by a researcher, veterinarian, medical doctor or other clinician. In some embodiments, the therapeutic effect is reduced hepcidin level or activity, increased level of transferrin saturation (TSAT%), increased erythropoiesis, decreased level of circulating transferrin level, and / or alleviated disease conditions (e.g., reduced anemia).NAI-5008944785v1 Page 8 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO

[0036] The term “subject” as used herein refers to a mammal, including but not limited to, human, non-human primate, cow, sheep, goat, horse, dog, cat, rabbit, rat. In some embodiments, the subject is a patient, e.g., a human patient that has or is suspected of having a disease or a condition associated with, or may give rise to, a functional iron deficiency.

[0037] “G,” “C,” “A,” “T” and “U” each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine and uracil as a base, respectively. However, it will be understood that the term “ribonucleotide” or nucleotide” can also refer to a modified nucleotide, as further detailed below, or a surrogate replacement moiety (see, e.g., Table 1 ). The skilled person understands that guanine, cytosine, adenine, and uracil can be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide comprising inosine as its base can pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine can be replaced in the nucleotide sequences of siRNA provided herein by a nucleotide containing, for example, inosine. In another example, adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively, to form G-U Wobble base pairing with the target mRNA. Sequences containing such replacement moieties are suitable forthe compositions and methods provided in the disclosure.Table 1. Abbreviations of nucleotide monomers used in nucleic acid sequence representation. It will be understood that, unless otherwise indicated, these monomers, when present in an oligonucleotide, are mutually linked by 5’-3’-phosphodiester bonds. Abbreviation DescriptionA adenosine-3’-phosphatea 2’-O-methyladenosine-3’-phosphateAf 2’-fluoroadenosine-3’-phosphateNAI-5008944785v1 Page 9 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Abbreviation DescriptionAfs 2’-fluoroadenosine-3’-phosphorothioateAs adenosine-3’-phosphorothioateas 2’-O-methyladenosine-3’-phosophorothioateC cytidine-3’-phosphatec 2’-O-methylcytidine-3’-phosphateCf 2’-fluorocytidine-3’-phosphateCfs 2’-fluorocytidine-3’-phosphorothioateCs cytidine-3’-phosphorothioatecs 2’-0-methylcytidine-3’-phosphorothioateG guanosine-3’-phosphateg 2’-O-methylguanosine-3’-phosphateGf 2’-fluoroguanosine-3’-phosphateGfs 2’-fluoroguanosine-3’-phosphorothioateGs guanosine-3’-phosphorothioategs 2’-O-methylguanosine-3’-phosphorothioateN any nucleotideS phosphorothioate linkageU uridine-3’-phosphateu 2’-O-methyluridine-3’-phosphateUf 2’-fluorouridine-3’-phosphateUfs 2’-fluorouridine-3’-phosphorothioateUs uridine-3’-phosphorothioateus 2’-0-methyluridine-3’-phosphorothioate(L96) triantennary GalNAc(vinu) 5’-(E)-vinylphosphonate-2’-O-methyluridineNAI-5008944785v1 Page 10 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO siRNAs

[0038] In one aspect, provided herein are siRNAs designed to specifically target a region of the HFE2 mRNA that is conserved among different species or that is critical to the gene’s expression. An siRNA as provided herein can, for example, bind to HFE2 mRNA in a cell and thereby result cleavage and degradation of the mRNA, leading to reduced HFE2 protein expression.

[0039] In some embodiments, the siRNA is 19-25 nucleotides in length and consists of a sense strand and an antisense strand, where the antisense strand is complementary to a region of the mRNA of HFE2. The sense and antisense strands are typically duplexed, but in some embodiments may be present as single-stranded RNA molecules capable of inducing RNA interference.

[0040] In some embodiments, the siRNA is complementary to a sequence within the 5’ untranslated region (UTR), 3’ untranslated region (UTR), and / or coding region of the mRNA of HFE2.

[0041] The siRNA can be synthesized by standard methods known in the art.

[0042] In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 2.

[0043] In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 3.

[0044] It will be understood that a siRNA sense strand and / or antisense strand as provided herein (e.g., in TABLE 2 and TABLE 3) can be optimized for stability and efficacy, such as by incorporating chemical modifications to the sugar-phosphate backbone or the RNA bases. Suitable modifications can enhance the stability of the siRNA and improve its resistance to nucleases.

[0045] In some embodiments, the siRNA is a modified version of a siRNA duplex listed in Table 2 or Table 3. A “modified version” refers to sequences in which a chemical NAI-5008944785v1 Page 11 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO modification is made to one, some, or all of the nucleosides or linkages of a given sequence including, e.g., a 2'-O-methyl group, 2'-O-methoxyethyl group, a 2’-fluoro group, and / or phosphorothioate linkage.

[0046] In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 2 and modified versions thereof. In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 3 and modified versions thereof.

[0047] In some embodiments, the siRNA (e.g., in TABLE 2 and TABLE 3), further comprises a ligand. In some embodiments, the the siRNA (e.g., in TABLE 2 and TABLE 3) is conjugated to a carbohydrate through a linker, such as described in U. S. PatentNo. 9,228,188, the content of which is incorporated herein. In some embodiments, the ligand is an N-acetylgalactosamine (GalNAc). The ligand can, for example, be one or more GalNAc attached to the siRNA through a monovalent, a bivalent, or a trivalent branched linker. In some embodiments, the ligand is attached to the 3’ end of the sense strand of the siRNA or to the 5’ end of the sense strand of the siRNA. In some embodiments, the ligand is attached to the 3’ end of the antisense strand of the siRNA or to the 5’ end of the antisense strand of the siRNA.

[0048] In certain embodiments, the ligand isNAI-5008944785v1 Page 12 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO

[0049] In certain embodiments, the siRNA is conjugated to the ligand as shown in the following schematicwherein X is O or S.NAI-5008944785v1 Page 13 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO

[0050] In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 4.

[0051] In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 5.

[0052] In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 6.

[0053] In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 7.

[0054] In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 8.

[0055] In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of BD-11900, BD-11984, BD-12044, BD-12212, BD-12296, BD-12380, BD-12572 and BD-12596. In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of BD-12044, BD-12212, BD-12296 and BD-12596. In some embodiments, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of BD-12044 and BD-12296.

[0056] In one embodiment, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form duplex BD-12044.

[0057] In one embodiment, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand form duplex BD-12296.NAI-5008944785v1 Page 14 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO

[0058] In one embodiment of an siRNA as provided herein, the 5'-end of the sense strand is modified with a cap or blocking group. Without intending to be limited by any theory or mechanism, it is believed that 5'-phosphorylation of the sense strand facilitates its unintended loading into Argonaute proteins, which can lead to off-target gene silencing. A 5'-cap or blocking group can prevent phosphorylation at the 5'-terminus of the sense strand. A number of 5'-caps or blocking groups suitable for modifying a sense strand are known in the art. In some embodiments the 5'cap or blocking group is 5'-biotin,5'-morpholino, 5'-O-methyl-2'-deoxythymidine, 5'-amino-2',5'-dideoxythymidine, an inverted abasic residue, a bulky hydrophobic cap such as cholesterol or a polyethylene glycol (PEG) conjugate, 5'-phosphorothioate, 5'-fluorobenzyl group, or a 5'-inverted nucleoside.

[0059] In one embodiment of an siRNA as provided herein, the antisense strand comprises one or more modifications within the seed region (positions 2–8 from the 5' end). Without intending to be limited by any theory or mechanism, it is believed that introducing structural modifications in this region decreases hybridization to partially complementary transcripts, thereby mitigating miRNA-like off -target repression.Modifications suitable for reducing seed-mediated off-target activity are well known in the art. In some embodiments the modification is incorporation of a GNA (glycol nucleic acid) nucleotides at position 6 or position 7.Pharmaceutical Compositions

[0060] In one aspect, provided herein is a pharmaceutical composition comprising the siRNA (e.g., in TABLE 2, 3, or 4) and a pharmaceutically acceptable excipient, carrier or delivery vehicle. In one aspect, provided herein is a pharmaceutical composition comprising the siRNA (e.g., in TABLE 2, 3, 4, 5, 6, 7 or 8) and a pharmaceutically acceptable excipient, carrier or delivery vehicle. In some embodiments of the pharmaceutical composition provided herein, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 2 and modified versions thereof. In some embodiments of the pharmaceutical composition provided herein, the siRNA is a duplex NAI-5008944785v1 Page 15 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO selected from the group consisting of duplexes listed in TABLE 3 and modified versions thereof. In some embodiments of the pharmaceutical composition provided herein, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 4.

[0061] In some embodiments of the pharmaceutical composition provided herein, the siRNA is a duplex selected from the group consisting of BD-11900, BD-11984, BD-12044, BD-12212, BD-12296, BD-12380, BD-12572 and BD-12596. In some embodiments of the pharmaceutical composition provided herein, the siRNA is a duplex selected from the group consisting of BD-12044, BD-12212, BD-12296 and BD-12596. In some embodiments of the pharmaceutical composition provided herein, the siRNA is a duplex selected from the group consisting of BD-12044 and BD-12296.

[0062] In one embodiment of the pharmaceutical composition provided herein, the siRNA is duplex BD-12044.

[0063] In one embodiment of the pharmaceutical composition provided herein, the siRNA is duplex BD-12296.

[0064] It will be understood that pharmaceutical compositions as provided herein are formulated based on the mode of delivery. In some embodiments, the pharmaceutical composition is formulated for intravenous (IV), subcutaneous (SC), or intramuscular (IM) administration. In some embodiments, the pharmaceutical composition is formulated for transdermal, oral, parenteral, infusion, subdermal, intraperitoneal, intraparenchymal, intrathecal, or intraventricular administration.

[0065] In some embodiments, the siRNA (e.g., in TABLE 2, 3, or 4) is delivered in a manner to target a particular tissue, such as the liver (e.g., the hepatocytes of the liver). In some embodiments, the siRNA (e.g., in TABLE 2, 3, 4, 5, 6, 7, or 8) is delivered in a manner to target a particular tissue, such as the liver (e.g., the hepatocytes of the liver).

[0066] In some embodiments, siRNA BD-12044 or BD-12596 is delivered in a manner to target a particular tissue, such as the liver (e.g., the hepatocytes of the liver). In one embodiment, siRNA BD-12044 is delivered in a manner to target a particular tissue, such as the liver (e.g., the hepatocytes of the liver). In one embodiment, siRNA BD-12296 isNAI-5008944785v1 Page 16 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO delivered in a manner to target a particular tissue, such as the liver (e.g., the hepatocytes of the liver).

[0067] A “pharmaceutically acceptable excipient” refers to a broad range of ingredients that may be combined with the siRNA (e.g., in TABLE 2, 3, or 4) to prepare the pharmaceutical composition. Excipients include, but are not limited to, diluents, colorants, vehicles, anti-adherents, glidants, disintegrants, binders, lubricants, sorbents, preservatives, and the like.

[0068] Pharmaceutically acceptable delivery vehicles for delivering siRNAs are known in art, see, e.g., Kalina Paunovska, et al., Nature Reviews Genetics, vol. 23, pages 265-280 (2022), and Hyun Jin Kim etal., Advanced Drug Delivery Reviews, vol. 104, pages 61-77 (2016), the contents of which are incorporated herein by reference in their entireties.

[0069] In some embodiments, the pharmaceutical composition comprises liposomes, lipid nanoparticles, polymeric nanoparticles, or other suitable delivery vehicles to facilitate the efficient delivery of the siRNA (e.g., in TABLE 2, 3, or 4) to target tissues or cells. In some embodiments, the pharmaceutical composition comprises liposomes, lipid nanoparticles, polymeric nanoparticles, or other suitable delivery vehicles to facilitate the efficient delivery of the siRNA (e.g., in TABLE 2, 3, 4, 5, 6, 7, or 8) to target tissues or cells. In some embodiments of the pharmaceutical composition provided herein, the pharmaceutical composition is in the form of a lipid nanoparticle (LNP).

[0070] In some embodiments, the pharmaceutical composition comprises liposomes, lipid nanoparticles, polymeric nanoparticles, or other suitable delivery vehicles to facilitate the efficient delivery of siRNA BD-12044 or BD-12296 to target tissues or cells. In some embodiments of the pharmaceutical composition provided herein, the pharmaceutical composition is in the form of a lipid nanoparticle (LNP).

[0071] In one embodiment, the pharmaceutical composition comprises liposomes, lipid nanoparticles, polymeric nanoparticles, or other suitable delivery vehicles to facilitate the efficient delivery of siRNA BD-12044 to target tissues or cells. In some embodiments ofNAI-5008944785v1 Page 17 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO the pharmaceutical composition provided herein, the pharmaceutical composition is in the form of a lipid nanoparticle (LNP).

[0072] In one embodiment, the pharmaceutical composition comprises liposomes, lipid nanoparticles, polymeric nanoparticles, or other suitable delivery vehicles to facilitate the efficient delivery of siRNA BD-12296 to target tissues or cells. In some embodiments of the pharmaceutical composition provided herein, the pharmaceutical composition is in the form of a lipid nanoparticle (LNP).

[0073] Methods for producing stable polynucleotide delivery vehicles that incorporate a polynucleotide / cationic lipid complex as structural components of the delivery vehicle are described in, e.g., PCT Publication No. WO 96 / 37104, the content of which is incorporated herein by reference in its entirety.

[0074] In some embodiments, the siRNA (e.g., in TABLE 2, 3, or 4) can, for example, be fully encapsulated in a lipid formulation, such as, an LNP or other polynucleotide / lipid particles. In some embodiments, the siRNA (e.g., in TABLE 2, 3, 4, 5, 6, 7 or 8) can, for example, be fully encapsulated in a lipid formulation, such as, an LNP or other polynucleotide / lipid particles. An LNP can, for example, contains a ionizable amino lipid (cationic lipid), a phosphatidylcholine, a steroid (cholesterol), and a coat lipid (e.g., a PEG-lipid conjugate), see, e.g., Yuen Yi C. Tam, et al., Pharmaceutics, vol. 5, pages 498-507 (2013), the content of which is incorporated herein by reference in its entirety.Polynucleotide-lipid particles and their method of preparation are disclosed in, e.g., U. S. Patent Nos. 5,976.567; 5,981.501; 6,534,484; 6,586,410; 6,815,432; 9,228,188 and PCT Publication No. 96 / 40964.

[0075] In some embodiments of the pharmaceutical compositions provided herein, siRNA BD-12044 or BD-12296 is fully encapsulated in a lipid formulation, such as, an LNP or other polynucleotide / lipid particles. In some embodiments of the pharmaceutical compositions provided herein, siRNA BD-12044 is fully encapsulated in a lipid formulation, such as, an LNP or other polynucleotide / lipid particles. In some embodiments of theNAI-5008944785v1 Page 18 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO pharmaceutical compositions provided herein, siRNA BD-12296 is fully encapsulated in a lipid formulation, such as, an LNP or other polynucleotide / lipid particles.Methods

[0076] In one aspect, provided herein is a method of reducing expression of HFE2 in a cell comprising administering to the subject an siRNA, wherein the siRNA is a duplex selected from the group of duplexes consisting of those listed in TABLE 2 and modified versions thereof, TABLE 3 and modified versions thereof, and TABLE 4. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 2. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 3. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 4. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 5. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 6. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 7. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 8.

[0077] In one aspect, provided herein is a method of reducing expression of HFE2 in a cell comprising administering to the subject an siRNA, wherein the siRNA is a duplex selected from the group of duplexes consisting of BD-11900, BD-11984, BD-12044, BD-12212, BD-12296, BD-12380, BD-12572 and BD-12596. In one aspect, provided herein is a method of reducing expression of HFE2 in a cell comprising administering to the subject an siRNA, wherein the siRNA is a duplex selected from the group of duplexes consisting of BD-12044, BD-12212, BD-12296 and BD-12596. In one aspect, provided herein is a method of reducing expression of HFE2 in a cell comprising administering to the subject an siRNA, wherein the siRNA is a duplex selected from the group of duplexes consisting of BD-12044 and BD-12296.NAI-5008944785v1 Page 19 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO

[0078] In one aspect, provided herein is a method of reducing expression of HFE2 in a cell comprising administering to the subject an siRNA, wherein the siRNA is duplex BD-12044.

[0079] In one aspect, provided herein is a method of reducing expression of HFE2 in a cell comprising administering to the subject an siRNA, wherein the siRNA is duplex BD-12296.

[0080] In one aspect, provided herein is an siRNA of the instant disclosure for use in a method of reducing expression of HFE2 in a cell.

[0081] In one aspect, provided herein is use of an siRNA of the instant disclosure in the manufacture of a medicament for use in reducing expression of HFE2 in a cell.

[0082] In one aspect, provided herein is a method of reducing expression of HFE2 in a cell comprising contacting the cell with an siRNA as provided in the instant disclosure. In one aspect, provided herein is a method of reducing expression of HFE2 in a cell comprising contacting the cell with an siRNA, wherein the siRNA is a duplex selected from the group of duplexes consisting of those listed in TABLE 2 and modified versions thereof, TABLE 3 and modified versions thereof, and TABLE 4. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 2. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 3. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 4. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 5. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 6. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 7. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 8.

[0083] In one aspect, provided herein is a method of reducing expression of HFE2 in a cell comprising contacting the cell with an siRNA, wherein the siRNA is a duplex selected from the group of duplexes consisting of BD-11900, BD-11984, BD-12044, BD-12212, BD-NAI-5008944785v1 Page 20 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO 12296, BD-12380, BD-12572 and BD-12596. In one aspect, provided herein is a method of reducing expression of HFE2 in a ceil comprising contacting the ceil with an siRNA, wherein the siRNA is a duplex selected from the group of duplexes consisting of BD-12044, BD-12212, BD-12296 and BD-12596. In one aspect, provided herein is a method of reducing expression of HFE2 in a cell comprising contacting the cell with an siRNA, wherein the siRNA is a duplex selected from the group of duplexes consisting of BD-12044 and BD-12296.

[0084] In one aspect, provided herein is a method of reducing expression of HFE2 in a cell comprising contacting the cell with an siRNA, wherein the siRNA is duplex BD-12044.

[0085] In one aspect, provided herein is a method of reducing expression of HFE2 in a cell comprising contacting the cell with an siRNA, wherein the siRNA is duplex BD-12296.

[0086] In some embodiments, the HFE2 expression is reduced by about 30% to about 99%. In some embodiments, the HFE2 expression is reduced by about 30% to about 95%. In some embodiments, the HFE2 expression is reduced by about 50% to about 95%. In some embodiments, the HFE2 expression is reduced by about 75% to about 95%. In some embodiments, the HFE2 expression is reduced by about 85% to about 95%. In some embodiments, the HFE2 expression is reduced by at least 30%. In some embodiments, the HFE2 expression is reduced by at least 50%. In some embodiments, the HFE2 expression is reduced by at least 75%. In some embodiments, the HFE2 expression is reduced by at least 80%. In some embodiments, the HFE2 expression is reduced by at least 85%. In some embodiments, the HFE2 expression is reduced by at least 95%.

[0087] Methods for quantifying HFE2 expression in a cell are known in the art, which include, for instance, measuring mRNA levels (e.g., quantitative PCR, RNA sequencing, northern blotting) or measuring protein levels (e.g., western blotting, enzyme-linked immunosorbent assay).

[0088] The siRNAs and pharmaceutical compositions of the present disclosure can be used to treat diseases and conditions associated with abnormal iron metabolism. TheseNAI-5008944785v1 Page 21 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO include, but are not limited to, iron deficiency anemia and other disorders where the dysregulation of HFE2 or hepcidin contributes to the pathogenesis of the condition.

[0089] In one aspect, provided herein is a method of reducing hepcidin serum concentration in a subject comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is a duplex selected from the group of duplexes consisting of those listed in TABLE 2 and modified versions thereof, TABLE 3 and modified versions thereof, and TABLE 4. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 2. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 3. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 4. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 5. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 6. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 7. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 8.

[0090] In one aspect, provided herein is a method of reducing hepcidin serum concentration in a subject comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is a duplex selected from BD-11900, BD-11984, BD-12044, BD-12212, BD-12296, BD-12380, BD-12572 and BD-12596. In one aspect, provided herein is a method of reducing hepcidin serum concentration in a subject comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is a duplex selected from BD-12044, BD-12212, BD-12296 and BD-12596. In one aspect, provided herein is a method of reducing hepcidin serum concentration in a subject comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is a duplex selected from BD-12044 and BD-12296.NAI-5008944785v1 Page 22 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO

[0091] In one aspect, provided herein is a method of reducing hepcidin serum concentration in a subject comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is BD-12044.

[0092] In one aspect, provided herein is a method of reducing hepcidin serum concentration in a subject comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is BD-12296.

[0093] In one aspect, provided herein is an siRNA of the instant disclosure for use in a method of reducing hepcidin serum concentration in a subject.

[0094] In one aspect, provided herein is use of an siRNA of the instant disclosure in the manufacture of a medicament for reducing hepcidin serum concentration in a subject.

[0095] In one aspect, provided herein is a method to boost erythropoiesis in a subject having an anemia, the method comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is a duplex selected from the group of duplexes consisting of those listed in TABLE 2 and modified versions thereof, TABLE 3 and modified versions thereof, and TABLE 4. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 2. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 3. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 4. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 5. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 6. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 7. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 8.

[0096] In one aspect, provided herein is a method to boost erythropoiesis in a subject having an anemia, the method comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is a duplex selected from BD-11900, BD-11984, BD-12044, BD-12212, BD-12296, BD-12380, BD-12572 and BD-NAI-5008944785v1 Page 23 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO 12596. In one aspect, provided herein is a method to boost erythropoiesis in a subject having an anemia, the method comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is a duplex selected from BD-12044, BD-12212, BD-12296 and BD-12596. In one aspect, provided herein is a method to boost erythropoiesis in a subject having an anemia, the method comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is a duplex selected from BD-12044 and BD-12296.

[0097] In one aspect, provided herein is a method to boost erythropoiesis in a subject having an anemia, the method comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is BD-12044.

[0098] In one aspect, provided herein is a method to boost erythropoiesis in a subject having an anemia, the method comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is BD-12296.

[0099] In one aspect, provided herein is an siRNA of the instant disclosure for use in a method to boost erythropoiesis in a subject having an anemia.

[0100] In one aspect, provided herein is use of an siRNA of the instant disclosure in the manufacture of a medicament for boosting erythropoiesis in a subject having an anemia.

[0101] In one aspect, provided herein is a method of treating a disorder associated with elevated serum hepcidin concentration in a subject, comprising administering to the subject with a disorder associated with elevated serum hepcidin concentration a therapeutically effective amount of an siRNA, wherein the siRNA is a duplex selected from the group of duplexes consisting of those listed in TABLE 2 and modified versions thereof, TABLE 3 and modified versions thereof, and TABLE 4. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 2. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 3. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 4. In some embodiments, the siRNA is a duplexNAI-5008944785v1 Page 24 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO selected from the group consisting of duplexes listed in TABLE 5. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 6. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 7. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 8.

[0102] In one aspect, provided herein is a method of treating a disorder associated with elevated serum hepcidin concentration in a subject, comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is a duplex selected from BD-11900, BD-11984, BD-12044, BD-12212, BD-12296, BD-12380, BD-12572 and BD-12596. In one aspect, provided herein is a method of treating a disorder associated with elevated serum hepcidin concentration in a subject, comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is a duplex selected from BD-12044, BD-12212, BD-12296 and BD-12596. In one aspect, provided herein is a method of treating a disorder associated with elevated serum hepcidin concentration in a subject, comprising administeringto the subject a therapeutically effective amount of an siRNA, wherein the siRNA is a duplex selected from BD-12044 and BD-12296.

[0103] In one aspect, provided herein is a method of treating a disorder associated with elevated serum hepcidin concentration in a subject, comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is BD-12044.

[0104] In one aspect, provided herein is a method of treating a disorder associated with elevated serum hepcidin concentration in a subject, comprising administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is BD-12296.

[0105] In one aspect, provided herein is an siRNA of the instant disclosure for use in a method of treating a disorder associated with elevated serum hepcidin concentration.

[0106] In one aspect, provided herein is use of an siRNA of the instant disclosure in the manufacture of a medicament for treating a disorder associated with elevated serum hepcidin concentrationNAI-5008944785v1 Page 25 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO

[0107] In one aspect, provided herein is a method of treating a disease, disorder or condition selected from:(i) an anemia associated with elevated hepcidin;(ii) an iron refractory iron deficiency anemia;(iii) a hepcidin-producing adenoma; and(iv) an anemia of inflammation (“Al”)in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of an siRNA, wherein the siRNA is a duplex selected from the group of duplexes consisting of those listed in TABLE 2 and modified versions thereof, TABLE 3 and modified versions thereof, and TABLE 4. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 2. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 3. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 4. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 5. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 6. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 7. In some embodiments, the siRNA is a duplex selected from the group consisting of duplexes listed in TABLE 8.

[0108] In one aspect, the siRNA is a duplex selected from BD-11900, BD-11984, BD-12044, BD-12212, BD-12296, BD-12380, BD-12572 and BD-12596. In one aspect, the siRNA is a duplex selected from BD-12044, BD-12212, BD-12296 and BD-12596. In one aspect, the siRNA is a duplex selected from BD-12044 and BD-12296. In one aspect, the siRNA is BD-12044. In one aspect, the siRNA is BD-12296.

[0109] In one aspect, provided herein is an siRNA of the instant disclosure for use in a method of treating a disease, disorder or condition selected from:(i) an anemia associated with elevated hepcidin;(ii) an iron refractory iron deficiency anemia;NAI-5008944785v1 Page 26 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO (iii) a hepcidin-producing adenoma; and(iv) an anemia of inflammation (“Al”)in a subject.

[0110] In one aspect, provided herein is use of an siRNA of the instant disclosure in the manufacture of a medicament for treating a disease, disorder or condition selected from:(i) an anemia associated with elevated hepcidin;(ii) an iron refractory iron deficiency anemia;(iii) a hepcidin-producing adenoma; and(iv) an anemia of inflammation (“Al”).

[0111] In some embodiments wherein the disease, disorder or condition treated is Al, the Al is associated with, or caused by, an underlying condition or disease. For example, in some embodiments, the subject has a chronic infection, an autoimmune disease, chronic kidney disease, an anemia of the elderly, an advanced cancer, graft versus host disease, congestive heart failure, myelofibrosis, irritable bowel syndrome, rheumatoid arthritis, sepsis, or chronic obstructive pulmonary disease.

[0112] In some embodiments of the methods provided above where an siRNA (e.g., in TABLE 2, 3, 4, 5, 6, 7, or 8) is administered to a subject, the siRNA is administered as a weight-based dose. A “weight-based dose” (e.g., a dose in mg / kg) is a dose where the amount of siRNA administered to a subject will depend on the subject’s weight. In one embodiment, the amount of siRNA administered is between 0.01 mg / kg to 45 mg / kg bodyweight of the subject.

[0113] In some embodiments of the methods provided above where an siRNA (e.g., in TABLE 2, 3, 4, 5, 6, 7, or 8) is administered to a subject, the siRNA is administered as a fixed dose. A “fixed dose” (e.g., a dose in mg) is an amount of siRNA administered irrespective of any subject-related factors such as weight. In one embodiment, the amount of siRNA administered is between 0.5 mg to 900 mg.NAI-5008944785v1 Page 27 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO

[0114] The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease, disorder or condition, previous treatments, the general health, weight, and age of the subject, concomitant treatments, if any, and other individual characteristics of the subject to be treated.

[0115] In some embodiments of the methods provided above where an siRNA (e.g., in TABLE 2, 3, 4, 5, 6, 7, or 8) is administered to a subject, the method further comprises administering a therapeutically effective amount of a second therapeutic agent useful in the treatment of the disease. In certain embodiments, the second therapeutic agent is iron supplementation, a JAK inhibitor, a BET inhibitor, a hepcidin antagonist (e.g., an anti-hepcidin antibody or small molecule inhibitor), or another gene modulating therapy other than an siRNA as disclosed herein.Enumerated Embodiments

[0116] Embodiment 1: An isolated small interfering RNA (siRNA) comprising a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 2 and modified versions thereof.

[0117] Embodiment 2: An isolated small interfering RNA (siRNA) comprising a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 3 and modified versions thereof.

[0118] Embodiment 3: An isolated small interfering RNA (siRNA) comprising a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 4.

[0119] Embodiment 4: The isolated siRNA of Embodiment 4, wherein the siRNA is selected from the group consisting of BD-11900, BD-11984, BD-12044, BD-12212, BD-12296, BD-12380, BD-12572 and BD-12596.NAI-5008944785v1 Page 28 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO

[0120] Embodiment 5: The isolated siRNA of Embodiment 3 or 4, wherein the siRNA is selected from the group consisting of BD-12044, BD-12212, BD-12296 and BD-12596.

[0121] Embodiment 6: The isolated siRNA of Embodiment 3, 4 or 5, wherein the siRNA is selected from the group consisting of BD-12044 and BD-12296.

[0122] Embodiment 7: The isolated siRNA of Embodiment 3, 4 or 5, wherein the siRNA is BD-12044.

[0123] Embodiment 8: The isolated siRNA of Embodiment 3, 4 or 5, wherein the siRNA is BD-12296.

[0124] Embodiment 9: A pharmaceutical composition comprisingthe siRNA of any one of Embodiments 1 to 8, and a pharmaceutically acceptable excipient, carrier or delivery vehicle.

[0125] Embodiment 10: The pharmaceutical composition of Embodiment 9, wherein the composition is in the form of a lipid nanoparticle.

[0126] Embodiment 11: A method of reducing expression of HFE2 in a cell comprising contacting the cell with the siRNA of any one of Embodiments 1 to 8.

[0127] Embodiment 12: A method of reducing hepcidin serum concentration in a subject comprising administering to the subject a therapeutically effective amount of the siRNA of any one of Embodiments 1 to 8.

[0128] Embodiment 13: A method to boost erythropoiesis in a subject having an anemia, the method comprising administering to the subject a therapeutically effective amount of the siRNA of any one of Embodiments 1 to 8.

[0129] Embodiment 14: A method of treating a disorder associated with elevated serum hepcidin concentration in a subject, comprising administering to the subject with a disorder associated with elevated serum hepcidin concentration a therapeutically effective amount of the siRNA of anyone of Embodiments 1 to 8.NAI-5008944785v1 Page 29 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO

[0130] Embodiment 15: A method of treating (i) an anemia associated with elevated hepcidin; (ii) an iron refractory iron deficiency anemia; (iii) a hepcidin-producing adenoma; or (iv) an anemia of inflammation (“Al”) in a subject in need thereof, the method comprising administeringto the subject a therapeutically effective amount of the siRNA of any one of Embodiments 1 to 8.

[0131] Embodiment 16: The method of Embodiment 15, wherein the subject has Al.

[0132] Embodiment 17: The method of Embodiment 16, wherein the subject has a chronic infection, an autoimmune disease, chronic kidney disease, an anemia of the elderly, an advanced cancer, graft versus host disease, congestive heart failure, myelofibrosis, irritable bowel syndrome, rheumatoid arthritis, sepsis, or chronic obstructive pulmonary disease.

[0133] Embodiment 18: The method of any one of Embodiments 14 to 17, wherein the method further comprises administering a therapeutically effective amount of a second therapeutic agent useful in the treatment of the disease, disorder or condition.EXAMPLESExample 1: Design of siRNAs Targeting HFE2 gene

[0134] Design of siRNA was carried out to identify siRNAs targeting human HFE2 with cross-reactivity for cynomolgus monkey, and / or rhesus monkey using annotations from the NCBI RefSeq and Ensembl databases. All siRNA duplexes designed shared a minimum 17mer full match (antisense positions 2-18) identity with human / cynomolgus or human / rhesus transcripts, and preferably a 19mer full match (antisense positions 1-19) identity with human / cynomolgus or human / rhesus. Target sites with abundant single nucleotide polymorphisms (NCBI, dbSNP) were excluded. An alignment was created by performing a BLASTn search with human HFE2 NCBI RefSeq transcript NM_213653.4 versus HFE2 transcripts of human, cynomolgus and rhesus from NCBI RefSeq (releaseNAI-5008944785v1 Page 30 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO 225) and Ensembl (release 112) databases:■ Human: ENST00000336751.11, NM_001379352.1, NM_145277.5, and ENST00000357836.5;■ Rhesus monkey: XM_001093102.4, XM_001092987.3, XM_028847320.1, XM_015149644.2;■ Cynomolgus monkey: XM_005542085.4, XM_005542084.4, XM_065532894.1, and ENSMFAT00000028516.2.

[0135] Specificity was predicted based on full or partial complementarity of the siRNA antisense strand to off-target transcripts, classified by the number of mismatches (≤4) within antisense positions 2-18. Seed-dependent microRNA-like off-target effects were predicted based on homology with known seed regions described in miRbase R22. Sequences were prioritized if they had a high predicted sequence specificity and low miRNA homology. A total of 168 duplexed siRNAs were selected.

[0136] Table 2 shows a total of 336 unique siRNA duplexes targeting the HFE2 gene, when considered as both 19 / 21 mer and 21 / 23mer formats.

[0137] Table 3 shows all 336 unique siRNA duplexes targetingthe HFE2 gene, wherein siRNA AS1 = U, and the corresponding siRNASS19 = A. Thermodynamically preferred A / U base pairing at the 5’-end of the antisense strand is advantageous for strand orientation during RISC loading.

[0138] Table 4 shows fully modified siRNA sequences. It is known that unmodified siRNAs are highly unstable and prone to exonuclease and endonuclease degradation. The combination of 2’-fluoro and 2’-O-methyl modifications allowfor compound stabilization, exonuclease / endonuclease resistance, and preservation of activity. Phosphorothioates, in place of phosphodiester linkages, at positions on the sense and antisense strand provide additional stabilization against exonuclease degradation and contribute to cellular internalization. The triantennary GalNAc conjugate is recognized by the asialoglycoprotein receptor (ASGPR) expressed on the surface of hepatocytes and is responsible for the endocytosis mechanism of GalNAc-conjugated siRNAs. The 5’-vinylphosphonateNAI-5008944785v1 Page 31 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO modification is a phosphatase-resistant analog at the 5’-terminal of the antisense strand and is responsible for improving the RISC loading and potency of siRNAs.Example 2: In Vitro Evaluation of siRNA Activity in Hep3B

[0139] This example describes an assay using a cultured human cell line known to express HFE2 to evaluate the efficacy of siRNA provided herein in silencing HFE2.

[0140] Cell Culture and Transfections. Hep3B cells (ATCC, HB-8064) were cultured in Eagle’s Minimum Essential Medium (Wisent, 220-020-LL) supplemented with 10% FBS at 37°C in an atmosphere containing 5% CO2. For siRNA transfections, cells were seeded at a density of 10,000 cells per well in 96-well plates. Lipofectamine RNAiMAX (Invitrogen, 13778150) was diluted in Opti-MEM medium (ThermoFisher, 31985062), and siRNA was similarly diluted in Opti-MEM. Equal volumes of the diluted siRNA and RNAiMAX were combined in a 1:1 ratio, followed by a 10-minute incubation at room temperature. The resulting si RNA-lipid mixture was then added to cells to achieve final siRNA concentrations of 0, 0.1, or 10 nM. Transfected cells were incubated with the siRNA-lipid mixture for 72 hours prior to cell lysis for downstream analysis.

[0141] RT-qPCR. After 72 hours of siRNA treatment, cells were lysed and subjected to reverse transcription and real-time quantitative PCR (RT-qPCR) using the CELLS-TO-CT™ 1-STEPTAQMAN™ Kit (ThermoFisher, A25603) according to the manufacturer’s protocol.

[0142] Relative fold change was calculated using the ΔΔCt method, with RT-qPCR data normalized to mock-treated control cells.

[0143] Knockdown efficiency was determined by quantifying the percentage reduction in HFE2 expression in cells treated with HFE2-targeting siRNA relative to those treated with a non-targeting control siRNA. siRNAs achieving ~>85% knockdown at a dose of 10 nM and / or ~>50% at 0.1 nM were selected for further dose-response testing per the protocol above, with doses ranging from 30 nM to 0.458 pM.

[0144] Table 5 shows screening data of siRNAs at concentrations of 0.1 and 10 nM.

[0145] Table 6 shows dose response siRNA data in Hep3B cells.NAI-5008944785v1 Page 32 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WC

[0146] Table 7 shows dose response of siRNAs in Hep3B cells of parent sequences with various backbone modifications (structure activity relationship). There are 59 siRNAs in Table 7 with sequences that originate from 12 gene start sites.Example 3: In Vitro Evaluation of siRNA Activity in Primary Human Hepatocytes

[0147] Eight siRNAs were selected from those listed in Table 7 for testing in primary human hepatocyte. Each GalNAc-conjugated siRNA was tested in primary human hepatocytes in dose response from 30 uM to 1.8 pM with 3 biological replicates. Primary human hepatocytes were sourced from a third-party commercial vendor, which were isolated from normal human liver donors and cryopreserved.

[0148] Cell Culture and Free Uptake. Cells were seeded at a density of 60,000 cells per well in collagen coated 96-well plates and treated with GalNAc-conjugated siRNAs prior to hepatocyte attachment, as solutions prepared in ultra-pure DNase / RNase-free water. The presence of the GalNAc moiety facilitates uptake in primary human hepatocytes without transfection reagents (“free uptake”). After plating, cells were maintained in an incubator at 37 °C and 5% CO2for the remainder of the study.

[0149] RT-qPCR. After 72 hours of siRNA treatment, the MagMAX mirVana™ Total RNA Isolation Kit (Applied Biosystems, A27828) was used for RNA isolation according to the manufacturer’s protocol. Measurement of HFE2 mRNA levels utilized real-time reverse transcriptase polymerase chain reaction (RT-PCR). RNA was multiplexed with probes specific for human HFE2 and GAPDH (Applied Biosystems, Cat. No. Hs02378779_s1 and Hs02786624_g1 ). Relative fold change was calculated using the ΔΔCt method, with RT-qPCR data normalized to mock-treated control cells. Knockdown efficiency was determined by quantifying the percentage reduction in HFE2 expression in cells treated with HFE2-targeting siRNA relative to those treated with a non-targeting control siRNA. Table 8 shows dose response siRNA data in primary human hepatocytes.NAI-5008944785v1 Page 33 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Example 4. In vivo Target Engagement of HFE2-targeting siRNA

[0150] siRNAs described herein can have long-acting in vivo pharmacology when studied in non-human primates (NHPs). Cynomolgus monkeys (n=3 per group) received a liver biopsy to characterize baseline HFE2 and HAMP mRNA. Animals were given 14 days to recover prior to dosing of an exemplary siRNA, BD-12296, or vehicle (PBS). Animals received a second liver biopsy 28 days after treatment.

[0151] Figure 1 shows knockdown of HFE2 mRNA for both PBS and BD-12296 treated groups, normalized to GAPDH from baseline (Day -14) to Day 28

[0152] Figure 2 shows knockdown of HAMP mRNA for both PBS and BD-12296 treated groups, normalized to GAPDH from baseline (Day -14) to Day 28.Example 5: In Vivo Efficacy in Animal Model

[0153] The in vivo efficacy of the siRNA as provided herein can be tested in a mouse model of anemia associated with elevated hepcidin levels. Mouse models are described in, e.g., Arie Kim et aL, Blood, vol. 123, pages 1129-1136 (2014) and Seth Rivers et aL, Blood, vol. 105, pages 1797-1802 (2005). The siRNA can be delivered, for example, via subcutaneous injection in phosphate buffered saline (PBS) orvia lipid nanoparticles, and the serum concentration of hepcidin is measured and / or the expression level of HFE2 quantitated.Example 6: Inhibition ofHFE2 in Humans

[0154] A human subject is treated with a siRNA as provided herein to inhibit expression of the HFE2 gene to treat a condition, e.g., an anemia of inflammation. In some instances, one or additional therapy is administered to the subject, such as, for instance, iron supplementation or a hepcidin antagonist (e.g., an anti-hepcidin antibody or small molecule inhibitor).

[0155] A subject in need of treatment is selected or identified. The identification of the subject can occur in a clinical setting. On the first day of treatment, a suitable firstNAI-5008944785v1 Page 34 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO dose of an siRNA as provided herein is administered to the subject. The siRNA is formulated as described herein. Following the first dose, e.g., 7 days, 14 days, and 21 days, the subject’s condition is evaluated and relevant criteria measured, including, for instance, measurement of hepcidin levels and / or HFE2 expression in the subject. The number and dose amounts are adjusted according to the subject’s needs.Table 2. Unmodified Sense and Antisense Strand Sequences of HFE2 siRNAs UNMODIFIED SEQUENCES SEQDuplex SEQ ID ID Name Sense Sequence (5’ to 3’) NO Antisense Sequence (5 ’to 3’)NO BD- 10001 GGCUGGAUAGGUAUGGGGG 1 CCCCCAUACCUAUCCAGCCAG 607 BD-10002 GGCUGGAUAGGUAUGGGGGAG 2 CUCCCCCAUACCUAUCCAGCCAG 608 BD-10003 UCAUUCUCAAUGCAAGAUC 3 GAUCUUGCAUUGAGAAUGAGC 609 BD-10004 UCAUUCUCAAUGCAAGAUCCU 4 AGGAUCUUGCAUUGAGAAUGAGC 610 BD-10005 AUUCUCAAUGCAAGAUCCU 5 AGGAUCUUGCAUUGAGAAUGA 611 BD-10006 AUUCUCAAUGCAAGAUCCUCC 6 GGAGGAUCUUGCAUUGAGAAUGA 612 BD-10007 UCAAUGCAAGAUCCUCCGC 7 GCGGAGGAUCUUGCAUUGAGA 613 BD-10008 UCAAUGCAAGAUCCUCCGCUG 8 CAGCGGAGGAUCUUGCAUUGAGA 614 BD-10009 CAAUGCAAGAUCCUCCGCU 9 AGCGGAGGAUCUUGCAUUGAG 615 BD-10010 CAAUGCAAGAUCCUCCGCUGC 10 GCAGCGGAGGAUCUUGCAUUGAG 616 BD-10011 AAUGCAAGAUCCUCCGCUG 11 CAGCGGAGGAUCUUGCAUUGA 617 BD-10012 AAUGCAAGAUCCUCCGCUGCA 12 UGCAGCGGAGGAUCUUGCAUUGA 618 BD-10013 UGCAAGAUCCUCCGCUGCA 13 UGCAGCGGAGGAUCUUGCAUU 619 BD-10014 UGCAAGAUCCUCCGCUGCAAU 14 AUUGCAGCGGAGGAUCUUGCAUU 620 BD-10015 CAAGAUCCUCCGCUGCAAU 15 AUUGCAGCGGAGGAUCUUGCA 621 BD-10016 CAAGAUCCUCCGCUGCAAUGC 16 GCAUUGCAGCGGAGGAUCUUGCA 622 BD-10017 AGAUCCUCCGCUGCAAUGC 17 GCAUUGCAGCGGAGGAUCUUG 623 BD-10018 AGAUCCUCCGCUGCAAUGCUG 18 CAGCAUUGCAGCGGAGGAUCUUG 624 BD-10019 GAUCCUCCGCUGCAAUGCU 19 AGCAUUGCAGCGGAGGAUCUU 625 BD-10020 GAUCCUCCGCUGCAAUGCUGA 20 UCAGCAUUGCAGCGGAGGAUCUU 626 BD-10021 AUCCUCCGCUGCAAUGCUG 21 CAGCAUUGCAGCGGAGGAUCU 627 BD-10022 AUCCUCCGCUGCAAUGCUGAG 22 CUCAGCAUUGCAGCGGAGGAUCU 628 BD-10023 UCCUCCGCUGCAAUGCUGA 23 UCAGCAUUGCAGCGGAGGAUC 629 BD-10024 UCCUCCGCUGCAAUGCUGAGU 24 ACUCAGCAUUGCAGCGGAGGAUC 630 BD- 10025 CUCCGCUGCAAUGCUGAGU 25 ACUCAGCAUUGCAGCGGAGGA 631 BD-10026 CUCCGCUGCAAUGCUGAGUAC 26 GUACUCAGCAUUGCAGCGGAGGA 632 BD-10027 CCGCUGCAAUGCUGAGUAC 27 GUACUCAGCAUUGCAGCGGAG 633 BD-10028 CCGCUGCAAUGCUGAGUACGU 28 ACGUACUCAGCAUUGCAGCGGAG 634 BD-10029 CGUAUCGUCCACUCUGAGC 29 GCUCAGAGUGGACGAUACGUA 635 BD-10030 CGUAUCGUCCACUCUGAGCCU 30 AGGCUCAGAGUGGACGAUACGUA 636 BD-10031 CGUCCACUCUGAGCCUUAG 31 CUAAGGCUCAGAGUGGACGAU 637 BD-10032 CGUCCACUCUGAGCCUUAGAG 32 CUCUAAGGCUCAGAGUGGACGAU 638 BD- 10033 UUCAUCAGGAGCACUUCGA 33 UCGAAGUGCUCCUGAUGAACC 639 BD-10034 UUCAUCAGGAGCACUUCGAGG 34 CCUCGAAGUGCUCCUGAUGAACC 640BD-10035 UCUGGCGGCCUCUGUCGAG 35 CU CGAC AGAGGCCGCC AGAGC 641 NAI-5008944785v1 Page 35 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO UNMODIF ED SEQUENCES SEQDuplex SEQ ID ID Name Sense Sequence (5’ to 3’) NO Antisense Sequence (5 ’to 3‘)NO BD-10036 UCUGGCGGCCUCUGUCGAGCC 36 GGCUCGACAGAGGCCGCCAGAGC 642 BD-10037 CUGGCGGCCUCUGUCGAGC 37 GCUCGACAGAGGCCGCCAGAG 643 BD-10038 CUGGCGGCCUCUGUCGAGCCC 38 GGGCUCGACAGAGGCCGCCAGAG 644 BD-10039 UGGCGGCCUCUGUCGAGCC 39 GGCUCGACAGAGGCCGCCAGA 645 BD-10040 UGGCGGCCUCUGUCGAGCCCU 40 AGGGCUCGACAGAGGCCGCCAGA 646 BD- 10041 CUCUGUCGAGCCCUCCGCU 41 AGCGGAGGGCUCGACAGAGGC 647 BD-10042 CUCUGUCGAGCCCUCCGCUCC 42 GGAGCGGAGGGCUCGACAGAGGC 648 BD-10043 CUGUCGAGCCCUCCGCUCC 43 GGAGCGGAGGGCUCGACAGAG 649 BD- 10044 CUGUCGAGCCCUCCGCUCCUA 44 UAGGAGCGGAGGGCUCGACAGAG 650 BD-10045 UGUCGAGCCCUCCGCUCCU 45 AGGAGCGGAGGGCUCGACAGA 651 BD-10046 UGUCGAGCCCUCCGCUCCUAU 46 AUAGGAGCGGAGGGCUCGACAGA 652 BD-10047 UCGAGCCCUCCGCUCCUAU 47 AUAGGAGCGGAGGGCUCGACA 653 BD-10048 UCGAGCCCUCCGCUCCUAUGC 48 GCAUAGGAGCGGAGGGCUCGACA 654 BD- 10049 CGAGCCCUCCGCUCCUAUG 49 CAUAGGAGCGGAGGGCUCGAC 655 BD-10050 CGAGCCCUCCGCUCCUAUGCG 50 CGCAUAGGAGCGGAGGGCUCGAC 656 BD-10051 AGCCCUCCGCUCCUAUGCG 51 CGCAU AGGAGCGGAGGGCU CG 657 BD-10052 AGCCCUCCGCUCCUAUGCGCU 52 AGCGCAUAGGAGCGGAGGGCUCG 658 BD-10053 GCCCUCCGCUCCUAUGCGC 53 GCGCAUAGGAGCGGAGGGCUC 659 BD-10054 GCCCUCCGCUCCUAUGCGCUC 54 GAGCGCAUAGGAGCGGAGGGCUC 660 BD-10055 CCCUCCGCUCCUAUGCGCU 55 AGCGCAUAGGAGCGGAGGGCU 661 BD-10056 CCCUCCGCUCCUAUGCGCUCU 56 AGAGCGCAUAGGAGCGGAGGGCU 662 BD-10057 CCGCUCCUAUGCGCUCUGC 57 GCAGAGCGCAUAGGAGCGGAG 663 BD-10058 CCGCUCCUAUGCGCUCUGCAC 58 GUGCAGAGCGCAUAGGAGCGGAG 664 BD-10059 CUAUGCGCUCUGCACUCGG 59 CCGAGUGCAGAGCGCAUAGGA 665 BD- 10060 CUAUGCGCUCUGCACUCGGCG 60 CGCCGAGUGCAGAGCGCAUAGGA 666 BD-10061 UAUGCGCUCUGCACUCGGC 61 GCCGAGUGCAGAGCGCAUAGG 667 BD-10062 UAUGCGCUCUGCACUCGGCGC 62 GCGCCGAGUGCAGAGCGCAUAGG 668 BD-10063 UGCGCUCUGCACUCGGCGC 63 GCGCCGAGUGCAGAGCGCAUA 669 BD-10064 UGCGCUCUGCACUCGGCGCAC 64 GUGCGCCGAGUGCAGAGCGCAUA 670 BD-10065 CGCUCUGCACUCGGCGCAC 65 GUGCGCCGAGUGCAGAGCGCA 671 BD-10066 CGCUCUGCACUCGGCGCACCG 66 CGGUGCGCCGAGUGCAGAGCGCA 672 BD-10067 GCCCGCACCUGCCGCGGGG 67 CCCCGCGGCAGGUGCGGGCGG 673 BD-10068 GCCCGCACCUGCCGCGGGGAC 68 GUCCCCGCGGCAGGUGCGGGCGG 674 BD-10069 CACCUGCCGCGGGGACCUC 69 GAGGUCCCCGCGGCAGGUGCG 675 BD-10070 CACCUGCCGCGGGGACCUCGC 70 GCGAGGUCCCCGCGGCAGGUGCG 676 BD- 10071 GGGACCUCGCCUUCCAUUC 71 GAAUGGAAGGCGAGGUCCCCG 677 BD-10072 GGGACCUCGCCUUCCAUUCGG 72 CCGAAUGGAAGGCGAGGUCCCCG 678 BD-10073 GACCUCGCCUUCCAUUCGG 73 CCGAAUGGAAGGCGAGGUCCC 679 BD-10074 GACCUCGCCUUCCAUUCGGCG 74 CGCCGAAUGGAAGGCGAGGUCCC 680 BD-10075 ACCUCGCCUUCCAUUCGGC 75 GCCGAAUGGAAGGCGAGGUCC 681 BD- 10076 ACCUCGCCUUCCAUUCGGCGG 76 CCGCCGAAUGGAAGGCGAGGUCC 682 BD-10077 CCUCGCCUUCCAUUCGGCG 77 CGCCGAAUGGAAGGCGAGGUC 683 BD-10078 CCUCGCCUUCCAUUCGGCGGU 78 ACCGCCGAAUGGAAGGCGAGGUC 684 BD-10079 CUCGCCUUCCAUUCGGCGG 79 CCGCCGAAUGGAAGGCGAGGU 685 BD-10080 CUCGCCUUCCAUUCGGCGGUA 80 UACCGCCGAAUGGAAGGCGAGGU 686 BD-10081 CGCCUUCCAUUCGGCGGUA 81 UACCGCCGAAUGGAAGGCGAG 687BD-10082 CGCCUUCCAUUCGGCGGUACA 82 UGUACCGCCGAAUGGAAGGCGAG 688 NAI-5008944785v1 Page 36 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO UNMODIF ED SEQUENCES SEQDuplex SEQ ID ID Name Sense Sequence (5’ to 3’) NO Antisense Sequence (5 ’to 3‘)NO BD-10083 GCCUUCCAUUCGGCGGUAC 83 GUACCGCCGAAUGGAAGGCGA 689 BD-10084 GCCUUCCAUUCGGCGGUACAU 84 AUGUACCGCCGAAUGGAAGGCGA 690 BD- 10085 CCUUCCAUUCGGCGGUACA 85 UGUACCGCCGAAUGGAAGGCG 691 BD-10086 CCUUCCAUUCGGCGGUACAUG 86 CAUGUACCGCCGAAUGGAAGGCG 692 BD-10087 CUUCCAUUCGGCGGUACAU 87 AUGUACCGCCGAAUGGAAGGC 693 BD- 10088 CUUCCAUUCGGCGGUACAUGG 88 CCAUGUACCGCCGAAUGGAAGGC 694 BD-10089 UUCCAUUCGGCGGUACAUG 89 CAUGUACCGCCGAAUGGAAGG 695 BD-10090 UUCCAUUCGGCGGUACAUGGC 90 GCCAUGUACCGCCGAAUGGAAGG 696 BD-10091 UCCAUUCGGCGGUACAUGG 91 CCAUGUACCGCCGAAUGGAAG 697 BD-10092 UCCAUUCGGCGGUACAUGGCA 92 UGCCAUGUACCGCCGAAUGGAAG 698 BD-10093 CCAUUCGGCGGUACAUGGC 93 GCCAUGUACCGCCGAAUGGAA 699 BD-10094 CCAUUCGGCGGUACAUGGCAU 94 AUGCCAUGUACCGCCGAAUGGAA 700 BD-10095 CAUUCGGCGGUACAUGGCA 95 UGCCAUGUACCGCCGAAUGGA 701 BD- 10096 CAUUCGGCGGUACAUGGCAUC 96 GAUGCCAUGUACCGCCGAAUGGA 702 BD-10097 UUCGGCGGUACAUGGCAUC 97 GAUGCCAUGUACCGCCGAAUG 703 BD-10098 UUCGGCGGUACAUGGCAUCGA 98 UCGAUGCCAUGUACCGCCGAAUG 704 BD-10099 UCGGCGGUACAUGGCAUCG 99 CGAUGCCAUGUACCGCCGAAU 705 BD-10100 UCGGCGGUACAUGGCAUCGAA 100 UUCGAUGCCAUGUACCGCCGAAU 706 BD-10101 CGGCGGUACAUGGCAUCGA 101 UCGAUGCCAUGUACCGCCGAA 707 BD-10102 CGGCGGUACAUGGCAUCGAAG 102 CUUCGAUGCCAUGUACCGCCGAA 708 BD-10103 GGCGGUACAUGGCAUCGAA 103 UUCGAUGCCAUGUACCGCCGA 709 BD-10104 GGCGGUACAUGGCAUCGAAGA 104 UCUUCGAUGCCAUGUACCGCCGA 710 BD-10105 GCGGUACAUGGCAUCGAAG 105 CUUCGAUGCCAUGUACCGCCG 711 BD-10106 GCGGUACAUGGCAUCGAAGAC 106 GUCUUCGAUGCCAUGUACCGCCG 712 BD-10107 CGGUACAUGGCAUCGAAGA 107 UCUUCGAUGCCAUGUACCGCC 713 BD-10108 CGGUACAUGGCAUCGAAGACC 108 GGUCUUCGAUGCCAUGUACCGCC 714 BD-10109 GGUACAUGGCAUCGAAGAC 109 GUCUUCGAUGCCAUGUACCGC 715 BD-10110 GGUACAUGGCAUCGAAGACCU 110 AGGUCUUCGAUGCCAUGUACCGC 716 BD-10111 AUCGAAGACCUGAUGAUCC 111 GGAUCAUCAGGUCUUCGAUGC 717 BD-10112 AUCGAAGACCUGAUGAUCCAG 112 CUGGAUCAUCAGGUCUUCGAUGC 718 BD-10113 CUGAUGAUCCAGCACAACU 113 AGUUGUGCUGGAUCAUCAGGU 719 BD-10114 CUGAUGAUCCAGCACAACUGC 114 GCAGUUGUGCUGGAUCAUCAGGU 720 BD-10115 UGAUGAUCCAGCACAACUG 115 CAGUUGUGCUGGAUCAUCAGG 721 BD-10116 UGAUGAUCCAGCACAACUGCU 116 AGCAGUUGUGCUGGAUCAUCAGG 722 BD-10117 GCCCCGGACCCUUGUGACU 117 AGUCACAAGGGUCCGGGGCAG 723 BD-10118 GCCCCGGACCCUUGUGACUAU 118 AUAGUCACAAGGGUCCGGGGCAG 724 BD-10119 CCCCGGACCCUUGUGACUA 119 UAGUCACAAGGGUCCGGGGCA 725 BD-10120 CCCCGGACCCUUGUGACUAUG 120 CAUAGUCACAAGGGUCCGGGGCA 726 BD-10121 CCCGGACCCUUGUGACUAU 121 AUAGUCACAAGGGUCCGGGGC 727 BD-10122 CCCGGACCCUUGUGACUAUGA 122 UCAUAGUCACAAGGGUCCGGGGC 728 BD-10123 GUGACUAUGAAGGCCGGUU 123 AACCGGCCUUCAUAGUCACAA 729 BD-10124 GUGACUAUGAAGGCCGGUUUU 124 AAAACCGGCCUUCAUAGUCACAA 730 BD-10125 UGACUAUGAAGGCCGGUUU 125 AAACCGGCCUUCAUAGUCACA 731 BD-10126 UGACUAUGAAGGCCGGUUUUC 126 GAAAACCGGCCUUCAUAGUCACA 732 BD-10127 ACUAUGAAGGCCGGUUUUC 127 GAAAACCGGCCUUCAUAGUCA 733 BD-10128 ACUAUGAAGGCCGGUUUUCCC 128 GGGAAAACCGGCCUUCAUAGUCA 734BD-10129 UAUGAAGGCCGGUUUUCCC 129 GGGAAAACCGGCCUUCAUAGU 735 NAI-5008944785v1 Page 37 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO UNMODIF ED SEQUENCES SEQDuplex SEQ ID ID Name Sense Sequence (5’ to 3’) NO Antisense Sequence (5 ’to 3‘)NO BD-10130 UAUGAAGGCCGGUUUUCCCGG 130 CCGGGAAAACCGGCCUUCAUAGU 736 BD-10131 UGAAGGCCGGUUUUCCCGG 131 CCGGGAAAACCGGCCUUCAUA 737 BD-10132 UGAAGGCCGGUUUUCCCGGCU 132 AGCCGGGAAAACCGGCCUUCAUA 738 BD-10133 GAAGGCCGGUUUUCCCGGC 133 GCCGGGAAAACCGGCCUUCAU 739 BD-10134 GAAGGCCGGUUUUCCCGGCUG 134 CAGCCGGGAAAACCGGCCUUCAU 740 BD-10135 AAGGCCGGUUUUCCCGGCU 135 AGCCGGGAAAACCGGCCUUCA 741 BD-10136 AAGGCCGGUUUUCCCGGCUGC 136 GCAGCCGGGAAAACCGGCCUUCA 742 BD-10137 CGGUUUUCCCGGCUGCAUG 137 CAUGCAGCCGGGAAAACCGGC 743 BD-10138 CGGUUUUCCCGGCUGCAUGGU 138 ACCAUGCAGCCGGGAAAACCGGC 744 BD-10139 GGUUUUCCCGGCUGCAUGG 139 CCAUGCAGCCGGGAAAACCGG 745 BD-10140 GGUUUUCCCGGCUGCAUGGUC 140 GACCAUGCAGCCGGGAAAACCGG 746 BD-10141 UUCCCGGCUGCAUGGUCGU 141 ACGACCAUGCAGCCGGGAAAA 747 BD-10142 UUCCCGGCUGCAUGGUCGUCC 142 GGACGACCAUGCAGCCGGGAAAA 748 BD-10143 UCCCGGCUGCAUGGUCGUC 143 GACGACCAUGCAGCCGGGAAA 749 BD-10144 UCCCGGCUGCAUGGUCGUCCC 144 GGGACGACCAUGCAGCCGGGAAA 750 BD-10145 CCCGGCUGCAUGGUCGUCC 145 GGACGACCAUGCAGCCGGGAA 751 BD-10146 CCCGGCUGCAUGGUCGUCCCC 146 GGGGACGACCAUGCAGCCGGGAA 752 BD-10147 CCGGCUGCAUGGUCGUCCC 147 GGGACGACCAUGCAGCCGGGA 753 BD-10148 CCGGCUGCAUGGUCGUCCCCC 148 GGGGGACGACCAUGCAGCCGGGA 754 BD-10149 GGCUGCAUGGUCGUCCCCC 149 GGGGGACGACCAUGCAGCCGG 755 BD-10150 GGCUGCAUGGUCGUCCCCCGG 150 CCGGGGGACGACCAUGCAGCCGG 756 BD-10151 CCGGGGUUCUUGCAUUGCG 151 CGCAAUGCAAGAACCCCGGGG 757 BD-10152 CCGGGGUUCUUGCAUUGCGCU 152 AGCGCAAUGCAAGAACCCCGGGG 758 BD-10153 GUUCUUGCAUUGCGCUUCC 153 GGAAGCGCAAUGCAAGAACCC 759 BD-10154 GUUCUUGCAUUGCGCUUCCUU 154 AAGGAAGCGCAAUGCAAGAACCC 760 BD-10155 UCUUGCAUUGCGCUUCCUU 155 AAGGAAGCGCAAUGCAAGAAC 761 BD-10156 UCUUGCAUUGCGCUUCCUUCG 156 CGAAGGAAGCGCAAUGCAAGAAC 762 BD-10157 CUUGCAUUGCGCUUCCUUC 157 GAAGGAAGCGCAAUGCAAGAA 763 BD-10158 CUUGCAUUGCGCUUCCUUCGG 158 CCGAAGGAAGCGCAAUGCAAGAA 764 BD-10159 UGCAUUGCGCUUCCUUCGG 159 CCGAAGGAAGCGCAAUGCAAG 765 BD-10160 UGCAUUGCGCUUCCUUCGGGG 160 CCCCGAAGGAAGCGCAAUGCAAG 766 BD-10161 CAUUGCGCUUCCUUCGGGG 161 CCCCGAAGGAAGCGCAAUGCA 767 BD-10162 CAUUGCGCUUCCUUCGGGGAC 162 GUCCCCGAAGGAAGCGCAAUGCA 768 BD-10163 AUUGCGCUUCCUUCGGGGA 163 UCCCCGAAGGAAGCGCAAUGC 769 BD-10164 AUUGCGCUUCCUUCGGGGACC 164 GGUCCCCGAAGGAAGCGCAAUGC 770 BD-10165 CGCUUCCUUCGGGGACCCC 165 GGGGUCCCCGAAGGAAGCGCA 771 BD-10166 CGCUUCCUUCGGGGACCCCCA 166 UGGGGGUCCCCGAAGGAAGCGCA 772 BD-10167 AUCACUUUCACACAUGCCG 167 CGGCAUGUGUGAAAGUGAUGG 773 BD-10168 AUCACUUUCACACAUGCCGUG 168 CACGGCAUGUGUGAAAGUGAUGG 774 BD-10169 UCACACAUGCCGUGUCCAA 169 UUGGACACGGCAUGUGUGAAA 775 BD-10170 UCACACAUGCCGUGUCCAAGG 170 CCUUGGACACGGCAUGUGUGAAA 776 BD-10171 GUGUCCAAGGAGCUUGGCC 171 GGCCAAGCUCCUUGGACACGG 777 BD-10172 GUGUCCAAGGAGCUUGGCCUC 172 GAGGCCAAGCUCCUUGGACACGG 778 BD-10173 UGUCCAAGCCACCAGCUCC 173 GGAGCUGGUGGCUUGGACAAA 779 BD-10174 UGUCCAAGCCACCAGCUCCCC 174 GGGGAGCUGGUGGCUUGGACAAA 780 BD-10175 CACCCGGAAGCUCACCAUC 175 GAUGGUGAGCUUCCGGGUGGC 781BD-10176 CACCCGGAAGCUCACCAUCAU 176 AUGAUGGUGAGCUUCCGGGUGGC 782 NAI-5008944785v1 Page 38 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO UNMODIF ED SEQUENCES SEQDuplex SEQ ID ID Name Sense Sequence (5’ to 3’) NO Antisense Sequence (5 ’to 3‘)NO BD-10177 AAGCUCACCAUCAUAUUUA 177 UAAAUAUGAUGGUGAGCUUCC 783 BD-10178 AAGCUCACCAUCAUAUUUAAG 178 CUUAAAUAUGAUGGUGAGCUUCC 784 BD-10179 ACAUGCAGGAAUGCAUUGA 179 UCAAUGCAUUCCUGCAUGUUC 785 BD-10180 ACAUGCAGGAAUGCAUUGAUC 180 GAUCAAUGCAUUCCUGCAUGUUC 786 BD-10181 CAUGCAGGAAUGCAUUGAU 181 AUCAAUGCAUUCCUGCAUGUU 787 BD-10182 CAUGCAGGAAUGCAUUGAUCA 182 UGAUCAAUGCAUUCCUGCAUGUU 788 BD-10183 AUCAGGCUGAGGUGGAUAA 183 UUAUCCACCUCAGCCUGAUAC 789 BD-10184 AUCAGGCUGAGGUGGAUAAUC 184 GAUUAUCCACCUCAGCCUGAUAC 790 BD-10185 GGCUGAGGUGGAUAAUCUU 185 AAGAUUAUCCACCUCAGCCUG 791 BD-10186 GGCUGAGGUGGAUAAUCUUCC 186 GGAAGAUUAUCCACCUCAGCCUG 792 BD-10187 GCUGAGGUGGAUAAUCUUC 187 GAAGAUUAUCCACCUCAGCCU 793 BD-10188 GCUGAGGUGGAUAAUCUUCCU 188 AGGAAGAUUAUCCACCUCAGCCU 794 BD-10189 AUCAAUGGAGGUGACCGAC 189 GUCGGUCACCUCCAUUGAUAG 795 BD-10190 AUCAAUGGAGGUGACCGACCU 190 AGGUCGGUCACCUCCAUUGAUAG 796 BD-10191 UCAAUGGAGGUGACCGACC 191 GGUCGGUCACCUCCAUUGAUA 797 BD-10192 U C A AU GGAGGU GACCGACCU G 192 CAGGUCGGUCACCUCCAUUGAUA 798 BD-10193 CAAUGGAGGUGACCGACCU 193 AGGUCGGUCACCUCCAUUGAU 799 BD-10194 CAAUGGAGGUGACCGACCUGG 194 CCAGGUCGGUCACCUCCAUUGAU 800 BD-10195 GGAGGUGACCGACCUGGGG 195 CCCCAGGUCGGUCACCUCCAU 801 BD-10196 GGAGGUGACCGACCUGGGGGA 196 UCCCCCAGGUCGGUCACCUCCAU 802 BD-10197 GAGGUGACCGACCUGGGGG 197 CCCCCAGGUCGGUCACCUCCA 803 BD-10198 GAGGUGACCGACCUGGGGGAU 198 AUCCCCCAGGUCGGUCACCUCCA 804 BD-10199 GGAUCCAGUUUGUCGAUUC 199 GAAUCGACAAACUGGAUCCCC 805 BD-10200 GGAUCCAGUUUGUCGAUUCAA 200 UUGAAUCGACAAACUGGAUCCCC 806 BD- 10201 UCCAGUUUGUCGAUUCAAA 201 UUUGAAUCGACAAACUGGAUC 807 BD-10202 UCCAGUUUGUCGAUUCAAACU 202 AGUUUGAAUCGACAAACUGGAUC 808 BD-10203 CAGUUUGUCGAUUCAAACU 203 AGUUUGAAUCGACAAACUGGA 809 BD-10204 CAGUUUGUCGAUUCAAACUGC 204 GCAGUUUGAAUCGACAAACUGGA 810 BD-10205 AGUUUGUCGAUUCAAACUG 205 CAGUUUGAAUCGACAAACUGG 811 BD-10206 AGUUUGUCGAUUCAAACUGCU 206 AGCAGUUUGAAUCGACAAACUGG 812 BD-10207 UUUGUCGAUUCAAACUGCU 207 AGCAGUUUGAAUCGACAAACU 813 BD-10208 UUUGUCGAUUCAAACUGCUAA 208 UUAGCAGUUUGAAUCGACAAACU 814 BD-10209 UUGUCGAUUCAAACUGCUA 209 UAGCAGUUUGAAUCGACAAAC 815 BD-10210 UUGUCGAUUCAAACUGCUAAC 210 GUUAGCAGUUUGAAUCGACAAAC 816 BD-10211 UGUCGAUUCAAACUGCUAA 211 UUAGCAGUUUGAAUCGACAAA 817 BD-10212 UGUCGAUUCAAACUGCUAACC 212 GGUUAGCAGUUUGAAUCGACAAA 818 BD-10213 GUCGAUUCAAACUGCUAAC 213 GUUAGCAGUUUGAAUCGACAA 819 BD-10214 GUCGAUUCAAACUGCUAACCC 214 GGGUUAGCAGUUUGAAUCGACAA 820 BD-10215 UCGAUUCAAACUGCUAACC 215 GGUUAGCAGUUUGAAUCGACA 821 BD-10216 UCGAUUCAAACUGCUAACCCU 216 AGGGUUAGCAGUUUGAAUCGACA 822 BD-10217 GAUUCAAACUGCUAACCCU 217 AGGGUUAGCAGUUUGAAUCGA 823 BD-10218 GAUUCAAACUGCUAACCCUGG 218 CCAGGGUUAGCAGUUUGAAUCGA 824 BD-10219 AACUGCUAACCCUGGGAAC 219 GUUCCCAGGGUUAGCAGUUUG 825 BD-10220 AACUGCUAACCCUGGGAACCA 220 UGGUUCCCAGGGUUAGCAGUUUG 826 BD-10221 CUGCUAACCCUGGGAACCA 221 UGGUUCCCAGGGUUAGCAGUU 827 BD-10222 CUGCUAACCCUGGGAACCAUG 222 CAUGGUUCCCAGGGUUAGCAGUU 828BD-10223 AUCCAAGCUGCCUACAUUG 223 CAAUGUAGGCAGCUUGGAUCU 829 NAI-5008944785v1 Page 39 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO UNMODIF ED SEQUENCES SEQDuplex SEQ ID ID Name Sense Sequence (5’ to 3’) NO Antisense Sequence (5 ’to 3‘)NO BD-10224 AUCCAAGCUGCCUACAUUGGC 224 GCCAAUGUAGGCAGCUUGGAUCU 830 BD-10225 CCAAGCUGCCUACAUUGGC 225 GCCAAUGUAGGCAGCUUGGAU 831 BD-10226 CCAAGCUGCCUACAUUGGCAC 226 GUGCCAAUGUAGGCAGCUUGGAU 832 BD-10227 CAAGCUGCCUACAUUGGCA 227 UGCCAAUGUAGGCAGCUUGGA 833 BD-10228 CAAGCUGCCUACAUUGGCACA 228 UGUGCCAAUGUAGGCAGCUUGGA 834 BD- 10229 UGCCUACAUUGGCACAACU 229 AGUUGUGCCAAUGUAGGCAGC 835 BD-10230 UGCCUACAUUGGCACAACUAU 230 AUAGUUGUGCCAAUGUAGGCAGC 836 BD-10231 CCUACAUUGGCACAACUAU 231 AUAGUUGUGCCAAUGUAGGCA 837 BD-10232 CCUACAUUGGCACAACUAUAA 232 UUAUAGUUGUGCCAAUGUAGGCA 838 BD-10233 UUGGCACAACUAUAAUCAU 233 AUGAUUAUAGUUGUGCCAAUG 839 BD-10234 UUGGCACAACUAUAAUCAUUC 234 GAAUGAUUAUAGUUGUGCCAAUG 840 BD-10235 UGGCACAACUAUAAUCAUU 235 AAUGAUUAUAGUUGUGCCAAU 841 BD-10236 UGGCACAACUAUAAUCAUUCG 236 CGAAUGAUUAUAGUUGUGCCAAU 842 BD-10237 ACAACUAUAAUCAUUCGGC 237 GCCGAAUGAUUAUAGUUGUGC 843 BD-10238 ACAACUAUAAUCAUUCGGCAG 238 CUGCCGAAUGAUUAUAGUUGUGC 844 BD-10239 CAACUAUAAUCAUUCGGCA 239 UGCCGAAUGAUUAUAGUUGUG 845 BD- 10240 CAACUAUAAUCAUUCGGCAGA 241 UCUGCCGAAUGAUUAUAGUUGUG 846 BD-10241 AACUAUAAUCAUUCGGCAG 241 CUGCCGAAUGAUUAUAGUUGU 847 BD-10242 AACUAUAAUCAUUCGGCAGAC 242 GUCUGCCGAAUGAUUAUAGUUGU 848 BD-10243 AUAAUCAUUCGGCAGACAG 243 CUGUCUGCCGAAUGAUUAUAG 849 BD-10244 AUAAUCAUUCGGCAGACAGCU 244 AGCUGUCUGCCGAAUGAUUAUAG 850 BD- 10245 CAUUCGGCAGACAGCUGGG 246 CCCAGCUGUCUGCCGAAUGAU 851 BD-10246 CAUUCGGCAGACAGCUGGGCA 246 UGCCCAGCUGUCUGCCGAAUGAU 852 BD-10247 CUUCUCCAUCAAGGUAGCA 247 UGCUACCUUGAUGGAGAAGGA 853 BD-10248 CUUCUCCAUCAAGGUAGCAGA 248 UCUGCUACCUUGAUGGAGAAGGA 854 BD-10249 AUCAAGGUAGCAGAGGAUG 249 CAUCCUCUGCUACCUUGAUGG 855 BD-10250 AUCAAGGUAGCAGAGGAUGUG 250 CACAUCCUCUGCUACCUUGAUGG 856 BD-10251 GCCCUCCAAGUCAGCGACU 251 AGUCGCUGACUUGGAGGGCAC 857 BD-10252 GCCCUCCAAGUCAGCGACUCU 252 AGAGUCGCUGACUUGGAGGGCAC 858 BD-10253 AAGUCAGCGACUCUCUCGA 253 UCGAGAGAGUCGCUGACUUGG 859 BD-10254 AAGUCAGCGACUCUCUCGAUC 254 GAUCGAGAGAGUCGCUGACUUGG 860 BD-10255 AGUCAGCGACUCUCUCGAU 255 AUCGAGAGAGUCGCUGACUUG 861 BD- 10256 AGUCAGCGACUCUCUCGAUCA 258 UGAUCGAGAGAGUCGCUGACUUG 862 BD-10257 GACUCUCUCGAUCAGAGCG 257 CGCUCUGAUCGAGAGAGUCGC 863 BD-10258 GACUCUCUCGAUCAGAGCGCA 258 UGCGCUCUGAUCGAGAGAGUCGC 864 BD-10259 ACUCUCUCGAUCAGAGCGC 259 GCGCUCUGAUCGAGAGAGUCG 865 BD-10260 ACUCUCUCGAUCAGAGCGCAA 260 UUGCGCUCUGAUCGAGAGAGUCG 866 BD-10261 CUCUCUCGAUCAGAGCGCA 261 UGCGCUCUGAUCGAGAGAGUC 867 BD-10262 CUCUCUCGAUCAGAGCGCAAU 262 AUUGCGCUCUGAUCGAGAGAGUC 868 BD-10263 AUCGUCGGGGAGCUAUAAC 263 GUUAUAGCUCCCCGACGAUUG 869 BD- 10264 AUCGUCGGGGAGCUAUAACCA 266 UGGUUAUAGCUCCCCGACGAUUG 870 BD-10265 UCGUCGGGGAGCUAUAACC 265 GGUUAUAGCUCCCCGACGAUU 871 BD-10266 UCGUCGGGGAGCUAUAACCAU 266 AUGGUUAUAGCUCCCCGACGAUU 872 BD- 10267 CGUCGGGGAGCUAUAACCA 269 UGGUUAUAGCUCCCCGACGAU 873 BD-10268 CGUCGGGGAGCUAUAACCAUU 268 AAUGGUUAUAGCUCCCCGACGAU 874 BD-10269 CGGGGAGCUAUAACCAUUG 269 CAAUGGUUAUAGCUCCCCGAC 875BD-10270 CGGGGAGCUAUAACCAUUGAU 270 AUCAAUGGUUAUAGCUCCCCGAC 876 NAI-5008944785v1 Page 40 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO UNMODIF ED SEQUENCES SEQDuplex SEQ IDSense Sequence (5’ to 3’) Antisense Sequence (5 ’to 3‘) ID Name NO NO BD- 10271 GGGGAGCUAUAACCAUUGA 273 UCAAUGGUUAUAGCUCCCCGA 877 BD-10272 GGGGAGCUAUAACCAUUGAUA 274 UAUCAAUGGUUAUAGCUCCCCGA 878 BD-10273 GGGAGCUAUAACCAUUGAU 275 AUCAAUGGUUAUAGCUCCCCG 879 BD-10274 GGGAGCUAUAACCAUUGAUAC 276 GUAUCAAUGGUUAUAGCUCCCCG 880 BD-10275 GGAGCUAUAACCAUUGAUA 277 UAUCAAUGGUUAUAGCUCCCC 881 BD- 10276 GGAGCUAUAACCAUUGAUACU 278 AGUAUCAAUGGUUAUAGCUCCCC 882 BD-10277 AGCUAUAACCAUUGAUACU 279 AGUAUCAAUGGUUAUAGCUCC 883 BD-10278 AGCUAUAACCAUUGAUACUGC 280 GCAGUAUCAAUGGUUAUAGCUCC 884 BD-10279 CUAUAACCAUUGAUACUGC 281 GCAGUAUCAAUGGUUAUAGCU 885 BD-10280 CUAUAACCAUUGAUACUGCCA 282 UGGCAGUAUCAAUGGUUAUAGCU 886 BD-10281 UAUAACCAUUGAUACUGCC 283 GGCAGUAUCAAUGGUUAUAGC 887 BD-10282 UAUAACCAUUGAUACUGCCAG 284 CUGGCAGUAUCAAUGGUUAUAGC 888 BD-10283 CCAUUGAUACUGCCAGACG 285 CGUCUGGCAGUAUCAAUGGUU 889 BD- 10284 CCAUUGAUACUGCCAGACGGC 286 GCCGUCUGGCAGUAUCAAUGGUU 890 BD-10285 CAUUGAUACUGCCAGACGG 287 CCGUCUGGCAGUAUCAAUGGU 891 BD-10286 CAUUGAUACUGCCAGACGGCU 288 AGCCGUCUGGCAGUAUCAAUGGU 892 BD-10287 UUGAUACUGCCAGACGGCU 289 AGCCGUCUGGCAGUAUCAAUG 893 BD-10288 UUGAUACUGCCAGACGGCUGU 290 ACAGCCGUCUGGCAGUAUCAAUG 894 BD-10289 GAUACUGCCAGACGGCUGU 291 ACAGCCGUCUGGCAGUAUCAA 895 BD-10290 GAUACUGCCAGACGGCUGUGC 292 GCACAGCCGUCUGGCAGUAUCAA 896 BD-10291 UCCUGUGUCUUUGAUGUUU 293 AAACAUCAAAGACACAGGAAU 897 BD- 10292 UCCUGUGUCUUUGAUGUUUUA 294 UAAAACAUCAAAGACACAGGAAU 898 BD-10293 UUUAAUUUCUGGUGAUCCC 295 GGGAUCACCAGAAAUUAAAAC 899 BD-10294 UUUAAUUUCUGGUGAUCCCAA 296 UUGGGAUCACCAGAAAUUAAAAC 900 BD-10295 AUUACUAGUUUGGAAAUGA 297 UCAUUUCCAAACUAGUAAUGG 901 BD-10296 AUUACUAGUUUGGAAAUGAUU 298 AAUCAUUUCCAAACUAGUAAUGG 902 BD-10297 AGAUUGGCAUAGAAGAAUG 299 CAUUCUUCUAUGCCAAUCUGU 903 BD-10298 AGAUUGGCAUAGAAGAAUGUA 300 UACAUUCUUCUAUGCCAAUCUGU 904 BD-10299 AGAAUAAGGAUUCUGGGCA 301 UGCCCAGAAUCCUUAUUCUGU 905 BD-10300 AGAAUAAGGAUUCUGGGCAAG 302 CUUGCCCAGAAUCCUUAUUCUGU 906 BD-10301 AGGUCAUGAAGGUUUUAAU 303 AUUAAAACCUUCAUGACCUCU 907 BD-10302 AGGUCAUGAAGGUUUUAAUGA 304 UCAUUAAAACCUUCAUGACCUCU 908 BD-10303 UUAAGAGGCAAGAGCUGAA 305 UUCAGCUCUUGCCUCUUAAAA 909 BD-10304 UUAAGAGGCAAGAGCUGAAAG 306 CUUUCAGCUCUUGCCUCUUAAAA 910 BD-10305 UGAUCAUUAGCCAUAAGAA 307 UUCUUAUGGCUAAUGAUCAUG 911 BD-10306 UGAUCAUUAGCCAUAAGAAAC 308 GUUUCUUAUGGCUAAUGAUCAUG 912 BD-10307 UUAGGGAAAGAAGUCUAUU 309 AAUAGACUUCUUUCCCUAAUU 913 BD-10308 UUAGGGAAAGAAGUCUAUUUG 310 CAAAUAGACUUCUUUCCCUAAUU 914 BD-10309 UAGGGAAAGAAGUCUAUUU 311 AAAUAGACUUCUUUCCCUAAU 915 BD-10310 UAGGGAAAGAAGUCUAUUUGA 312 UCAAAUAGACUUCUUUCCCUAAU 916 BD-10311 AAAGAAGUCUAUUUGAUGA 313 UCAUCAAAUAGACUUCUUUCC 917 BD-10312 AAAGAAGUCUAUUUGAUGAAU 314 AUUCAUCAAAUAGACUUCUUUCC 918 BD-10313 AAGAAGUCUAUUUGAUGAA 315 UUCAUCAAAUAGACUUCUUUC 919 BD-10314 AAGAAGUCUAUUUGAUGAAUA 316 UAUUCAUCAAAUAGACUUCUUUC 920 BD-10315 CUCUUAGGUGAAGGGAGUC 317 GACUCCCUUCACCUAAGAGCU 921 BD-10316 CUCUUAGGUGAAGGGAGUCUC 318 GAGACUCCCUUCACCUAAGAGCU 922BD-10317 GUGAAGGGAGUCUCUGCUU 319 AAGCAGAGACUCCCUUCACCU 923 NAI-5008944785v1 Page 41 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO UNMODIF ED SEQUENCES SEQDuplex SEQ ID ID Name Sense Sequence (5’ to 3’) NO Antisense Sequence (5 ’to 3‘)NO BD-10318 GUGAAGGGAGUCUCUGCUUUU 320 AAAAGCAGAGACUCCCUUCACCU 924 BD-10319 UGAAGGGAGUCUCUGCUUU 321 AAAGCAGAGACUCCCUUCACC 925 BD-10320 UGAAGGGAGUCUCUGCUUUUG 322 CAAAAGCAGAGACUCCCUUCACC 926 BD-10321 AGGUAGGACAGAAGUAUCA 323 UGAUACUUCUGUCCUACCUGU 927 BD-10322 AGGUAGGACAGAAGUAUCAUC 324 GAUGAUACUUCUGUCCUACCUGU 928 BD-10323 GGUAGGACAGAAGUAUCAU 325 AUGAUACUUCUGUCCUACCUG 929 BD-10324 GGUAGGACAGAAGUAUCAUCC 326 GGAUGAUACUUCUGUCCUACCUG 930 BD-10325 GUAGGACAGAAGUAUCAUC 327 GAUGAUACUUCUGUCCUACCU 931 BD-10326 GUAGGACAGAAGUAUCAUCCC 328 GGGAUGAUACUUCUGUCCUACCU 932 BD-10327 AGGACAGAAGUAUCAUCCC 329 GGGAUGAUACUUCUGUCCUAC 933 BD-10328 AGGACAGAAGUAUCAUCCCUA 330 UAGGGAUGAUACUUCUGUCCUAC 934 BD-10329 GGACAGAAGUAUCAUCCCU 331 AGGGAUGAUACUUCUGUCCUA 935 BD-10330 GGACAGAAGUAUCAUCCCUAC 332 GUAGGGAUGAUACUUCUGUCCUA 936 BD-10331 AGAAGUAUCAUCCCUACCC 333 GGGUAGGGAUGAUACUUCUGU 937 BD-10332 AGAAGUAUCAUCCCUACCCCC 334 GGGGGUAGGGAUGAUACUUCUGU 938 BD-10333 UAUUAAAGCUACAAAUUCU 335 AGAAU U U GU AGCU U U AAU AAC 939 BD-10334 UAUUAAAGCUACAAAUUCUUC 336 GAAGAAUUUGUAGCUUUAAUAAC 940 BD-10335 GCUACAAAUUCUUCACACC 337 GGUGUGAAGAAUUUGUAGCUU 941BD-10336 GCUACAAAUUCUUCACACCAN 338 NAGGUGUGAAGAAUUUGUAGCUU 942Table 3. Unmodified Sense and Antisense Strand Sequences of HFE2 siRNAs with Soft EndsUNMODIFIED with Soft endsSEQDuplex ID Sense (5 ’-3’) SEQ IDAntisense (5’-3 ’) ID NO NO BD-10337 GGCUGGAUAGGUAUGGGGA 339 UCCCCAUACCUAUCCAGCCAG 943 BD-10338 GGCUGGAUAGGUAUGGGGGAA 340 UUCCCCCAUACCUAUCCAGCCAG 944 BD-10339 UCAUUCUCAAUGCAAGAUA 341 UAUCUUGCAUUGAGAAUGAGC 945 BD-10340 UCAUUCUCAAUGCAAGAUCCA 342 UGGAUCUUGCAUUGAGAAUGAGC 946 BD-10341 AUUCUCAAUGCAAGAUCCA 343 UGGAUCUUGCAUUGAGAAUGA 947 BD-10342 AUUCUCAAUGCAAGAUCCUCA 344 UGAGGAUCUUGCAUUGAGAAUGA 948 BD-10343 UCAAUGCAAGAUCCUCCGA 345 UCGGAGGAUCUUGCAUUGAGA 949 BD-10344 UCAAUGCAAGAUCCUCCGCUA 346 UAGCGGAGGAUCUUGCAUUGAGA 950 BD-10345 CAAUGCAAGAUCCUCCGCA 347 UGCGGAGGAUCUUGCAUUGAG 951 BD-10346 CAAUGCAAGAUCCUCCGCUGA 348 UCAGCGGAGGAUCUUGCAUUGAG 952 BD-10347 AAUGCAAGAUCCUCCGCUA 349 UAGCGGAGGAUCUUGCAUUGA 953 BD-10012 AAUGCAAGAUCCUCCGCUGCA 12 UGCAGCGGAGGAUCUUGCAUUGA 618 BD-10013 UGCAAGAUCCUCCGCUGCA 13 UGCAGCGGAGGAUCUUGCAUU 619 BD-10348 UGCAAGAUCCUCCGCUGCAAA 350 UUUGCAGCGGAGGAUCUUGCAUU 954 BD-10349 CAAGAUCCUCCGCUGCAAA 351 UUUGCAGCGGAGGAUCUUGCA 955 BD-10350 CAAGAUCCUCCGCUGCAAUGA 352 UCAUUGCAGCGGAGGAUCUUGCA 956 BD-10351 AGAUCCUCCGCUGCAAUGA 353 UCAUUGCAGCGGAGGAUCUUG 957 BD-10352 AGAUCCUCCGCUGCAAUGCUA 354 UAGCAUUGCAGCGGAGGAUCUUG 958BD-10353 GAUCCUCCGCUGCAAUGCA 355 UGCAUUGCAGCGGAGGAUCUU 959 NAI-5008944785v1 Page 42 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO UNMODIFI ED with Soft endsSEQDuplex ID SEQ IDSense (5’-3‘) ID NO Antisense (5 ’-3’)NO BD-10020 GAUCCUCCGCUGCAAUGCUGA 20 UCAGCAUUGCAGCGGAGGAUCUU 626 BD-10354 AUCCUCCGCUGCAAUGCUA 356 UAGCAUUGCAGCGGAGGAUCU 960 BD-10355 AUCCUCCGCUGCAAUGCUGAA 357 UUCAGCAUUGCAGCGGAGGAUCU 961 BD-10023 UCCUCCGCUGCAAUGCUGA 23 UCAGCAUUGCAGCGGAGGAUC 629 BD-10356 UCCUCCGCUGCAAUGCUGAGA 358 UCUCAGCAUUGCAGCGGAGGAUC 962 BD-10357 CUCCGCUGCAAUGCUGAGA 359 UCUCAGCAUUGCAGCGGAGGA 963 BD-10358 CUCCGCUGCAAUGCUGAGUAA 360 UUACUCAGCAUUGCAGCGGAGGA 964 BD-10359 CCGCUGCAAUGCUGAGUAA 361 UUACUCAGCAUUGCAGCGGAG 965 BD-10360 CCGCUGCAAUGCUGAGUACGA 362 UCGUACUCAGCAUUGCAGCGGAG 966 BD-10361 CGUAUCGUCCACUCUGAGA 363 UCUCAGAGUGGACGAUACGUA 967 BD-10362 CGUAUCGUCCACUCUGAGCCA 364 UGGCUCAGAGUGGACGAUACGUA 968 BD-10363 CGUCCACUCUGAGCCUUAA 365 UUAAGGCUCAGAGUGGACGAU 969 BD-10364 CGUCCACUCUGAGCCUUAGAA 366 UUCUAAGGCUCAGAGUGGACGAU 970 BD- 10033 UUCAUCAGGAGCACUUCGA 33 UCGAAGUGCUCCUGAUGAACC 639 BD-10365 UUCAUCAGGAGCACUUCGAGA 367 UCUCGAAGUGCUCCUGAUGAACC 971 BD-10366 UCUGGCGGCCUCUGUCGAA 368 UUCGACAGAGGCCGCCAGAGC 972 BD-10367 UCUGGCGGCCUCUGUCGAGCA 369 UGCUCGACAGAGGCCGCCAGAGC 973 BD-10368 CUGGCGGCCUCUGUCGAGA 370 UCUCGACAGAGGCCGCCAGAG 974 BD-10369 CUGGCGGCCUCUGUCGAGCCA 371 UGGCUCGACAGAGGCCGCCAGAG 975 BD-10370 UGGCGGCCUCUGUCGAGCA 372 UGCUCGACAGAGGCCGCCAGA 976 BD-10371 UGGCGGCCUCUGUCGAGCCCA 373 UGGGCUCGACAGAGGCCGCCAGA 977 BD- 10372 CUCUGUCGAGCCCUCCGCA 374 UGCGGAGGGCUCGACAGAGGC 978 BD-10373 CUCUGUCGAGCCCUCCGCUCA 375 UGAGCGGAGGGCUCGACAGAGGC 979 BD-10374 CUGUCGAGCCCUCCGCUCA 376 UGAGCGGAGGGCUCGACAGAG 980 BD- 10044 CUGUCGAGCCCUCCGCUCCUA 44 UAGGAGCGGAGGGCUCGACAGAG 650 BD-10375 UGUCGAGCCCUCCGCUCCA 377 UGGAGCGGAGGGCUCGACAGA 981 BD-10376 UGUCGAGCCCUCCGCUCCUAA 378 UUAGGAGCGGAGGGCUCGACAGA 982 BD-10377 UCGAGCCCUCCGCUCCUAA 379 UUAGGAGCGGAGGGCUCGACA 983 BD-10378 UCGAGCCCUCCGCUCCUAUGA 380 UCAUAGGAGCGGAGGGCUCGACA 984 BD-10379 CGAGCCCUCCGCUCCUAUA 381 UAUAGGAGCGGAGGGCUCGAC 985 BD-10380 CGAGCCCUCCGCUCCUAUGCA 382 UGCAUAGGAGCGGAGGGCUCGAC 986 BD-10381 AGCCCUCCGCUCCUAUGCA 383 UGCAUAGGAGCGGAGGGCUCG 987 BD-10382 AGCCCUCCGCUCCUAUGCGCA 384 UGCGCAUAGGAGCGGAGGGCUCG 988 BD-10383 GCCCUCCGCUCCUAUGCGA 385 UCGCAUAGGAGCGGAGGGCUC 989 BD-10384 GCCCUCCGCUCCUAUGCGCUA 386 UAGCGCAUAGGAGCGGAGGGCUC 990 BD-10385 CCCUCCGCUCCUAUGCGCA 387 UGCGCAUAGGAGCGGAGGGCU 991 BD-10386 CCCUCCGCUCCUAUGCGCUCA 388 UGAGCGCAUAGGAGCGGAGGGCU 992 BD-10387 CCGCUCCUAUGCGCUCUGA 389 UCAGAGCGCAUAGGAGCGGAG 993 BD-10388 CCGCUCCUAUGCGCUCUGCAA 390 UUGCAGAGCGCAUAGGAGCGGAG 994 BD-10389 CUAUGCGCUCUGCACUCGA 391 UCGAGUGCAGAGCGCAUAGGA 995 BD-10390 CUAUGCGCUCUGCACUCGGCA 392 UGCCGAGUGCAGAGCGCAUAGGA 996 BD-10391 UAUGCGCUCUGCACUCGGA 393 UCCGAGUGCAGAGCGCAUAGG 997 BD-10392 UAUGCGCUCUGCACUCGGCGA 394 UCGCCGAGUGCAGAGCGCAUAGG 998 BD-10393 UGCGCUCUGCACUCGGCGA 395 UCGCCGAGUGCAGAGCGCAUA 999 BD-10394 UGCGCUCUGCACUCGGCGCAA 396 UUGCGCCGAGUGCAGAGCGCAUA 1000 BD-10395 CGCUCUGCACUCGGCGCAA 397 UUGCGCCGAGUGCAGAGCGCA 1001BD-10396 CGCUCUGCACUCGGCGCACCA 398 UGGUGCGCCGAGUGCAGAGCGCA 1002 NAI-5008944785v1 Page 43 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO UNMODIFI ED with Soft endsSEQDuplex ID SEQ IDSense (5’-3‘) ID NO Antisense (5 ’-3’)NO BD-10397 GCCCGCACCUGCCGCGGGA 399 UCCCGCGGCAGGUGCGGGCGG 1003 BD-10398 GCCCGCACCUGCCGCGGGGAA 400 UUCCCCGCGGCAGGUGCGGGCGG 1004 BD-10399 CACCUGCCGCGGGGACCUA 401 UAGGUCCCCGCGGCAGGUGCG 1005 BD-10400 CACCUGCCGCGGGGACCUCGA 402 UCGAGGUCCCCGCGGCAGGUGCG 1006 BD-10401 GGGACCUCGCCUUCCAUUA 403 UAAUGGAAGGCGAGGUCCCCG 1007 BD- 10402 GGGACCUCGCCUUCCAUUCGA 404 UCGAAUGGAAGGCGAGGUCCCCG 1008 BD-10403 GACCUCGCCUUCCAUUCGA 405 UCGAAUGGAAGGCGAGGUCCC 1009 BD-10404 GACCUCGCCUUCCAUUCGGCA 406 UGCCGAAUGGAAGGCGAGGUCCC 1010 BD-10405 ACCUCGCCUUCCAUUCGGA 407 UCCGAAUGGAAGGCGAGGUCC 1011 BD-10406 ACCUCGCCUUCCAUUCGGCGA 408 UCGCCGAAUGGAAGGCGAGGUCC 1012 BD-10407 CCUCGCCUUCCAUUCGGCA 409 UGCCGAAUGGAAGGCGAGGUC 1013 BD-10408 CCUCGCCUUCCAUUCGGCGGA 410 UCCGCCGAAUGGAAGGCGAGGUC 1014 BD-10409 CUCGCCUUCCAUUCGGCGA 411 UCGCCGAAUGGAAGGCGAGGU 1015 BD- 10080 CUCGCCUUCCAUUCGGCGGUA 80 UACCGCCGAAUGGAAGGCGAGGU 686 BD-10081 CGCCUUCCAUUCGGCGGUA 81 UACCGCCGAAUGGAAGGCGAG 687 BD-10082 CGCCUUCCAUUCGGCGGUACA 82 UGUACCGCCGAAUGGAAGGCGAG 688 BD-10410 GCCUUCCAUUCGGCGGUAA 412 UUACCGCCGAAUGGAAGGCGA 1016 BD-10411 GCCUUCCAUUCGGCGGUACAA 413 UUGUACCGCCGAAUGGAAGGCGA 1017 BD- 10085 CCUUCCAUUCGGCGGUACA 85 UGUACCGCCGAAUGGAAGGCG 691 BD-10412 CCUUCCAUUCGGCGGUACAUA 414 UAUGUACCGCCGAAUGGAAGGCG 1018 BD-10413 CUUCCAUUCGGCGGUACAA 415 UUGUACCGCCGAAUGGAAGGC 1019 BD-10414 CUUCCAUUCGGCGGUACAUGA 416 UCAUGUACCGCCGAAUGGAAGGC 1020 BD-10415 UUCCAUUCGGCGGUACAUA 417 UAUGUACCGCCGAAUGGAAGG 1021 BD-10416 UUCCAUUCGGCGGUACAUGGA 418 UCCAUGUACCGCCGAAUGGAAGG 1022 BD-10417 UCCAUUCGGCGGUACAUGA 419 UCAUGUACCGCCGAAUGGAAG 1023 BD-10092 UCCAUUCGGCGGUACAUGGCA 92 UGCCAUGUACCGCCGAAUGGAAG 698 BD-10418 CCAUUCGGCGGUACAUGGA 420 UCCAUGUACCGCCGAAUGGAA 1024 BD-10419 CCAUUCGGCGGUACAUGGCAA 421 UUGCCAUGUACCGCCGAAUGGAA 1025 BD-10095 CAUUCGGCGGUACAUGGCA 95 UGCCAUGUACCGCCGAAUGGA 701 BD-10420 CAUUCGGCGGUACAUGGCAUA 422 UAUGCCAUGUACCGCCGAAUGGA 1026 BD-10421 UUCGGCGGUACAUGGCAUA 423 UAUGCCAUGUACCGCCGAAUG 1027 BD-10098 UUCGGCGGUACAUGGCAUCGA 98 UCGAUGCCAUGUACCGCCGAAUG 704 BD-10422 UCGGCGGUACAUGGCAUCA 424 UGAUGCCAUGUACCGCCGAAU 1028 BD-10100 UCGGCGGUACAUGGCAUCGAA 100 UUCGAUGCCAUGUACCGCCGAAU 706 BD-10101 CGGCGGUACAUGGCAUCGA 101 UCGAUGCCAUGUACCGCCGAA 707 BD-10423 CGGCGGUACAUGGCAUCGAAA 425 UUUCGAUGCCAUGUACCGCCGAA 1029 BD-10103 GGCGGUACAUGGCAUCGAA 103 UUCGAUGCCAUGUACCGCCGA 709 BD-10104 GGCGGUACAUGGCAUCGAAGA 104 UCUUCGAUGCCAUGUACCGCCGA 710 BD-10424 GCGGUACAUGGCAUCGAAA 426 UUUCGAUGCCAUGUACCGCCG 1030 BD-10425 GCGGUACAUGGCAUCGAAGAA 427 UUCUUCGAUGCCAUGUACCGCCG 1031 BD-10107 CGGUACAUGGCAUCGAAGA 107 UCUUCGAUGCCAUGUACCGCC 713 BD-10426 CGGUACAUGGCAUCGAAGACA 428 UGUCUUCGAUGCCAUGUACCGCC 1032 BD-10427 GGUACAUGGCAUCGAAGAA 429 UUCUUCGAUGCCAUGUACCGC 1033 BD-10428 GGUACAUGGCAUCGAAGACCA 430 UGGUCUUCGAUGCCAUGUACCGC 1034 BD-10429 AUCGAAGACCUGAUGAUCA 431 UGAUCAUCAGGUCUUCGAUGC 1035 BD-10430 AUCGAAGACCUGAUGAUCCAA 432 UUGGAUCAUCAGGUCUUCGAUGC 1036BD-10431 CUGAUGAUCCAGCACAACA 433 UGUUGUGCUGGAUCAUCAGGU 1037 NAI-5008944785v1 Page 44 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO UNMODIFI ED with Soft endsSEQDuplex ID Sense (5’-3‘) SEQ IDA ID NO ntisense (5 ’-3’)NO BD-10432 CUGAUGAUCCAGCACAACUGA 434 UCAGUUGUGCUGGAUCAUCAGGU 1038 BD-10433 UGAUGAUCCAGCACAACUA 435 UAGUUGUGCUGGAUCAUCAGG 1039 BD-10434 UGAUGAUCCAGCACAACUGCA 436 UGCAGUUGUGCUGGAUCAUCAGG 1040 BD-10435 GCCCCGGACCCUUGUGACA 437 UGUCACAAGGGUCCGGGGCAG 1041 BD-10436 GCCCCGGACCCUUGUGACUAA 438 UUAGUCACAAGGGUCCGGGGCAG 1042 BD-10119 CCCCGGACCCUUGUGACUA 119 UAGUCACAAGGGUCCGGGGCA 725 BD-10437 CCCCGGACCCUUGUGACUAUA 439 UAUAGUCACAAGGGUCCGGGGCA 1043 BD-10438 CCCGGACCCUUGUGACUAA 440 UUAGUCACAAGGGUCCGGGGC 1044 BD-10122 CCCGGACCCUUGUGACUAUGA 122 UCAUAGUCACAAGGGUCCGGGGC 728 BD-10439 GUGACUAUGAAGGCCGGUA 441 UACCGGCCUUCAUAGUCACAA 1045 BD-10440 GUGACUAUGAAGGCCGGUUUA 442 UAAACCGGCCUUCAUAGUCACAA 1046 BD-10441 UGACUAUGAAGGCCGGUUA 443 UAACCGGCCUUCAUAGUCACA 1047 BD-10442 UGACUAUGAAGGCCGGUUUUA 444 UAAAACCGGCCUUCAUAGUCACA 1048 BD- 10443 ACUAUGAAGGCCGGUUUUA 445 UAAAACCGGCCUUCAUAGUCA 1049 BD-10444 ACUAUGAAGGCCGGUUUUCCA 446 UGGAAAACCGGCCUUCAUAGUCA 1050 BD-10445 U AU G AAGGCCGGU U U U CCA 447 UGGAAAACCGGCCUUCAUAGU 1051 BD- 10446 UAUGAAGGCCGGUUUUCCCGA 448 UCGGGAAAACCGGCCUUCAUAGU 1052 BD-10447 UGAAGGCCGGUUUUCCCGA 449 UCGGGAAAACCGGCCUUCAUA 1053 BD-10448 UGAAGGCCGGUUUUCCCGGCA 450 UGCCGGGAAAACCGGCCUUCAUA 1054 BD-10449 GAAGGCCGGUUUUCCCGGA 451 UCCGGGAAAACCGGCCUUCAU 1055 BD-10450 GAAGGCCGGUUUUCCCGGCUA 452 UAGCCGGGAAAACCGGCCUUCAU 1056 BD- 10451 AAGGCCGGUUUUCCCGGCA 453 UGCCGGGAAAACCGGCCUUCA 1057 BD-10452 AAGGCCGGUUUUCCCGGCUGA 454 UCAGCCGGGAAAACCGGCCUUCA 1058 BD-10453 CGGUUUUCCCGGCUGCAUA 455 UAUGCAGCCGGGAAAACCGGC 1059 BD- 10454 CGGUUUUCCCGGCUGCAUGGA 456 UCCAUGCAGCCGGGAAAACCGGC 1060 BD-10455 GGUUUUCCCGGCUGCAUGA 457 UCAUGCAGCCGGGAAAACCGG 1061 BD-10456 GGUUUUCCCGGCUGCAUGGUA 458 UACCAUGCAGCCGGGAAAACCGG 1062 BD-10457 UUCCCGGCUGCAUGGUCGA 459 UCGACCAUGCAGCCGGGAAAA 1063 BD-10458 UUCCCGGCUGCAUGGUCGUCA 460 UGACGACCAUGCAGCCGGGAAAA 1064 BD-10459 UCCCGGCUGCAUGGUCGUA 461 UACGACCAUGCAGCCGGGAAA 1065 BD-10460 UCCCGGCUGCAUGGUCGUCCA 462 UGGACGACCAUGCAGCCGGGAAA 1066 BD-10461 CCCGGCUGCAUGGUCGUCA 463 UGACGACCAUGCAGCCGGGAA 1067 BD- 10462 CCCGGCUGCAUGGUCGUCCCA 464 UGGGACGACCAUGCAGCCGGGAA 1068 BD-10463 CCGGCUGCAUGGUCGUCCA 465 UGGACGACCAUGCAGCCGGGA 1069 BD-10464 CCGGCUGCAUGGUCGUCCCCA 466 UGGGGACGACCAUGCAGCCGGGA 1070 BD-10465 GGCUGCAUGGUCGUCCCCA 467 UGGGGACGACCAUGCAGCCGG 1071 BD-10466 GGCUGCAUGGUCGUCCCCCGA 468 UCGGGGGACGACCAUGCAGCCGG 1072 BD-10467 CCGGGGUUCUUGCAUUGCA 469 UGCAAUGCAAGAACCCCGGGG 1073 BD-10468 CCGGGGUUCUUGCAUUGCGCA 470 UGCGCAAUGCAAGAACCCCGGGG 1074 BD-10469 GUUCUUGCAUUGCGCUUCA 471 UGAAGCGCAAUGCAAGAACCC 1075 BD- 10470 GUUCUUGCAUUGCGCUUCCUA 472 UAGGAAGCGCAAUGCAAGAACCC 1076 BD-10471 UCUUGCAUUGCGCUUCCUA 473 UAGGAAGCGCAAUGCAAGAAC 1077 BD-10472 UCUUGCAUUGCGCUUCCUUCA 474 UGAAGGAAGCGCAAUGCAAGAAC 1078 BD-10473 CUUGCAUUGCGCUUCCUUA 475 UAAGGAAGCGCAAUGCAAGAA 1079 BD-10474 CUUGCAUUGCGCUUCCUUCGA 476 UCGAAGGAAGCGCAAUGCAAGAA 1080 BD- 10475 UGCAUUGCGCUUCCUUCGA 477 UCGAAGGAAGCGCAAUGCAAG 1081BD-10476 UGCAUUGCGCUUCCUUCGGGA 478 UCCCGAAGGAAGCGCAAUGCAAG 1082 NAI-5008944785v1 Page 45 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO UNMODIFI ED with Soft endsSEQDuplex ID Sense (5’-3‘) SEQ IDA ID NO ntisense (5 ’-3’)NO BD- 10477 CAUUGCGCUUCCUUCGGGA 479 UCCCGAAGGAAGCGCAAUGCA 1083 BD-10478 CAUUGCGCUUCCUUCGGGGAA 480 UUCCCCGAAGGAAGCGCAAUGCA 1084 BD-10163 AUUGCGCUUCCUUCGGGGA 163 UCCCCGAAGGAAGCGCAAUGC 769 BD-10479 AUUGCGCUUCCUUCGGGGACA 481 UGUCCCCGAAGGAAGCGCAAUGC 1085 BD-10480 CGCUUCCUUCGGGGACCCA 482 UGGGUCCCCGAAGGAAGCGCA 1086 BD-10166 CGCUUCCUUCGGGGACCCCCA 166 UGGGGGUCCCCGAAGGAAGCGCA 772 BD-10481 AUCACUUUCACACAUGCCA 483 UGGCAUGUGUGAAAGUGAUGG 1087 BD-10482 AUCACUUUCACACAUGCCGUA 484 UACGGCAUGUGUGAAAGUGAUGG 1088 BD-10169 UCACACAUGCCGUGUCCAA 169 UUGGACACGGCAUGUGUGAAA 775 BD-10483 UCACACAUGCCGUGUCCAAGA 485 UCUUGGACACGGCAUGUGUGAAA 1089 BD-10484 GUGUCCAAGGAGCUUGGCA 486 UGCCAAGCUCCUUGGACACGG 1090 BD-10485 GUGUCCAAGGAGCUUGGCCUA 487 UAGGCCAAGCUCCUUGGACACGG 1091 BD-10486 UGUCCAAGCCACCAGCUCA 488 UGAGCUGGUGGCUUGGACAAA 1092 BD- 10487 UGUCCAAGCCACCAGCUCCCA 489 UGGGAGCUGGUGGCUUGGACAAA 1093 BD-10488 CACCCGGAAGCUCACCAUA 490 UAUGGUGAGCUUCCGGGUGGC 1094 BD-10489 CACCCGGAAGCUCACCAUCAA 491 UUGAUGGUGAGCUUCCGGGUGGC 1095 BD-10177 AAGCUCACCAUCAUAUUUA 177 UAAAUAUGAUGGUGAGCUUCC 783 BD-10490 AAGCUCACCAUCAUAUUUAAA 492 UUUAAAUAUGAUGGUGAGCUUCC 1096 BD-10179 ACAUGCAGGAAUGCAUUGA 179 UCAAUGCAUUCCUGCAUGUUC 785 BD-10491 ACAUGCAGGAAUGCAUUGAUA 493 UAUCAAUGCAUUCCUGCAUGUUC 1097 BD-10492 CAUGCAGGAAUGCAUUGAA 494 UUCAAUGCAUUCCUGCAUGUU 1098 BD-10182 CAUGCAGGAAUGCAUUGAUCA 182 UGAUCAAUGCAUUCCUGCAUGUU 788 BD-10183 AUCAGGCUGAGGUGGAUAA 183 UUAUCCACCUCAGCCUGAUAC 789 BD-10493 AUCAGGCUGAGGUGGAUAAUA 495 UAUUAUCCACCUCAGCCUGAUAC 1099 BD-10494 GGCUGAGGUGGAUAAUCUA 496 UAGAUUAUCCACCUCAGCCUG 1100 BD-10495 GGCUGAGGUGGAUAAUCUUCA 497 UGAAGAUUAUCCACCUCAGCCUG 1101 BD-10496 GCUGAGGUGGAUAAUCUUA 498 UAAGAUUAUCCACCUCAGCCU 1102 BD-10497 GCUGAGGUGGAUAAUCUUCCA 499 UGGAAGAUUAUCCACCUCAGCCU 1103 BD-10498 AUCAAUGGAGGUGACCGAA 500 UUCGGUCACCUCCAUUGAUAG 1104 BD-10499 AUCAAUGGAGGUGACCGACCA 501 UGGUCGGUCACCUCCAUUGAUAG 1105 BD-10500 UCAAUGGAGGUGACCGACA 502 UGUCGGUCACCUCCAUUGAUA 1106 BD-10501 UCAAUGGAGGUGACCGACCUA 503 UAGGUCGGUCACCUCCAUUGAUA 1107 BD-10502 CAAUGGAGGUGACCGACCA 504 UGGUCGGUCACCUCCAUUGAU 1108 BD-10503 CAAUGGAGGUGACCGACCUGA 505 UCAGGUCGGUCACCUCCAUUGAU 1109 BD- 10504 GGAGGUGACCGACCUGGGA 506 UCCCAGGUCGGUCACCUCCAU 1110 BD-10196 GGAGGUGACCGACCUGGGGGA 196 UCCCCCAGGUCGGUCACCUCCAU 802 BD-10505 GAGGUGACCGACCUGGGGA 507 UCCCCAGGUCGGUCACCUCCA 1111 BD- 10506 GAGGUGACCGACCUGGGGGAA 508 UUCCCCCAGGUCGGUCACCUCCA 1112 BD-10507 GGAUCCAGUUUGUCGAUUA 509 UAAUCGACAAACUGGAUCCCC 1113 BD-10200 GGAUCCAGUUUGUCGAUUCAA 200 UUGAAUCGACAAACUGGAUCCCC 806 BD- 10201 UCCAGUUUGUCGAUUCAAA 201 UUUGAAUCGACAAACUGGAUC 807 BD-10508 UCCAGUUUGUCGAUUCAAACA 510 UGUUUGAAUCGACAAACUGGAUC 1114 BD- 10509 CAGUUUGUCGAUUCAAACA 511 UGUUUGAAUCGACAAACUGGA 1115 BD-10510 CAGUUUGUCGAUUCAAACUGA 512 UCAGUUUGAAUCGACAAACUGGA 1116 BD-10511 AGUUUGUCGAUUCAAACUA 513 UAGUUUGAAUCGACAAACUGG 1117 BD-10512 AGUUUGUCGAUUCAAACUGCA 514 UGCAGUUUGAAUCGACAAACUGG 1118BD-10513 UUUGUCGAUUCAAACUGCA 515 UGCAGUUUGAAUCGACAAACU 1119 NAI-5008944785v1 Page 46 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO UNMODIFI ED with Soft endsSEQDuplex ID Sense (5’-3‘) SEQ IDA ID NO ntisense (5 ’-3’)NO BD-10208 UUUGUCGAUUCAAACUGCUAA 208 UUAGCAGUUUGAAUCGACAAACU 814 BD-10209 UUGUCGAUUCAAACUGCUA 209 UAGCAGUUUGAAUCGACAAAC 815 BD-10514 UUGUCGAUUCAAACUGCUAAA 516 UUUAGCAGUUUGAAUCGACAAAC 1120 BD-10211 UGUCGAUUCAAACUGCUAA 211 UUAGCAGUUUGAAUCGACAAA 817 BD-10515 UGUCGAUUCAAACUGCUAACA 517 UGUUAGCAGUUUGAAUCGACAAA 1121 BD-10516 GUCGAUUCAAACUGCUAAA 518 UUUAGCAGUUUGAAUCGACAA 1122 BD-10517 GUCGAUUCAAACUGCUAACCA 519 UGGUUAGCAGUUUGAAUCGACAA 1123 BD-10518 UCGAUUCAAACUGCUAACA 520 UGUUAGCAGUUUGAAUCGACA 1124 BD-10519 UCGAUUCAAACUGCUAACCCA 521 UGGGUUAGCAGUUUGAAUCGACA 1125 BD-10520 GAUUCAAACUGCUAACCCA 522 UGGGUUAGCAGUUUGAAUCGA 1126 BD- 10521 GAUUCAAACUGCUAACCCUGA 523 UCAGGGUUAGCAGUUUGAAUCGA 1127 BD-10522 AACUGCUAACCCUGGGAAA 524 UUUCCCAGGGUUAGCAGUUUG 1128 BD-10220 AACUGCUAACCCUGGGAACCA 220 UGGUUCCCAGGGUUAGCAGUUUG 826 BD- 10221 CUGCUAACCCUGGGAACCA 221 UGGUUCCCAGGGUUAGCAGUU 827 BD-10523 CUGCUAACCCUGGGAACCAUA 525 UAUGGUUCCCAGGGUUAGCAGUU 1129 BD-10524 AUCCAAGCUGCCUACAUUA 526 UAAUGUAGGCAGCUUGGAUCU 1130 BD-10525 AUCCAAGCUGCCUACAUUGGA 527 UCCAAUGUAGGCAGCUUGGAUCU 1131 BD-10526 CCAAGCUGCCUACAUUGGA 528 UCCAAUGUAGGCAGCUUGGAU 1132 BD- 10527 CCAAGCUGCCUACAUUGGCAA 529 UUGCCAAUGUAGGCAGCUUGGAU 1133 BD-10227 CAAGCUGCCUACAUUGGCA 227 UGCCAAUGUAGGCAGCUUGGA 833 BD-10228 CAAGCUGCCUACAUUGGCACA 228 UGUGCCAAUGUAGGCAGCUUGGA 834 BD- 10528 UGCCUACAUUGGCACAACA 530 UGUUGUGCCAAUGUAGGCAGC 1134 BD-10529 UGCCUACAUUGGCACAACUAA 531 UUAGUUGUGCCAAUGUAGGCAGC 1135 BD-10530 CCUACAUUGGCACAACUAA 532 UUAGUUGUGCCAAUGUAGGCA 1136 BD-10232 CCUACAUUGGCACAACUAUAA 232 UUAUAGUUGUGCCAAUGUAGGCA 838 BD-10531 UUGGCACAACUAUAAUCAA 533 UUGAUUAUAGUUGUGCCAAUG 1137 BD-10532 UUGGCACAACUAUAAUCAUUA 534 UAAUGAUUAUAGUUGUGCCAAUG 1138 BD-10533 UGGCACAACUAUAAUCAUA 535 UAUGAUUAUAGUUGUGCCAAU 1139 BD-10534 UGGCACAACUAUAAUCAUUCA 536 UGAAUGAUUAUAGUUGUGCCAAU 1140 BD-10535 ACAACUAUAAUCAUUCGGA 537 UCCGAAUGAUUAUAGUUGUGC 1141 BD-10536 ACAACUAUAAUCAUUCGGCAA 538 UUGCCGAAUGAUUAUAGUUGUGC 1142 BD-10239 CAACUAUAAUCAUUCGGCA 239 UGCCGAAUGAUUAUAGUUGUG 845 BD- 10240 CAACUAUAAUCAUUCGGCAGA 241 UCUGCCGAAUGAUUAUAGUUGUG 846 BD-10537 AACUAUAAUCAUUCGGCAA 539 UUGCCGAAUGAUUAUAGUUGU 1143 BD-10538 AACUAUAAUCAUUCGGCAGAA 540 UUCUGCCGAAUGAUUAUAGUUGU 1144 BD-10539 AUAAUCAUUCGGCAGACAA 541 UUGUCUGCCGAAUGAUUAUAG 1145 BD-10540 AUAAUCAUUCGGCAGACAGCA 542 UGCUGUCUGCCGAAUGAUUAUAG 1146 BD- 10541 CAUUCGGCAGACAGCUGGA 543 UCCAGCUGUCUGCCGAAUGAU 1147 BD-10246 CAUUCGGCAGACAGCUGGGCA 246 UGCCCAGCUGUCUGCCGAAUGAU 852 BD-10247 CUUCUCCAUCAAGGUAGCA 247 UGCUACCUUGAUGGAGAAGGA 853 BD-10248 CUUCUCCAUCAAGGUAGCAGA 248 UCUGCUACCUUGAUGGAGAAGGA 854 BD-10542 AUCAAGGUAGCAGAGGAUA 544 UAUCCUCUGCUACCUUGAUGG 1148 BD- 10543 AUCAAGGUAGCAGAGGAUGUA 545 UACAUCCUCUGCUACCUUGAUGG 1149 BD-10544 GCCCUCCAAGUCAGCGACA 546 UGUCGCUGACUUGGAGGGCAC 1150 BD-10545 GCCCUCCAAGUCAGCGACUCA 547 UGAGUCGCUGACUUGGAGGGCAC 1151 BD-10253 AAGUCAGCGACUCUCUCGA 253 UCGAGAGAGUCGCUGACUUGG 859BD-10546 AAGUCAGCGACUCUCUCGAUA 548 UAUCGAGAGAGUCGCUGACUUGG 1152 NAI-5008944785v1 Page 47 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO UNMODIFI ED with Soft endsSEQDuplex ID Sense (5’-3‘) SEQ ID ID NO Antisense (5 ’-3’)NO BD-10547 AGUCAGCGACUCUCUCGAA 549 UUCGAGAGAGUCGCUGACUUG 1153 BD-10256 AGUCAGCGACUCUCUCGAUCA 256 UGAUCGAGAGAGUCGCUGACUUG 862 BD- 10548 GACUCUCUCGAUCAGAGCA 550 UGCUCUGAUCGAGAGAGUCGC 1154 BD-10258 GACUCUCUCGAUCAGAGCGCA 258 UGCGCUCUGAUCGAGAGAGUCGC 864 BD-10549 ACUCUCUCGAUCAGAGCGA 551 UCGCUCUGAUCGAGAGAGUCG 1155 BD-10260 ACUCUCUCGAUCAGAGCGCAA 260 UUGCGCUCUGAUCGAGAGAGUCG 866 BD-10261 CUCUCUCGAUCAGAGCGCA 261 UGCGCUCUGAUCGAGAGAGUC 867 BD-10550 CUCUCUCGAUCAGAGCGCAAA 552 UUUGCGCUCUGAUCGAGAGAGUC 1156 BD-10551 AUCGUCGGGGAGCUAUAAA 553 UUUAUAGCUCCCCGACGAUUG 1157 BD-10264 AUCGUCGGGGAGCUAUAACCA 264 UGGUUAUAGCUCCCCGACGAUUG 870 BD-10552 UCGUCGGGGAGCUAUAACA 554 UGUUAUAGCUCCCCGACGAUU 1158 BD-10553 UCGUCGGGGAGCUAUAACCAA 555 UUGGUUAUAGCUCCCCGACGAUU 1159 BD-10267 CGUCGGGGAGCUAUAACCA 267 UGGUUAUAGCUCCCCGACGAU 873 BD- 10554 CGUCGGGGAGCUAUAACCAUA 556 UAUGGUUAUAGCUCCCCGACGAU 1160 BD-10555 CGGGGAGCUAUAACCAUUA 557 UAAUGGUUAUAGCUCCCCGAC 1161 BD-10556 CGGGGAGCUAUAACCAUUGAA 558 UUCAAUGGUUAUAGCUCCCCGAC 1162 BD- 10271 GGGGAGCUAUAACCAUUGA 273 UCAAUGGUUAUAGCUCCCCGA 877 BD-10272 GGGGAGCUAUAACCAUUGAUA 274 UAUCAAUGGUUAUAGCUCCCCGA 878 BD-10557 GGGAGCUAUAACCAUUGAA 559 UUCAAUGGUUAUAGCUCCCCG 1163 BD-10558 GGGAGCUAUAACCAUUGAUAA 560 UUAUCAAUGGUUAUAGCUCCCCG 1164 BD-10275 GGAGCUAUAACCAUUGAUA 277 UAUCAAUGGUUAUAGCUCCCC 881 BD-10559 GGAGCUAUAACCAUUGAUACA 561 UGUAUCAAUGGUUAUAGCUCCCC 1165 BD-10560 AGCUAUAACCAUUGAUACA 562 UGUAUCAAUGGUUAUAGCUCC 1166 BD-10561 AGCUAUAACCAUUGAUACUGA 563 UCAGUAUCAAUGGUUAUAGCUCC 1167 BD-10562 CUAUAACCAUUGAUACUGA 564 UCAGUAUCAAUGGUUAUAGCU 1168 BD-10280 CUAUAACCAUUGAUACUGCCA 282 UGGCAGUAUCAAUGGUUAUAGCU 886 BD- 10563 UAUAACCAUUGAUACUGCA 565 UGCAGUAUCAAUGGUUAUAGC 1169 BD-10564 UAUAACCAUUGAUACUGCCAA 566 UUGGCAGUAUCAAUGGUUAUAGC 1170 BD-10565 CCAUUGAUACUGCCAGACA 567 UGUCUGGCAGUAUCAAUGGUU 1171 BD- 10566 CCAUUGAUACUGCCAGACGGA 568 UCCGUCUGGCAGUAUCAAUGGUU 1172 BD-10567 CAUUGAUACUGCCAGACGA 569 UCGUCUGGCAGUAUCAAUGGU 1173 BD-10568 CAUUGAUACUGCCAGACGGCA 570 UGCCGUCUGGCAGUAUCAAUGGU 1174 BD-10569 UUGAUACUGCCAGACGGCA 571 UGCCGUCUGGCAGUAUCAAUG 1175 BD-10570 UUGAUACUGCCAGACGGCUGA 572 UCAGCCGUCUGGCAGUAUCAAUG 1176 BD-10571 GAUACUGCCAGACGGCUGA 573 UCAGCCGUCUGGCAGUAUCAA 1177 BD-10572 GAUACUGCCAGACGGCUGUGA 574 UCACAGCCGUCUGGCAGUAUCAA 1178 BD-10573 UCCUGUGUCUUUGAUGUUA 575 UAACAUCAAAGACACAGGAAU 1179 BD-10292 UCCUGUGUCUUUGAUGUUUUA 294 UAAAACAUCAAAGACACAGGAAU 898 BD-10574 UUUAAUUUCUGGUGAUCCA 576 UGGAUCACCAGAAAUUAAAAC 1180 BD-10294 UUUAAUUUCUGGUGAUCCCAA 296 UUGGGAUCACCAGAAAUUAAAAC 900 BD-10295 AUUACUAGUUUGGAAAUGA 297 UCAUUUCCAAACUAGUAAUGG 901 BD-10575 AUUACUAGUUUGGAAAUGAUA 577 UAUCAUUUCCAAACUAGUAAUGG 1181 BD- 10576 AGAUUGGCAUAGAAGAAUA 578 UAUUCUUCUAUGCCAAUCUGU 1182 BD-10298 AGAUUGGCAUAGAAGAAUGUA 300 UACAUUCUUCUAUGCCAAUCUGU 904 BD-10299 AGAAUAAGGAUUCUGGGCA 301 UGCCCAGAAUCCUUAUUCUGU 905 BD- 10577 AGAAUAAGGAUUCUGGGCAAA 579 UUUGCCCAGAAUCCUUAUUCUGU 1183BD-10578 AGGUCAUGAAGGUUUUAAA 580 UUUAAAACCUUCAUGACCUCU 1184 NAI-5008944785v1 Page 48 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO UNMODIFI ED with Soft endsSEQ SEQ IDDuplex ID Sense (5’-3‘) Antisense (5 ’-3’) ID NO NO BD-10302 AGGUCAUGAAGGUUUUAAUGA 304 UCAUUAAAACCUUCAUGACCUCU 908 BD-10303 UUAAGAGGCAAGAGCUGAA 305 UUCAGCUCUUGCCUCUUAAAA 909 BD-10579 UUAAGAGGCAAGAGCUGAAAA 581 UUUUCAGCUCUUGCCUCUUAAAA 1185 BD-10305 UGAUCAUUAGCCAUAAGAA 307 UUCUUAUGGCUAAUGAUCAUG 911 BD-10580 UGAUCAUUAGCCAUAAGAAAA 582 UUUUCUUAUGGCUAAUGAUCAUG 1186 BD- 10581 UUAGGGAAAGAAGUCUAUA 583 UAUAGACUUCUUUCCCUAAUU 1187 BD-10582 UUAGGGAAAGAAGUCUAUUUA 584 UAAAUAGACUUCUUUCCCUAAUU 1188 BD-10583 UAGGGAAAGAAGUCUAUUA 585 UAAUAGACUUCUUUCCCUAAU 1189 BD-10310 UAGGGAAAGAAGUCUAUUUGA 312 UCAAAUAGACUUCUUUCCCUAAU 916 BD-10311 AAAGAAGUCUAUUUGAUGA 313 UCAUCAAAUAGACUUCUUUCC 917 BD- 10584 AAAGAAGUCUAUUUGAUGAAA 586 UUUCAUCAAAUAGACUUCUUUCC 1190 BD-10313 AAGAAGUCUAUUUGAUGAA 315 UUCAUCAAAUAGACUUCUUUC 919 BD-10314 AAGAAGUCUAUUUGAUGAAUA 316 UAUUCAUCAAAUAGACUUCUUUC 920 BD- 10585 CUCUUAGGUGAAGGGAGUA 587 UACUCCCUUCACCUAAGAGCU 1191 BD-10586 CUCUUAGGUGAAGGGAGUCUA 588 UAGACUCCCUUCACCUAAGAGCU 1192 BD-10587 GUGAAGGGAGUCUCUGCUA 589 UAGCAGAGACUCCCUUCACCU 1193 BD-10588 GUGAAGGGAGUCUCUGCUUUA 590 UAAAGCAGAGACUCCCUUCACCU 1194 BD-10589 UGAAGGGAGUCUCUGCUUA 591 UAAGCAGAGACUCCCUUCACC 1195 BD- 10590 UGAAGGGAGUCUCUGCUUUUA 592 UAAAAGCAGAGACUCCCUUCACC 1196 BD-10321 AGGUAGGACAGAAGUAUCA 323 UGAUACUUCUGUCCUACCUGU 927 BD-10591 AGGUAGGACAGAAGUAUCAUA 593 UAUGAUACUUCUGUCCUACCUGU 1197 BD- 10592 GGUAGGACAGAAGUAUCAA 594 UUGAUACUUCUGUCCUACCUG 1198 BD-10593 GGUAGGACAGAAGUAUCAUCA 595 UGAUGAUACUUCUGUCCUACCUG 1199 BD-10594 GUAGGACAGAAGUAUCAUA 596 UAUGAUACUUCUGUCCUACCU 1200 BD-10595 GUAGGACAGAAGUAUCAUCCA 597 UGGAUGAUACUUCUGUCCUACCU 1201 BD-10596 AGGACAGAAGUAUCAUCCA 598 UGGAUGAUACUUCUGUCCUAC 1202 BD-10328 AGGACAGAAGUAUCAUCCCUA 330 UAGGGAUGAUACUUCUGUCCUAC 934 BD-10597 GGACAGAAGUAUCAUCCCA 599 UGGGAUGAUACUUCUGUCCUA 1203 BD-10598 GGACAGAAGUAUCAUCCCUAA 600 UUAGGGAUGAUACUUCUGUCCUA 1204 BD-10599 AGAAGUAUCAUCCCUACCA 601 UGGUAGGGAUGAUACUUCUGU 1205 BD-10600 AGAAGUAUCAUCCCUACCCCA 602 UGGGGUAGGGAUGAUACUUCUGU 1206 BD-10601 UAUUAAAGCUACAAAUUCA 603 UGAAUUUGUAGCUUUAAUAAC 1207 BD- 10602 UAUUAAAGCUACAAAUUCUUA 604 UAAGAAUUUGUAGCUUUAAUAAC 1208 BD-10603 GCUACAAAUUCUUCACACA 605 UGUGUGAAGAAUUUGUAGCUU 1209BD-10604 GCUACAAAUUCUUCACACCAA 606 UAGGUGUGAAGAAUUUGUAGCUU 1210Table 4. Modified Sense and Antisense Strand Sequences of HFE2 siRNAsDuplex ID Sense (5 ’-3’) Antisense (5 ’-3’)BD-10628 uscsauUfcUfCfAfaugcaagaua(L96) (vinu)sAfsucuUfgCfAfuugaGfaAfugasgsc BD-10640 asusucUfcAfAfUfgcaagaucca(L96) (vinu)sGfsgauCfuUfGfcauuGfaGfaausgsa BD-10649 uscsaaugCfaAfGfAfuccuCfCfgcua(L96) (vinu)sAfsgcgGfaGfGfaucuUfgCfauugasgsa BD-10652 uscsaaUfgCfAfAfgauccuccga(L96) (vinu)sCfsggaGfgAfUfcuugCfaUfugasgsa BD-10664 csasauGfcAfAfGfauccuccgca(L96) (vinu)sGfscggAfgGfAfucuuGfcAfuugsasg BD-10673 gsgscuGfgAfUfAfgguaUfggGfga(L96) (vinu)sCfscccAfuaccuauCfcAfgccsasgBD-10674 gsgscuGfgAfUfAfgguaUfggGfga(L96) (vinu)sCfscccAfuAfCfcuauCfcAfgccsasg NAI-5008944785v1 Page 49 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-10675 gsgscuGfgAfUfAfgguaUfGfggga(L96) (vinu)sCfscccAfuaccuauCfcAfgccsasgBD-10676 gsgscuGfgAfUfAfgguaUfGfggga(L96) (vinu)sCfscccAfuAfCfcuauCfcAfgccsasg BD-10677 gsgscuGfgAfUfAfgguaugggga(L96) (vinu)sCfscccAfuaccuauCfcAfgccsasgBD-10678 gsgscuggAfuAfGfGfuaugGfggGfaa(L96) (vinu)sUfscccCfcauaccuAfuCfcagccsasg BD-10679 gsgscuggAfuAfGfGfuaugGfggGfaa(L96) (vinu)sUfscccCfcAfUfaccuAfuCfcagccsasg BD-10680 gsgscuggAfuAfGfGfuaugGfGfggaa(L96) (vinu)sUfscccCfcauaccuAfuCfcagccsasg BD-10681 gsgscuggAfuAfGfGfuaugGfGfggaa(L96) (vinu)sUfscccCfcAfUfaccuAfuCfcagccsasg BD-10682 gsgscuggAfuAfGfGfuaugggggaa(L96) (vinu)sUfscccCfcauaccuAfuCfcagccsasg BD-10683 gsgscuggAfuAfGfGfuaugggggaa(L96) (vinu)sUfscccCfcAfUfaccuAfuCfcagccsasg BD-10684 gsgscuGfgAfUfAfgguaugggga(L96) (vinu)sCfscccAfuAfCfcuauCfcAfgccsasg BD-10685 uscsauUfcUfCfAfaugcAfagAfua(L96) (vinu)sAfsucuUfgcauugaGfaAfugasgscBD-10686 uscsauUfcUfCfAfaugcAfagAfua(L96) (vinu)sAfsucuUfgCfAfuugaGfaAfugasgsc BD-10687 uscsauUfcUfCfAfaugcAfAfgaua(L96) (vinu)sAfsucuUfgcauugaGfaAfugasgscBD-10688 uscsauUfcUfCfAfaugcAfAfgaua(L96) (vinu)sAfsucuUfgCfAfuugaGfaAfugasgsc BD-10689 uscsauUfcUfCfAfaugcaagaua(L96) (vinu)sAfsucuUfgcauugaGfaAfngasgscBD-10690 uscsauucUfcAfAfUfgcaaGfauCfca(L96) (vinu)sGfsgauCfuugcauuGfaGfaaugasgsc BD-10691 uscsauucUfcAfAfUfgcaaGfauCfca(L96) (vinu)sGfsgauCfuUfGfcauuGfaGfaaugasgsc BD-10692 uscsauucUfcAfAfUfgcaaGfAfucca(L96) (vinu)sGfsgauCfuugcauuGfaGfaaugasgsc BD-10693 uscsauucUfcAfAfUfgcaaGfAfucca(L96) (vinu)sGfsgauCfuUfGfcauuGfaGfaaugasgsc BD-10694 uscsauucUfcAfAfUfgcaagaucca(L96) (vinu)sGfsgauCfuugcauuGfaGfaaugasgsc BD-10695 uscsauucUfcAfAfUfgcaagaucca(L96) (vinu)sGfsgauCfuUfGfcauuGfaGfaaugasgsc BD-10696 uscsauUfcUfCfAfaugcaagaua(L96) (vinu)sAfsucuUfgCfAfuugaGfaAfugasgsc BD-10697 asusucUfcAfAfUfgcaaGfauCfca(L96) (vinu)sGfsgauCfuugcauuGfaGfaausgsaBD-10698 asusucUfcAfAfUfgcaaGfauCfca(L96) (vinu)sGfsgauCfuUfGfcauuGfaGfaausgsa BD-10699 asusucUfcAfAfUfgcaaGfAfucca(L96) (vinu)sGfsgauCfuugcauuGfaGfaausgsaBD-10700 asusucUfcAfAfUfgcaaGfAfucca(L96) (vinu)sGfsgauCfuUfGfcauuGfaGfaausgsa BD-10701 asusucUfcAfAfUfgcaagaucca(L96) (vinu)sGfsgauCfuugcauuGfaGfaausgsaBD-10702 asusucucAfaUfGfCfaagaUfccUfca(L96) (vinu)sGfsaggAfucuugcaUfuGfagaausgsa BD-10703 asusucucAfaUfGfCfaagaUfccUfca(L96) (vinu)sGfsaggAfuCfUfugcaUfuGfagaausgsa BD-10704 asusucucAfaUfGfCfaagaUfCfcuca(L96) (vinu)sGfsaggAfucuugcaUfuGfagaausgsa BD-10705 asusucucAfaUfGfCfaagaUfCfcuca(L96) (vinu)sGfsaggAfuCfUfugcaUfuGfagaausgsa BD-10706 asusucucAfaUfGfCfaagauccuca(L96) (vinu)sGfsaggAfucuugcaUfuGfagaausgsa BD-10707 asusucucAfaUfGfCfaagauccuca(L96) (vinu)sGfsaggAfuCfUfugcaUfuGfagaausgsa BD-10708 asusucUfcAfAfUfgcaagaucca(L96) (vinu)sGfsgauCfuUfGfcauuGfaGfaausgsa BD-10709 uscsaaUfgCfAfAfgaucCfucCfga(L96) (vinu)sCfsggaGfgaucuugCfaUfugasgsaBD-10710 uscsaaUfgCfAfAfgaucCfucCfga(L96) (vinu)sCfsggaGfgAfUfcuugCfaUfugasgsa BD-10711 uscsaaUfgCfAfAfgaucCfUfccga(L96) (vinu)sCfsggaGfgaucuugCfaUfugasgsaBD-10712 uscsaaUfgCfAfAfgaucCfUfccga(L96) (vinu)sCfsggaGfgAfUfcuugCfaUfugasgsa BD-10713 uscsaaUfgCfAfAfgauccuccga(L96) (vinu)sCfsggaGfgaucuugCfaUfugasgsaBD-10714 uscsaaugCfaAfGfAfuccuCfcgCfua(L96) (vinu)sAfsgcgGfaggaucuUfgCfauugasgsa BD-10715 uscsaaugCfaAfGfAfuccuCfcgCfua(L96) (vinu)sAfsgcgGfaGfGfaucuUfgCfauugasgsa BD-10716 uscsaaugCfaAfGfAfuccuCfCfgcua(L96) (vinu)sAfsgcgGfaggaucuUfgCfauugasgsa BD-10717 uscsaaugCfaAfGfAfuccuCfCfgcua(L96) (vinu)sAfsgcgGfaGfGfaucuUfgCfauugasgsa BD-10718 uscsaaugCfaAfGfAfuccuccgcua(L96) (vinu)sAfsgcgGfaggaucuUfgCfauugasgsa BD-10719 uscsaaugCfaAfGfAfuccuccgcua(L96) (vinu)sAfsgcgGfaGfGfaucuUfgCfauugasgsa BD-10720 uscsaaUfgCfAfAfgauccuccga(L96) (vinu)sCfsggaGfgAfUfcuugCfaUfugasgsa BD-10721 csasauGfcAfAfGfauccUfccGfca(L96) (vinu)sGfscggAfggaucuuGfcAfuugsasgBD-10722 csasauGfcAfAfGfauccUfccGfca(L96) (vinu)sGfscggAfgGfAfucuuGfcAfuugsasg BD-10723 csasauGfcAfAfGfauccUfCfcgca(L96) (vinu)sGfscggAfggaucuuGfcAfuugsasgBD-10724 csasauGfcAfAfGfauccUfCfcgca(L96) (vinu)sGfscggAfgGfAfucuuGfcAfuugsasgBD-10725 csasauGfcAfAfGfauccuccgca(L96) (vinu)sGfscggAfggaucuuGfcAfuugsasgNAI-5008944785v1 Page 50 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-10726 csasaugcAfaGfAfUfccucCfgcUfga(L96) (vinu)sCfsagcGfgaggaucUfuGfcauugsasg BD-10727 csasaugcAfaGfAfUfccucCfgcUfga(L96) (vinu)sCfsagcGfgAfGfgaucUfuGfcauugsasg BD-10728 csasaugcAfaGfAfUfccucCfGfcuga(L96) (vinu)sCfsagcGfgaggaucUfuGfcauugsasg BD-10729 csasaugcAfaGfAfUfccucCfGfcuga(L96) (vinu)sCfsagcGfgAfGfgaucUfuGfcauugsasg BD-10730 csasaugcAfaGfAfUfccuccgcuga(L96) (vinu)sCfsagcGfgaggaucUfuGfcauugsasg BD-10731 csasaugcAfaGfAfUfccuccgcuga(L96) (vinu)sCfsagcGfgAfGfgaucUfuGfcauugsasg BD-10732 csasauGfcAfAfGfauccuccgca(L96) (vinu)sGfscggAfgGfAfucuuGfcAfuugsasg BD-10733 asasugCfaAfGfAfuccuCfcgCfua(L96) (vinu)sAfsgcgGfaggaucuUfgCfauusgsaBD-10734 asasugCfaAfGfAfuccuCfcgCfua(L96) (vinu)sAfsgcgGfaGfGfaucuUfgCfauusgsa BD-10735 asasugCfaAfGfAfuccuCfCfgcua(L96) (vinu)sAfsgcgGfaggaucuUfgCfauusgsaBD-10736 asasugCfaAfGfAfuccuCfCfgcua(L96) (vinu)sAfsgcgGfaGfGfaucuUfgCfauusgsa BD-10737 asasugCfaAfGfAfuccuccgcua(L96) (vinu)sAfsgcgGfaggaucuUfgCfauusgsaBD-10738 asasugcaAfgAfUfCfcuccGfcuGfca(L96) (vinu)sGfscagCfggaggauCfuUfgcauusgsa BD-10739 asasugcaAfgAfUfCfcuccGfcuGfca(L96) (vinu)sGfscagCfgGfAfggauCfuUfgcauusgsa BD-10740 asasugcaAfgAfUfCfcuccGfCfugca(L96) (vinu)sGfscagCfggaggauCfuUfgcauusgsa BD-10741 asasugcaAfgAfUfCfcuccGfCfugca(L96) (vinu)sGfscagCfgGfAfggauCfuUfgcauusgsa BD-10742 asasugcaAfg AfU fCfcuccgcugca(L96) (vinu)sGfscagCfggaggauCfuUfgcauusgsa BD-10743 asasugcaAfgAfUfCfcuccgcugca(L96) (vinu)sGfscagCfgGfAfggauCfuUfgcauusgsa BD-10744 asasugCfaAfGfAfuccuccgcua(L96) (vinu)sAfsgcgGfaGfGfaucuUfgCfauusgsa BD-10745 usgscaAfgAfUfCfcuccGfcuGfca(L96) (vinu)sGfscagCfggaggauCfuUfgcasusuBD-10746 usgscaAfgAfUfCfcuccGfcuGfca(L96) (vinu)sGfscagCfgGfAfggauCfuUfgcasusu BD-10747 usgscaAfgAIUfCfcuccGfCfugca(L96) (vinu)sGfscagCfggaggauCfuUfgcasusuBD-10748 usgsca AfgAfU fCfcuccGfCfugca(L96) (vinu)sGfscagCfgGfAfggauCfuUfgcasusu BD-10749 usgscaAfgAfUfCfcuccgcugca(L96) (vinu)sGfscagCfggaggauCfuUfgcasusuBD-10750 usgscaagAfuCfCfUfccgcLJfgcAfaa(L96) (vinu)sUfsugcAfgcggaggAfuCfuugcasusu BD-10751 usgscaagAfuCfCfUfccgcUfgcAfaa(L96) (vinu)sUfsugcAfgCfGfgaggAfuCfuugcasusu BD-10752 usgscaagAfuCfCIUfccgcUfGfcaaa(L96) (vinu)sUfsugcAfgcggaggAfuCfuugcasusu BD-10753 usgscaagAfuCfCfUfccgcUfGfcaaa(L96) (vinu)sUfsugcAfgCfGfgaggAfuCfuugcasusu BD-10754 usgscaagAfuCfCfUfccgcugcaaa(L96) (vinu)sUfsugcAfgcggaggAfuCfuugcasusu BD-10755 usgscaagAfuCfCfUfccgcugcaaa(L96) (vinu)sUfsugcAfgCfGfgaggAfuCfuugcasusu BD-10756 usgscaAfgAfUfCfcuccgcugca(L96) (vinu)sGfscagCfgGfAfggauCfuUfgcasusu BD-10757 csasagAfuCfCfUfccgcUfgcAfaa(L96) (vinu)sUfsugcAfgcggaggAfuCfuugscsaBD-10758 csasagAfuCfCfUfccgcUfgcAfaa(L96) (vinu)sUfsugcAfgCfGfgaggAfuCfuugscsa BD-10759 csasagAfuCfCfUfccgcUfGfcaaa(L96) (vinu) sU fsugc Afgcggagg AfuCfuugscsaBD-10760 csasagAfuCfCfUfccgcUfGfcaaa(L96) (vinu) sU fsugc AfgCf Gfgagg AfuCfuugsc sa BD-10761 csasagAfuCfCfUfccgcugcaaa(L96) (vinu)sUfsugcAfgcggaggAfuCfuugscsaBD-10762 csasagauCfcUfCfCfgcugCfaaUfga(L96) (vinu)sCfsauuGfcagcggaGfgAfucuugscsa BD-10763 csasagauCfcUfCfCfgcugCfaaUfga(L96) (vinu)sCfsauuGfcAfGfcggaGfgAfucuugscsa BD-10764 csasagauCfcUfCfCfgcugCfAfauga(L96) (vinu)sCfsauuGfcagcggaGfgAfucuugscsa BD-10765 csasagauCfcUfCfCfgcugCfAfauga(L96) (vinu)sCfsauuGfcAfGfcggaGfgAfucuugscsa BD-10766 csasagauCfcUfCfCfgcugcaauga(L96) (vinu)sCfsauuGfcagcggaGfgAfucuugscsa BD-10767 csasagauCfcUfCfCfgcugcaauga(L96) (vinu)sCfsauuGfcAfGfcggaGfgAfucuugscsa BD-10768 csasagAfuCfCfUfccgcugcaaa(L96) (vinu)sUfsugcAfgCfGfgaggAfuCfuugscsa BD-10769 asgsauCfcUfCfCfgcugCfaaUfga(L96) (vinu)sCfsauuGfcagcggaGfgAfucususgBD-10770 asgsauCfcUfCfCfgcugCfaaUfga(L96) (vinu)sCfsauuGfcAfGfcggaGfgAfucususg BD-10771 asgsauCfcUfCfCfgcugCfAfauga(L96) (vinu)sCfsauuGfcagcggaGfgAfucususgBD-10772 asgsauCfcUfCfCfgcugCfAfauga(L96) (vinu)sCfsauuGfcAfGfcggaGfgAfucususg BD-10773 asgsauCfcUfCfCfgcugcaauga(L96) (vinu)sCfsauuGfcagcggaGfgAfucususgBD-10774 asgsauccUfcCfGfCfugcaAfugCfua(L96) (vinu)sAfsgcaUfugcagcgGfaGfgaucususg BD-10775 asgsauccUfcCfGfCfugcaAfugCfua(L96) (vinu)sAfsgcaUfuGfCfagcgGfaGfgaucususgBD-10776 asgsauccUfcCfGfCfugcaAfUfgcua(L96) (vinu)sAfsgcaUfugcagcgGfaGfgaucususg NAI-5008944785v1 Page 51 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-10777 asgsauccUfcCfGfCfugcaAfUfgcua(L96) (vinu)sAfsgcaUfuGfCfagcgGfaGfgaucususg BD-10778 asgsauccUfcCfGfCfugcaaugcua(L96) (vinu)sAfsgcaUfugcagcgGfaGfgaucususg BD-10779 asgsauccUfcCfGfCfugcaaugcua(L96) (vinu)sAfsgcaUfuGfCfagcgGfaGfgaucususg BD-10780 asgsauCfcUfCfCfgcugcaauga(L96) (vinu)sCfsauuGfcAfGfcggaGfgAfucususg BD-10781 gsasucCfuCfCfGfcugcAfauGfca(L96) (vinu)sGfscauUfgcagcggAfgGfaucsusuBD-10782 gsasucCTuC fCIGfcugc AfauGfca(L 96 ) (vinu)sGfscauUfgCfAfgcggAfgGfaucsusu BD-10783 gsasucCfuCfCfGfcugcAfAfugca(L96) (vinu)sGfscauUfgcagcggAfgGfaucsusuBD-10784 gsasucCfuCfCfGfcugcAfAfugca(L96) (vinu)sGfscauUfgCfAfgcggAfgGfaucsusu BD-10785 gsasucCfuCfCfGfcugcaaugca(L96) (vinu)sGfscauUfgcagcggAfgGfaucsusuBD-10786 gsasuccuCfcGfCfUfgcaaUfgcUfga(L96) (vinu)sCfsagcAfuugcagcGfgAfggaucsusu BD-10787 gsasuccuCfcGfCfUfgcaaUfgcUfga(L96) (vinu)sCfsagcAfuUfGfcagcGfgAfggaucsusu BD-10788 gsasuccuCfcGfCfUfgcaaUfGfcuga(L96) (vinu)sCfsagcAfuugcagcGfgAfggaucsusu BD-10789 gsasuccuCfcGfCfUfgcaaUfGfcuga(L96) (vinu)sCfsagcAfuUfGfcagcGfgAfggaucsusu BD-10790 gsasuccuCfcGfCfUfgcaaugcuga(L96) (vinu)sCfsagcAfuugcagcGfgAfggaucsusu BD-10791 gsasuccuCfcGfCfUfgcaaugcuga(L96) (vinu)sCfsagcAfuUfGfcagcGfgAfggaucsusu BD-10792 gsasucCfuCfCfGfcugcaaugca(L96) (vinu)sGfscauUfgCfAfgcggAfgGfaucsusu BD-10793 asusccUfcCfGfCfugcaAfugCfua(L96) (vinu)sAfsgcaUfugcagcgGfaGfgauscsuBD-10794 asusccUfcCfGfCfugcaAfugCfua(L96) (vinu)sAfsgcaUfuGfCfagcgGfaGfgauscsu BD-10795 asusccUfcCfGfCfugcaAIUfgcua(L96) (vinu)sAfsgcaUfugcagcgGfaGfgauscsuBD-10796 asusccUfcCfGfCfugcaAfUfgcua(L96) (vinu)sAfsgcaUfuGfCfagcgGfaGfgauscsu BD-10797 asusccUfcCfGfCfugcaaugcua(L96) (vinu)sAfsgcaUfugcagcgGfaGfgauscsuBD-10798 asusccucCfgCfUfGfcaauGfcuGfaa(L96) (vinu)sUfscagCfauugcagCfgGfaggauscsu BD-10799 asusccucCfgCfUfGfcaauGfcuGfaa(L96) (vinu)sUfscagCfaUfUfgcagCfgGfaggauscsu BD-10800 asusccucCfgCfUfGfcaauGfCfugaa(L96) (vinu)sUfscagCfauugcagCfgGfaggauscsu BD-10801 asusccucCfgCfUfGfcaauGfCfugaa(L96) (vinu)sUfscagCfaUfUfgcagCfgGfaggauscsu BD-10802 asusccucCfgCfUfGfcaaugcugaa(L96) (vinu)sUfscagCfauugcagCfgGfaggauscsu BD-10803 asusccucCfgCIUIGfcaaugcugaa(L96) (vinu)sUfscagCfaUlUfgcagCfgGfaggauscsu BD-10804 asusccUfcCfGfCfugcaaugcua(L96) (vinu)sAfsgcaUfuGfCfagcgGfaGfgauscsu BD-10805 uscscuCfcGfCfUfgcaaUfgcUfga(L96) (vinu)sCfsagcAfuugcagcGfgAfggasuscBD-10806 uscscuCfcGfCfUfgcaaUfgcUfga(L96) (vinu)sCfsagcAfuUfGfcagcGfgAfggasusc BD-10807 uscscuCfcGfCfUfgcaaUfGfcuga(L96) (vinu)sCfsagcAfuugcagcGfgAfggasuscBD-10808 uscscuCfcGfCfUfgcaaUfGfcuga(L96) (vinu)sCfsagcAfuUfGfcagcGfgAfggasusc BD-10809 uscscuCfcGfCfUfgcaaugcuga(L96) (vinu)sCfsagcAfuugcagcGfgAfggasuscBD-10810 uscscuccGfcUfGfCfaaugCfugAfga(L96) (vinu)sCfsucaGfcauugcaGfcGfgaggasusc BD-10811 uscscuccGfcUfGfCfaaugCfugAfga(L96) (vinu)sCfsucaGfcAIUfugcaGfcGfgaggasusc BD-10812 uscscuccGfcUfGfCfaaugCfUfgaga(L96) (vinu)sCfsucaGfcauugcaGfcGfgaggasusc BD-10813 uscscuccGfcUfGfCfaaugCfUfgaga(L96) (vinu)sCfsucaGfcAfUfLigcaGfcGfgaggasusc BD-10814 uscscuccGfcUfGfCfaaugcugaga(L96) (vinu)sCfsucaGfcauugcaGfcGfgaggasusc BD-10815 uscscuccGfcUfGfCfaaugcugaga(L96) (vinu)sCfsucaGfcAfUfugcaGfcGfgaggasusc BD-10816 uscscuCfcGfCfUfgcaaugcuga(L96) (vinu)sCfsagcAfuUfGfcagcGfgAfggasusc BD-10817 csusccGfcUfGfCfaaugCfugAfga(L96) (vinu)sCfsucaGfcauugcaGfcGfgagsgsaBD-10818 csusccGfcUfGfCfaaugCfugAfga(L96) (vinu)sCfsucaGfcAfUfLigcaGfcGfgagsgsa BD-10819 csusccGfcUfGfCfaaugCfUfgaga(L96) (vinu)sCfsucaGfcauugcaGfcGfgagsgsaBD-10820 csusccGfcUfGfCfaaugCfUfgaga(L96) (vinu)sCfsucaGfcAfUfugcaGfcGfgagsgsa BD-10821 csusccGfcUfGfCfaaugcugaga(L96) (vinu)sCfsucaGfcauugcaGfcGfgagsgsaBD-10822 csusccgcUfgCfAfAfugcuGfagUfaa(L96) (vinu)sUfsacuCfagcauugCfaGfcggagsgsa BD-10823 csusccgcUfgCfAfAfugcuGfagUfaa(L96) (vinu)sUfsacuCfaGfCfauugCfaGfcggagsgsa BD-10824 csusccgcUfgCfAfAfugcuGfAfguaa(L96) (vinu)sUfsacuCfagcauugCfaGfcggagsgsa BD-10825 csusccgcUfgCfAfAfugcuGfAfguaa(L96) (vinu)sUfsacuCfaGfCfauugCfaGfcggagsgsa BD-10826 csusccgcUfgCfAfAfugcugaguaa(L96) (vinu)sUfsacuCfagcauugCfaGfcggagsgsaBD-10827 csusccgcUfgCfAfAfugcugaguaa(L96) (vinu)sUfsacuCfaGfCfauugCfaGfcggagsgsa NAI-5008944785v1 Page 52 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-10828 csusccGfcUfGfCfaaugcugaga(L96) (vinu)sCfsucaGfcAfUfugcaGfcGfgagsgsa BD-10829 cscsgcUfgCfAfAfugcuGfagUfaa(L96) (vinu)sUfsacuCfagcauugCfaGfcggsasgBD-10830 cscsgcUfgCfAfAfugcuGfagUfaa(L96) (vinu)sUfsacuCfaGfCfauugCfaGfcggsasg BD-10831 cscsgcUfgCfAfAfugcuGfAfguaa(L96) (vinu)sUfsacuCfagcauugCfaGfcggsasgBD-10832 cscsgcUfgCfAfAfugcuGfAfguaa(L96) (vinu)sUfsacuCfaGfCfauugCfaGfcggsasg BD-10833 cscsgcUfgCfAfAfugcugaguaa(L96) (vinu)sUfsacuCfagcauugCfaGfcggsasgBD-10834 cscsgcugCfaAfUfGfcugaGfuaCfga(L96) (vinu)sCfsguaCfucagcauUfgCfagcggsasg BD-10835 cscsgcugCfaAfUfGfcugaGfuaCfga(L96) (vinu)sCfsguaCfuCfAfgcauUfgCfagcggsasg BD-10836 cscsgcugCfaAfUfGfcugaGfUfacga(L96) (vinu)sCfsguaCfucagcauUfgCfagcggsasg BD-10837 cscsgcugCfaAfUfGfcugaGfUfacga(L96) (vinu)sCfsguaCfuCfAfgcauUfgCfagcggsasg BD-10838 cscsgcugCfaAIUfGfcugaguacga(L96) (vinu)sCfsguaCfucagcauUfgCfagcggsasg BD-10839 cscsgcugCfaAfUfGfcugaguacga(L96) (vinu)sCfsguaCfuCfAfgcauUfgCfagcggsasg BD-10840 cscsgcUfgCfAfAfugcugaguaa(L96) (vinu)sUfsacuCfaGfCfauugCfaGfcggsasg BD-10841 csgsuaUfcGfUfCfcacuCfugAfga(L96) (vinu)sCfsucaGfaguggacGfaUfacgsusaBD-10842 csgsuaUfcGfUfCfcacuCfugAfga(L96) (vinu)sCfsucaGfaGfUfggacGfaUfacgsusa BD-10843 csgsuaUfcGfUfCfcacuCfUfgaga(L96) (vinu)sCfsucaGfaguggacGfaUfacgsusaBD-10844 csgsuaUfcGfUfCfcacuCfUfgaga(L96) (vinu)sCfsucaGfaGfUfggacGfaUfacgsusa BD-10845 csgsuaUfcGfUfCfcacucugaga(L96) (vinu)sCfsucaGfaguggacGfaUfacgsusaBD-10846 csgsuaucGfuCfCfAfcucuGfagCfca(L96) (vinu)sGfsgcuCfagaguggAfcGfauacgsusa BD-10847 csgsuaucGfuCfCfAfcucuGfagCfca(L96) (vinu)sGfsgcuCfaGfAfguggAfcGfauacgsusa BD-10848 csgsuaucGfuCfCfAfcucuGfAfgcca(L96) (vinu)sGfsgcuCfagaguggAfcGfauacgsusa BD-10849 csgsuaucGfuCfCfAfcucuGfAfgcca(L96) (vinu)sGfsgcuCfaGfAfguggAfcGfauacgsusa BD- 10850 csgsuaucGfuCfCfAfcucugagcca(L96) (vinu)sGfsgcuCfagaguggAfcGfauacgsusa BD-10851 csgsuaucGfuCfCfAfcucugagcca(L96) (vinu)sGfsgcuCfaGfAfguggAfcGfauacgsusa BD-10852 csgsuaU fcGfU fCfcacucugaga(L96) (vinu)sCfsucaGfaGfU fggacGfaU facgsusa BD-10853 csgsucCfaCIUfCfugagCfcuUfaa(L96) (vinu)sUfsaagGfcucagagUfgGfacgsasuBD-10854 csgsucCfaCIUfCfugagCfcuUfaa(L96) (vinu)sUfsaagGfcUfCfagagUfgGfacgsasu BD-10855 csgsucCfaCfUfCfugagCfCfuuaa(L96) (vinu)sUfsaagGfcucagagUfgGfacgsasuBD-10856 csgsucCfaCfUfCfugagCfCfuuaa(L96) (vinu)sUfsaagGfcUfCfagagUfgGfacgsasu BD-10857 csgsucCfaCIUfCfugagccuuaa(L96) (vinu)sUfsaagGfcucagagUfgGfacgsasuBD-10858 csgsuccaCfuCfUfGfagccUfuaGfaa(L96) (vinu)sUfscuaAfggcucagAfgUfggacgsasu BD-10859 csgsuccaCfuCfUfGfagccUfuaGfaa(L96) (vinu)sUfscuaAfgGfCfucagAfgUfggacgsasu BD-10860 csgsuccaCfuCfUfGfagccUIUfagaa(L96) (vinu)sUfscuaAfggcucagAfgUfggacgsasu BD-10861 csgsuccaCfuCfUfGfagccUfUfagaa(L96) (vinu)sUfscuaAfgGfCfucagAfgUfggacgsasu BD-10862 csgsuccaCfuCfUfGfagccuuagaa(L96) (vinu)sUfscuaAfggcucagAfgUfggacgsasu BD-10863 csgsuccaCfuCfUfGfagccuuagaa(L96) (vinu)sUfscuaAfgGfCfucagAfgUfggacgsasu BD-10864 csgsucCfaCIUfCfugagccuuaa(L96) (vinu)sUfsaagGfcUfCfagagUfgGfacgsasu BD-10865 ususcaUfcAfGfGfagcaCfuuCfga(L96) (vinu)sCfsgaaGfugcuccuGfaUfgaascscBD-10866 ususcaUfcAfGfGfagcaCfuuCfga(L96) (vinu)sCfsgaaGfuGfCfuccuGfaUfgaascsc BD-10867 ususcaUfcAfGfGfagcaCfUfucga(L96) (vinu)sCfsgaaGfugcuccuGfaUfgaascscBD-10868 ususcaUfcAfGfGfagcaCIUfucga(L96) (vinu)sCfsgaaGfuGfCfuccuGfaUfgaascsc BD-10869 ususcaUfcAfGfGfagcacuucga(L96) (vinu)sCfsgaaGfugcuccuGfaUfgaascscBD-10870 ususcaucAfgGfAfGfcacuUfcgAfga(L96) (vinu)sCfsucgAfagugcucCfuGfaugaascsc BD-10871 ususcaucAfgGfAfGfcacuUfcgAfga(L96) (vinu)sCfsucgAfaGfUfgcucCfuGfaugaascsc BD-10872 ususcaucAfgGfAfGfcacuUfCfgaga(L96) (vinu)sCfsucgAfagugcucCfuGfaugaascsc BD-10873 ususcaucAfgGfAfGfcacuUfCfgaga(L96) (vinu)sCfsucgAfaGIUfgcucCfuGfaugaascsc BD-10874 ususcaucAfgGfAfGfcacuucgaga(L96) (vinu)sCfsucgAfagugcucCfiiGfaugaascsc BD-10875 ususcaucAfgGfAfGfcacuucgaga(L96) (vinu)sCfsucgAfaGfUfgcucCfuGfaugaascsc BD-10876 ususcaUfcAfGfGfagcacuucga(L96) (vinu)sCfsgaaGfuGfCfuccuGfaUfgaascsc BD-10877 uscsugGfcGfGfCfcucuGfucGfaa(L96) (vinu)sUfscgaCfagaggccGfcCfagasgscBD-10878 uscsugGfcGfGfCfcucuGfucGfaa(L96) (vinu)sUfscgaCfaGfAfggccGfcCfagasgsc NAI-5008944785v1 Page 53 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-10879 uscsugGfcGIGfCfcucuGfUfcgaa(L96) (vinu)sUfscgaCfagaggccGfcCfagasgscBD-10880 uscsugGfcGfGfCfcucuGfUfcgaa(L96) (vinu)sUfscgaCfaGfAfggccGfcCfagasgsc BD-10881 uscsugGfcGfGfCfcucugucgaa(L96 ) (vinu)sUfscgaCfagaggccGfcCfagasgscBD-10882 uscsuggcGfgCfCfUfcuguCfgaGfca(L96) (vinu)sGfscucGfacagaggCfcGfccagasgsc BD-10883 uscsuggcGfgCfCfUfcuguCfgaGfca(L96) (vinu)sGfscucGfaCfAfgaggCfcGfccagasgsc BD-10884 uscsuggcGfgCfCfUfcuguCfGfagca(L96) (vinu)sGfscucGfacagaggCfcGfccagasgsc BD-10885 uscsuggcGfgCfCfUfcuguCfGfagca(L96) (vinu)sGfscucGfaCfAfgaggCfcGfccagasgsc BD-10886 uscsuggcGfgCfCfUfcugucgagca(L96) (vinu)sGfscucGfacagaggCfcGfccagasgsc BD-10887 uscsuggcGfgCfCfUfcugucgagca(L96) (vinu)sGfscucGfaCfAfgaggCfcGfccagasgsc BD-10888 uscsugGfcGfGfCfcucugucgaa(L96) (vinu)sUfscgaCfaGfAfggccGfcCfagasgsc BD-10889 csusggCfgGfCfCfucugUfcgAfga(L96) (vinu)sCfsucgAfcagaggcCfgCfcagsasgBD-10890 csusggCfgGfCfCfucugUfcgAfga(L96) (vinu)sCfsucgAfcAfGfaggcCfgCfcagsasg BD-10891 csusggCfgGfCfCfucugUfCfgaga(L96) (vinu)sCfsucgAfcagaggcCfgCfcagsasgBD-10892 csusggCfgGfCfCfucugUfCfgaga(L96) (vinu)sCfsucgAfcAfGfaggcCfgCfcagsasg BD-10893 csusggCfgGfCfCfucugucgaga(L96) (vinu)sCfsucgAfcagaggcCfgCfcagsasgBD-10894 csusggcgGfcCfUfCfugucGfagCfca(L96) (vinu)sGfsgcuCfgacagagGfcCfgccagsasg BD-10895 csusggcgGfcCfUfCfugucGfagCfca(L96) (vinu)sGfsgcuCfgAfCfagagGfcCfgccagsasg BD-10896 csusggcgGfcCfUfCfugucGfAfgcca(L96) (vinu)sGfsgcuCfgacagagGfcCfgccagsasg BD-10897 csusggcgGfcCfUfCfugucGfAfgcca(L96) (vinu)sGfsgcuCfgAfCfagagGfcCfgccagsasg BD-10898 csusggcgGfcCfUfCfugucgagcca(L96) (vinu)sGfsgcuCfgacagagGfcCfgccagsasg BD-10899 csusggcgGfcCfUfCfugucgagcca(L96) (vinu)sGfsgcuCfgAfCfagagGfcCfgccagsasg BD-10900 csusggCfgGfCfCfucugucgaga(L96) (vinu)sCfsucgAfcAfGfaggcCfgCfcagsasg BD-10901 usgsgcGfgCfCfUfcuguCfgaGfca(L96) (vinu)sGfscucGfacagaggCfcGfccasgsaBD-10902 usgsgcGfgCfCfUfcuguCfgaGfca(L96) (vinu)sGfscucGfaCfAfgaggCfcGfccasgsa BD-10903 usgsgcGfgCfCfUfcuguCfGfagca(L96) (vinu)sGfscucGfacagaggCfcGfccasgsaBD-10904 usgsgcGfgCfCfUfcuguCfGfagca(L96) (vinu)sGfscucGfaCfAfgaggCfcGfccasgsa BD-10905 usgsgcGfgCfCIUfcugucgagca(L96) (vinu)sGfscucGfacagaggCfcGfccasgsaBD-10906 usgsgcggCfcUfCfUfgucgAfgcCfca(L96) (vinu)sGfsggcUfcgacagaGfgCfcgccasgsa BD-10907 usgsgcggCfcUfCfUfgucgAfgcCfca(L96) (vinu)sGfsggcUfcGfAfcagaGfgCfcgccasgsa BD-10908 usgsgcggCfcUfCfUfgucgAfGfccca(L96) (vinu)sGfsggcUfcgacagaGfgCfcgccasgsa BD-10909 usgsgcggCfcUfCfUfgucgAfGfccca(L96) (vinu)sGfsggcUfcGfAfcagaGfgCfcgccasgsa BD-10910 usgsgcggCfcUfCfUfgucgagccca(L96) (vinu)sGfsggcUfcgacagaGfgCfcgccasgsa BD-10911 usgsgcggCfcUfCIUfgucgagccca(L96) (vinu)sGfsggcUfcGfAfcagaGfgCfcgccasgsa BD-10912 usgsgcGfgCfCfUfcugucgagca(L96) (vinu)sGfscucGfaCfAfgaggCfcGfccasgsa BD-10913 csuscuGfuCfGfAfgcccUfccGfca(L96) (vinu)sGfscggAfgggcucgAfcAfgagsgscBD-10914 csuscuGfuCfGfAfgcccUfccGfca(L96) (vinu)sGfscggAfgGfGfcucgAfcAfgagsgsc BD-10915 csuscuGfuCfGfAfgcccUfCfcgca(L96) (vinu)sGfscggAfgggcucgAfcAfgagsgscBD-10916 csuscuGfuCfGfAfgcccUfCfcgca(L96) (vinu)sGfscggAfgGfGfcucgAfcAfgagsgsc BD-10917 csuscuGfuCfGfAfgcccuccgca(L96) (vinu)sGfscggAfgggcucgAfcAfgagsgscBD-10918 csuscuguCfgAfGfCfccucCfgcUfca(L96) (vinu)sGfsagcGfgagggcuCfgAfcagagsgsc BD-10919 csuscuguCfgAfGfCfccucCfgcUfca(L96) (vinu)sGfsagcGfgAfGfggcuCfgAfcagagsgsc BD-10920 csuscuguCfgAfGfCfccucCfGfcuca(L96) (vinu)sGfsagcGfgagggcuCfgAfcagagsgsc BD-10921 csuscuguCfgAfGfCfccucCfGfcuca(L96) (vinu)sGfsagcGfgAfGfggcuCfgAfcagagsgsc BD-10922 csuscuguCfgAfGfCfccuccgcuca(L96) (vinu)sGfsagcGfgagggcuCfgAfcagagsgsc BD-10923 csuscuguCfgAfGfCfccuccgcuca(L96) (vinu)sGfsagcGfgAfGfggcuCfgAfcagagsgsc BD-10924 csuscuGfuCfGfAfgcccuccgca(L96) (vinu)sGfscggAfgGfGfcucgAfcAfgagsgsc BD-10925 csusguCfgAfGfCfccucCfgcUfca(L96) (vinu)sGfsagcGfgagggcuCfgAfcagsasgBD-10926 csusguCfgAfGfCfccucCfgcUfca(L96) (vinu)sGfsagcGfgAfGfggcuCfgAfcagsasg BD-10927 csusguCfgAfGfCfccucCfGfcuca(L96) (vinu)sGfsagcGfgagggcuCfgAfcagsasgBD-10928 csusguCfgAfGfCfccucCfGfcuca(L96) (vinu)sGfsagcGfgAfGfggcuCfgAfcagsasgBD-10929 csusguCfgAfGfCfccuccgcuca(L96) (vinu)sGfsagcGfgagggcuCfgAfcagsasgNAI-5008944785v1 Page 54 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-10930 csusgucgAfgCfCfCfuccgCfucCfua(L96) (vinu)sAfsggaGfcggagggCfuCfgacagsasg BD-10931 csusgucgAfgCfCfCfuccgCfucCfua(L96) (vinu)sAfsggaGfcGfGfagggCfuCfgacagsasg BD-10932 csusgucgAfgCfCfCfuccgCIUfccua(L96) (vinu)sAfsggaGfcggagggCfuCfgacagsasg BD-10933 csusgucgAfgCfCfCfuccgCfUfccua(L96) (vinu)sAfsggaGfcGfGfagggCfuCfgacagsasg BD-10934 csusgucgAfgCfCfCfuccgcuccua(L96) (vinu)sAfsggaGfcggagggCfuCfgacagsasg BD-10935 csusgucgAfgCfCfCfuccgcuccua(L96) (vinu)sAfsggaGfcGfGfagggCfuCfgacagsasg BD-10936 csusguCfgAfGfCfccuccgcuca(L96) (vinu)sGfsagcGfgAfGfggcuCfgAfcagsasg BD-10937 usgsucGfaGfCfCfcuccGfcuCfca(L96) (vinu)sGfsgagCfggagggcUfcGfacasgsaBD-10938 usgsucGfaGfCfCfcuccGfcuCfca(L96) (vinu)sGfsgagCfgGfAfgggcUfcGfacasgsa BD-10939 usgsucGfaGfCfCfcuccGfCfucca(L96) (vinu)sGfsgagCfggagggcUfcGfacasgsaBD-10940 usgsucGfaGfCfCfcuccGfCfucca(L96) (vinu)sGfsgagCfgGfAfgggcUfcGfacasgsa BD-10941 usgsucGfaGfCfCfcuccgcucca(L96) (vinu)sGfsgagCfggagggcUfcGfacasgsaBD-10942 usgsucgaGfcCfCfUfccgcUfccUfaa(L96) (vinu)sUfsaggAfgcggaggGfcUfcgacasgsa BD-10943 usgsucgaGfcCfCfUfccgcUfccUfaa(L96) (vinu)sUfsaggAfgCfGfgaggGfcUfcgacasgsa BD-10944 usgsucgaGfcCfCfUfccgcUfCfcuaa(L96) (vinu)sUfsaggAfgcggaggGfcUfcgacasgsa BD-10945 usgsucgaGfcCfCfUfccgcUfCfcuaa(L96) (vinu)sUfsaggAfgCfGfgaggGfcUfcgacasgsa BD-10946 usgsucgaGfcCfCfUfccgcuccuaa(L96) (vinu)sUfsaggAfgcggaggGfcUfcgacasgsa BD-10947 usgsucgaGfcCfCfUfccgcuccuaa(L96) (vinu)sUfsaggAfgCfGfgaggGfcUfcgacasgsa BD-10948 usgsucGfaGfCfCfcuccgcucca(L96) (vinu)sGfsgagCfgGfAfgggcUfcGfacasgsa BD-10949 uscsgaGfcCfCfUfccgcUfccUfaa(L96) (vinu)sUfsaggAfgcggaggGfcUfcgascsaBD-10950 uscsgaGfcCfCfUfccgcUfccUfaa(L96) (vinu)sUfsaggAfgCfGfgaggGfcUfcgascsa BD-10951 uscsgaGfcCfCfUfccgcUfCfcuaa(L96) (vinu)sUfsaggAfgcggaggGfcUfcgascsaBD-10952 uscsgaGfcCfCfUfccgcUfCfcuaa(L96) (vinu)sUfsaggAfgCfGfgaggGfcUfcgascsa BD-10953 uscsgaGfcCfCfUfccgcuccuaa(L96) (vinu)sUfsaggAfgcggaggGfcUfcgascsaBD-10954 uscsgagcCfcUfCfCfgcucCfuaLJfga(L96) (vinu)sCfsauaGfgagcggaGfgGfcucgascsa BD-10955 uscsgagcCfcUfCfCfgcucCfuaUfga(L96) (vinu)sCfsauaGfgAfGfcggaGfgGfcucgascsa BD-10956 uscsgagcCfcUfCfCfgcucClUfauga(L96) (vinu)sCfsauaGfgagcggaGfgGfcucgascsa BD-10957 uscsgagcCfcUfCfCfgcucCfUfauga(L96) (vinu)sCfsauaGfgAfGfcggaGfgGfcucgascsa BD-10958 uscsgagcCfcUfCfCfgcuccuauga(L96) (vinu)sCfsauaGfgagcggaGfgGfcucgascsa BD-10959 uscsgagcCfcUfCfCfgcuccuauga(L96) (vinu)sCfsauaGfgAfGfcggaGfgGfcucgascsa BD-10960 uscsgaGfcCfCfUfccgcuccuaa(L96) (vinu)sUfsaggAfgCfGfgaggGfcUfcgascsa BD-10961 csgsagCfcCfUfCfcgcuCfcuAfua(L96) (vinu)sAfsuagGfagcggagGfgCfucgsascBD-10962 csgsagCfcCfUfCfcgcuCfcuAfua(L96) (vinu)sAfsuagGfaGfCfggagGfgCfucgsasc BD-10963 csgsagCfcCfUfCfcgcuCfCfuaua(L96) (vinu)sAfsuagGfagcggagGfgCfLicgsascBD-10964 csgsagCfcCfUfCfcgcuCfCfuaua(L96) (vinu)sAfsuagGfaGfCfggagGfgCfucgsasc BD-10965 csgsagCfcCfUfCfcgcuccuaua(L96) (vinu)sAfsuagGfagcggagGfgCfucgsascBD-10966 csgsagccCfuCfCfGfcuccUfauGfca(L96) (vinu)sGfscauAfggagcggAfgGfgcucgsasc BD-10967 csgsagccCfuCfCfGfcuccUfauGfca(L96) (vinu)sGfscauAfgGfAfgcggAfgGfgcucgsasc BD-10968 csgsagccCfuCfCfGfcuccUfAfugca(L96) (vinu)sGfscauAfggagcggAfgGfgcucgsasc BD-10969 csgsagccCfuCfCfGfcuccUfAfugca(L96) (vinu)sGfscauAfgGfAfgcggAfgGfgcucgsasc BD-10970 csgsagccCfuCfCfGfcuccuaugca(L96) (vinu)sGfscauAfggagcggAfgGfgcucgsasc BD-10971 csgsagccCfuCfCfGfcuccuaugca(L96) (vinu)sGfscauAfgGfAfgcggAfgGfgcucgsasc BD-10972 csgsagCfcCfUfCfcgcuccuaua(L96) (vinu)sAfsuagGfaGfCfggagGfgCfucgsasc BD-10973 asgsccCfuCfCfGfcuccUfauGfca(L96) (vinu)sGfscauAfggagcggAfgGfgcuscsgBD-10974 asgsccCfuCfCfGfcuccUfauGfca(L96) (vinu)sGfscauAfgGfAfgcggAfgGfgcuscsg BD-10975 asgsccCfuCfCfGfcuccUfAfugca(L96) (vinu)sGfscauAfggagcggAfgGfgcuscsgBD-10976 asgsccCfuCfCfGfcuccUfAfugca(L96) (vinu)sGfscauAfgGfAfgcggAfgGfgcuscsg BD-10977 asgsccCfuCfCfGfcuccuaugca(L96) (vinu)sGfscauAfggagcggAfgGfgcuscsgBD-10978 asgscccuCfcGfCfUfccuaUfgcGfca(L96) (vinu)sGfscgcAfuaggagcGfgAfgggcuscsg BD-10979 asgscccuCfcGfCfUfccuaUfgcGfca(L96) (vinu)sGfscgcAfuAfGfgagcGfgAfgggcuscsgBD-10980 asgscccuCfcGfCfUfccuaUfGfcgca(L96) (vinu)sGfscgcAfuaggagcGfgAfgggcuscsg NAI-5008944785v1 Page 55 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-10981 asgscccuCfcGfCfUfccuaUfGfcgca(L96) (vinu)sGfscgcAfuAfGfgagcGfgAfgggcuscsg BD-10982 asgscccuCfcGfCfUfccuaugcgca(L96) (vinu)sGfscgcAfuaggagcGfgAfgggcuscsg BD-10983 asgscccuCfcGfCfUfccuaugcgca(L96) (vinu)sGfscgcAfuAfGfgagcGfgAfgggcuscsg BD-10984 asgsccCfuCfCfGfcuccuaugca(L96) (vinu)sGfscauAfgGfAfgcggAfgGfgcuscsg BD-10985 gscsccUfcCfGfCfuccuAfugCfga(L96) (vinu)sCfsgcaUfaggagcgGfaGfggcsuscBD-10986 gscsccUfcCfGfCfuccuAfugCfga(L96) (vinu)sCfsgcaUfaGfGfagcgGfaGfggcsusc BD-10987 gscsccUfcCfGfCfuccuAfUfgcga(L96) (vinu)sCfsgcaUfaggagcgGfaGfggcsuscBD-10988 gscsccUfcCfGfCfuccuAfUfgcga(L96) (vinu)sCfsgcaUfaGfGfagcgGfaGfggcsusc BD-10989 gscsccUfcCfGfCfuccuaugcga(L96) (vinu)sCfsgcaUfaggagcgGfaGfggcsuscBD-10990 gscsccucCfgCfUfCfcuauGfcgCfua(L96) (vinu) s Af sgcgCfauaggagCfgGfagggc susc BD-10991 gscsccucCfgCfUfCfcuauGfcgCfua(L96) (vinu)sAfsgcgCfaUfAfggagCfgGfagggcsusc BD-10992 gscsccucCfgCfUfCfcuauGfCfgcua(L96) (vinu)sAfsgcgCfauaggagCfgGfagggcsusc BD-10993 gscsccucCfgCfUfCfcuauGfCfgcua(L96) (vinu)sAfsgcgCfaUfAfggagCfgGfagggcsusc BD-10994 gscsccucCfgCfUfCfcuaugcgcua(L96) (vinu)sAfsgcgCfauaggagCfgGfagggcsusc BD-10995 gscsccucCfgCfUfCfcuaugcgcua(L96) (vinu)sAfsgcgCfaUfAfggagCfgGfagggcsusc BD-10996 gscsccUfcCfGfCfuccuaugcga(L96) (vinu)sCfsgcaUfaGfGfagcgGfaGfggcsusc BD-10997 cscscuCfcGfCfUfccuaUfgcGfca(L96) (vinu)sGfscgcAfuaggagcGfgAfgggscsuBD-10998 cscscuCfcGfCfUfccuaUfgcGfca(L96) (vinu)sGfscgcAfuAfGfgagcGfgAfgggscsu BD-10999 cscscuCfcGfCfUfccuaUfGfcgca(L96) (vinu)sGfscgcAfuaggagcGfgAfgggscsuBD-11000 cscscuCfcGfCIUfccuaUfGfcgca(L96) (vinu)sGfscgcAfuAfGfgagcGfgAfgggscsu BD-11001 cscscuCfcGfCfUfccuaugcgca(L96) (vinu)sGfscgcAfuaggagcGfgAfgggscsuBD-11002 cscscuccGfcUfCfCfuaugCfgcUfca(L96) (vinu)sGfsagcGfcauaggaGfcGfgagggscsu BD-11003 cscscuccGfcUfCfCfuaugCfgcUfca(L96) (vinu)sGfsagcGfcAfUfaggaGfcGfgagggscsu BD-11004 cscscuccGfcUfCfCfuaugCfGfcuca(L96) (vinu)sGfsagcGfcauaggaGfcGfgagggscsu BD-11005 cscscuccGfcUfCfCfuaugCfGfcuca(L96) (vinu)sGfsagcGfcAfUfaggaGfcGfgagggscsu BD-11006 cscscuccGfcUfCfCfuaugcgcuca(L96) (vinu)sGfsagcGfcauaggaGfcGfgagggscsu BD-11007 cscscuccGfcUfCfCfuaugcgcuca(L96) (vinu)sGfsagcGfcAfUfaggaGfcGfgagggscsu BD-11008 cscscuCfcGfCfUfccuaugcgca(L96) (vinu)sGfscgcAfuAfGfgagcGfgAfgggscsu BD-11009 cscsgcUfcCfUfAfugcgCfucUfga(L96) (vinu)sCfsagaGfcgcauagGfaGfcggsasgBD-11010 cscsgcUfcCfUfAfugcgCfucUfga(L96) (vinu)sCfsagaGfcGfCfauagGfaGfcggsasg BD-11011 cscsgcUfcCfUfAfugcgCfUfcuga(L96) (vinu)sCfsagaGfcgcauagGfaGfcggsasgBD-11012 cscsgcUfcCfUfAfugcgCfUfcuga(L96) (vinu)sCfsagaGfcGfCfauagGfaGfcggsasg BD-11013 cscsgcUfcCfUfAfugcgcucuga(L96) (vinu)sCfsagaGfcgcauagGfaGfcggsasgBD-11014 cscsgcucCfuAfUfGfcgcuCfugCfaa(L96) (vinu)sUfsgcaGfagcgcauAfgGfagcggsasg BD-11015 cscsgcucCfuAIUfGfcgcuCfugCfaa(L96) (vinu)sUfsgcaGfaGfCfgcauAfgGfagcggsasg BD-11016 cscsgcucCfuAfUfGfcgcuCfUfgcaa(L96) (vinu)sUfsgcaGfagcgcauAfgGfagcggsasg BD-11017 cscsgcucCfuAfUfGfcgcuCfUfgcaa(L96) (vinu)sUfsgcaGfaGfCfgcauAfgGfagcggsasg BD-11018 cscsgcucCfuAIUfGfcgcucugcaa(L96) (vinu)sUfsgcaGfagcgcauAfgGfagcggsasg BD-11019 cscsgcucCfuAfUfGfcgcucugcaa(L96) (vinu)sUfsgcaGfaGfCfgcauAfgGfagcggsasg BD-11020 cscsgcUfcCfUfAfugcgcucuga(L96) (vinu)sCfsagaGfcGfCfauagGfaGfcggsasg BD-11021 csusauGfcGfCfUfcugcAfcuCfga(L96) (vinu)sCfsgagUfgcagagcGfcAfuagsgsaBD-11022 csusauGfcGfCfUfcugcAfcuCfga(L96) (vinu)sCfsgagUfgCfAfgagcGfcAfuagsgsa BD-11023 csusauGfcGfCfUfcugcAfCfucga(L96) (vinu)sCfsgagUfgcagagcGfcAfuagsgsaBD-11024 csusauGfcGfCfUfcugcAfCfucga(L96) (vinu)sCfsgagUfgCfAfgagcGfcAfuagsgsa BD-11025 csusauGfcGfCfUfcugcacucga(L96) (vinu)sCfsgagUfgcagagcGfcAfuagsgsaBD-11026 csusaugcGfcUfCfUfgcacUfcgGfca(L96) (vinu)sGfsccgAfgugcagaGfcGfcauagsgsa BD-11027 csusaugcGfcUfCfUfgcacUfcgGfca(L96) (vinu)sGfsccgAfgUfGfcagaGfcGfcauagsgsa BD-11028 csusaugcGfcUfCfUfgcacUfCfggca(L96) (vinu)sGfsccgAfgugcagaGfcGfcauagsgsa BD-11029 csusaugcGfcUfCfUfgcacUfCfggca(L96) (vinu)sGfsccgAfgUfGfcagaGfcGfcauagsgsa BD-11030 csusaugcGfcUfCfUfgcacucggca(L96) (vinu)sGfsccgAfgugcagaGfcGfcauagsgsaBD-11031 csusaugcGfcUfCfUfgcacucggca(L96) (vinu)sGfsccgAfgUfGfcagaGfcGfcauagsgsa NAI-5008944785v1 Page 56 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11032 csusauGfcGfCfUfcugcacucga(L96) (vinu)sCfsgagUfgCfAfgagcGfcAfuagsgsa BD-11033 usasugCfgCfUfCfugcaCfucGfga(L96) (vinu)sCfscgaGfugcagagCfgCfauasgsgBD-11034 usasugCfgCfUfCfugcaCfucGfga(L96) (vinu)sCfscgaGfuGfCfagagCfgCfauasgsg BD-11035 usasugCfgCfUfCfugcaCfUfcgga(L96) (vinu)sCfscgaGfugcagagCfgCfauasgsgBD-11036 usasugCfgCfUfCfugcaCfUfcgga(L96) (vinu)sCfscgaGfuGfCfagagCfgCfauasgsg BD-11037 usasugCfgCfUfCfugcacucgga(L96) (vinu)sCfscgaGfugcagagCfgCfauasgsgBD-11038 usasugcgCfuCfUfGfcacuCfggCfga(L96) (vinu)sCfsgccGfagugcagAfgCfgcauasgsg BD-11039 usasugcgCfuCfUfGfcacuCfggCfga(L96) (vinu)sCfsgccGfaGfUfgcagAfgCfgcauasgsg BD-11040 usasugcgCfuCfUfGfcacuCfGfgcga(L96) (vinu)sCfsgccGfagugcagAfgCfgcauasgsg BD-11041 usasugcgCfuCfUfGfcacuCfGfgcga(L96) (vinu)sCfsgccGfaGfUfgcagAfgCfgcauasgsg BD-11042 usasugcgCfuCfUfGfcacucggcga(L96) (vinu)sCfsgccGfagugcagAfgCfgcauasgsg BD-11043 usasugcgCfuCfUfGfcacucggcga(L96) (vinu)sCfsgccGfaGfUfgcagAfgCfgcauasgsg BD-11044 usasugCfgCfUfCfugcacucgga(L96) (vinu)sCfscgaGfuGfCfagagCfgCfauasgsg BD-11045 usgscgCfuCfUfGfcacuCfggCfga(L96) (vinu)sCfsgccGfagugcagAfgCfgcasusaBD-11046 usgscgCfuCfUfGfcacuCfggCfga(L96) (vinu)sCfsgccGfaGfUfgcagAfgCfgcasusa BD-11047 usgscgCfuCfUfGfcacuCfGfgcga(L96) (vinu)sCfsgccGfagugcagAfgCfgcasusaBD-11048 usgscgCfuCfUfGfcacuCfGfgcga(L96) (vinu)sCfsgccGfaGfUfgcagAfgCfgcasusa BD-11049 usgscgCfuCfUfGfcacucggcga(L96) (vinu)sCfsgccGfagugcagAfgCfgcasusaBD-11050 usgscgcuCfuGfCfAfcucgGfcgCfaa(L96) (vinu)sUfsgcgCfcgagugcAfgAfgcgcasusa BD-11051 usgscgcuCfuGfCfAfcucgGfcgCfaa(L96) (vinu)sUfsgcgCfcGfAfgugcAfgAfgcgcasusa BD-11052 usgscgcuCfuGfCfAfcucgGfCfgcaa(L96) (vinu)sUfsgcgCfcgagugcAfgAfgcgcasusa BD-11053 usgscgcuCfuGfCfAfcucgGfCfgcaa(L96) (vinu)sUfsgcgCfcGfAfgugcAfgAfgcgcasusa BD-11054 usgscgcuCfuGfCfAfcucggcgcaa(L96) (vinu) sUfsgcgCfcga gugc Afg Afgcgca susa BD-11055 usgscgcuCfuGfCfAfcucggcgcaa(L96) (vinu)sUfsgcgCfcGfAfgugcAfgAfgcgcasusa BD-11056 usgscgCfuCfU fGfcacucggcga(L96) (vinu)sCfsgccGfaGfUfgcagAfgCfgcasusa BD-11057 csgscuCfuGfCfAfcucgGfcgCfaa(L96) (vinu)sUfsgcgCfcgagugcAfgAfgcgscsaBD-11058 csgscuCfuGfCfAfcucgGfcgCfaa(L96) (vinu)sUfsgcgCfcGfAfgugcAfgAfgcgscsa BD-11059 csgscuCfuGfCfAfcucgGfCfgcaa(L96) (vinu)sUfsgcgCfcgagugcAfgAfgcgscsaBD-11060 csgscuCfuGfCfAfcucgGfCfgcaa(L96) (vinu)sUfsgcgCfcGfAfgugcAfgAfgcgscsa BD-11061 csgscuCfuGfCfAfcucggcgcaa(L96) (vinu)sUfsgcgCfcgagugcAfgAfgcgscsaBD-11062 csgscucuGfcAfCfUfcggcGfcaCfca(L96) (vinu)sGfsgugCfgccgaguGfcAfgagcgscsa BD-11063 csgscucuGfcAfCfUfcggcGfcaCfca(L96) (vinu)sGfsgugCfgCfCfgaguGfcAfgagcgscsa BD-11064 csgscucuGfcAfCfUfcggcGfCfacca(L96) (vinu)sGfsgugCfgccgaguGfcAfgagcgscsa BD-11065 csgscucuGfcAfCfUfcggcGfCfacca(L96) (vinu)sGfsgugCfgCfCfgaguGfcAfgagcgscsa BD-11066 csgscucuGfcAfCfUfcggcgcacca(L96) (vinu)sGfsgugCfgccgaguGfcAfgagcgscsa BD-11067 csgscucuGfcAfCfUfcggcgcacca(L96) (vinu)sGfsgugCfgCfCfgaguGfcAfgagcgscsa BD-11068 csgscuCfuGfCfAfcucggcgcaa(L96) (vinu)sUfsgcgCfcGfAfgugcAfgAfgcgscsa BD-11069 gscsccGfcAfCfCfugccGfcgGfga(L96) (vinu)sCfsccgCfggcagguGfcGfggcsgsgBD-11070 gscsccGfcAfCfCfugccGfcgGfga(L96) (vinu)sCfsccgCfgGfCfagguGfcGfggcsgsg BD-11071 gscsccGfcAfCfCfugccGfCfggga(L96) (vinu)sCfsccgCfggcagguGfcGfggcsgsgBD-11072 gscsccGfcAfCfCfugccGfCfggga(L96) (vinu)sCfsccgCfgGfCfagguGfcGfggcsgsg BD-11073 gscsccGfcAfCfCfugccgcggga(L96) (vinu)sCfsccgCfggcagguGfcGfggcsgsgBD-11074 gscsccgcAfcCfUfGfccgcGfggGfaa(L96) (vinu)sUfscccCfgcggcagGfuGfcgggcsgsg BD-11075 gscsccgcAfcCfUfGfccgcGfggGfaa(L96) (vinu)sUfscccCfgCfGfgcagGfuGfcgggcsgsg BD-11076 gscsccgcAfcCfUfGfccgcGfGfggaa(L96) (vinu)sUfscccCfgcggcagGfuGfcgggcsgsg BD-11077 gscsccgcAfcCfUfGfccgcGfGfggaa(L96) (vinu)sUfscccCfgCfGfgcagGfuGfcgggcsgsg BD-11078 gscsccgcAfcCfUfGfccgcggggaa(L96) (vinu)sUfscccCfgcggcagGfuGfcgggcsgsg BD-11079 gscsccgcAfcCfUfGfccgcggggaa(L96) (vinu)sUfscccCfgCfGfgcagGfuGfcgggcsgsg BD-11080 gscsccGfcAfCfCfugccgcggga(L96) (vinu)sCfsccgCfgGfCfagguGfcGfggcsgsg BD-11081 csasccUfgCfCfGfcgggGfacCfua(L96) (vinu) s Af sgguCfcccgcggCfaGfgugsc sgBD-11082 csasccUfgCfCfGfcgggGfacCfua(L96) (vinu) s Af sgguCfc Cf CfgcggCfaGfgugsc sg NAI-5008944785v1 Page 57 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11083 csasccUfgCfCfGfcgggGfAfccua(L96) (vinu)sAfsgguCfcccgcggCfaGfgugscsgBD-11084 csasccUfgCfCfGfcgggGfAfccua(L96) (vinu) s Af sgguCfc Cf CfgcggCfaGfgugsc sg BD-11085 csasccUfgCfCfGfcggggaccua(L96) (vinu)sAfsgguCfcccgcggCfaGfgugscsgBD-11086 csasccugCfcGfCfGfgggaCfcuCfga(L96) (vinu)sCfsgagGfuccccgcGfgCfaggugscsg BD-11087 csasccugCfcGfCfGfgggaCfcuCfga(L96) (vinu)sCfsgagGfuCfCfccgcGfgCfaggugscsg BD-11088 csasccugCfcGfCfGfgggaCfCfucga(L96) (vinu)sCfsgagGfuccccgcGfgCfaggugscsg BD-11089 csasccugCfcGfCfGfgggaCfCfucga(L96) (vinu)sCfsgagGfuCfCfccgcGfgCfaggugscsg BD-11090 csasccugCfc GfCfGfgggaccucga(L 96 ) (vinu)sCfsgagGfuccccgcGfgCfaggugscsg BD-11091 csasccugCfcGfCfGfgggaccucga(L96) (vinu)sCfsgagGfuCfCfccgcGfgCfaggugscsg BD-11092 csasccUfgCfCfGfcggggaccua(L96) (vinu) sAf sgguCfc Cf CfgcggCfaGfgugsc sg BD-11093 gsgsgaCfcUfCfGfccuuCfcaUfua(L96) (vinu)sAfsaugGfaaggcgaGfgUfcccscsgBD-11094 gsgsgaCfcUfCfGfccuuCfcaUfua(L96) (vinu)sAfsaugGfaAfGfgcgaGfgUfcccscsg BD-11095 gsgsgaCfcUfCfGfccuuCfCfauua(L96) (vinu)sAfsaugGfaaggcgaGfgUfcccscsgBD-11096 gsgsgaCfcUfCfGfccuuCfCfauua(L96) (vinu)sAfsaugGfaAfGfgcgaGfgUfcccscsg BD-11097 gsgsgaCfcUfCfGfccuuccauua(L96) (vinu)sAfsaugGfaaggcgaGfgUfcccscsgBD-11098 gsgsgaccUfcGfCfCfuuccAfuuCfga(L96) (vinu)sCfsgaaUfggaaggcGfaGfgucccscsg BD-11099 gsgsgaccUfcGfCfCfuuccAfuuCfga(L96) (vinu)sCfsgaaUfgGfAfaggcGfaGfgucccscsg BD-11100 gsgsgaccUfcGfCfCfuuccAfUfucga(L96) (vinu)sCfsgaaUfggaaggcGfaGfgucccscsg BD-11101 gsgsgaccUfcGfCfCfuuccAIUfucga(L96) (vinu)sCfsgaaUfgGfAfaggcGfaGfgucccscsg BD-11102 gsgsgaccUfcGfCfCfuuccauucga(L96) (vinu)sCfsgaaUfggaaggcGfaGfgucccscsg BD-11103 gsgsgaccUfcGfCfCfuuccauucga(L96) (vinu)sCfsgaaUfgGfAfaggcGfaGfgucccscsg BD-11104 gsgsgaCfcUfCfGfccuuccauua(L96) (vinu)sAfsaugGfaAfGfgcgaGfgUfcccscsg BD-11105 gsasccUfcGfCfCfuuccAfuuCfga(L96) (vinu)sCfsgaaUfggaaggcGfaGfgucscscBD-11106 gsasccUfcGfCfCfuuccAfuuCfga(L96) (vinu)sCfsgaaUfgGfAfaggcGfaGfgucscsc BD-11107 gsasccUfcGfCfCfuuccAfUfucga(L96) (vinu)sCfsgaaUfggaaggcGfaGfgucscscBD-11108 gsasccUfcGfCfCfuuccAfUfucga(L96) (vinu)sCfsgaaUfgGfAfaggcGfaGfgucscsc BD-11109 gsasccUfcGfCfCfuuccauucga(L96) (vinu)sCfsgaaUfggaaggcGfaGfgucscscBD-11110 gsasccucGfcCfUfUfccauUfcgGfca(L96) (vinu)sGfsccgAfauggaagGfcGfaggucscsc BD-11111 gsasccucGfcCfUfUfccauUfcgGfca(L96) (vinu)sGfsccgAfaUfGfgaagGfcGfaggucscsc BD-11112 gsasccucGfcCfUfUfccauUfCfggca(L96) (vinu)sGfsccgAfauggaagGfcGfaggucscsc BD-11113 gsasccucGfcCfUfUfccauUfCfggca(L96) (vinu)sGfsccgAfaUfGfgaagGfcGfaggucscsc BD-11114 gsasccucGfcCfUfUfccauucggca(L96) (vinu)sGfsccgAfauggaagGfcGfaggucscsc BD-11115 gsasccucGfcCfUfUfccauucggca(L96) (vinu)sGfsccgAfaUfGfgaagGfcGfaggucscsc BD-11116 gsasccUfcGfCfCfuuccauucga(L96) (vinu)sCfsgaaUfgGfAfaggcGfaGfgucscsc BD-11117 ascscuCfgCfCfUfuccaUfucGfga(L96) (vinu)sCfscgaAfuggaaggCfgAfgguscscBD-11118 ascscuCfgCfCfUfuccaUfucGfga(L96) (vinu)sCfscgaAfuGfGfaaggCfgAfgguscsc BD-11119 ascscuCfgCfCfUfuccaUfUfcgga(L96) (vinu)sCfscgaAfuggaaggCfgAfgguscscBD-11120 ascscuCfgCfCfUfuccaUfUfcgga(L96) (vinu)sCfscgaAfuGfGfaaggCfgAfgguscsc BD-11121 ascscuCfgCfCfUfuccauucgga(L96) (vinu)sCfscgaAfuggaaggCfgAfgguscscBD-11122 ascscucgCfcUfUfCfcauuCfggCfga(L96) (vinu)sCfsgccGfaauggaaGfgCfgagguscsc BD-11123 ascscucgCfcUfUfCfcauuCfggCfga(L96) (vinu)sCfsgccGfaAfUfggaaGfgCfgagguscsc BD-11124 ascscucgCfcUfUfCfcauuCfGfgcga(L96) (vinu)sCfsgccGfaauggaaGfgCfgagguscsc BD-11125 ascscucgCfcUfUfCfcauuCfGfgcga(L96) (vinu)sCfsgccGfaAfUfggaaGfgCfgagguscsc BD-11126 ascscucgCfcUfUfCfcauucggcga(L96) (vinu)sCfsgccGfaauggaaGfgCfgagguscsc BD-11127 ascscucgCfcUfUfCfcauucggcga(L96) (vinu)sCfsgccGfaAfUfggaaGfgCfgagguscsc BD-11128 ascscuCfgCfCfUfuccauucgga(L96) (vinu)sCfscgaAfuGfGfaaggCfgAfgguscsc BD-11129 cscsucGfcCfUfUfccauUfcgGfca(L96) (vinu)sGfsccgAfauggaagGfcGfaggsuscBD-11130 cscsucGfcCfUfUfccauUfcgGfca(L96) (vinu)sGfsccgAfaUfGfgaagGfcGfaggsusc BD-11131 cscsucGfcCfUfUfccauUfCfggca(L96) (vinu)sGfsccgAfauggaagGfcGfaggsuscBD-11132 cscsucGfcCfUfUfccauUfCfggca(L96) (vinu)sGfsccgAfaUfGfgaagGfcGfaggsuscBD-11133 cscsucGfcCIUfUfccauucggca(L96) (vinu)sGfsccgAfauggaagGfcGfaggsuscNAI-5008944785v1 Page 58 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11134 cscsucgcCfuUfCfCfauucGfgcGfga(L96) (vinu)sCfscgcCfgaauggaAfgGfcgaggsusc BD-11135 cscsucgcCfuUfCfCfauucGfgcGfga(L96) (vinu)sCfscgcCfgAfAfuggaAfgGfcgaggsusc BD-11136 cscsucgcCfuUfCfCfauucGIGfcgga(L96) (vinu)sCfscgcCfgaauggaAfgGfcgaggsusc BD-11137 cscsucgcCfuUfCfCfauucGfGfcgga(L96) (vinu)sCfscgcCfgAfAfuggaAfgGfcgaggsusc BD-11138 cscsucgcCfuUfCfCfauucggcgga(L96) (vinu)sCfscgcCfgaauggaAfgGfcgaggsusc BD-11139 cscsucgcCfuUfCfCfauucggcgga(L96) (vinu)sCfscgcCfgAfAfuggaAfgGfcgaggsusc BD-11140 cscsucGfcCfUfUfccauucggca(L96) (vinu)sGfsccgAfaUfGfgaagGfcGfaggsusc BD-11141 csuscgCfcUfUfCfcauuCfggCfga(L96) (vinu)sCfsgccGfaauggaaGfgCfgagsgsuBD-11142 csuscgCfcUfUfCfcauuCfggCfga(L96) (vinu)sCfsgccGfaAfUfggaaGfgCfgagsgsu BD-11143 csuscgCfcUfUfCfcauuCfGfgcga(L96) (vinu)sCfsgccGfaauggaaGfgCfgagsgsuBD-11144 csuscgCfcUfUfCfcauuCIGfgcga(L96) (vinu)sCfsgccGfaAIUfggaaGfgCfgagsgsu BD-11145 csuscgCfcUfUfCfcauucggcga(L96) (vinu)sCfsgccGfaauggaaGfgCfgagsgsuBD-11146 csuscgccUfuCfCfAfuucgGfcgGfua(L96) (vinu)sAfsccgCfcgaauggAfaGfgcgagsgsu BD-11147 csuscgccUfuCfCfAfuucgGfcgGfua(L96) (vinu)sAfsccgCfcGfAfauggAfaGfgcgagsgsu BD-11148 csuscgccUfuCfCfAfuucgGfCfggua(L96) (vinu)sAfsccgCfcgaauggAfaGfgcgagsgsu BD-11149 csuscgccUfuCfCfAfuucgGfCfggua(L96) (vinu)sAfsccgCfcGfAfauggAfaGfgcgagsgsu BD-11150 csuscgccUfuCfCfAfuucggcggua(L96) (vinu)sAfsccgCfcgaauggAfaGfgcgagsgsu BD-11151 csuscgccUfuCfCfAfuucggcggua(L96) (vinu)sAfsccgCfcGfAfauggAfaGfgcgagsgsu BD-11152 csuscgCfcUIUfCfcauucggcga(L96) (vinu)sCfsgccGfaAfUfggaaGfgCfgagsgsu BD-11153 csgsccUfuCfCfAfuucgGfcgGfua(L96) (vinu)sAfsccgCfcgaauggAfaGfgcgsasgBD-11154 csgsccUfuCfCfAfuucgGfcgGfua(L96) (vinu)sAfsccgCfcGfAfauggAfaGfgcgsasg BD-11155 csgsccU fuCfCf AfuucgGfCfggua(L96) (vinu)sAfsccgCfcgaauggAfaGfgcgsasgBD-11156 csgsccUfuCfCfAfuucgGfCfggua(L96) (vinu)s AfsccgCfcGf Afaugg Afa Gfgcgsa sg BD-11157 csgsccUfuCfCfAfuucggcggua(L96) (vinu)sAfsccgCfcgaauggAfaGfgcgsasgBD-11158 csgsccuuCfcAfUfUfcggcGfguAfca(L96) (vinu)sGfsuacCfgccgaauGfgAfaggcgsasg BD-11159 csgsccuuCfcAfUfUfcggcGfguAfca(L96) (vinu)sGfsuacCfgCfCfgaauGfgAfaggcgsasg BD-11160 csgsccuuCfcAfUIUfcggcGfGfuaca(L96) (vinu)sGfsuacCfgccgaauGfgAfaggcgsasg BD-11161 csgsccuuCfcAfUfUfcggcGfGfuaca(L96) (vinu)sGfsuacCfgCfCfgaauGfgAfaggcgsasg BD-11162 csgsccuuCfcAIUfUfcggcgguaca(L96) (vinu)sGfsuacCfgccgaauGfgAfaggcgsasg BD-11163 csgsccuuCfcAIUfUfcggcgguaca(L96) (vinu)sGfsuacCfgCfCfgaauGfgAfaggcgsasg BD-11164 csgsccUfuCfCfAfuucggcggua(L96) (vinu)sAfsccgCfcGfAfauggAfaGfgcgsasg BD-11165 gscscuUfcCfAfUfucggCfggUfaa(L96) (vinu)sUfsaccGfccgaaugGfaAfggcsgsaBD-11166 gscscuUfcCfAfUfucggCfggUfaa(L96) (vinu)sUfsaccGfcCfGfaaugGfaAfggcsgsa BD-11167 gscscuUfcCfAfUfucggCfGfguaa(L96) (vinu)sUfsaccGfccgaaugGfaAfggcsgsaBD-11168 gscscuUfcCfAfUfucggCfGfguaa(L96) (vinu)sUfsaccGfcCfGfaaugGfaAfggcsgsa BD-11169 gscscuUfcCfAfUfucggcgguaa(L96) (vinu)sUfsaccGfccgaaugGfaAfggcsgsaBD-11170 gscscuucCfaUfUfCfggcgGfuaCfaa(L96) (vinu)sUfsguaCfcgccgaaUfgGfaaggcsgsa BD-11171 gscscuucCfaUfUfCfggcgGfuaCfaa(L96) (vinu)sUfsguaCfcGfCfcgaaUfgGfaaggcsgsa BD-11172 gscscuucCfaUfUfCfggcgGfUfacaa(L96) (vinu)sUfsguaCfcgccgaaUfgGfaaggcsgsa BD-11173 gscscuucCfaUfUfCfggcgGfUfacaa(L96) (vinu) sU fsguaCfc Gf CfcgaaU fgGfaaggc sgsa BD-11174 gscscuucCfaUfUfCfggcgguacaa(L96) (vinu)sUfsguaCfcgccgaaUfgGfaaggcsgsa BD-11175 gscscuucCfaUfUfCfggcgguacaa(L96) (vinu)sUfsguaCfcGfCfcgaaUfgGfaaggcsgsa BD-11176 gscscuUfcCfAfUfucggcgguaa(L96) (vinu)sUfsaccGfcCfGfaaugGfaAfggcsgsa BD-11177 cscsuuCfcAfUfUfcggcGfguAfca(L96) (vinu)sGfsuacCfgccgaauGfgAfaggscsgBD-11178 cscsuuCfcAfUfUfcggcGfguAfca(L96) (vinu)sGfsuacCfgCfCfgaauGfgAfaggscsg BD-11179 cscsuuCfcAIUfUfcggcGfGfuaca(L96) (vinu)sGfsuacCfgccgaauGfgAfaggscsgBD-11180 cscsuuCfcAfUfUfcggcGfGIuaca(L96) (vinu)sGfsuacCfgCfCfgaauGfgAfaggscsg BD-11181 cscsuuCfcAIUfUfcggcgguaca(L96) (vinu)sGfsuacCfgccgaauGfgAfaggscsgBD-11182 cscsuuccAfuUfCfGfgcggUfacAfua(L96) (vinu)sAfsuguAfccgccgaAfuGfgaaggscsg BD-11183 cscsuuccAfuUfCfGfgcggUfacAfua(L96) (vinu)sAfsuguAfcCfGfccgaAfuGfgaaggscsgBD-11184 cscsuuccAfuUfCfGfgcggUfAfcaua(L96) (vinu)sAfsuguAfccgccgaAfuGfgaaggscsg NAI-5008944785v1 Page 59 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11185 cscsuuccAfuUfCfGfgcggUfAfcaua(L96) (vinu)sAfsuguAfcCfGfccgaAfuGfgaaggscsg BD-11186 cscsuuccAfuUfCfGfgcgguacaua(L96) (vinu)sAfsuguAfccgccgaAfuGfgaaggscsg BD-11187 cscsuuccAfuUfCfGfgcgguacaua(L96) (vinu)sAfsuguAfcCfGfccgaAfuGfgaaggscsg BD-11188 cscsuuCfcAfUfUfcggcgguaca(L96) (vinu)sGfsuacCfgCfCfgaauGfgAfaggscsg BD-11189 csusucCfaUfUfCfggcgGfuaCfaa(L96) (vinu)sUfsguaCfcgccgaaUfgGfaagsgscBD-11190 csusucCfaUfUfCfggcgGfuaCfaa(L96) (vinu)sUfsguaCfcGfCfcgaaUfgGfaagsgsc BD-11191 csusucCfaUfUfCfggcgGfUfacaa(L96) (vinu)sUfsguaCfcgccgaaUfgGfaagsgscBD-11192 csusucCfaUfUfCfggcgGfUfacaa(L96) (vinu) sUf sguaCfc Gf CfcgaaU fgGfaagsgsc BD-11193 csusucCfaUfUfCfggcgguacaa(L96) (vinu)sUfsguaCfcgccgaaUfgGfaagsgscBD-11194 csusuccaUfuCfGfGfcgguAfcaUfga(L96) (vinu)sCfsaugUfaccgccgAfaUfggaagsgsc BD-11195 csusuccaUfuCfGfGfcgguAfcaUfga(L96) (vinu)sCfsaugUfaCfCfgccgAfaUfggaagsgsc BD-11196 csusuccaUfuCfGfGfcgguAfCfauga(L96) (vinu)sCfsaugUfaccgccgAfaUfggaagsgsc BD-11197 csusuccaUfuCfGfGfcgguAfCfauga(L96) (vinu)sCfsaugUfaCfCfgccgAfaUfggaagsgsc BD-11198 csusuccaUfuCfGfGfcgguacauga(L96) (vinu)sCfsaugUfaccgccgAfaUfggaagsgsc BD-11199 csusuccaUfuCfGfGfcgguacauga(L96) (vinu)sCfsaugUfaCfCfgccgAfaUfggaagsgsc BD-11200 csusucCfaUfUfCfggcgguacaa(L96) (vinu) sUf sguaCfc Gf CfcgaaU fgGfaagsgsc BD-11201 ususccAfuUfCfGfgcggUfacAfua(L96) (vinu)sAfsuguAfccgccgaAfuGfgaasgsgBD-11202 ususccAfuUfCfGfgcggUfacAfua(L96) (vinu)sAfsuguAfcCfGfccgaAfuGfgaasgsg BD-11203 ususccAfuUfCfGfgcggUfAfcaua(L96) (vinu)sAfsuguAfccgccgaAfuGfgaasgsgBD-11204 ususccAfuUfCfGfgcggUfAfcaua(L96) (vinu)sAfsuguAfcCfGfccgaAfuGfgaasgsg BD-11205 ususccAfuUfCfGfgcgguacaua(L96) (vinu)sAfsuguAfccgccgaAfuGfgaasgsgBD-11206 ususccauUfcGfGfCfgguaCfauGfga(L96) (vinu)sCfscauGfuaccgccGfaAfuggaasgsg BD-11207 ususccauUfcGfGfCfgguaCfauGfga(L96) (vinu)sCfscauGfuAfCfcgccGfaAfuggaasgsg BD-11208 ususccauUfcGfGfCfgguaCfAfugga(L96) (vinu)sCfscauGfuaccgccGfaAfuggaasgsg BD-11209 ususccauUfcGfGfCfgguaCfAfugga(L96) (vinu)sCfscauGfuAfCfcgccGfaAfuggaasgsg BD-11210 ususccauUfcGfGfCfgguacaugga(L96) (vinu)sCfscauGfuaccgccGfaAfuggaasgsg BD-11211 ususccauUfcGfGfCfgguacaugga(L96) (vinu)sCfscauGfuAfCfcgccGfaAfuggaasgsg BD-11212 ususccAfuUfCfGfgcgguacaua(L96) (vinu)sAfsuguAfcCfGfccgaAfuGfgaasgsg BD-11213 uscscaUfuCfGfGfcgguAfcaUfga(L96) (vinu)sCfsaugUfaccgccgAfaUfggasasgBD-11214 uscscaUfuCfGfGfcgguAfcaUfga(L96) (vinu)sCfsaugUfaCfCfgccgAfaUfggasasg BD-11215 uscscaUfuCfGfGfcgguAfCfauga(L96) (vinu)sCfsaugUfaccgccgAfaUfggasasgBD-11216 uscscaUfuCfGfGfcgguAfCfauga(L96) (vinu)sCfsaugUfaCfCfgccgAfaUfggasasg BD-11217 uscscaUfuCfGfGfcgguacauga(L96) (vinu)sCfsaugUfaccgccgAfaUfggasasgBD-11218 uscscauuCfgGfCfGfguacAfugGfca(L96) (vinu)sGfsccaUfguaccgcCfgAfauggasasg BD-11219 uscscauuCfgGfCfGfguacAfugGfca(L96) (vinu)sGfsccaUfgUfAfccgcCfgAfauggasasg BD-11220 uscscauuCfgGfCfGfguacAfUfggca(L96) (vinu)sGfsccaUfguaccgcCfgAfauggasasg BD-11221 uscscauuCfgGfCfGfguacAfUfggca(L96) (vinu)sGfsccaUfgUfAfccgcCfgAfauggasasg BD-11222 uscscauuCfgGfCfGfguacauggca(L96) (vinu)sGfsccaUfguaccgcCfgAfauggasasg BD-11223 uscscauuCfgGfCfGfguacauggca(L96) (vinu)sGfsccaUfgUfAfccgcCfgAfauggasasg BD-11224 uscscaUfuCfGfGfcgguacauga(L96) (vinu)sCfsaugUfaCfCfgccgAfaUfggasasg BD-11225 cscsauUfcGfGfCfgguaCfauGfga(L96) (vinu)sCfscauGfuaccgccGfaAfuggsasaBD-11226 cscsauUfcGfGfCfgguaCfauGfga(L96) (vinu)sCfscauGfuAfCfcgccGfaAfuggsasa BD-11227 cscsauUfcGfGfCfgguaCfAfugga(L96) (vinu)sCfscauGfuaccgccGfaAfuggsasaBD-11228 cscsauUfcGfGfCfgguaCfAfugga(L96) (vinu)sCfscauGfuAfCfcgccGfaAfuggsasa BD-11229 cscsauUfcGfGfCfgguacaugga(L96) (vinu)sCfscauGfuaccgccGfaAfuggsasaBD-11230 cscsauucGfgCfGfGfuacaUfggCfaa(L96) (vinu)sUfsgccAfuguaccgCfcGfaauggsasa BD-11231 cscsauucGfgCfGfGfuacaUfggCfaa(L96) (vinu)sUfsgccAfuGfUfaccgCfcGfaauggsasa BD-11232 cscsauucGfgCfGfGfuacaUfGfgcaa(L96) (vinu)sUfsgccAfuguaccgCfcGfaauggsasa BD-11233 cscsauucGfgCfGfGfuacaUfGfgcaa(L96) (vinu)sUfsgccAfuGfUfaccgCfcGfaauggsasa BD-11234 cscsauucGfgCfGfGfuacauggcaa(L96) (vinu)sUfsgccAfuguaccgCfcGfaauggsasaBD-11235 cscsauucGfgCfGfGfuacauggcaa(L96) (vinu)sUfsgccAfuGfUfaccgCfcGfaauggsasa NAI-5008944785v1 Page 60 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11236 cscsauUfcGIGfCfgguacaugga(L96) (vinu)sCfscauGfuAfCfcgccGfaAfuggsasa BD-11237 csasuuCfgGfCfGfguacAfugGfca(L96) (vinu)sGfsccaUfguaccgcCfgAfaugsgsaBD-11238 csasuuCfgGfCfGfguacAfugGfca(L96) (vinu)sGfsccaUfgUfAfccgcCfgAfaugsgsa BD-11239 csasuuCfgGfCfGfguacAfUfggca(L96) (vinu)sGfsccaUfguaccgcCfgAfaugsgsaBD-11240 csasuuCfgGfCfGfguacAfUfggca(L96) (vinu)sGfsccaUfgUfAfccgcCfgAfaugsgsa BD-11241 csasuuCfgGfCfGfguacauggca(L96) (vinu)sGfsccaUfguaccgcCfgAfaugsgsaBD-11242 csasuucgGfcGfGfUfacauGfgcAfua(L96) (vinu)sAfsugcCfauguaccGfcCfgaaugsgsa BD-11243 csasuucgGfcGfGfUfacauGfgcAfua(L96) (vinu)sAfsugcCfaUfGfuaccGfcCfgaaugsgsa BD-11244 csasuucgGfcGfGfUfacauGfGfcaua(L96) (vinu)sAfsugcCfauguaccGfcCfgaaugsgsa BD-11245 csasuucgGfcGfGfUfacauGfGfcaua(L96) (vinu)sAfsugcCfaUfGfuaccGfcCfgaaugsgsa BD-11246 csasuucgGfcGfGfUfacauggcaua(L96) (vinu)sAfsugcCfauguaccGfcCfgaaugsgsa BD-11247 csasuucgGfcGfGfUfacauggcaua(L96) (vinu)sAfsugcCfaUfGfuaccGfcCfgaaugsgsa BD-11248 csasuuCfgGfCfGfguacauggca(L96) (vinu)sGfsccaUfgUfAfccgcCfgAfaugsgsa BD-11249 ususcgGfcGfGfUfacauGfgcAfua(L96) (vinu)sAfsugcCfauguaccGfcCfgaasusgBD-11250 ususcgGfcGfGfUfacauGfgcAfua(L96) (vinu)sAfsugcCfaUfGfuaccGfcCfgaasusg BD-11251 ususcgGfcGfGfUfacauGfGfcaua(L96) (vinu)sAfsugcCfauguaccGfcCfgaasusgBD-11252 ususcgGfcGfGfUfacauGfGfcaua(L96) (vinu)sAfsugcCfaUfGfuaccGfcCfgaasusg BD-11253 ususcgGfcGfGfUfacauggcaua(L96) (vinu)sAfsugcCfauguaccGfcCfgaasusgBD-11254 ususcggcGfgUfAfCfauggCfauCfga(L96) (vinu)sCfsgauGfccauguaCfcGfccgaasusg BD-11255 ususcggcGfgUfAfCfauggCfauCfga(L96) (vinu)sCfsgauGfcCfAfuguaCfcGfccgaasusg BD-11256 ususcggcGfgUfAfCfauggCfAfucga(L96) (vinu)sCfsgauGfccauguaCfcGfccgaasusg BD-11257 ususcggcGfgUfAfCfauggCfAfucga(L96) (vinu)sCfsgauGfcCfAfuguaCfcGfccgaasusg BD-11258 ususcggcGfgUfAfCfauggcaucga(L96) (vinu)sCfsgauGfccauguaCfcGfccgaasusg BD-11259 ususcggcGfgUfAfCfauggcaucga(L96) (vinu)sCfsgauGfcCfAfuguaCfcGfccgaasusg BD-11260 ususcgGfcGfGfUfacauggcaua(L96) (vinu)sAfsugcCfaUfGfuaccGfcCfgaasusg BD-11261 uscsggCfgGfUfAfcaugGfcaUfca(L96) (vinu)sGfsaugCfcauguacCfgCfcgasasuBD-11262 uscsggCfgGlU f AfcaugGfcaUfca(L96) (vinu)sGfsaugCfcAlUfguacCfgCfcgasasu BD-11263 uscsggCfgGIUfAfcaugGfCfauca(L96) (vinu)sGfsaugCfcauguacCfgCfcgasasuBD-11264 uscsggCfgGfUfAfcaugGfCfauca(L96) (vinu)sGfsaugCfcAfUfguacCfgCfcgasasu BD-11265 uscsggCfgGIUfAfcauggcauca(L96) (vinu)sGfsaugCfcauguacCfgCfcgasasuBD-11266 uscsggcgGfuAfCfAfuggcAfucGfaa(L96) (vinu)sUfscgaUfgccauguAfcCfgccgasasu BD-11267 uscsggcgGfuAfCfAfuggcAfucGfaa(L96) (vinu)sUfscgaUfgCfCfauguAfcCfgccgasasu BD-11268 uscsggcgGfuAfCfAfuggcAfUfcgaa(L96) (vinu)sUfscgaUfgccauguAfcCfgccgasasu BD-11269 uscsggcgGfuAfCfAfuggcAfUfcgaa(L96) (vinu)sUfscgaUfgCfCfauguAfcCfgccgasasu BD-11270 uscsggcgGfuAfCfAfuggcaucgaa(L96) (vinu)sUfscgaUfgccauguAfcCfgccgasasu BD-11271 uscsggcgGfuAfCfAfuggcaucgaa(L96) (vinu)sUfscgaUfgCfCfauguAfcCfgccgasasu BD-11272 uscsggCfgGfUfAfcauggcauca(L96) (vinu)sGfsaugCfcAfUfguacCfgCfcgasasu BD-11273 csgsgcGfgUfAfCfauggCfauCfga(L96) (vinu)sCfsgauGfccauguaCfcGfccgsasaBD-11274 csgsgcGfgUfAfCfauggCfauCfga(L96) (vinu)sCfsgauGfcCfAfuguaCfcGfccgsasa BD-11275 csgsgcGfgUfAfCfauggCfAfucga(L96) (vinu)sCfsgauGfccauguaCfcGfccgsasaBD-11276 csgsgcGfgUfAfCfauggCfAfucga(L96) (vinu)sCfsgauGfcCfAfuguaCfcGfccgsasa BD-11277 csgsgcGfgUfAfCfauggcaucga(L96) (vinu)sCfsgauGfccauguaCfcGfccgsasaBD-11278 csgsgcggUfaCfAfUfggcaUfcgAfaa(L96) (vinu)sUfsucgAfugccaugUfaCfcgccgsasa BD-11279 csgsgcggUfaCfAfUfggcaUfcgAfaa(L96) (vinu)sUfsucgAfuGfCfcaugUfaCfcgccgsasa BD-11280 csgsgcggUfaCfAfUfggcaUfCfgaaa(L96) (vinu)sUfsucgAfugccaugUfaCfcgccgsasa BD-11281 csgsgcggUfaCfAfUfggcaUfCfgaaa(L96) (vinu)sUfsucgAfuGfCfcaugUfaCfcgccgsasa BD-11282 csgsgcggUfaCfAfUfggcaucgaaa(L96) (vinu)sUfsucgAfugccaugUfaCfcgccgsasa BD-11283 csgsgcggUfaCfAfUfggcaucgaaa(L96) (vinu)sUfsucgAfuGfCfcaugUfaCfcgccgsasa BD-11284 csgsgcGfgUfAfCfauggcaucga(L96) (vinu)sCfsgauGfcCfAfuguaCfcGfccgsasa BD-11285 gsgscgGfuAfCfAfuggcAfucGfaa(L96) (vinu)sUfscgaUfgccauguAfcCfgccsgsaBD-11286 gsgscgGfuAfCfAfuggcAfucGfaa(L96) (vinu)sUfscgaUfgCfCfauguAfcCfgccsgsa NAI-5008944785v1 Page 61 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11287 gsgscgGfuAfCfAfuggcAfUfcgaa(L96) (vinu)sUfscgaUfgccauguAfcCfgccsgsaBD-11288 gsgscgGfuAfCfAfuggcAfUfcgaa(L96) (vinu)sUfscgaUfgCfCfauguAfcCfgccsgsa BD-11289 gsgscgGfuAfCf Afuggcaucgaa(L96 ) (vinu)sUfscgaUfgccauguAfcCfgccsgsaBD-11290 gsgscgguAfcAfUfGfgcauCfgaAfga(L96) (vinu)sCfsuucGfaugccauGfuAfccgccsgsa BD-11291 gsgscgguAfcAfUfGfgcauCfgaAfga(L96) (vinu)sCfsuucGfaUfGfccauGfuAfccgccsgsa BD-11292 gsgscgguAfcAfUfGfgcauCfGfaaga(L96) (vinu)sCfsuucGfaugccauGfuAfccgccsgsa BD-11293 gsgscgguAfcAIUfGfgcauCfGfaaga(L96) (vinu)sCfsuucGfaUfGfccauGfuAfccgccsgsa BD-11294 gsgscgguAfcAfUfGfgcaucgaaga(L96) (vinu)sCfsuucGfaugccauGfuAfccgccsgsa BD-11295 gsgscgguAfcAfUfGfgcaucgaaga(L96) (vinu)sCfsuucGfaUfGfccauGfuAfccgccsgsa BD-11296 gsgscgGfuAfCfAfuggcaucgaa(L96) (vinu)sUfscgaUfgCfCfauguAfcCfgccsgsa BD-11297 gscsggUfaCfAfUfggcaUfcgAfaa(L96) (vinu)sUfsucgAfugccaugUfaCfcgcscsgBD-11298 gscsggUfaCfAfUfggcaUfcgAfaa(L96) (vinu)sUfsucgAfuGfCfcaugUfaCfcgcscsg BD-11299 gscsggUfaCfAfUfggcaUfCfgaaa(L96) (vinu)sUfsucgAfugccaugUfaCfcgcscsgBD-11300 gscsggUfaCfAfUfggcaUfCfgaaa(L96) (vinu)sUfsucgAfuGfCfcaugUfaCfcgcscsg BD-11301 gscsggUfaCfAfUfggcaucgaaa(L96) (vinu)sUfsucgAfugccaugUfaCfcgcscsgBD-11302 gscsgguaCfaUfGfGfcaucGfaaGfaa(L96) (vinu)sUfscuuCfgaugccaUfgUfaccgcscsg BD-11303 gscsgguaCfaUfGfGfcaucGfaaGfaa(L96) (vinu)sUfscuuCfgAfUfgccaUfgUfaccgcscsg BD-11304 gscsgguaCfaUfGfGfcaucGfAfagaa(L96) (vinu)sUfscuuCfgaugccaUfgUfaccgcscsg BD-11305 gscsgguaCfaUfGIGfcaucGfAfagaa(L96) (vinu)sUfscuuCfgAIUfgccaUfgUfaccgcscsg BD-11306 gscsgguaCfaUfGfGfcaucgaagaa(L96) (vinu)sUfscuuCfgaugccaUfgUfaccgcscsg BD-11307 gscsgguaCfaUfGfGfcaucgaagaa(L96) (vinu)sUfscuuCfgAfUfgccaUfgUfaccgcscsg BD-11308 gscsggUfaCfAfUfggcaucgaaa(L96) (vinu)sUfsucgAfuGfCfcaugUfaCfcgcscsg BD-11309 csgsguAfcAfUfGfgcauCfgaAfga(L96) (vinu)sCfsuucGfaugccauGfuAfccgscscBD-11310 csgsguAfcAfUfGfgcauCfgaAfga(L96) (vinu)sCfsuucGfaUfGfccauGfuAfccgscsc BD-11311 csgsguAfcAfUfGfgcauCfGfaaga(L96) (vinu)sCfsuucGfaugccauGfuAfccgscscBD-11312 csgsguAfcAfUfGfgcauCfGfaaga(L96) (vinu)sCfsuucGfaUfGfccauGfuAfccgscsc BD-11313 csgsguAfcAfUIGfgcaucgaaga(L96) (vinu)sCfsuucGfaugccauGfuAfccgscscBD-11314 csgsguacAfuGfGfCfaucgAfagAfca(L96) (vinu)sGfsucuUfcgaugccAfuGfuaccgscsc BD-11315 csgsguacAfuGfGfCfaucgAfagAfca(L96) (vinu)sGfsucuUfcGfAfugccAfuGfuaccgscsc BD-11316 csgsguacAfuGfGfCfaucgAfAfgaca(L96) (vinu)sGfsucuUfcgaugccAfuGfuaccgscsc BD-11317 csgsguacAfuGfGfCfaucgAfAfgaca(L96) (vinu)sGfsucuUfcGfAfugccAfuGfuaccgscsc BD-11318 csgsguacAfuGfGfCfaucgaagaca(L96) (vinu)sGfsucuUfcgaugccAfuGfuaccgscsc BD-11319 csgsguacAfuGfGfCfaucgaagaca(L96) (vinu)sGfsucuUfcGfAfugccAfuGfuaccgscsc BD-11320 csgsguAfcAfUfGfgcaucgaaga(L96) (vinu)sCfsuucGfaUfGfccauGfuAfccgscsc BD-11321 gsgsuaCfaUfGfGfcaucGfaaGfaa(L96) (vinu)sUfscuuCfgaugccaUfgUfaccsgscBD-11322 gsgsuaCfaUfGfGfcaucGfaaGfaa(L96) (vinu)sUfscuuCfgAfUfgccaUfgUfaccsgsc BD-11323 gsgsuaCfaUfGfGfcaucGfAfagaa(L96) (vinu)sUfscuuCfgaugccaUfgUfaccsgscBD-11324 gsgsuaCfaUfGfGfcaucGfAfagaa(L96) (vinu)sUfscuuCfgAIUfgccaUfgUfaccsgsc BD-11325 gsgsuaCfaUfGfGfcaucgaagaa(L96) (vinu)sUfscuuCfgaugccaUfgUfaccsgscBD-11326 gsgsuacaUfgGfCfAfucgaAfgaCfca(L96) (vinu)sGfsgucUfucgaugcCfaUfguaccsgsc BD-11327 gsgsuacaUfgGfCfAfucgaAfgaCfca(L96) (vinu)sGfsgucUfiiCfGfaugcCfaUfguaccsgsc BD-11328 gsgsuacaUfgGfCfAfucgaAfGfacca(L96) (vinu)sGfsgucUfucgaugcCfaUfguaccsgsc BD-11329 gsgsuacaUfgGfCfAfucgaAfGfacca(L96) (vinu)sGfsgucUfuCfGfaugcCfaUfguaccsgsc BD-11330 gsgsuacaUfgGfCfAfucgaagacca(L96) (vinu)sGfsgucUfucgaugcCfaUfguaccsgsc BD-11331 gsgsuacaUfgGfCfAfucgaagacca(L96) (vinu)sGfsgucUfuCfGfaugcCfaUfguaccsgsc BD-11332 gsgsuaCfaUfGfGfcaucgaagaa(L96) (vinu)sUfscuuCfgAIUfgccaUfgUfaccsgsc BD-11333 asuscgAfaGfAfCfcugaUfgaUfca(L96) (vinu)sGfsaucAfucaggucUfuCfgausgscBD-11334 asuscgAfaGfAfCfcugaUfgaUfca(L96) (vinu)sGfsaucAfuCfAfggucUfuCfgausgsc BD-11335 asuscgAfaGfAfCfcugaUfGfauca(L96) (vinu)sGfsaucAfucaggucUfuCfgausgscBD-11336 asuscgAfaGfAfCfcugaUfGfauca(L96) (vinu)sGfsaucAfuCfAfggucUfuCfgausgscBD-11337 asuscgAfaGfAfCfcugaugauca(L96) (vinu)sGfsaucAfucaggucUfuCfgausgscNAI-5008944785v1 Page 62 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11338 asuscgaaGfaCfCfUfgaugAfucCfaa(L96) (vinu)sUfsggaUfcaucaggUfcUfucgausgsc BD-11339 asuscgaaGfaCfCfUfgaugAfucCfaa(L96) (vinu)sUfsggaUfcAfUfcaggUfcUfucgausgsc BD-11340 asuscgaaGfaCfCfUfgaugAIUfccaa(L96) (vinu)sUfsggaUfcaucaggUfcUfucgausgsc BD-11341 asuscgaaGfaCfCfUfgaugAfUfccaa(L96) (vinu)sUfsggaUfcAfUfcaggUfcUfucgausgsc BD-11342 asuscgaaGfaCfCfUfgaugauccaa(L96) (vinu)sUfsggaUfcaucaggUfcUfucgausgsc BD-11343 asuscgaaGfaCfCfUfgaugauccaa(L96) (vinu)sUfsggaUfcAfUfcaggUfcUfucgausgsc BD-11344 asuscgAfaGfAfCfcugaugauca(L96) (vinu)sGfsaucAfuCfAfggucUfuCfgausgsc BD-11345 csusgaUfgAfUfCfcagcAfcaAfca(L96) (vinu)sGfsuugUfgcuggauCfaUfcagsgsuBD-11346 csusgaUfgAfUfCfcagcAfcaAfca(L96) (vinu)sGfsuugUfgCfUfggauCfaUfcagsgsu BD-11347 csusgaUfgAfUfCfcagcAfCfaaca(L96) (vinu)sGfsuugUfgcuggauCfaUfcagsgsuBD-11348 csusgaUfgAfUfCfcagcAfCfaaca(L96) (vinu)sGfsuugUfgCIUfggauCfaUfcagsgsu BD-11349 csusgaUfgAfUfCfcagcacaaca(L96) (vinu)sGfsuugUfgcuggauCfaUfcagsgsuBD-11350 csusgaugAfuCfCfAfgcacAfacUfga(L96) (vinu)sCfsaguUfgugcuggAfuCfaucagsgsu BD-11351 csusgaugAfuCfCfAfgcacAfacUfga(L96) (vinu)sCfsaguUfgUfGfcuggAfuCfaucagsgsu BD-11352 csusgaugAfuCfCfAfgcacAfAfcuga(L96) (vinu)sCfsaguUfgugcuggAfuCfaucagsgsu BD-11353 csusgaugAfuCfCfAfgcacAfAfcuga(L96) (vinu)sCfsaguUfgUfGfcuggAfuCfaucagsgsu BD-11354 csusgaugAfuCfCfAfgcacaacuga(L96) (vinu)sCfsaguUfgugcuggAfuCfaucagsgsu BD-11355 csusgaugAfuCfCfAfgcacaacuga(L96) (vinu)sCfsaguUfgUfGfcuggAfuCfaucagsgsu BD-11356 csusgaUfgAfUfCfcagcacaaca(L96) (vinu)sGfsuugUfgCIUfggauCfaUfcagsgsu BD-11357 usgsauGfaUfCfCfagcaCfaaCfua(L96) (vinu)sAfsguuGfugcuggaUfcAfucasgsgBD-11358 usgsauGfaUfCfCfagcaCfaaCfua(L96) (vinu)sAfsguuGfuGfCfuggaUfcAfucasgsg BD-11359 usgsauGfaUfCfCfagcaCfAfacua(L96) (vinu)sAfsguuGfugcuggaUfcAfucasgsgBD-11360 usgsauGfaUfCfCfagcaCfAfacua(L96) (vinu)sAfsguuGfuGfCfuggaUfcAfucasgsg BD-11361 usgsauGfaUfCfCfagcacaacua(L96) (vinu)sAfsguuGfugcuggaUfcAfucasgsgBD-11362 usgsaugaUfcCfAfGfcacaAfcuGfca(L96) (vinu)sGfscagUfugugcugGfaLJfcaucasgsg BD-11363 usgsaugaUfcCfAfGfcacaAfcuGfca(L96) (vinu)sGfscagUfuGfUfgcugGfaUfcaucasgsg BD-11364 usgsaugaUfcCfAfGfcacaAfCfugca(L96) (vinu)sGfscagUfugugcugGfaUfcaucasgsg BD-11365 usgsaugaUfcCfAfGfcacaAfCfugca(L96) (vinu)sGfscagUfuGfUfgcugGfaUfcaucasgsg BD-11366 usgsaugaUfcCfAfGfcacaacugca(L96) (vinu)sGfscagUfugugcugGfaUfcaucasgsg BD-11367 usgsaugaUfcCfAfGfcacaacugca(L96) (vinu)sGfscagUfuGIUfgcugGfaUfcaucasgsg BD-11368 usgsauGfaUfCfCfagcacaacua(L96) (vinu)sAfsguuGfuGfCfuggaUfcAfucasgsg BD-11369 gscsccCfgGfAfCfccuuGfugAfca(L96) (vinu)sGfsucaCfaagggucCfgGfggcsasgBD-11370 gscsccCfgGfAfCfccuuGfugAfca(L96) (vinu)sGfsucaCfaAfGfggucCfgGfggcsasg BD-11371 gscsccCfgGfAfCfccuuGfUfgaca(L96) (vinu)sGfsucaCfaagggucCfgGfggcsasgBD-11372 gscsccCfgGfAfCfccuuGfUfgaca(L96) (vinu)sGfsucaCfaAfGfggucCfgGfggcsasg BD-11373 gscsccCfgGfAfCfccuugugaca(L96) (vinu)sGfsucaCfaagggucCfgGfggcsasgBD-11374 gscscccgGfaCfCfCfuuguGfacUfaa(L96) (vinu)sUfsaguCfacaagggUfcCfggggcsasg BD-11375 gscscccgGfaCfCfCfuuguGfacUfaa(L96) (vinu)sUfsaguCfaCfAfagggUfcCfggggcsasg BD-11376 gscscccgGfaCfCfCfuuguGfAfcuaa(L96) (vinu)sUfsaguCfacaagggUfcCfggggcsasg BD-11377 gscscccgGfaCfCfCfuuguGfAfcuaa(L96) (vinu)sUfsaguCfaCfAfagggUfcCfggggcsasg BD-11378 gscscccgGfaCfCfCfuugugacuaa(L96) (vinu)sUfsaguCfacaagggUfcCfggggcsasg BD-11379 gscscccgGfaCfCfCfuugugacuaa(L96) (vinu)sUfsaguCfaCfAfagggUfcCfggggcsasg BD-11380 gscsccCfgGfAfCfccuugugaca(L96) (vinu)sGfsucaCfaAfGfggucCfgGfggcsasg BD-11381 cscsccGfgAfCfCfcuugUfgaCfua(L96) (vinu)sAfsgucAfcaaggguCfcGfgggscsaBD-11382 cscsccGfgAfCfCfcuugUfgaCfua(L96) (vinu) s Af sguc Afc Af AfggguC fcGfgggsc sa BD-11383 cscsccGfgAfCfCfcuugUfGfacua(L96) (vinu)sAfsgucAfcaaggguCfcGfgggscsaBD-11384 cscsccGfgAfCfCfcuugUfGfacua(L96) (vinu)sAfsgucAfcAfAfggguCfcGfgggscsa BD-11385 cscsccGfgAfCfCfcuugugacua(L96) (vinu)sAfsgucAfcaaggguCfcGfgggscsaBD-11386 cscsccggAfcCfCfUfugugAfcuAfua(L96) (vinu)sAfsuagUfcacaaggGfuCfcggggscsa BD-11387 cscsccggAfcCfCfUfugugAfcuAfua(L96) (vinu)sAfsuagUfcAfCfaaggGfuCfcggggscsaBD-11388 cscsccggAfcCfCfUfugugAfCfuaua(L96) (vinu)sAfsuagUfcacaaggGfuCfcggggscsa NAI-5008944785v1 Page 63 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11389 cscsccggAfcCfCfUfugug7VfCfuaua(L96) (vinu)sAfsuagUfcAfCfaaggGfuCfcggggscsa BD-11390 cscsccggAfcCfCfUfugugacuaua(L96) (vinu)sAfsuagUfcacaaggGfuCfcggggscsa BD-11391 cscsccggAfcCfCfUfugugacuaua(L96) (vinu)sAfsuagUfcAfCfaaggGfuCfcggggscsa BD-11392 cscsccGfgAfCfCfcuugugacua(L96) (vinu)sAfsgucAfcAfAfggguCfcGfgggscsa BD-11393 cscscgGfaCfCfCfuuguGfacUfaa(L96) (vinu)sUfsaguCfacaagggUfcCfgggsgscBD-11394 cscscgGfaCfCfCfuuguGfacUfaa(L96) (vinu)sUfsaguCfaCfAfagggUfcCfgggsgsc BD-11395 cscscgGfaCfCfCfuuguGfAfcuaa(L96) (vinu)sUfsaguCfacaagggUfcCfgggsgscBD-11396 cscscgGfaCfCfCfuuguGfAfcuaa(L96) (vinu)sUfsaguCfaCfAfagggUfcCfgggsgsc BD-11397 cscscgGfaCfCfCfuugugacuaa(L96) (vinu)sUfsaguCfacaagggUfcCfgggsgscBD-11398 cscscggaCfcCfUfUfgugaCfuaUfga(L96) (vinu)sCfsauaGfucacaagGfgUfccgggsgsc BD-11399 cscscggaCfcCfUfUfgugaCfuaUfga(L96) (vinu)sCfsauaGfuCfAfcaagGfgUfccgggsgsc BD-11400 cscscggaCfcCfUfUfgugaCfUfauga(L96) (vinu)sCfsauaGfucacaagGfgUfccgggsgsc BD-11401 cscscggaCfcCfUfUfgugaCfUfauga(L96) (vinu)sCfsauaGfuCfAfcaagGfgUfccgggsgsc BD-11402 cscscggaCfcCfUfUfgugacuauga(L96) (vinu)sCfsauaGfucacaagGfgUfccgggsgsc BD-11403 cscscggaCfcCfUfUfgugacuauga(L96) (vinu)sCfsauaGfuCfAfcaagGfgUfccgggsgsc BD-11404 cscscgGfaCfCfCfuugugacuaa(L96) (vinu)sUfsaguCfaCfAfagggUfcCfgggsgsc BD-11405 gsusgaCfuAfUfGfaaggCfcgGfua(L96) (vinu)sAfsccgGfccuucauAfgUfcacsasaBD-11406 gsusgaCfuAfUfGfaaggCfcgGfua(L96) (vinu)sAfsccgGfcCfUfucauAfgUfcacsasa BD-11407 gsusgaCfuAfUfGfaaggCfCfggua(L96) (vinu)sAfsccgGfccuucauAfgUfcacsasaBD-11408 gsusgaCfuAfUfGfaaggCfCfggua(L96) (vinu)sAfsccgGfcCfUfucauAfgUfcacsasa BD-11409 gsusgaCfuAIUfGfaaggccggua(L96) (vinu)sAfsccgGfccuucauAfgUfcacsasaBD-11410 gsusgacuAfuGfAfAfggccGfguUfua(L96) (vinu)sAfsaacCfggccuucAfuAfgucacsasa BD-11411 gsusgacuAfuGfAfAfggccGfguUfua(L96) (vinu)sAfsaacCfgGfCfcuucAfuAfgucacsasa BD-11412 gsusgacuAfuGfAfAfggccGfGfuuua(L96) (vinu)sAfsaacCfggccuucAfuAfgucacsasa BD-11413 gsusgacuAfuGfAfAfggccGfGfuuua(L96) (vinu)sAfsaacCfgGfCfcuucAfuAfgucacsasa BD-11414 gsusgacuAfuGfAfAfggccgguuua(L96) (vinu)sAfsaacCfggccuucAfuAfgucacsasa BD-11415 gsusgacuAfuGfAfAfggccgguuua(L96) (vinu)sAfsaacCfgGfCfcuucAfuAfgucacsasa BD-11416 gsusgaCfuAfUfGfaaggccggua(L96) (vinu)sAfsccgGfcCfUfucauAfgUfcacsasa BD-11417 usgsacUfaUfGfAfaggcCfggUfua(L96) (vinu)sAfsaccGfgccuucaUfaGfucascsaBD-11418 usgsacUfaUfGfAfaggcCfggUfua(L96) (vinu)sAfsaccGfgCfCfuucaUfaGfucascsa BD-11419 usgsacUfaUfGfAfaggcCfGfguua(L96) (vinu)sAfsaccGfgccuucaUfaGfucascsaBD-11420 usgsacUfaUfGfAfaggcCfGfguua(L96) (vinu)sAfsaccGfgCfCfuucaUfaGfucascsa BD-11421 usgsacUfaUfGfAfaggccgguua(L96) (vinu)sAfsaccGfgccuucaUfaGfucascsaBD-11422 usgsacuaUfgAfAfGfgccgGfuuUfua(L96) (vinu)sAfsaaaCfcggccuuCfaUfagucascsa BD-11423 usgsacuaUfgAfAfGfgccgGfuuUfua(L96) (vinu) s Af saaaCfc Gf GfccuuCfaUfagucasc sa BD-11424 usgsacuaUfgAfAfGfgccgGfUfuuua(L96) (vinu)sAfsaaaCfcggccuuCfaUfagucascsa BD-11425 usgsacuaUfgAfAfGfgccgGfUfuuua(L96) (vinu)sAfsaaaCfcGfGfccuuCfaUfagucascsa BD-11426 usgsacuaUfgAfAfGfgccgguuuua(L96) (vinu)sAfsaaaCfcggccuuCfaUfagucascsa BD-11427 usgsacuaUfgAfAfGfgccgguuuua(L96) (vinu)sAfsaaaCfcGfGfccuuCfaUfagucascsa BD-11428 usgsacUfaUfGfAfaggccgguua(L96) (vinu) s Af sacc GfgCfCfuucaUfaGfucasc sa BD-11429 ascsuaUfgAfAfGfgccgGfuuUfua(L96) (vinu)sAfsaaaCfcggccuuCfaUfaguscsaBD-11430 ascsuaUfgAfAfGfgccgGfuuUfua(L96) (vinu)sAfsaaaCfcGfGfccuuCfaUfaguscsa BD-11431 ascsuaUfgAfAfGfgccgGIUIuuua(L96) (vinu)sAfsaaaCfcggccuuCfaUfaguscsaBD-11432 ascsuaUfgAfAfGfgccgGfUfuuua(L96) (vinu)sAfsaaaCfcGfGfccuuCfaUfaguscsa BD-11433 ascsuaUfgAfAfGfgccgguuuua(L96) (vinu)sAfsaaaCfcggccuuCfaUfaguscsaBD-11434 ascsuaugAfaGfGfCfcgguUfuuCfca(L96) (vinu)sGfsgaaAfaccggccUfuCfauaguscsa BD-11435 ascsuaugAfaGfGfCfcgguUfuuCfca(L96) (vinu)sGfsgaaAfaCfCfggccUfuCfauaguscsa BD-11436 ascsuaugAfaGfGfCfcgguUfUfucca(L96) (vinu)sGfsgaaAfaccggccUfuCfauaguscsa BD-11437 ascsuaugAfaGfGfCfcgguUfUfucca(L96) (vinu)sGfsgaaAfaCfCfggccUfuCfauaguscsa BD-11438 ascsuaugAfaGfGfCfcgguuuucca(L96) (vinu)sGfsgaaAfaccggccUfuCfauaguscsaBD-11439 ascsuaugAfaGfGfCfcgguuuucca(L96) (vinu)sGfsgaaAfaCfCfggccUfuCfauaguscsa NAI-5008944785v1 Page 64 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11440 ascsuaUfgAfAfGfgccgguuuua(L96) (vinu)sAfsaaaCfcGfGfccuuCfaUfaguscsa BD-11441 usasugAfaGfGfCfcgguUfuuCfca(L96) (vinu)sGfsgaaAfaccggccUfuCfauasgsuBD-11442 usasugAfaGfGfCfcgguUfuuCfca(L96) (vinu)sGfsgaaAfaCfCfggccUfuCfauasgsu BD-11443 usasugAfaGfGfCfcgguUfUfucca(L96) (vinu)sGfsgaaAfaccggccUfuCfauasgsuBD-11444 usasugAfaGfGfCfcgguUfUfucca(L96) (vinu)sGfsgaaAfaCfCfggccUfuCfauasgsu BD-11445 usasugAfaGfGfCfcgguuuucca(L96) (vinu)sGfsgaaAfaccggccUfuCfauasgsuBD-11446 usasugaaGfgCfCfGfguuuUfccCfga(L96) (vinu)sCfsgggAfaaaccggCfcUfucauasgsu BD-11447 usasugaaGfgCfCfGfguuuUfccCfga(L96) (vinu)sCfsgggAfaAfAfccggCfcUfucauasgsu BD-11448 usasugaaGfgCfCfGfguuuUfCfccga(L96) (vinu)sCfsgggAfaaaccggCfcUfucauasgsu BD-11449 usasugaaGfgCfCfGfguuuUfCfccga(L96) (vinu)sCfsgggAfaAfAfccggCfcUfucauasgsu BD-11450 usasugaaGfgCfCfGfguuuucccga(L96 ) (vinu)sCfsgggAfaaaccggCfcUfucauasgsu BD-11451 usasugaaGfgCfCfGfguuuucccga(L96) (vinu)sCfsgggAfaAfAfccggCfcUfucauasgsu BD-11452 usasugAfaGfGfCfcgguuuucca(L96) (vinu)sGfsgaaAfaCfCfggccUfuCfauasgsu BD-11453 usgsaaGfgCfCfGfguuuUfccCfga(L96) (vinu)sCfsgggAfaaaccggCfcUfucasusaBD-11454 usgsaaGfgCfCfGfguuuUfccCfga(L96) (vinu)sCfsgggAfaAfAfccggCfcUfucasusa BD-11455 usgsaaGfgCfCfGfguuuUfCfccga(L96) (vinu)sCfsgggAfaaaccggCfcUfucasusaBD-11456 usgsaaGfgCfCfGfguuuUfCfccga(L96) (vinu)sCfsgggAfaAfAfccggCfcUfucasusa BD-11457 usgsaaGfgCfCfGfguuuucccga(L96) (vinu)sCfsgggAfaaaccggCfcUfucasusaBD-11458 usgsaaggCfcGfGIUfuuucCfcgGfca(L96) (vinu)sGfsccgGfgaaaaccGfgCfcuucasusa BD-11459 usgsaaggCfcGfGfUfuuucCfcgGfca(L96) (vinu)sGfsccgGfgAfAfaaccGfgCfcuucasusa BD-11460 usgsaaggCfcGfGfUfuuucCfCfggca(L96) (vinu)sGfsccgGfgaaaaccGfgCfcuucasusa BD-11461 usgsaaggCfcGfGfUfuuucCfCfggca(L96) (vinu)sGfsccgGfgAfAfaaccGfgCfcuucasusa BD-11462 usgsaaggCfcGfGfUfuuucccggca(L96) (vinu)sGfsccgGfgaaaaccGfgCfcuucasusa BD-11463 usgsaaggCfcGfGfUfuuucccggca(L96) (vinu)sGfsccgGfgAfAfaaccGfgCfcuucasusa BD-11464 usgsaaGfgCfCfGfguuuucccga(L96) (vinu)sCfsgggAfaAfAfccggCfcUfucasusa BD-11465 gsasagGfcCfGfGfuuuuCfccGfga(L96) (vinu)sCfscggGfaaaaccgGfcCfuucsasuBD-11466 gsasagGfcCfGIGfuuuuCfccGfga(L96) (vinu)sCfscggGfaAfAfaccgGfcCfuucsasu BD-11467 gsasagGfcCfGfGfuuuuCfCfcgga(L96) (vinu)sCfscggGfaaaaccgGfcCfuucsasuBD-11468 gsasagGfcCfGfGfuuuuCfCfcgga(L96) (vinu)sCfscggGfaAfAfaccgGfcCfuucsasu BD-11469 gsasagGfcCfGfGfuuuucccgga(L96) (vinu)sCfscggGfaaaaccgGfcCfuucsasuBD-11470 gsasaggcCfgGfUfUfuuccCfggCfua(L96) (vinu)sAfsgccGfggaaaacCfgGfccuucsasu BD-11471 gsasaggcCfgGfUfUfuuccCfggCfua(L96) (vinu)sAfsgccGfgGfAfaaacCfgGfccuucsasu BD-11472 gsasaggcCfgGIUfUfuuccCfGfgcua(L96) (vinu)sAfsgccGfggaaaacCfgGfccuucsasu BD-11473 gsasaggcCfgGfUfUfuuccCfGfgcua(L96) (vinu)sAfsgccGfgGfAfaaacCfgGfccuucsasu BD-11474 gsasaggcCfgGfUfUfuucccggcua(L96) (vinu)sAfsgccGfggaaaacCfgGfccuucsasu BD-11475 gsasaggcCfgGfUfUfuucccggcua(L96) (vinu)sAfsgccGfgGfAfaaacCfgGfccuucsasu BD-11476 gsasagGfcCfGfGfuuuucccgga(L96) (vinu)sCfscggGfaAfAfaccgGfcCfuucsasu BD-11477 asasggCfcGfGfUfuuucCfcgGfca(L96) (vinu)sGfsccgGfgaaaaccGfgCfcuuscsaBD-11478 asasggCfcGfGfUfuuucCfcgGfca(L96) (vinu)sGfsccgGfgAfAfaaccGfgCfcuuscsa BD-11479 asasggCfcGfGfUfuuucCfCfggca(L96) (vinu)sGfsccgGfgaaaaccGfgCfcuuscsaBD-11480 asasggCfcGfGfUfuuucCfCfggca(L96) (vinu)sGfsccgGfgAfAfaaccGfgCfcuuscsa BD-11481 asasggCfcGfGfUfuuucccggca(L96) (vinu)sGfsccgGfgaaaaccGfgCfcuuscsaBD-11482 asasggcc GfgU fUfUfuccc GfgcUfga(L 96) (vinu)sCfsagcCfgggaaaaCfcGfgccuuscsa BD-11483 asasggccGfgUfUfUfucccGfgcUfga(L96) (vinu)sCfsagcCfgGfGfaaaaCfcGfgccuuscsa BD-11484 asasggccGfgUfUfUfucccGfGfcuga(L96) (vinu)sCfsagcCfgggaaaaCfcGfgccuuscsa BD-11485 asasggccGfgUfUfUfucccGfGfcuga(L96) (vinu)sCfsagcCfgGfGfaaaaCfcGfgccuuscsa BD-11486 asasggccGfgUfUfUfucccggcuga(L96) (vinu)sCfsagcCfgggaaaaCfcGfgccuuscsa BD-11487 asasggccGfgUfUfUfucccggcuga(L96) (vinu)sCfsagcCfgGfGfaaaaCfcGfgccuuscsa BD-11488 asasggCfcGfGfUfuuucccggca(L96) (vinu)sGfsccgGfgAfAfaaccGfgCfcuuscsa BD-11489 csgsguUfuUfCfCfcggcUfgcAfua(L96) (vinu)sAfsugcAfgccgggaAfaAfccgsgscBD-11490 csgsguUfuUfCfCfcggcUfgcAfua(L96) (vinu)sAfsugcAfgCfCfgggaAfaAfccgsgsc NAI-5008944785v1 Page 65 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11491 csgsguUfuUfCfCfcggcUfGfcaua(L96) (vinu)sAfsugcAfgccgggaAfaAfccgsgscBD-11492 csgsguUfuUfCfCfcggcUfGfcaua(L96) (vinu)sAfsugcAfgCfCfgggaAfaAfccgsgsc BD-11493 csgsguUfuUfCfCfcggcugcaua(L96) (vinu)sAfsugcAfgccgggaAfaAfccgsgscBD-11494 csgsguuuUfcCfCfGfgcugCfauGfga(L96) (vinu)sCfscauGfcagccggGfaAfaaccgsgsc BD-11495 csgsguuuUfcCfCfGfgcugCfauGfga(L96) (vinu)sCfscauGfcAfGfccggGfaAfaaccgsgsc BD-11496 csgsguuuUfcCfCfGfgcugCfAfugga(L96) (vinu)sCfscauGfcagccggGfaAfaaccgsgsc BD-11497 csgsguuuUfcCfCfGfgcugCfAfugga(L96) (vinu)sCfscauGfcAfGfccggGfaAfaaccgsgsc BD-11498 csgsguuuUfcCfCfGfgcugcaugga(L96) (vinu)sCfscauGfcagccggGfaAfaaccgsgsc BD-11499 csgsguuuUfcCfCfGfgcugcaugga(L96) (vinu)sCfscauGfcAfGfccggGfaAfaaccgsgsc BD-11500 csgsguUfuUfCfCfcggcugcaua(L96) (vinu)sAfsugcAfgCfCfgggaAfaAfccgsgsc BD-11501 gsgsuuUfuCfCfCfggcuGfcaUfga(L96) (vinu)sCfsaugCfagccgggAfaAfaccsgsgBD-11502 gsgsuuUfuCfCfCfggcuGfcaUfga(L96) (vinu)sCfsaugCfaGfCfcgggAfaAfaccsgsg BD-11503 gsgsuuUfuCfCfCfggcuGfCfauga(L96) (vinu)sCfsaugCfagccgggAfaAfaccsgsgBD-11504 gsgsuuUfuCfCfCfggcuGfCfauga(L96) (vinu)sCfsaugCfaGfCfcgggAfaAfaccsgsg BD-11505 gsgsuuUfuCfCfCfggcugcauga(L96) (vinu)sCfsaugCfagccgggAfaAfaccsgsgBD-11506 gsgsuuuuCfcCfGfGfcugcAlugGfua(L96) (vinu)sAfsccaUfgcagccgGfgAfaaaccsgsg BD-11507 gsgsuuuuCfcCfGfGfcugcAlugGfua(L96) (vinu)sAfsccaUfgCfAfgccgGfgAfaaaccsgsg BD-11508 gsgsuuuuCfcCfGfGfcugcAlUfggua(L96) (vinu)sAfsccaUfgcagccgGfgAfaaaccsgsg BD-11509 gsgsuuuuCfcClGfGfcugcAlUlggua(L96) (vinu)sAfsccaUfgCfAfgccgGfgAfaaaccsgsg BD-11510 gsgsuuuuCfcCfGfGfcugcauggua(L96) (vinu)sAfsccaUfgcagccgGfgAfaaaccsgsg BD-11511 gsgsuuuuCfcCfGfGfcugcauggua(L96) (vinu)sAfsccaUfgCfAfgccgGfgAfaaaccsgsg BD-11512 gsgsuuUfuCfCfCfggcugcauga(L96) (vinu)sCfsaugCfaGfCfcgggAfaAfaccsgsg BD-11513 ususccCfgGfCfUfgcauGfguCfga(L96) (vinu)sCfsgacCfaugcagcCfgGfgaasasaBD-11514 ususccCfgGfCfUfgcauGfguCfga(L96) (vinu)sCfsgacCfaUfGfcagcCfgGfgaasasa BD-11515 ususccCfgGfCfUfgcauGfGlucga(L96) (vinu)sCfsgacCfaugcagcCfgGfgaasasaBD-11516 ususccCfgGfCfUfgcauGfGfucga(L96) (vinu)sCfsgacCfaUfGfcagcCfgGfgaasasa BD-11517 ususccClgGfClUfgcauggucga(L96) (vinu)sCfsgacCfaugcagcCfgGfgaasasaBD-11518 ususcccgGfcUfGfCfauggUfcgUfca(L96) (vinu)sGfsacgAfccaugcaGfcCfgggaasasa BD-11519 ususcccgGfcUfGfCfauggUfcgUfca(L96) (vinu)sGfsacgAfcCfAfugcaGfcCfgggaasasa BD-11520 ususcccgGfcUfGfCfauggUfCfguca(L96) (vinu)sGfsacgAfccaugcaGfcCfgggaasasa BD-11521 ususcccgGfcUfGfCfauggUfCfguca(L96) (vinu)sGfsacgAfcCfAfugcaGfcCfgggaasasa BD-11522 ususcccgGfcUfGfCfauggucguca(L96) (vinu)sGfsacgAfccaugcaGfcCfgggaasasa BD-11523 ususcccgGfcUfGfCfauggucguca(L96) (vinu)sGfsacgAfcCfAfugcaGfcCfgggaasasa BD-11524 ususccCfgGfCfUfgcauggucga(L96) (vinu)sCfsgacCfaUfGfcagcCfgGfgaasasa BD-11525 uscsccGfgClUfGfcaugGfucGfua(L96) (vinu)sAfscgaCfcaugcagCfcGfggasasaBD- 11526 uscsccGfgCfUfGfcaugGfucGfua(L96) (vinu)sAfscgaCfcAfUfgcagCfcGfggasasa BD-11527 uscsccGfgCfUfGfcaugGlUfcgua(L96) (vinu)sAfscgaCfcaugcagCfcGfggasasaBD-11528 uscsccGfgCfUfGfcaugG! Ufcgua(L96) (vinu)sAfscgaCfcAfUfgcagCfcGfggasasa BD-11529 uscsccGfgCfUfGfcauggucgua(L96) (vinu)sAfscgaCfcaugcagCfcGfggasasaBD-11530 uscsccggCfuGfCfAfugguCfguCfca(L96) (vinu)sGfsgacGfaccaugcAfgCfcgggasasa BD-11531 uscsccggCfuGfCfAfugguCfguCfca(L96) (vinu)sGfsgacGfaCfCfaugcAfgCfcgggasasa BD-11532 uscsccggCfuGfCfAfugguCfGfucca(L96) (vinu)sGfsgacGfaccaugcAfgCfcgggasasa BD-11533 uscsccggCfuGfCfAfugguCfGfucca(L96) (vinu)sGfsgacGfaCfCfaugcAfgCfcgggasasa BD-11534 uscsccggCfuGfCfAfuggucgucca(L96) (vinu)sGfsgacGfaccaugcAfgCfcgggasasa BD-11535 uscsccggCfuGfCfAfuggucgucca(L96) (vinu)sGfsgacGfaCfCfaugcAfgCfcgggasasa BD-11536 uscsccGfgCfUfGfcauggucgua(L96) (vinu)sAfscgaCfcAfUfgcagCfcGfggasasa BD-11537 cscscgGfcUfGfCfauggUfcgUfca(L96) (vinu)sGfsacgAfccaugcaGfcCfgggsasaBD-11538 cscscgGfcUfGfCfauggUfcgUfca(L96) (vinu)sGfsacgAfcCfAfugcaGfcCfgggsasa BD-11539 cscscgGfcUfGfCfauggUfCfguca(L96) (vinu)sGfsacgAfccaugcaGfcCfgggsasaBD-11540 cscscgGfcUfGfCfauggUfCfguca(L96) (vinu)sGfsacgAfcCfAfugcaGfcCfgggsasaBD-11541 cscscgGfcUfGfCfauggucguca(L96) (vinu)sGfsacgAfccaugcaGfcCfgggsasaNAI-5008944785v1 Page 66 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11542 cscscggcUfgCfAfUfggucGfucCfca(L96) (vinu)sGfsggaCfgaccaugCfaGfccgggsasa BD-11543 cscscggcUfgCfAfUfggucGfucCfca(L96) (vinu)sGfsggaCfgAfCfcaugCfaGfccgggsasa BD-11544 cscscggcUfgCfAfUfggucGfUfccca(L96) (vinu)sGfsggaCfgaccaugCfaGfccgggsasa BD-11545 cscscggcUfgCfAfUfggucGfUfccca(L96) (vinu)sGfsggaCfgAfCfcaugCfaGfccgggsasa BD-11546 cscscggcUfgCfAfUfggucguccca(L96) (vinu)sGfsggaCfgaccaugCfaGfccgggsasa BD-11547 cscscggcUfgCfAfUfggucguccca(L96) (vinu)sGfsggaCfgAfCfcaugCfaGfccgggsasa BD-11548 cscscgGfcUfGfCfauggucguca(L96) (vinu)sGfsacgAfcCfAfugcaGfcCfgggsasa BD-11549 cscsggCfuGfCfAfugguCfguCfca(L96) (vinu)sGfsgacGfaccaugcAfgCfcggsgsaBD-11550 cscsggCfuGfCfAfugguCfguCfca(L96) (vinu)sGfsgacGfaCfCfaugcAfgCfcggsgsa BD-11551 cscsggCfuGfCfAfugguCfGfucca(L96) (vinu)sGfsgacGfaccaugcAfgCfcggsgsaBD-11552 cscsggCfiiGfCfAfugguCfGfucca(L96) (vinu)sGfsgacGfaCfCfaugcAfgCfcggsgsa BD-11553 cscsggCfuGfCfAfuggucgucca(L96) (vinu)sGfsgacGfaccaugcAfgCfcggsgsaBD-11554 cscsggcuGfcAfUfGfgucgUfccCfca(L96) (vinu)sGfsgggAfcgaccauGfcAfgccggsgsa BD-11555 cscsggcuGfcAfUfGfgucgUfccCfca(L96) (vinu)sGfsgggAfcGfAfccauGfcAfgccggsgsa BD-11556 cscsggcuGfcAfUfGfgucgUfCfccca(L96) (vinu)sGfsgggAfcgaccauGfcAfgccggsgsa BD-11557 cscsggcuGfcAlUfGfgucgUfCfccca(L96) (vinu)sGfsgggAfcGfAfccauGfcAfgccggsgsa BD-11558 cscsggcuGfcAfUfGfgucgucccca(L96) (vinu)sGfsgggAfcgaccauGfcAfgccggsgsa BD-11559 cscsggcuGfcAfUfGfgucgucccca(L96) (vinu)sGfsgggAfcGfAfccauGfcAfgccggsgsa BD-11560 cscsggCfuGfClAfuggucgucca(L96) (vinu)sGfsgacGfaCfCfaugcAfgCfcggsgsa BD-11561 gsgscuGfcAfUfGfgucgUfccCfca(L96) (vinu)sGfsgggAfcgaccauGfcAfgccsgsgBD-11562 gsgscuGfcAfUfGfgucgUfccCfca(L96) (vinu)sGfsgggAfcGfAfccauGfcAfgccsgsg BD-11563 gsgscuGfcAfUfGfgucgUfCfccca(L96) (vinu)sGfsgggAfcgaccauGfcAfgccsgsgBD-11564 gsgscuGfcAfUfGfgucgUfCfccca(L96) (vinu)sGfsgggAfcGfAfccauGfcAfgccsgsg BD-11565 gsgscuGfcAfUfGfgucgucccca(L96) (vinu)sGfsgggAfcgaccauGfcAfgccsgsgBD-11566 gsgscugcAfuGfGlUfcgucCfccCfga(L96) (vinu)sCfsgggGfgacgaccAfuGfcagccsgsg BD-11567 gsgscugcAfuGfGlUfcgucCfccCfga(L96) (vinu)sCfsgggGfgAfCfgaccAfuGfcagccsgsg BD-11568 gsgscugcAfuGlGfUfcgucCfCfccga(L96) (vinu)sCfsgggGfgacgaccAfuGfcagccsgsg BD- 11569 gsgscugcAfuGfGfUfcgucCfCfccga(L96) (vinu)sCfsgggGfgAfCfgaccAfuGfcagccsgsg BD-11570 gsgscugcAfuGfGlUfcgucccccga(L96) (vinu)sCfsgggGfgacgaccAfuGfcagccsgsg BD-11571 gsgscugcAfuGfGfUfcgucccccga(L96) (vinu)sCfsgggGfgAfCfgaccAfuGfcagccsgsg BD-11572 gsgscuGfcAfUfGfgucgucccca(L96) (vinu)sGfsgggAfcGfAfccauGfcAfgccsgsg BD-11573 cscsggGfgUfUfCfuugcAfuuGfca(L96) (vinu)sGfscaaUfgcaagaaCfcCfcggsgsgBD-11574 cscsggGfgU 1U fCfuugc AfuuGfca(L96) (vinu)sGfscaaUfgCfAfagaaCfcCfcggsgsg BD-11575 cscsggGfgUfUfCfuugcAfUfugca(L96) (vinu)sGfscaaUfgcaagaaCfcCfcggsgsgBD-11576 cscsggGfgUlUfCfuugcAlUfugca(L96) (vinu)sGfscaaUfgCfAfagaaCfcCfcggsgsg BD- 11577 cscsggGfgUfUfCfuugcauugca(L96) (vinu)sGfscaaUfgcaagaaCfcCfcggsgsgBD-11578 cscsggggUfuCfUlUfgcauUfgcGfca(L96) (vinu)sGfscgcAfaugcaagAfaCfcccggsgsg BD-11579 cscsggggUfuCfUfUfgcauUfgcGfca(L96) (vinu)sGfscgcAfaUfGfcaagAfaCfcccggsgsg BD-11580 cscsggggUfuCfUfUfgcauUfGfcgca(L96) (vinu)sGfscgcAfaugcaagAfaCfcccggsgsg BD-11581 cscsggggUfuCfUlUfgcauUfGfcgca(L96) (vinu)sGfscgcAfaUfGfcaagAfaCfcccggsgsg BD-11582 cscsggggUfuCfUfUfgcauugcgca(L96) (vinu)sGfscgcAfaugcaagAfaCfcccggsgsg BD-11583 cscsggggUfuCfUlUfgcauugcgca(L96) (vinu)sGfscgcAfaUfGfcaagAfaCfcccggsgsg BD-11584 cscsggGfgUlUfCfuugcauugca(L96) (vinu)sGfscaaUfgCfAfagaaCfcCfcggsgsg BD-11585 gsusucUfuGfCfAfuugcGfcuUfca(L96) (vinu)sGfsaagCfgcaaugcAfaGfaacscscBD-11586 gsusucUfuGfCfAfuugcGfcuUfca(L96) (vinu)sGfsaagCfgCfAfaugcAfaGfaacscsc BD-11587 gsusucUfuGfCfAfuugcGfCfuuca(L96) (vinu)sGfsaagCfgcaaugcAfaGfaacscscBD-11588 gsusucUfuGfCfAfuugcGfCfuuca(L96) (vinu)sGfsaagCfgCfAfaugcAfaGfaacscsc BD-11589 gsusucUfuGfCfAfuugcgcuuca(L96) (vinu)sGfsaagCfgcaaugcAfaGfaacscscBD-11590 gsusucuuGfcAfUlUfgcgcUfucCfua(L96) (vinu)sAfsggaAfgcgcaauGfcAfagaacscsc BD-11591 gsusucuuGfcAfUlUfgcgcUfucCfua(L96) (vinu)sAfsggaAfgCfGfcaauGfcAfagaacscscBD-11592 gsusucuuGfcAfUfUfgcgcUlUfccua(L96) (vinu)sAfsggaAfgcgcaauGfcAfagaacscsc NAI-5008944785v1 Page 67 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11593 gsusucuuGfcAfUfUfgcgcUfUfccua(L96) (vinu)sAfsggaAfgCfGfcaauGfcAfagaacscsc BD-11594 gsusucuuGfcAfUfUfgcgcuuccua(L96) (vinu)sAfsggaAfgcgcaauGfcAfagaacscsc BD-11595 gsusucuuGfcAfUIUfgcgcuuccua(L96) (vinu)sAfsggaAfgCfGfcaauGfcAfagaacscsc BD-11596 gsusucUfuGfCfAfuugcgcuuca(L96) (vinu)sGfsaagCfgCfAfaugcAfaGfaacscsc BD-11597 uscsuuGfcAfUfUfgcgcUfucCfua(L96) (vinu)sAfsggaAfgcgcaauGfcAfagasascBD-11598 uscsuuGfcAfUfUfgcgcUfucCfua(L96) (vinu)sAfsggaAfgCfGfcaauGfcAfagasasc BD-11599 uscsuuGfcAfUfUfgcgcUfUfccua(L96) (vinu)sAfsggaAfgcgcaauGfcAfagasascBD-11600 uscsuuGfcAfUfUfgcgcUfUfccua(L96) (vinu)sAfsggaAfgCfGfcaauGfcAfagasasc BD-11601 uscsuuGfcAfUfUfgcgcuuccua(L96) (vinu)sAfsggaAfgcgcaauGfcAfagasascBD-11602 uscsuugcAfuUfGfCfgcuuCfcuUfca(L96) (vinu)sGfsaagGfaagcgcaAfuGfcaagasasc BD-11603 uscsuugcAfuUfGfCfgcuuCfcuUfca(L96) (vinu)sGfsaagGfaAfGfcgcaAfuGfcaagasasc BD-11604 uscsuugcAfuUfGfCfgcuuCfCfuuca(L96) (vinu)sGfsaagGfaagcgcaAfuGfcaagasasc BD-11605 uscsuugcAfuUfGfCfgcuuCfCfuuca(L96) (vinu)sGfsaagGfaAfGfcgcaAfuGfcaagasasc BD-11606 uscsuugcAfuUfGfCfgcuuccuuca(L96) (vinu)sGfsaagGfaagcgcaAfuGfcaagasasc BD-11607 uscsuugcAfuUfGfCfgcuuccuuca(L96) (vinu)sGfsaagGfaAfGfcgcaAfuGfcaagasasc BD-11608 uscsuuGfcAfUfUfgcgcuuccua(L96) (vinu)sAfsggaAfgCfGfcaauGfcAfagasasc BD-11609 csusugCfaUfUfGfcgcuUfccUfua(L96) (vinu)sAfsaggAfagcgcaaUfgCfaagsasaBD-11610 csusugCfaUfUfGfcgcuUfccUfua(L96) (vinu)sAfsaggAfaGfCfgcaaUfgCfaagsasa BD-11611 csusugCfaUIUIGfcgcuUfCfcuua(L96) (vinu)sAfsaggAfagcgcaaUfgCfaagsasaBD-11612 csusugCfaUfUfGfcgcuUfCfcuua(L96) (vinu)sAfsaggAfaGfCfgcaaUfgCfaagsasa BD-11613 csusugCfaUfUfGfcgcuuccuua(L96) (vinu) s Af sagg AfagcgcaaU fgCfaagsasaBD-11614 csusugcaUfuGfCfGfcuucCfuuCfga(L96) (vinu)sCfsgaaGfgaagcgcAfaUfgcaagsasa BD-11615 csusugcaUfuGfCfGfcuucCfuuCfga(L96) (vinu)sCfsgaaGfgAfAfgcgcAfaUfgcaagsasa BD-11616 csusugcaUfuGfCfGfcuucCfUfucga(L96) (vinu)sCfsgaaGfgaagcgcAfaUfgcaagsasa BD-11617 csusugcaUfuGfCfGfcuucCfUfucga(L96) (vinu)sCfsgaaGfgAfAfgcgcAfaUfgcaagsasa BD-11618 csusugcaUfuGfCfGfcuuccuucga(L96) (vinu)sCfsgaaGfgaagcgcAfaUfgcaagsasa BD-11619 csusugcaUfuGfCfGfcuuccuucga(L96) (vinu)sCfsgaaGfgAfAfgcgcAfaUfgcaagsasa BD-11620 csusugCfaUfUfGfcgcuuccuua(L96) (vinu)sAfsaggAfaGfCfgcaaUfgCfaagsasa BD-11621 usgscaUfuGfCfGfcuucCfuuCfga(L96) (vinu)sCfsgaaGfgaagcgcAfaUfgcasasgBD-11622 usgscaUfuGfCfGfcuucCfuuCfga(L96) (vinu)sCfsgaaGfgAfAfgcgcAfaUfgcasasg BD-11623 usgscaUfuGfCfGfcuucCfUfucga(L96) (vinu)sCfsgaaGfgaagcgcAfaUfgcasasgBD-11624 usgscaUfuGfCfGfcuucCIUfucga(L96) (vinu)sCfsgaaGfgAfAfgcgcAfaUfgcasasg BD-11625 usgscaUfuGfCfGfcuuccuucga(L96) (vinu)sCfsgaaGfgaagcgcAfaUfgcasasgBD-11626 usgscauuGfcGfCfUfuccuUfcgGfga(L96) (vinu)sCfsccgAfaggaagcGfcAfaugcasasg BD-11627 usgscauuGfcGfCfUfuccuUfcgGfga(L96) (vinu)sCfsccgAfaGfGfaagcGfcAfaugcasasg BD-11628 usgscauuGfcGfCfUfuccuUfCfggga(L96) (vinu)sCfsccgAfaggaagcGfcAfaugcasasg BD-11629 usgscauuGfcGfCfUfuccuUfCfggga(L96) (vinu)sCfsccgAfaGfGfaagcGfcAfaugcasasg BD-11630 usgscauuGfcGfCfUfuccuucggga(L96) (vinu)sCfsccgAfaggaagcGfcAfaugcasasg BD-11631 usgscauuGfcGfCfUfuccuucggga(L96) (vinu)sCfsccgAfaGfGfaagcGfcAfaugcasasg BD-11632 usgscaUfuGfCfGfcuuccuucga(L96) (vinu)sCfsgaaGfgAfAfgcgcAfaUfgcasasg BD-11633 csasuuGfcGfCfUfuccuUfcgGfga(L96) (vinu)sCfsccgAfaggaagcGfcAfaugscsaBD-11634 csasuuGfcGfCfUfuccuUfcgGfga(L96) (vinu)sCfsccgAfaGfGfaagcGfcAfaugscsa BD-11635 csasuuGfcGfCfUfuccuUfCfggga(L96) (vinu)sCfsccgAfaggaagcGfcAfaugscsaBD-11636 csasuuGfcGfCfUfuccuUfCfggga(L96) (vinu)sCfsccgAfaGfGfaagcGfcAfaugscsa BD-11637 csasuuGfcGfCfUfuccuucggga(L96) (vinu)sCfsccgAfaggaagcGfcAfaugscsaBD-11638 csasuugcGfcUfUfCfcuucGfggGfaa(L96) (vinu)sUfscccCfgaaggaaGfcGfcaaugscsa BD-11639 csasuugcGfcUfUfCfcuucGfggGfaa(L96) (vinu)sUfscccCfgAfAfggaaGfcGfcaaugscsa BD-11640 csasuugcGfcUfUfCfcuucGfGfggaa(L96) (vinu)sUfscccCfgaaggaaGfcGfcaaugscsa BD-11641 csasuugcGfcUfUfCfcuucGfGfggaa(L96) (vinu)sUfscccCfgAfAfggaaGfcGfcaaugscsa BD-11642 csasuugcGfcUfUfCfcuucggggaa(L96) (vinu)sUfscccCfgaaggaaGfcGfcaaugscsaBD-11643 csasuugcGfcUfUfCfcuucggggaa(L96) (vinu)sUfscccCfgAfAfggaaGfcGfcaaugscsa NAI-5008944785v1 Page 68 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11644 csasuuGfcGfCfUfuccuucggga(L96) (vinu)sCfsccgAfaGfGfaagcGfcAfaugscsa BD-11645 asusugCfgCfUfUfccuuCfggGfga(L96) (vinu)sCfscccGfaaggaagCfgCfaausgscBD-11646 asusugCfgCfUfUfccuuCfggGfga(L96) (vinu)sCfscccGfaAfGfgaagCfgCfaausgsc BD-11647 asusugCfgCfUfUfccuuCfGfggga(L96) (vinu)sCfscccGfaaggaagCfgCfaausgscBD-11648 asusugCfgCfUfUfccuuCfGfggga(L96) (vinu)sCfscccGfaAfGfgaagCfgCfaausgsc BD-11649 asusugCfgCfUfUfccuucgggga(L96) (vinu)sCfscccGfaaggaagCfgCfaausgscBD-11650 asusugcgCfuUfCfCfuucgGfggAfca(L96) (vinu)sGfsuccCfcgaaggaAfgCfgcaausgsc BD-11651 asusugcgCfuUfCfCfuucgGfggAfca(L96) (vinu)sGfsuccCfcGfAfaggaAfgCfgcaausgsc BD-11652 asusugcgCfuUfCfCfuucgGfGfgaca(L96) (vinu)sGfsuccCfcgaaggaAfgCfgcaausgsc BD-11653 asusugcgCfuUfCfCfuucgGfGfgaca(L96) (vinu)sGfsuccCfcGfAfaggaAfgCfgcaausgsc BD-11654 asusugcgCfuUfCfCfuucggggaca(L96) (vinu) s Gf succCfcgaaggaAf gCfgcaausgsc BD-11655 asusugcgCfuUfCfCfuucggggaca(L96) (vinu)sGfsuccCfcGfAfaggaAfgCfgcaausgsc BD-11656 asusugCfgCfUfUfccuucgggga(L96) (vinu)sCfscccGfaAfGfgaagCfgCfaausgsc BD-11657 csgscuUfcCfUfUfcgggGfacCfca(L96) (vinu)sGfsgguCfcccgaagGfaAfgcgscsaBD-11658 csgscuUfcCfUfUfcgggGfacCfca(L96) (vinu)sGfsgguCfcCfCfgaagGfaAfgcgscsa BD-11659 csgscuUfcCfUfUfcgggGfAfccca(L96) (vinu)sGfsgguCfcccgaagGfaAfgcgscsaBD-11660 csgscuUfcCfUfUfcgggGfAfccca(L96) (vinu)sGfsgguCfcCfCfgaagGfaAfgcgscsa BD-11661 csgscuUfcCfUfUfcggggaccca(L96) (vinu)sGfsgguCfcccgaagGfaAfgcgscsaBD-11662 csgscuucCfuUfCIGfgggaCfccCfca(L96) (vinu)sGfsgggGfuccccgaAfgGfaagcgscsa BD-11663 csgscuucCfuUfCfGfgggaCfccCfca(L96) (vinu)sGfsgggGfuCfCfccgaAfgGfaagcgscsa BD-11664 csgscuucCfuUfCfGfgggaCfCfccca(L96) (vinu)sGfsgggGfuccccgaAfgGfaagcgscsa BD-11665 csgscuucCfuUfCfGfgggaCfCfccca(L96) (vinu)sGfsgggGfuCfCfccgaAfgGfaagcgscsa BD-11666 csgscuucCfuUfCfGfgggaccccca(L96) (vinu)sGfsgggGfuccccgaAfgGfaagcgscsa BD-11667 csgscuucCfuUfCfGfgggaccccca(L96) (vinu)sGfsgggGfuCfCfccgaAfgGfaagcgscsa BD-11668 csgscuU fcCfU fU fcggggaccca(L96) (vinu)sGfsgguCfcCfCfgaagGfaAfgcgscsa BD-11669 asuscaCfuUfUfCfacacAfugCfca(L96) (vinu)sGfsgcaUfgugugaaAfgUfgausgsgBD-11670 asuscaCfuUfUfCfacacAfugCfca(L96) (vinu)sGfsgcaUfgUfGfugaaAfgUfgausgsg BD-11671 asuscaCfuUfUfCfacacAfUfgcca(L96) (vinu)sGfsgcaUfgugugaaAfgUfgausgsgBD-11672 asuscaCfuUfUfCfacacAfUfgcca(L96) (vinu)sGfsgcaUfgUfGfugaaAfgUfgausgsg BD-11673 asuscaCfuUfUfCfacacaugcca(L96) (vinu)sGfsgcaUfgugugaaAfgUfgausgsgBD-11674 asuscacuUfuCfAfCfacauGfccGfua(L96) (vinu)sAfscggCfaugugugAfaAfgugausgsg BD-11675 asuscacuUfuCfAfCfacauGfccGfua(L96) (vinu)sAfscggCfaUfGfugugAfaAfgugausgsg BD-11676 asuscacuUfuCfAfCfacauGfCfcgua(L96) (vinu)sAfscggCfaugugugAfaAfgugausgsg BD-11677 asuscacuUfuCfAfCfacauGfCfcgua(L96) (vinu)sAfscggCfaUfGfugugAfaAfgugausgsg BD-11678 asuscacuUfuCfAfCfacaugccgua(L96) (vinu)sAfscggCfaugugugAfaAfgugausgsg BD-11679 asuscacuUfuCfAfCfacaugccgua(L96) (vinu)sAfscggCfaUfGfugugAfaAfgugausgsg BD-11680 asuscaCfuUfUfCfacacaugcca(L96) (vinu)sGfsgcaUfgUfGfugaaAfgUfgausgsg BD-11681 uscsacAfcAIUfGfccguGfucCfaa(L96) (vinu)sUfsggaCfacggcauGIuGfugasasaBD-11682 uscsacAfcAfUfGfccguGfucCfaa(L96) (vinu)sUfsggaCfaCfGfgcauGfuGIugasasa BD-11683 uscsacAfcAIUfGfccguGfUfccaa(L96) (vinu) sUfsggaCfacggcauGfuGfugasasaBD-11684 uscsacAfcAfUfGfccguGfUfccaa(L96) (vinu)sUfsggaCfaCfGfgcauGfuGIugasasa BD-11685 uscsacAfcAfUfGfccguguccaa(L96) (vinu)sUfsggaCfacggcauGfuGfugasasaBD-11686 uscsacacAfuGfCfCfguguCfcaAfga(L96) (vinu)sCfsuugGfacacggcAfuGfugugasasa BD-11687 uscsacacAfuGfCfCfguguCfcaAfga(L96) (vinu)sCfsuugGfaCfAfcggcAfuGfugugasasa BD-11688 uscsacacAfuGfCfCfguguCfCfaaga(L96) (vinu)sCfsuugGfacacggcAfuGfugugasasa BD-11689 uscsacacAfuGfCfCfguguCfCfaaga(L96) (vinu)sCfsuugGfaCfAfcggcAfuGfugugasasa BD-11690 uscsacacAfuGfCfCfguguccaaga(L96) (vinu)sCfsuugGfacacggcAfuGfugugasasa BD-11691 uscsacacAfuGfCfCfguguccaaga(L96) (vinu)sCfsuugGfaCfAfcggcAfuGfugugasasa BD-11692 uscsacAfcAfUfGfccguguccaa(L96) (vinu)sUfsggaCfaCfGfgcauGfuGIugasasa BD-11693 gsusguCfcAfAfGfgagcUfugGfca(L96) (vinu)sGfsccaAfgcuccuuGfgAfcacsgsgBD-11694 gsusguCfcAfAfGfgagcUfugGfca(L96) (vinu)sGfsccaAfgCfUfccuuGfgAfcacsgsg NAI-5008944785v1 Page 69 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11695 gsusguCfcAfAfGfgagcUfUfggca(L96) (vinu)sGfsccaAfgcuccuuGfgAfcacsgsgBD-11696 gsusguCfcAfAfGfgagcUfUfggca(L96) (vinu)sGfsccaAfgCfUfccuuGfgAfcacsgsg BD-11697 gsusguCfcAfAfGfgagcuuggca(L96) (vinu)sGfsccaAfgcuccuuGfgAfcacsgsgBD-11698 gsusguccAfaGfGfAfgcuuGfgcCfua(L96) (vinu)sAfsggcCfaagcuccUfuGfgacacsgsg BD-11699 gsusguccAfaGfGfAfgcuuGfgcCfua(L96) (vinu)sAfsggcCfaAfGfcuccUfuGfgacacsgsg BD-11700 gsusguccAfaGfGfAfgcuuGfGfccua(L96) (vinu)sAfsggcCfaagcuccUfuGfgacacsgsg BD-11701 gsusguccAfaGfGfAfgcuuGfGfccua(L96) (vinu)sAfsggcCfaAfGfcuccUfuGfgacacsgsg BD-11702 gsusguccAfaGfGfAfgcuuggccua(L96) (vinu)sAfsggcCfaagcuccUfuGfgacacsgsg BD-11703 gsusguccAfaGfGfAfgcuuggccua(L96) (vinu)sAfsggcCfaAfGfcuccUfuGfgacacsgsg BD-11704 gsusguCfcAfAfGfgagcuuggca(L96) (vinu)sGfsccaAfgCfUfccuuGfgAfcacsgsg BD-11705 usgsucCfaAfGfCfcacc AfgcUfca(L96 ) (vinu)sGfsagcUfgguggcuUfgGfacasasaBD-11706 usgsucCfaAfGfCfcaccAfgcUfca(L96) (vinu)sGfsagcUfgGfUfggcuUfgGfacasasa BD-11707 usgsucCfaAfGfCfcaccAfGfcuca(L96) (vinu)sGfsagcUfgguggcuUfgGfacasasaBD-11708 usgsucCfaAfGfCfcaccAfGfcuca(L96) (vinu)sGfsagcUfgGIUfggcuUfgGfacasasa BD-11709 usgsucCfaAfGfCfcaccagcuca(L96) (vinu)sGfsagcUfgguggcuUfgGfacasasaBD-11710 usgsuccaAfgCfCfAfccagCfucCfca(L96) (vinu)sGfsggaGfcugguggCfuUfggacasasa BD-11711 usgsuccaAfgCfCfAfccagCfucCfca(L96) (vinu)sGfsggaGfcUfGfguggCfuUfggacasasa BD-11712 usgsuccaAfgCfCfAfccagCfUfccca(L96) (vinu)sGfsggaGfcugguggCfuUfggacasasa BD-11713 usgsuccaAfgCfCfAfccagClUfccca(L96) (vinu)sGfsggaGfcUfGfguggCfuUfggacasasa BD-11714 usgsuccaAfgCfCfAfccagcuccca(L96) (vinu)sGfsggaGfcugguggCfuUfggacasasa BD-11715 usgsuccaAfgCfCfAfccagcuccca(L96) (vinu)sGfsggaGfcUfGfguggCfuUfggacasasa BD-11716 usgsucCfaAfGfCfcaccagcuca(L96) (vinu)sGfsagcUfgGIUfggcuUfgGfacasasa BD-11717 csasccCfgGfAfAfgcucAfccAfua(L96) (vinu)sAfsuggUfgagcuucCfgGfgugsgscBD-11718 csasccCfgGfAfAfgcucAfccAfua(L96) (vinu)sAfsuggUfgAfGfcuucCfgGfgugsgsc BD-11719 csasccCfgGfAfAfgcucAfCfcaua(L96) (vinu)sAfsuggUfgagcuucCfgGfgugsgscBD-11720 csasccCfgGfAfAfgcucAfCfcaua(L96) (vinu)sAfsuggUfgAfGfcuucCfgGfgugsgsc BD-11721 csasccCfgGfAfAfgcucaccaua(L96) (vinu)sAfsuggUfgagcuucCfgGfgugsgscBD-11722 csascccgGfaAfGfCfucacCfauCfaa(L96) (vinu)sUfsgauGfgugagcuUfcCfgggugsgsc BD-11723 csascccgGfaAfGfCfucacCfauCfaa(L96) (vinu)sUfsgauGfgUfGfagcuUfcCfgggugsgsc BD-11724 csascccgGfaAfGfCfucacCfAfucaa(L96) (vinu)sUfsgauGfgugagcuUfcCfgggugsgsc BD-11725 csascccgGfaAfGfCfucacCfAfucaa(L96) (vinu)sUfsgauGfgUfGfagcuUfcCfgggugsgsc BD-11726 csascccgGfaAfGfCfucaccaucaa(L96) (vinu)sUfsgauGfgugagcuUfcCfgggugsgsc BD-11727 csascccgGfaAfGfCfucaccaucaa(L96) (vinu)sUfsgauGfgUfGfagcuUfcCfgggugsgsc BD-11728 csasccCfgGfAfAfgcucaccaua(L96) (vinu)sAfsuggUfgAfGfcuucCfgGfgugsgsc BD-11729 asasgcUfcAfCfCfaucaUfauUfua(L96) (vinu) s Af saau AfugaugguGfaGfcuusc scBD-11730 asasgcUfcAfCfCfaucaUfauUfua(L96) (vinu)sAfsaauAfuGfAfugguGfaGfcuuscsc BD-11731 asasgcUfcAfCfCfaucaUfAfuuua(L96) (vinu) sAf saau AfugaugguGfaGfcuusc scBD-11732 asasgcUfcAfCfCfaucaUfAfuuua(L96) (vinu)sAfsaauAfuGfAfugguGfaGfcuuscsc BD-11733 asasgcUfcAfCfCfaucauauuua(L96) (vinu)sAfsaauAfugaugguGfaGfcuuscscBD-11734 asasgcucAfcCfAfUfcauaUfuuAfaa(L96) (vinu)sUfsuaaAfuaugaugGfuGfagcuuscsc BD-11735 asasgcucAfcCfAfUfcauaUfuuAfaa(L96) (vinu)sUfsuaaAfuAfUfgaugGfuGfagcuuscsc BD-11736 asasgcucAfcCfAfUfcauaUfUfuaaa(L96) (vinu)sUfsuaaAfuaugaugGfuGfagcuuscsc BD-11737 asasgcucAfcCfAfUfcauaUfUfuaaa(L96) (vinu)sUfsuaaAfuAfUfgaugGfuGfagcuuscsc BD-11738 asasgcucAfcCfAfUfcauauuuaaa(L96) (vinu)sUfsuaaAfuaugaugGfuGfagcuuscsc BD-11739 asasgcucAfcCfAfUfcauauuuaaa(L96) (vinu)sUfsuaaAfuAfUfgaugGfuGfagcuuscsc BD-11740 asasgcU fc AfCfCfaucauauuua(L96) (vinu)sAfsaauAfuGfAfugguGfaGfcuuscsc BD-11741 ascsauGfcAfGfGfaaugCfauUfga(L96) (vinu)sCfsaauGfcauuccuGfcAfugususcBD-11742 ascsauGfcAfGfGfaaugCfauUfga(L96) (vinu)sCfsaauGfcAfUfuccuGfcAfugususc BD-11743 ascsauGfcAfGfGfaaugCfAfuuga(L96) (vinu)sCfsaauGfcauuccuGfcAfugususcBD-11744 ascsauGfcAfGfGfaaugCfAfuuga(L96) (vinu)sCfsaauGfcAfUfuccuGfcAfugususcBD-11745 ascsauGfcAfGfGfaaugcauuga(L96) (vinu)sCfsaauGfcauuccuGfcAfugususcNAI-5008944785v1 Page 70 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11746 ascsaugcAfgGfAf7\fugcaUfugAfua(L96) (vinu)sAfsucaAfugcauucCfuGfcaugususc BD-11747 ascsaugcAfgGfAfAfugcaUfugAfua(L96) (vinu)sAfsucaAfuGfCfauucCfuGfcaugususc BD-11748 ascsaugcAfgGfAfAfugcaUfUfgaua(L96) (vinu)sAfsucaAfugcauucCfuGfcaugususc BD-11749 ascsaugcAfgGfAfAfugcaUfUfgaua(L96) (vinu)sAfsucaAfuGfCfauucCfuGfcaugususc BD-11750 ascsaugcAfgGfAfAfugcauugaua(L96) (vinu) s Af suca Afugcaunc CfuGfcaugususc BD-11751 ascsaugcAfgGfAf7\fugcauugaua(L96) (vinu)sAfsucaAfuGfCfauucCfuGfcaugususc BD-11752 ascsauGfcAfGfGfaaugcauuga(L96) (vinu)sCfsaauGfcAfUfuccuGfcAfugususc BD-11753 csasugCfaGfGfAfaugcAfuuGfaa(L96) (vinu)sUfscaaUfgcauuccUfgCfaugsusuBD-11754 csasugCfaGfGfAfaugcAfuuGfaa(L96) (vinu)sUfscaaUfgCfAfuuccUfgCfaugsusu BD-11755 csasugCfaGfGfAfaugcAfUfugaa(L96) (vinu)sUfscaaUfgcauuccUfgCfaugsusuBD-11756 csasugCfaGfGfAfaugcAIUfugaa(L96) (vinu)sUfscaaUfgCfAfuuccUfgCfaugsusu BD-11757 csasugCfaGfGfAfaugcauugaa(L96) (vinu)sUfscaaUfgcauuccUfgCfaugsusuBD-11758 csasugcaGfgAfAfUfgcauUfgaUfca(L96) (vinu)sGfsaucAfaugcauuCfcUfgcaugsusu BD-11759 csasugcaGfgAfAfUfgcauUfgaUfca(L96) (vinu)sGfsaucAfaUfGfcauuCfcUfgcaugsusu BD-11760 csasugcaGfgAfAfUfgcauUfGfauca(L96) (vinu)sGfsaucAfaugcauuCfcUfgcaugsusu BD-11761 csasugcaGfgAfAfUfgcauUfGfauca(L96) (vinu)sGfsaucAfaUfGfcauuCfcUfgcaugsusu BD-11762 csasugcaGfgAfAfUfgcauugauca(L96) (vinu)sGfsaucAfaugcauuCfcUfgcaugsusu BD-11763 csasugcaGfgAfAfUfgcauugauca(L96) (vinu)sGfsaucAfaUfGfcauuCfcUfgcaugsusu BD-11764 csasugCfaGfGfAfaugcauugaa(L96) (vinu)sUfscaaUfgCfAfuuccUfgCfaugsusu BD-11765 asuscaGfgCfUfGfagguGfgaUfaa(L96) (vinu)sUfsaucCfaccucagCfcUfgausascBD-11766 asuscaGfgCfUfGfagguGfgaUfaa(L96) (vinu)sUfsaucCfaCfCfucagCfcUfgausasc BD-11767 asuscaGfgCfUfGfagguGfGfauaa(L96) (vinu)sUfsaucCfaccucagCfcUfgausascBD-11768 asuscaGfgCfUfGfagguGfGfauaa(L96) (vinu)sUfsaucCfaCfCfucagCfcUfgausasc BD-11769 asuscaGfgCfUfGfagguggauaa(L96) (vinu)sUfsaucCfaccucagCfcUfgausascBD-11770 asuscaggCfuGfAfGfguggAfuaAfua(L96) (vinu)sAfsuuaUfccaccucAfgCfcugausasc BD-11771 asuscaggCfuGfAfGfguggAfuaAfua(L96) (vinu)sAfsuuaUfcCfAfccucAfgCfcugausasc BD-11772 asuscaggCfuGfAfGfguggAIUfaaua(L96) (vinu)sAfsuuaUfccaccucAfgCfcugausasc BD-11773 asuscaggCfuGf AfGfguggAIU faaua(L96) (vinu)sAfsuuaUfcCfAfccucAfgCfcugausasc BD-11774 asuscaggCfuGfAfGfguggauaaua(L96) (vinu)sAfsuuaUfccaccucAfgCfcugausasc BD-11775 asuscaggCfuGfAfGfguggauaaua(L96) (vinu)sAfsuuaUfcCfAfccucAfgCfcugausasc BD-11776 asuscaGfgCfUfGfagguggauaa(L96) (vinu)sUfsaucCfaCfCfucagCfcUfgausasc BD-11777 gsgscuGfaGfGfUfggauAfauCfua(L96) (vinu)sAfsgauUfauccaccUfcAfgccsusgBD-11778 gsgscuGfaGfGfUfggauAfauCfua(L96) (vinu)sAfsgauUfaUfCfcaccUfcAfgccsusg BD-11779 gsgscuGfaGfGIUfggauAfAfucua(L96) (vinu)sAfsgauUfauccaccUfcAfgccsusgBD-11780 gsgscuGfaGfGfUfggauAfAfucua(L96) (vinu)sAfsgauUfaUfCfcaccUfcAfgccsusg BD-11781 gsgscuGfaGfGfUfggauaaucua(L96) (vinu)sAfsgauUfauccaccUfcAfgccsusgBD-11782 gsgscugaGfgUfGfGfauaaUfcuUfca(L96) (vinu)sGfsaagAfuuauccaCfcUfcagccsusg BD-11783 gsgscugaGfgUfGfGfauaaUfcuUfca(L96) (vinu)sGfsaagAfuUfAfuccaCfcUfcagccsusg BD-11784 gsgscugaGfgUfGfGfauaaUfCfuuca(L96) (vinu)sGfsaagAfuuauccaCfcUfcagccsusg BD-11785 gsgscugaGfgUfGfGfauaaUfCfuuca(L96) (vinu)sGfsaagAfuUfAfuccaCfcUfcagccsusg BD-11786 gsgscugaGfgUfGIGfauaaucuuca(L96) (vinu)sGfsaagAfuuauccaCfcUfcagccsusg BD-11787 gsgscugaGfgUfGfGfauaaucuuca(L96) (vinu)sGfsaagAfuUfAfuccaCfcUfcagccsusg BD-11788 gsgscuGfaGfGfUfggauaaucua(L96) (vinu)sAfsgauUfaUfCfcaccUfcAfgccsusg BD-11789 gscsugAfgGfUfGfgauaAfucUfua(L96) (vinu)sAfsagaUfuauccacCfuCfagcscsuBD-11790 gscsugAfgGfUfGfgauaAfucUfua(L96) (vinu)sAfsagaUfuAfUfccacCfuCfagcscsu BD-11791 gscsugAfgGfUfGfgauaAIUfcuua(L96) (vinu)sAfsagaUfuauccacCfuCfagcscsuBD-11792 gscsugAfgGfUfGfgauaAfUfcuua(L96) (vinu)sAfsagaUfuAfUfccacCfuCfagcscsu BD-11793 gscsugAfgGfUfGfgauaaucuua(L96) (vinu)sAfsagaUfuauccacCfuCfagcscsuBD-11794 gscsugagGfuGfGfAfuaauCfuuCfca(L96) (vinu)sGfsgaaGfauuauccAfcCfucagcscsu BD-11795 gscsugagGfuGfGfAfuaauCfuuCfca(L96) (vinu)sGfsgaaGfaUfUfauccAfcCfucagcscsuBD-11796 gscsugagGfuGfGfAfuaauCfUfucca(L96) (vinu)sGfsgaaGfauuauccAfcCfucagcscsu NAI-5008944785v1 Page 71 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11797 gscsugagGfuGfGfAfuaauCfUfucca(L96) (vinu)sGfsgaaGfaUfUfauccAfcCfucagcscsu BD-11798 gscsugagGfuGfGfAfuaaucuucca(L96) (vinu)sGfsgaaGfauuauccAfcCfucagcscsu BD-11799 gscsugagGfuGfGfAfuaaucuucca(L96) (vinu)sGfsgaaGfaUIUfauccAfcCfucagcscsu BD-11800 gscsugAfgGfUfGfgauaaucuua(L96) (vinu)sAfsagaUfuAfUfccacCfuCfagcscsu BD-11801 asuscaAfuGfGfAfggugAfccGfaa(L96) (vinu)sUfscggUfcaccuccAfuUfgausasgBD-11802 asuscaAfuGfGfAfggugAfccGfaa(L96) (vinu)sUfscggUfcAfCfcuccAfuUfgausasg BD-11803 asuscaAfuGfGfAfggugAfCfcgaa(L96) (vinu)sUfscggUfcaccuccAfuUfgausasgBD-11804 asuscaAfuGfGfAfggugAfCfcgaa(L96) (vinu)sUfscggUfcAfCfcuccAfuUfgausasg BD-11805 asuscaAfuGfGfAfggugaccgaa(L96) (vinu)sUfscggUfcaccuccAfuUfgausasgBD-11806 asuscaauGfgAfGfGfugacCfgaCfca(L96) (vinu)sGfsgucGfgucaccuCfcAfuugausasg BD-11807 asuscaauGfgAfGfGfugacCfgaCfca(L96) (vinu)sGfsgucGfgUfCfaccuCfcAfuugausasg BD-11808 asuscaauGfgAfGfGfugacCfGfacca(L96) (vinu)sGfsgucGfgucaccuCfcAfuugausasg BD-11809 asuscaauGfgAfGfGfugacCfGfacca(L96) (vinu)sGfsgucGfgUfCfaccuCfcAfuugausasg BD-11810 asuscaauGfgAfGfGfugaccgacca(L96) (vinu)sGfsgucGfgucaccuCfcAfuugausasg BD-11811 asuscaauGfgAfGfGfugaccgacca(L96) (vinu)sGfsgucGfgUfCfaccuCfcAfuugausasg BD-11812 asuscaAfuGfGfAfggugaccgaa(L96) (vinu)sUfscggUfcAfCfcuccAfuUfgausasg BD-11813 uscsaaUfgGfAfGfgugaCfcgAfca(L96) (vinu)sGfsucgGfucaccucCfaUfugasusaBD-11814 uscsaaUfgGfAfGfgugaCfcgAfca(L96) (vinu)sGfsucgGfuCfAfccucCfaUfugasusa BD-11815 uscsaaUfgGfAIGfgugaCfCfgaca(L96) (vinu)sGfsucgGfucaccucCfaUfugasusaBD-11816 uscsaaUfgGfAfGfgugaCfCfgaca(L96) (vinu)sGfsucgGfuCfAfccucCfaUfugasusa BD-11817 uscsaaUfgGfAfGfgugaccgaca(L96) (vinu)sGfsucgGfucaccucCfaUfugasusaBD-11818 uscsaaugGfaGfGfUfgaccGfacCfiia(L96) (vinu)sAfsgguCfggucaccUfcCfauugasusa BD-11819 uscsaaugGfaGfGfUfgaccGfacCfua(L96) (vinu)sAfsgguCfgGfUfcaccUfcCfauugasusa BD-11820 uscsaaugGfaGfGfUfgaccGfAfccua(L96) (vinu)sAfsgguCfggucaccUfcCfauugasusa BD-11821 uscsaaugGfaGfGfUfgaccGfAfccua(L96) (vinu)sAfsgguCfgGfUfcaccUfcCfauugasusa BD-11822 uscsaaugGfaGfGfUfgaccgaccua(L96) (vinu)sAfsgguCfggucaccUfcCfauugasusa BD-11823 uscsaaugGfaGfGIUfgaccgaccua(L96) (vinu)sAfsgguCfgGIUfcaccUfcCfauugasusa BD-11824 uscsaaUfgGfAfGfgugaccgaca(L96) (vinu)sGfsucgGfuCfAfccucCfaUfugasusa BD-11825 csasauGfgAfGfGfugacCfgaCfca(L96) (vinu)sGfsgucGfgucaccuCfcAfuugsasuBD-11826 csasauGfgAfGfGfugacCfgaCfca(L96) (vinu)sGfsgucGfgUfCfaccuCfcAfuugsasu BD-11827 csasauGfgAfGfGfugacCfGfacca(L96) (vinu)sGfsgucGfgucaccuCfcAfuugsasuBD-11828 csasauGfgAfGfGfugacCfGfacca(L96) (vinu)sGfsgucGfgUfCfaccuCfcAfuugsasu BD-11829 csasauGfgAfGfGfugaccgacca(L96) (vinu)sGfsgucGfgucaccuCfcAfuugsasuBD-11830 csasauggAfgGfUfGfaccgAfccUfga(L96) (vinu)sCfsaggUfcggucacCfuCfcauugsasu BD-11831 csasauggAfgGfUfGfaccgAfccUfga(L96) (vinu)sCfsaggUfcGfGfucacCfuCfcauugsasu BD-11832 csasauggAfgGfUfGfaccgAfCfcuga(L96) (vinu)sCfsaggUfcggucacCfuCfcauugsasu BD-11833 csasauggAfgGfUfGfaccgAfCfcuga(L96) (vinu)sCfsaggUfcGfGfucacCfuCfcauugsasu BD-11834 csasauggAfgGfUfGfaccgaccuga(L96) (vinu)sCfsaggUfcggucacCfuCfcauugsasu BD-11835 csasauggAfgGfUfGfaccgaccuga(L96) (vinu)sCfsaggUfcGfGfucacCfuCfcauugsasu BD-11836 csasauGfgAfGfGfugaccgacca(L96) (vinu)sGfsgucGfgUfCfaccuCfcAfuugsasu BD-11837 gsgsagGfuGfAfCfcgacCfugGfga(L96) (vinu)sCfsccaGfgucggucAfcCfuccsasuBD-11838 gsgsagGfuGfAfCfcgacCfugGfga(L96) (vinu)sCfsccaGfgUfCfggucAfcCfuccsasu BD-11839 gsgsagGfuGfAfCfcgacCIUfggga(L96) (vinu)sCfsccaGfgucggucAfcCfuccsasuBD-11840 gsgsagGfuGfAfCfcgacCfUfggga(L96) (vinu)sCfsccaGfgUfCfggucAfcCfuccsasu BD-11841 gsgsagGfuGfAfCfcgaccuggga(L96) (vinu)sCfsccaGfgucggucAfcCfuccsasuBD-11842 gsgsagguGfaCfGfGfaccuGfggGfga(L96) (vinu)sCfscccCfaggucggUfcAfccuccsasu BD-11843 gsgsagguGfaCfCfGfaccuGfggGfga(L96) (vinu)sCfscccCfaGfGfucggUfcAfccuccsasu BD-11844 gsgsagguGfaCfCfGfaccuGfGfggga(L96) (vinu)sCfscccCfaggucggUfcAfccuccsasu BD-11845 gsgsagguGfaCfCfGfaccuGfGfggga(L96) (vinu)sCfscccCfaGfGfucggUfcAfccuccsasu BD-11846 gsgsagguGfaCfCfGfaccuggggga(L96) (vinu)sCfscccCfaggucggUfcAfccuccsasuBD-11847 gsgsagguGfaCfCfGfaccuggggga(L96) (vinu) sCf sccc CfaGf GfucggU fc Af ccucc sasu NAI-5008944785v1 Page 2. of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11848 gsgsagGfuGfAfCfcgaccuggga(L96) (vinu)sCfsccaGfgUfCfggucAfcCfuccsasu BD-11849 gsasggUfgAfCfCfgaccUfggGfga(L96) (vinu)sCfscccAfggucgguCfaCfcucscsaBD-11850 gsasggUfgAfCfCfgaccUfggGfga(L96) (vinu)sCfscccAfgGIUfcgguCfaCfcucscsa BD-11851 gsasggUfgAfCfCfgaccUfGfggga(L96) (vinu)sCfscccAfggucgguCfaCfcucscsaBD-11852 gsasggUfgAfCfCfgaccUfGfggga(L96) (vinu)sCfscccAfgGfUfcgguCfaCfcucscsa BD-11853 gsasggUfgAfCfCfgaccugggga(L96) (vinu)sCfscccAfggucgguCfaCfcucscsaBD-11854 gsasggugAfcCfGfAfccugGfggGfaa(L96) (vinu)sUfscccCfcaggucgGfuCfaccucscsa BD-11855 gsasggugAfcCfGfAfccugGfggGfaa(L96) (vinu)sUfscccCfcAfGfgucgGfuCfaccucscsa BD-11856 gsasggugAfcCfGfAfccugGfGfggaa(L96) (vinu)sUfscccCfcaggucgGfuCfaccucscsa BD-11857 gsasggugAfcCfGfAfccugGfGfggaa(L96) (vinu)sUfscccCfcAfGfgucgGfuCfaccucscsa BD-11858 gsasggugAfcCfGfAfccugggggaa(L96) (vinu)sUfscccCfcaggucgGfuCfaccucscsa BD-11859 gsasggugAfcCfGfAfccugggggaa(L96) (vinu)sUfscccCfcAfGfgucgGfuCfaccucscsa BD-11860 gsasggUfgAfCfCfgaccugggga(L96) (vinu)sCfscccAfgGfUfcgguCfaCfcucscsa BD-11861 gsgsauCfcAfGfUfuuguCfgaUfua(L96) (vinu)sAfsaucGfacaaacuGfgAfuccscscBD-11862 gsgsauCfcAfGfUfuuguCfgaUfua(L96) (vinu)sAfsaucGfaCfAfaacuGfgAfuccscsc BD-11863 gsgsauCfcAfGfUfuuguCfGfauua(L96) (vinu)sAfsaucGfacaaacuGfgAfuccscscBD-11864 gsgsauCfcAfGfUfuuguCfGfauua(L96) (vinu)sAfsaucGfaCfAfaacuGfgAfuccscsc BD-11865 gsgsauCfcAfGfUfuugucgauua(L96) (vinu)sAfsaucGfacaaacuGfgAfuccscscBD-11866 gsgsauccAfgUIUfUfgucgAfuuCfaa(L96) (vinu)sUfsgaaUfcgacaaaCfuGfgauccscsc BD-11867 gsgsauccAfgUfUfUfgucgAfuuCfaa(L96) (vinu)sUfsgaaUfcGfAfcaaaCfuGfgauccscsc BD-11868 gsgsauccAfgUfUfUfgucgAfUfucaa(L96) (vinu)sUfsgaaUfcgacaaaCfuGfgauccscsc BD-11869 gsgsauccAfgUfUfUfgucgAIUfucaa(L96) (vinu)sUfsgaaUfcGfAfcaaaCfuGfgauccscsc BD-11870 gsgsauccAfgUfUfUfgucgauucaa(L96) (vinu)sUfsgaaUfcgacaaaCfuGfgauccscsc BD-11871 gsgsauccAfgUfUfUfgucgauucaa(L96) (vinu)sUfsgaaUfcGfAfcaaaCfuGfgauccscsc BD-11872 gsgsauCfcAfGfUfuugucgauua(L96) (vinu)sAfsaucGfaCfAfaacuGfgAfuccscsc BD-11873 uscscaGfuUfUfGfucgaUfucAfaa(L96) (vinu)sUfsugaAfucgacaaAfcUfggasuscBD-11874 uscscaGfuUIUfGfucgaUfucAfaa(L96) (vinu)sUfsugaAfuCfGfacaaAfcUfggasusc BD-11875 uscscaGfuUfUfGfucgaUfUfcaaa(L96) (vinu)sUfsugaAfucgacaaAfcUfggasuscBD-11876 uscscaGfuUfUfGfucgaUfUfcaaa(L96) (vinu)sUfsugaAfuCfGfacaaAfcUfggasusc BD-11877 uscscaGfuUfUfGfucgauucaaa(L96) (vinu)sUfsugaAIucgacaaAfcUfggasuscBD-11878 uscscaguUfuGfUfCfgauuCfaaAfca(L96) (vinu)sGfsuuuGfaaucgacAfaAfcuggasusc BD-11879 uscscaguUfuGfUfCfgauuCfaaAfca(L96) (vinu)sGfsuuuGfaAIUfcgacAfaAfcuggasusc BD-11880 uscscaguUfuGfUfCfgauuCfAfaaca(L96) (vinu)sGfsuuuGfaaucgacAfaAfcuggasusc BD-11881 uscscaguUfuGfUfCfgauuCfAfaaca(L96) (vinu)sGfsuuuGfaAfUfcgacAfaAfcuggasusc BD-11882 uscscaguUfuGfUfCfgauucaaaca(L96) (vinu)sGfsuuuGfaaucgacAfaAfcuggasusc BD-11883 uscscaguUfuGfUfCfgauucaaaca(L96) (vinu)sGfsuuuGfaAfUfcgacAfaAfcuggasusc BD-11884 uscscaGfuUfUfGfucgauucaaa(L96) (vinu)sUfsugaAfuCfGfacaaAfcUfggasusc BD-11885 csasguUfuGfUfCfgauuCfaaAfca(L96) (vinu)sGfsuuuGfaaucgacAfaAfcugsgsaBD-11886 csasguUfuGfUfCfgauuCfaaAfca(L96) (vinu)sGfsuuuGfaAfUfcgacAfaAfcugsgsa BD-11887 csasguUfuGfUfCfgauuCfAfaaca(L96) (vinu)sGfsuuuGfaaucgacAfaAfcugsgsaBD-11888 csasguUfuGfUfCfgauuCfAfaaca(L96) (vinu)sGfsuuuGfaAfUfcgacAfaAfcugsgsa BD-11889 csasguUfuGfUfCfgauucaaaca(L96) (vinu)sGfsuuuGfaaucgacAfaAfcugsgsaBD-11890 csasguuuGfuCfGfAfuucaAfacUfga(L96) (vinu)sCfsaguUfugaaucgAfcAfaacugsgsa BD-11891 csasguuuGfuCfGfAfuucaAfacUfga(L96) (vinu)sCfsaguUfuGfAfaucgAfcAfaacugsgsa BD-11892 csasguuuGfuCfGfAfuucaAfAfcuga(L96) (vinu)sCfsaguUfugaaucgAfcAfaacugsgsa BD-11893 csasguuuGfuCfGfAfuucaAfAfcuga(L96) (vinu)sCfsaguUfuGfAfaucgAfcAfaacugsgsa BD-11894 csasguuuGfuCfGfAfuucaaacuga(L96) (vinu)sCfsaguUfugaaucgAfcAfaacugsgsa BD-11895 csasguuuGfuCfGfAfuucaaacuga(L96) (vinu)sCfsaguUfuGfAfaucgAfcAfaacugsgsa BD-11896 csasguUfuGfUfCfgauucaaaca(L96) (vinu)sGfsuuuGfaAfUfcgacAfaAfcugsgsa BD-11897 asgsuuUfgUfCfGfauucAfaaCfua(L96) (vinu)sAfsguuUfgaaucgaCfaAfacusgsgBD-11898 asgsuuUfgUfCfGfauucAfaaCfua(L96) (vinu)sAfsguuUfgAfAfucgaCfaAfacusgsg NAI-5008944785v1 Page 73 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11899 asgsuuUfgUfCfGfauucAfAfacua(L96) (vinu)sAfsguuUfgaaucgaCfaAfacusgsgBD-11900 asgsuuUfgUfCfGfauucAfAfacua(L96) (vinu)sAfsguuUfgAfAfucgaCfaAfacusgsg BD-11901 asgsuuUfgUfCfGfauucaaacua(L96) (vinu)sAfsguuUfgaaucgaCfaAfacusgsgBD-11902 asgsuuugUfcGfAfUfucaaAfcuGfca(L96) (vinu)sGfscagUfuugaaucGfaCfaaacusgsg BD-11903 asgsuuugUfcGfAfUfucaaAfcuGfca(L96) (vinu)sGfscagUfuUfGfaaucGfaCfaaacusgsg BD-11904 asgsuuugUfcGfAIUfucaaAfCfugca(L96) (vinu)sGfscagUfuugaaucGfaCfaaacusgsg BD-11905 asgsuuugUfcGfAfUfucaaAfCfugca(L96) (vinu)sGfscagUfuUfGfaaucGfaCfaaacusgsg BD-11906 asgsuuugUfcGfAfUfucaaacugca(L96) (vinu)sGfscagUfuugaaucGfaCfaaacusgsg BD-11907 asgsuuugUfcGfAfUfucaaacugca(L96) (vinu)sGfscagUfuUfGfaaucGfaCfaaacusgsg BD-11908 asgsuuUfgUfCfGfauucaaacua(L96) (vinu)sAfsguuUfgAfAfucgaCfaAfacusgsg BD-11909 ususugUfcGfAfUfucaaAfcuGfca(L96) (vinu)sGfscagUfuugaaucGfaCfaaascsuBD-11910 ususugUfcGfAfUfucaaAfcuGfca(L96) (vinu)sGfscagUfuUfGfaaucGfaCfaaascsu BD-11911 ususugUfcGfAfUfucaaAfCfugca(L96) (vinu)sGfscagUfuugaaucGfaCfaaascsuBD-11912 ususugUfcGfAfUfucaaAfCfiigca(L96) (vinu)sGfscagUfuUfGfaaucGfaCfaaascsu BD-11913 ususugUfcGfAfUfucaaacugca(L96) (vinu)sGfscagUfuugaaucGfaCfaaascsuBD-11914 ususugucGfaUfUfCfaaacUfgcUfaa(L96) (vinu)sUfsagcAfguuugaaUfcGfacaaascsu BD-11915 ususugucGfaUfUfCfaaacUfgcUfaa(L96) (vinu)sUfsagcAfgUfUfugaaUfcGfacaaascsu BD-11916 ususugucGfaUfUfCfaaacUfGfcuaa(L96) (vinu)sUfsagcAfguuugaaUfcGfacaaascsu BD-11917 ususugucGfaUIUfCfaaacUfGfcuaa(L96) (vinu)sUfsagcAfgUIUfugaaUfcGfacaaascsu BD-11918 ususugucGfaUfUfCfaaacugcuaa(L96) (vinu)sUfsagcAfguuugaaUfcGfacaaascsu BD-11919 ususugucGfaUfUfCfaaacugcuaa(L96) (vinu)sUfsagcAfgUfUfugaaUfcGfacaaascsu BD-11920 ususugUfcGfAIUfucaaacugca(L96) (vinu)sGfscagUfuUfGfaaucGfaCfaaascsu BD-11921 ususguCfgAfUfUfcaaaCfugCfua(L96) (vinu)sAfsgcaGfuuugaauCfgAfcaasascBD-11922 ususguCfgAfUfUfcaaaCfugCfua(L96) (vinu)sAfsgcaGfuUfUfgaauCfgAfcaasasc BD-11923 ususguCfgAfUfUfcaaaCfUfgcua(L96) (vinu)sAfsgcaGfuuugaauCfgAfcaasascBD-11924 ususguCfgAfUfUfcaaaCfUfgcua(L96) (vinu)sAfsgcaGfuUfUfgaauCfgAfcaasasc BD-11925 ususguCfgAIUIUfcaaacugcua(L96) (vinu)sAfsgcaGfuuugaauCfgAfcaasascBD-11926 ususgucgAfuUfCfAfaacuGfcuAfaa(L96) (vinu)sUfsuagCfaguuugaAfuCfgacaasasc BD-11927 ususgucgAfuUfCfAfaacuGfcuAfaa(L96) (vinu)sUfsuagCfaGfUfuugaAfuCfgacaasasc BD-11928 ususgucgAfuUfCfAfaacuGfCfuaaa(L96) (vinu)sUfsuagCfaguuugaAfuCfgacaasasc BD-11929 ususgucgAfuUfCfAfaacuGfCfuaaa(L96) (vinu)sUfsuagCfaGfUfuugaAfLiCfgacaasasc BD-11930 ususgucgAfuUfCfAfaacugcuaaa(L96) (vinu)sUfsuagCfaguuugaAfuCfgacaasasc BD-11931 ususgucgAfuUfCfAfaacugcuaaa(L96) (vinu)sUfsuagCfaGfUfuugaAfuCfgacaasasc BD-11932 ususguCfgAfUfUfcaaacugcua(L96) (vinu)sAfsgcaGfuUfUfgaauCfgAfcaasasc BD-11933 usgsucGfaUfU fCfaaacUfgcUfaa(L96) (vinu)sUfsagcAfguuugaaUfcGfacasasaBD-11934 usgsucGfaUfUfCfaaacUfgcUfaa(L96) (vinu)sUfsagcAfgUfUfugaaUfcGfacasasa BD-11935 usgsucGfaUfUfCfaaacUfGfcuaa(L96) (vinu)sUfsagcAfguuugaaUfcGfacasasaBD-11936 usgsucGfaUfU fCfaaacUIGfcuaa(L96) (vinu)sUfsagcAfgUIUfugaaUfcGfacasasa BD-11937 usgsucGfaUfUfCfaaacugcuaa(L96) (vinu)sUfsagcAfguuugaaUfcGfacasasaBD-11938 usgsucgaUfuCfAfAfacugCfuaAfca(L96) (vinu)sGfsuuaGfcaguuugAfaUfcgacasasa BD-11939 usgsucgaUfuCfAfAfacugCfuaAfca(L96) (vinu)sGfsuuaGfcAfGfuuugAfaUfcgacasasa BD-11940 usgsucgaUfuCfAfAfacugCfUfaaca(L96) (vinu)sGfsuuaGfcaguuugAfaUfcgacasasa BD-11941 usgsucgaUfuCfAfAfacugCfUfaaca(L96) (vinu)sGfsuuaGfcAfGfuuugAfaUfcgacasasa BD-11942 usgsucgaUfuCfAfAfacugcuaaca(L96) (vinu)sGfsuuaGfcaguuugAfaUfcgacasasa BD-11943 usgsucgaU fuCf Af Afacugcuaaca(L96) (vinu)sGfsuuaGfcAfGfuuugAfaUfcgacasasa BD-11944 usgsucGfaUfUfCfaaacugcuaa(L96) (vinu)sUfsagcAfgUIUfugaaUfcGfacasasa BD-11945 gsuscgAfuUfCfAfaacuGfcuAfaa(L96) (vinu)sUfsuagCfaguuugaAfuCfgacsasaBD-11946 gsuscgAfuUfCfAfaacuGfcuAfaa(L96) (vinu) sU fsuagCfaGIUfuugaAfuCfgac sasa BD-11947 gsuscgAfuUfCfAfaacuGfCfuaaa(L96) (vinu)sUfsuagCfaguuugaAfuCfgacsasaBD-11948 gsuscgAfuUfCfAfaacuGfCfuaaa(L96) (vinu)sUfsuagCfaGfUfuugaAfuCfgacsasaBD-11949 gsuscgAfuUfCfAfaacugcuaaa(L96) (vinu)sUfsuagCfaguuugaAfuCfgacsasaNAI-5008944785v1 Page 74 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-11950 gsuscgauUfcAfAfAfcugcUfaaCfca(L96) (vinu)sGfsguuAfgcaguuuGfaAfucgacsasa BD-11951 gsuscgauUfcAfAfAfcugcUfaaCfca(L96) (vinu)sGfsguuAfgCfAfguuuGfaAfucgacsasa BD-11952 gsuscgauUfcAfAfAfcugcUfAfacca(L96) (vinu)sGfsguuAfgcaguuuGfaAfucgacsasa BD-11953 gsuscgauUfcAfAfAfcugcUfAfacca(L96) (vinu)sGfsguuAfgCfAfguuuGfaAfucgacsasa BD-11954 gsuscgauUfcAfAfAfcugcuaacca(L96) (vinu)sGfsguuAfgcaguuuGfaAfucgacsasa BD-11955 gsuscgauUfcAfAfAfcugcuaacca(L96) (vinu)sGfsguuAfgCfAfguuuGfaAfucgacsasa BD-11956 gsuscgAfuUfCfAfaacugcuaaa(L96) (vinu)sUfsuagCfaGfUfuugaAfuCfgacsasa BD-11957 uscsgaUfuCfAfAfacugCfuaAfca(L96) (vinu)sGfsuuaGfcaguuugAfaUfcgascsaBD-11958 uscsgaUfuCfAfAfacugCfuaAfca(L96) (vinu)sGfsuuaGfcAfGfuuugAfaUfcgascsa BD-11959 uscsgaUfuCfAfAfacugCfUfaaca(L96) (vinu)sGfsuuaGfcaguuugAfaUfcgascsaBD-11960 uscsgaUfuCfAfAfacugCfUfaaca(L96) (vinu)sGfsuuaGfcAfGfuuugAfaUfcgascsa BD-11961 uscsgaUfuCfAfAfacugcuaaca(L96) (vinu)sGfsuuaGfcaguuugAfaUfcgascsaBD-11962 uscsgauuCfaAfAfCfugcuAfacCfca(L96) (vinu)sGfsgguUfagcaguuUfgAfaucgascsa BD-11963 uscsgauuCfaAfAfCfugcuAfacCfca(L96) (vinu)sGfsgguUfaGfCfaguuUfgAfaucgascsa BD-11964 uscsgauuCfaAfAfCfugcuAfAfccca(L96) (vinu)sGfsgguUfagcaguuUfgAfaucgascsa BD-11965 uscsgauuCfaAfAfCfugcuAfAfccca(L96) (vinu)sGfsgguUfaGfCfaguuUfgAfaucgascsa BD-11966 uscsgauuCfaAfAfCfugcuaaccca(L96) (vinu)sGfsgguUfagcaguuUfgAfaucgascsa BD-11967 uscsgauuCfaAfAfCfugcuaaccca(L96) (vinu)sGfsgguUfaGfCfaguuUfgAfaucgascsa BD-11968 uscsgaUfuCIAfAfacugcuaaca(L96) (vinu)sGfsuuaGfcAfGfuuugAfaUfcgascsa BD-11969 gsasuuCfaAfAfCfugcuAfacCfca(L96) (vinu)sGfsgguUfagcaguuUfgAfaucsgsaBD-11970 gsasuuCfaAfAfCfugcuAfacCfca(L96) (vinu)sGfsgguUfaGfCfaguuUfgAfaucsgsa BD-11971 gsasuuCfaAfAfCfugcuAfAfccca(L96) (vinu)sGfsgguUfagcaguuUfgAfaucsgsaBD-11972 gsasuuCfaAfAfCfugcuAfAfccca(L96) (vinu)sGfsgguUfaGfCfaguuUfgAfaucsgsa BD-11973 gsasuuCfaAfAfCfugcuaaccca(L96) (vinu)sGfsgguUfagcaguuUfgAfaucsgsaBD-11974 gsasuucaAfaCfUfGfcuaaCfccUfga(L96) (vinu)sCfsaggGfuuagcagUfuLJfgaaucsgsa BD-11975 gsasuucaAfaCfUfGfcuaaCfccUfga(L96) (vinu)sCfsaggGfuUfAfgcagUfuUfgaaucsgsa BD-11976 gsasuucaAfaCfUIGfcuaaCfCfcuga(L96) (vinu)sCfsaggGfuuagcagUfuUfgaaucsgsa BD-11977 gsasuucaAfaCfUfGfcuaaCfCfcuga(L96) (vinu)sCfsaggGfuUfAfgcagUfuUfgaaucsgsa BD-11978 gsasuucaAfaCfUfGfcuaacccuga(L96) (vinu)sCfsaggGfuuagcagUfuUfgaaucsgsa BD-11979 gsasuucaAfaCfUfGfcuaacccuga(L96) (vinu)sCfsaggGfuUfAfgcagUfuUfgaaucsgsa BD-11980 gsasuuCfaAfAfCfugcuaaccca(L96) (vinu)sGfsgguUfaGfCfaguuUfgAfaucsgsa BD-11981 asascuGfcUfAfAfcccuGfggAfaa(L96) (vinu)sUfsuccCfaggguuaGfcAfguususgBD-11982 asascuGfcUfAfAfcccuGfggAfaa(L96) (vinu)sUfsuccCfaGfGfguuaGfcAfguususg BD-11983 asascuGfcUfAfAfcccuGfGfgaaa(L96) (vinu)sUfsuccCfaggguuaGfcAfguususgBD-11984 asascuGfcUfAfAfcccuGfGfgaaa(L96) (vinu)sUfsuccCfaGfGfguuaGfcAfguususg BD-11985 asascuGfcUfAfAfcccugggaaa(L96) (vinu)sUfsuccCfaggguuaGfcAfguususgBD-11986 asascugcUfaAfCfCfcuggGfaaCfca(L96) (vinu)sGfsguuCfccaggguUfaGfcaguususg BD-11987 asascugcUfaAfCfCfcuggGfaaCfca(L96) (vinu)sGfsguuCfcCfAfggguUfaGfcaguususg BD-11988 asascugcUfaAfCfCfcuggGfAfacca(L96) (vinu)sGfsguuCfccaggguUfaGfcaguususg BD-11989 asascugcUfaAfCfCfcuggGfAfacca(L96) (vinu)sGfsguuCfcCfAfggguUfaGfcaguususg BD-11990 asascugcUfaAfCfCfcugggaacca(L96) (vinu)sGfsguuCfccaggguUfaGfcaguususg BD-11991 asascugcUfaAfCfCfcugggaacca(L96) (vinu)sGfsguuCfcCfAfggguUfaGfcaguususg BD-11992 asascuGfcUfAfAfcccugggaaa(L96) (vinu)sUfsuccCfaGfGfguuaGfcAfguususg BD-11993 csusgcUfaAfCfCfcuggGfaaCfca(L96) (vinu)sGfsguuCfccaggguUfaGfcagsusuBD-11994 csusgcUfaAfCfCfcuggGfaaCfca(L96) (vinu)sGfsguuCfcCfAfggguUfaGfcagsusu BD-11995 csusgcUfaAfCfCfcuggGfAfacca(L96) (vinu)sGfsguuCfccaggguUfaGfcagsusuBD-11996 csusgcUfaAfCfCfcuggGfAfacca(L96) (vinu)sGfsguuCfcCfAfggguUfaGfcagsusu BD-11997 csusgcUfaAfCfCfcugggaacca(L96) (vinu)sGfsguuCfccaggguUfaGfcagsusuBD-11998 csusgcuaAfcCfCfUfgggaAfccAfua(L96) (vinu)sAfsuggUfucccaggGfuUfagcagsusu BD-11999 csusgcuaAfcCfCfUfgggaAfccAfua(L96) (vinu)sAfsuggUfuCfCfcaggGfuUfagcagsusuBD-12000 csusgcuaAfcCfCfUfgggaAfCfcaua(L96) (vinu)sAfsuggUfucccaggGfuUfagcagsusu NAI-5008944785v1 Page 75 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-12001 csusgcuaAfcCfCfUfgggaAfCfcaua(L96) (vinu)sAfsuggUfuCfCfcaggGfuUfagcagsusu BD-12002 csusgcuaAfcCfCfUfgggaaccaua(L96) (vinu)sAfsuggUfucccaggGfuUfagcagsusu BD-12003 csusgcuaAfcCfCfUfgggaaccaua(L96) (vinu)sAfsuggUfuCfCfcaggGfuUfagcagsusu BD-12004 csusgcUfaAfCfCfcugggaacca(L96) (vinu)sGfsguuCfcCfAfggguUfaGfcagsusu BD-12005 asusccAfaGfClUfgccuAfcaUfua(L96) (vinu)sAfsaugUfaggcagcUfuGfgauscsuBD-12006 asusccAfaGfCfUfgccuAfcaUfua(L96) (vinu)sAfsaugUfaGfGfcagcUfuGfgauscsu BD-12007 asusccAfaGfCfUfgccuAfCfauua(L96) (vinu)sAfsaugUfaggcagcUfuGfgauscsuBD-12008 asusccAfaGfCfUfgccuAfCfauua(L96) (vinu) sAf saugUfaGf GfcagcU fuGfgauscsu BD-12009 asusccAfaGfCfUfgccuacauua(L96) (vinu)sAfsaugUfaggcagcUfuGfgauscsuBD-12010 asusccaaGfcUfGfCfcuacAfuuGfga(L96) (vinu)sCfscaaUfguaggcaGfcUfuggauscsu BD-12011 asusccaaGfcUfGfCfcuacAfuuGfga(L96) (vinu)sCfscaaUfgUfAfggcaGfcUluggauscsu BD-12012 asusccaaGfcUfGfCfcuacAfUfugga(L96) (vinu)sCfscaaUfguaggcaGfcUfuggauscsu BD-12013 asusccaaGfcUfGfCfcuacAfUfugga(L96) (vinu)sCfscaaUfgUfAfggcaGfcUfuggauscsu BD-12014 asusccaaGfcUfGfCfcuacauugga(L96) (vinu)sCfscaaUfguaggcaGfcUfuggauscsu BD-12015 asusccaaGfcUfGfCfcuacauugga(L96) (vinu)sCfscaaUfgUfAfggcaGfcUluggauscsu BD-12016 asusccAfaGfCfUfgccuacauua(L96) (vinu) sAf saugUfaGf GfcagcU fuGfgauscsu BD-12017 cscsaaGfcUfGfCfcuacAfuuGfga(L96) (vinu)sCfscaaUfguaggcaGfcUfuggsasuBD-12018 cscsaaGfcUfGfCfcuacAfuuGfga(L96) (vinu)sCfscaaUfgUfAfggcaGfcUfuggsasu BD-12019 cscsaaGfcUfGfCfcuacAfUfugga(L96) (vinu)sCfscaaUfguaggcaGfcUfuggsasuBD- 12020 cscsaaGfcUfGfCfcuacAfUfugga(L96) (vinu)sCfscaaUfgUfAfggcaGfcUluggsasu BD-12021 cscsaaGfcUfGfCfcuacauugga(L96) (vinu)sCfscaaUfguaggcaGfcUfuggsasuBD-12022 cscsaagcUfgCfCfUfacauUfggCfaa(L96) (vinu)sUfsgccAfauguaggCfaGfcuuggsasu BD-12023 cscsaagcUfgCfCfUfacauUfggCfaa(L96) (vinu)sUfsgccAfaUfGfuaggCfaGfcuuggsasu BD-12024 cscsaagcUfgCfCfUfacauUfGfgcaa(L96) (vinu)sUfsgccAfauguaggCfaGfcuuggsasu BD-12025 cscsaagcUfgCfClUfacauUfGfgcaa(L96) (vinu)sUfsgccAfaUfGluaggCfaGfcuuggsasu BD-12026 cscsaagcUfgCfCfUfacauuggcaa(L96) (vinu)sUfsgccAfauguaggCfaGfcuuggsasu BD-12027 cscsaagcUfgCfCfUfacauuggcaa(L96) (vinu)sUfsgccAfaUfGfuaggCfaGfcuuggsasu BD-12028 cscsaaGfcUfGfCfcuacauugga(L96) (vinu)sCfscaaUfgUfAfggcaGfcUluggsasu BD-12029 csasagCfuGfCfCfuacaUfugGfca(L96) (vinu)sGfsccaAfuguaggcAfgCfuugsgsaBD-12030 csasagCfuGfCfCfuacaUfugGfca(L96) (vinu)sGfsccaAfuGfUfaggcAfgCfuugsgsa BD-12031 csasagCfuGfCfCfuacaUfUfggca(L96) (vinu)sGfsccaAfuguaggcAfgCfuugsgsaBD-12032 csasagCfuGfCfCfuacaUlUfggca(L96) (vinu)sGfsccaAfuGfUfaggcAfgCfuugsgsa BD-12033 csasagCfuGfCfCfuacauuggca(L96) (vinu)sGfsccaAfuguaggcAfgCfuugsgsaBD-12034 csasagcuGfcCfUfAfcauuGfgcAfca(L96) (vinu)sGfsugcCfaauguagGfcAfgcuugsgsa BD-12035 csasagcuGfcClUfAfcauuGfgcAfca(L96) (vinu)sGfsugcCfaAfUfguagGfcAfgcuugsgsa BD-12036 csasagcuGfcCfUfAfcauuGfGfcaca(L96) (vinu)sGfsugcCfaauguagGfcAfgcuugsgsa BD-12037 csasagcuGfcCfUfAfcauuGfGfcaca(L96) (vinu)sGfsugcCfaAfUfguagGfcAfgcuugsgsa BD-12038 csasagcuGfcCfUfAfcauuggcaca(L96) (vinu)sGfsugcCfaauguagGfcAfgcuugsgsa BD-12039 csasagcuGfcCfUfAfcauuggcaca(L96) (vinu)sGfsugcCfaAfUfguagGfcAfgcuugsgsa BD-12040 csasagCfuGfCfCfuacauuggca(L96) (vinu)sGfsccaAfuGfUfaggcAfgCfuugsgsa BD-12041 usgsccUfaCfAfUfuggcAfcaAfca(L96) (vinu)sGfsuugUfgccaaugUfaGfgcasgscBD-12042 usgsccUfaCfAfUfuggcAfcaAfca(L96) (vinu)sGfsuugUfgCfCfaaugUfaGfgcasgsc BD-12043 usgsccUfaCfAfUfuggcAfCfaaca(L96) (vinu)sGfsuugUfgccaaugUfaGfgcasgscBD- 12044 usgsccUfaCfAfUfuggcAfCfaaca(L96) (vinu)sGfsuugUfgCfCfaaugUfaGfgcasgsc BD- 12045 usgsccUfaCfAfUfuggcacaaca(L96) (vinu)sGfsuugUfgccaaugUfaGfgcasgscBD-12046 usgsccuaCfaUfUfGfgcacAfacUfaa(L96) (vinu)sUfsaguUfgugccaaUfgUfaggcasgsc BD- 12047 usgsccuaCfaUfUfGfgcacAfacUfaa(L96) (vinu)sUfsaguUfgUfGfccaaUfgUfaggcasgsc BD-12048 usgsccuaCfaUfUfGfgcacAfAfcuaa(L96) (vinu)sUfsaguUfgugccaaUfgUfaggcasgsc BD-12049 usgsccuaCfaUfUfGfgcacAfAfcuaa(L96) (vinu)sUfsaguUfgUfGfccaaUfgUfaggcasgsc BD- 12050 usgsccuaCfaUfUfGfgcacaacuaa(L96) (vinu)sUfsaguUfgugccaaUfgUfaggcasgscBD-12051 usgsccuaCfaUlUfGfgcacaacuaa(L96) (vinu)sUfsaguUfgUfGfccaaUfgUfaggcasgsc NAI-5008944785v1 Page 76 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-12052 usgsccUfaCfAfUfuggcacaaca(L96) (vinu)sGfsuugUfgCfCfaaugUfaGfgcasgsc BD-12053 cscsuaCfaUfUfGfgcacAfacUfaa(L96) (vinu)sUfsaguUfgugccaaUfgUfaggscsaBD-12054 cscsuaCfaUlUfGfgcacAfacUfaa(L96) (vinu)sUfsaguUfgUfGfccaaUfgUfaggscsa BD-12055 cscsuaCfaUfUfGfgcacAfAfcuaa(L96) (vinu)sUfsaguUfgugccaaUfgUfaggscsaBD-12056 cscsuaCfaUfUfGfgcacAfAfcuaa(L96) (vinu)sUfsaguUfgUfGfccaaUfgUfaggscsa BD-12057 cscsuaCfaUfUfGfgcacaacuaa(L96) (vinu)sUfsaguUfgugccaaUfgUfaggscsaBD-12058 cscsuacaUfuGfGfCfacaaCfuaUfaa(L96) (vinu)sUfsauaGfuugugccAfaUfguaggscsa BD-12059 cscsuacaUfuGfGfCfacaaCfuaUfaa(L96) (vinu)sUfsauaGfuUfGfugccAfaUfguaggscsa BD- 12060 cscsuacaUfuGfGfCfacaaCfUfauaa(L96) (vinu)sUfsauaGfuugugccAfaUfguaggscsa BD-12061 cscsuacaUfuGfGfCfacaaClUfauaa(L96) (vinu)sUfsauaGfuUfGfugccAfaUfguaggscsa BD-12062 cscsuacaUfuGfGfCfacaacuauaa(L96) (vinu)sUfsauaGfuugugccAfaUfguaggscsa BD-12063 cscsuacaUfuGfGfCfacaacuauaa(L96) (vinu)sUfsauaGfuUfGfugccAfaUfguaggscsa BD-12064 cscsuaCfaUlUfGfgcacaacuaa(L96) (vinu)sUfsaguUfgUfGfccaaUfgUfaggscsa BD-12065 ususggCfaCfAfAfcuauAfauCfaa(L96) (vinu)sUfsgauUfauaguugUfgCfcaasusgBD-12066 ususggCfaCfAfAfcuauAfauCfaa(L96) (vinu)sUfsgauUfaUfAfguugUfgCfcaasusg BD-12067 ususggCfaCfAfAfcuauAfAfucaa(L96) (vinu)sUfsgauUfauaguugUfgCfcaasusgBD-12068 ususggCfaCfAfAfcuauAfAfucaa(L96) (vinu)sUfsgauUfaUfAfguugUfgCfcaasusg BD-12069 ususggCfaCfAfAfcuauaaucaa(L96) (vinu)sUfsgauUfauaguugUfgCfcaasusgBD-12070 ususggcaCfaAfCfUfauaaUfcaUfua(L96) (vinu)sAfsaugAfuuauaguUfgUfgccaasusg BD- 12071 ususggcaCfaAfCfUfauaaUfcaUfua(L96) (vinu)sAfsaugAfuUfAfuaguUfgUfgccaasusg BD- 12072 ususggcaCfaAfCfUfauaaUfCfauua(L96) (vinu)sAfsaugAfuuauaguUfgUfgccaasusg BD-12073 ususggcaCfaAfCfUfauaaUfCfauua(L96) (vinu)sAfsaugAfuUfAfuaguUfgUfgccaasusg BD- 12074 ususggcaCfaAfCfUfauaaucauua(L96) (vinu)sAfsaugAfuuauaguUfgUfgccaasusg BD-12075 ususggcaCfaAfCfUfauaaucauua(L96) (vinu)sAfsaugAfuUfAfuaguUfgUfgccaasusg BD-12076 ususggCfaCfAfAfcuauaaucaa(L96) (vinu)sUfsgauUfaUfAfguugUfgCfcaasusg BD-12077 usgsgcAfcAfAfCfuauaAfucAfua(L96) (vinu)sAfsugaUfuauaguuGfuGfccasasuBD-12078 usgsgcAfcATAfCfuauaAfucAfua(L96) (vinu)sAfsugaUfuAfUfaguuGfuGfccasasu BD-12079 usgsgcAfcAfAfCfuauaAfUfcaua(L96) (vinu)sAfsugaUluauaguuGfuGfccasasuBD-12080 usgsgcAfcAfAfCfuauaAfUfcaua(L96) (vinu)sAfsugaUfuAlUfaguuGfuGfccasasu BD-12081 usgsgcAfcAfAfCfuauaaucaua(L96) (vinu)sAfsugaUluauaguuGfuGfccasasuBD-12082 usgsgcacAfaCfUfAfuaauCfauUfca(L96) (vinu)sGfsaauGfauuauagUfuGfugccasasu BD-12083 usgsgcacAfaCfUfAfuaauCfauUfca(L96) (vinu)sGfsaauGfaUfUfauagUfuGfugccasasu BD-12084 usgsgcacAfaCfUfAfuaauCfAfuuca(L96) (vinu)sGfsaauGfauuauagUfuGfugccasasu BD- 12085 usgsgcacAfaCfUfAfuaauCfAfuuca(L96) (vinu)sGfsaauGfaUfUfauagUfuGfugccasasu BD-12086 usgsgcacAfaCfUfAfuaaucauuca(L96) (vinu)sGfsaauGfauuauagUfuGfugccasasu BD-12087 usgsgcacAfaCfUfAfuaaucauuca(L96) (vinu)sGfsaauGfaUfUfauagUfuGfugccasasu BD-12088 usgsgcAfcAfAfCfuauaaucaua(L96) (vinu)sAfsugaUfuAlUfaguuGfuGfccasasu BD-12089 ascsaaCfuA! UfAfaucaUfucGfga(L96) (vinu)sCfscgaAfugauuauAfgUfugusgscBD-12090 ascsaaCfuAfUfAfaucaUfucGfga(L96) (vinu)sCfscgaAfuGfAluuauAfgUfugusgsc BD-12091 ascsaaCfuAlUfAfaucaUlUfcgga(L96) (vinu)sCfscgaAfugauuauAfgUfugusgscBD-12092 ascsaaCfuAfUfAfaucaUfUfcgga(L96) (vinu)sCfscgaAfuGfAfiiuauAfgUfugusgsc BD-12093 ascsaaCfuAfUfAfaucauucgga(L96) (vinu)sCfscgaAfugauuauAfgUfugusgscBD-12094 ascsaacuAfuAfAfUfcauuCfggCfaa(L96) (vinu)sUfsgccGfaaugauuAfuAfguugusgsc BD-12095 ascsaacuAfuAfAfUfcauuCfggCfaa(L96) (vinu)sUfsgccGfaAfUfgauuAfuAfguugusgsc BD-12096 ascsaacuAfuAfAfUfcauuCfGfgcaa(L96) (vinu)sUfsgccGfaaugauuAfuAfguugusgsc BD-12097 ascsaacuAfiiAfAfUfcauuCfGfgcaa(L96) (vinu)sUfsgccGfaAfUfgauuAfuAfguugusgsc BD-12098 ascsaacuAfuAfAfUfcauucggcaa(L96) (vinu)sUfsgccGfaaugauuAfuAfguugusgsc BD-12099 asc saacu Afu Af AfU fcauucggcaa(L 96) (vinu)sUfsgccGfaAlUfgauuAfuAfguugusgsc BD-12100 ascsaaCfuAfUfAfaucauucgga(L96) (vinu)sCfscgaAfuGfAfiiuauAfgUfugusgsc BD-12101 csasacUfaUfAfAfucauUfcgGfca(L96) (vinu)sGfsccgAfaugauuaUfaGfuugsusgBD-12102 csasacUfaUfAfAfucauUfcgGfca(L96) (vinu)sGfsccgAfaUfGfauuaUfaGfuugsusg NAI-5008944785v1 Page 77 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-12103 csasacUfaUfAfAfucauUfCfggca(L96) (vinu)sGfsccgAfaugauuaUfaGfuugsusgBD-12104 csasacUfaUfAfAfucauUfCfggca(L96) (vinu)sGfsccgAfaUfGfauuaUfaGfuugsusg BD-12105 csasacUfaUfAfAfucauucggca(L96) (vinu)sGfsccgAfaugauuaUfaGfuugsusgBD-12106 csasacuaUfaAfUfCfauucGfgcAfga(L96) (vinu)sCfsugcCfgaaugauUfaUfaguugsusg BD-12107 csasacuaUfaAIUfCfauucGfgcAfga(L96) (vinu)sCfsugcCfgAfAfugauUfaUfaguugsusg BD-12108 csasacuaU faAfUfCfauucGfGfcaga(L96 ) (vinu)sCfsugcCfgaaugauUfaUfaguugsusg BD-12109 csasacuaUfaAfUfCfauucGfGfcaga(L96) (vinu)sCfsugcCfgAfAfugauUfaUfaguugsusg BD-12110 csasacuaUfaAIUfCfauucggcaga(L96) (vinu)sCfsugcCfgaaugauUfaUfaguugsusg BD-12111 csasacuaUfaAfUfCfauucggcaga(L96) (vinu)sCfsugcCfgAfAlugauUfaUfaguugsusg BD-12112 csasacUfaUfAfAfucauucggca(L96) (vinu)sGfsccgAfaUfGfauuaUfaGfuugsusg BD-12113 asascuAfuAfAfUfcauuCfggCfaa(L96) (vinu)sUfsgccGfaaugauuAfuAfguusgsuBD-12114 asascuAfuAfAfUfcauuCfggCfaa(L96) (vinu)sUfsgccGfaAfUfgauuAfuAfguusgsu BD-12115 asascuAfuAfAfUfcauuCfGfgcaa(L96) (vinu)sUfsgccGfaaugauuAfuAfguusgsuBD-12116 asascuAfuAfAfUfcauuCIGfgcaa(L96) (vinu)sUfsgccGfaAfUfgauuAfuAfguusgsu BD-12117 asascuAfuAfAfUfcauucggcaa(L96) (vinu)sUfsgccGfaaugauuAfuAfguusgsuBD-12118 asascuauAfaUfCfAfuucgGfcaGfaa(L96) (vinu)sUfscugCfcgaaugaUfuAfuaguusgsu BD-12119 asascuauAfaUfCfAfuucgGfcaGfaa(L96) (vinu)sUfscugCfcGfAfaugaUfuAfuaguusgsu BD-12120 asascuauAfaUfCfAfuucgGfCfagaa(L96) (vinu)sUfscugCfcgaaugaUfuAfuaguusgsu BD-12121 asascuauAfaUfCfAfuucgGfCfagaa(L96) (vinu)sUfscugCfcGfAfaugaUfuAfuaguusgsu BD-12122 asascuauAfaUfCfAfuucggcagaa(L96) (vinu)sUfscugCfcgaaugaUfuAfuaguusgsu BD-12123 asascuauAfaUfCfAfuucggcagaa(L96) (vinu)sUfscugCfcGfAfaugaUfuAfuaguusgsu BD-12124 asascuAfuAfAfUfcauucggcaa(L96) (vinu)sUfsgccGfaAfUfgauuAfuAfguusgsu BD-12125 asusaaUfcAfUfUfcggcAfgaCfaa(L96) (vinu)sUfsgucUfgccgaauGfaUfuausasgBD-12126 asusaaUfcAIUfUfcggcAfgaCfaa(L96) (vinu)sUfsgucUfgCfCfgaauGfaUfuausasg BD-12127 asusaaU fc AfU fU fcggc AfGfacaa(L96) (vinu)sU fsgucU fgccgaauGfaU fuausasgBD-12128 asusaaUfcAIUfUfcggcAfGfacaa(L96) (vinu)sUfsgucUfgCfCfgaauGfaUfuausasg BD-12129 asusaaUfcAfUIUfcggcagacaa(L96) (vinu)sUfsgucUfgccgaauGfaUfuausasgBD-12130 asusaaucAfuUfCfGfgcagAfcaGfca(L96) (vinu)sGfscugUfcugccgaAfuGfauuausasg BD-12131 asusaaucAfuUfCfGfgcagAfcaGfca(L96) (vinu)sGfscugUfcUfGfccgaAfuGfauuausasg BD-12132 asusaaucAfuUfCfGfgcagAfCfagca(L96) (vinu)sGfscugUfcugccgaAfuGfauuausasg BD-12133 asusaaucAfuUfCfGfgcagAfCfagca(L96) (vinu)sGfscugUfcUfGfccgaAfuGfauuausasg BD-12134 asusaaucAfuUfCfGfgcagacagca(L96) (vinu)sGfscugUfcugccgaAfuGfauuausasg BD-12135 asusaaucAfuUfCfGfgcagacagca(L96) (vinu)sGfscugUfcUfGfccgaAfuGfauuausasg BD-12136 asusaaUfcAfUfUfcggcagacaa(L96) (vinu)sUfsgucUfgCfCfgaauGfaUfuausasg BD-12137 csasuuCfgGfCfAfgacaGfcuGfga(L96) (vinu)sCfscagCfugucugcCfgAfaugsasuBD-12138 csasuuCfgGfCfAfgacaGfcuGfga(L96) (vinu)sCfscagCfuGfUfcugcCfgAfaugsasu BD-12139 csasuuCfgGfCfAfgacaGfCfugga(L96) (vinu)sCfscagCfugucugcCfgAfaugsasuBD-12140 csasuuCfgGfCfAfgacaGfCfugga(L96) (vinu)sCfscagCfuGfUfcugcCfgAfaugsasu BD-12141 csasuuCfgGfCfAfgacagcugga(L96) (vinu)sCfscagCfugucugcCfgAfaugsasuBD-12142 csasuucgGfcAfGfAfcagcUfggGfca(L96) (vinu)sGfscccAfgcugucuGfcCfgaaugsasu BD-12143 csasuucgGfcAfGfAfcagcUfggGfca(L96) (vinu)sGfscccAfgCfUfgucuGfcCfgaaugsasu BD-12144 csasuucgGfcAfGfAfcagcUfGfggca(L96) (vinu)sGfscccAfgcugucuGfcCfgaaugsasu BD-12145 csasuucgGfcAfGfAfcagcUfGfggca(L96) (vinu)sGfscccAfgCIUfgucuGfcCfgaaugsasu BD-12146 csasuucgGfcAfGfAfcagcugggca(L96) (vinu)sGfscccAfgcugucuGfcCfgaaugsasu BD-12147 csasuucgGfcAfGfAfcagcugggca(L96) (vinu)sGfscccAfgCfUfgucuGfcCfgaaugsasu BD-12148 csasuuCfgGfCfAfgacagcugga(L96) (vinu)sCfscagCfuGfUfcugcCfgAfaugsasu BD-12149 csusucUfcCfAfUfcaagGfuaGfca(L96) (vinu)sGfscuaCfcuugaugGfaGfaagsgsaBD-12150 csusucUfcCfAfUfcaagGfuaGfca(L96) (vinu)sGfscuaCfcUfUfgaugGfaGfaagsgsa BD-12151 csusucUfcCfAfUfcaagGfUfagca(L96) (vinu)sGfscuaCfcuugaugGfaGfaagsgsaBD-12152 csusucUfcCfAfUfcaagGfUfagca(L96) (vinu)sGfscuaCfcUfUfgaugGfaGfaagsgsaBD-12153 csusucUfcCfAfUfcaagguagca(L96) (vinu)sGfscuaCfcuugaugGfaGfaagsgsaNAI-5008944785v1 Page 78 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-12154 csusucucCfaUfCfAfagguAfgcAfga(L96) (vinu)sCfsugcUfaccuugaUfgGfagaagsgsa BD-12155 csusucucCfaUfCfAfagguAfgcAfga(L96) (vinu)sCfsugcUfaCfCfuugaUfgGfagaagsgsa BD-12156 csusucucCfaUfCfAfagguAfGfcaga(L96) (vinu)sCfsugcUfaccuugaUfgGfagaagsgsa BD-12157 csusucucCfaUfCfAfagguAfGfcaga(L96) (vinu)sCfsugcUfaCfCfuugaUfgGfagaagsgsa BD-12158 csusucucCfaUfCfAfagguagcaga(L96) (vinu)sCfsugcUfaccuugaUfgGfagaagsgsa BD-12159 csusucucCfaUfCfAfagguagcaga(L96) (vinu)sCfsugcUfaCfCfuugaUfgGfagaagsgsa BD-12160 csusucUfcCfAfUfcaagguagca(L96) (vinu)sGfscuaCfcUfUfgaugGfaGfaagsgsa BD-12161 asuscaAfgGfUfAfgcagAfggAfua(L96) (vinu)sAfsuccUfcugcuacCfuUfgausgsgBD-12162 asuscaAfgGfUfMgcagAfggAfua(L96) (vinu)sAfsuccUfcUfGfcuacCfuUfgausgsg BD-12163 asuscaAfgGfUfAfgcagAfGfgaua(L96) (vinu)sAfsuccUfcugcuacCfuUfgausgsgBD-12164 asuscaAfgGfUfAfgcagAfGfgaua(L96) (vinu)sAfsuccUfcUfGfcuacCfuUfgausgsg BD-12165 asuscaAfgGfUfAfgcagaggaua(L96) (vinu)sAfsuccUfcugcuacCfuUfgausgsgBD-12166 asuscaagGfuAfGfCfagagGfauGfua(L96) (vinu)sAfscauCfcucugcuAfcCfuugausgsg BD-12167 asuscaagGfuAfGfCfagagGfauGfua(L96) (vinu)sAfscauCfcUfCfugcuAfcCfuugausgsg BD-12168 asuscaagGfuAfGfCfagagGfAfugua(L96) (vinu)sAfscauCfcucugcuAfcCfuugausgsg BD-12169 asuscaagGfuAfGfCfagagGfAfugua(L96) (vinu)sAfscauCfcUfCfugcuAfcCfuugausgsg BD-12170 asuscaagGfuAfGfCfagaggaugua(L96) (vinu)sAfscauCfcucugcuAfcCfuugausgsg BD-12171 asuscaagGfuAfGfCfagaggaugua(L96) (vinu)sAfscauCfcUfCfugcuAfcCfuugausgsg BD-12172 asuscaAfgGIUIAfgcagaggaua(L96) (vinu)sAfsuccUfcUfGfcuacCfuUfgausgsg BD-12173 gscsccUfcCfAfAfgucaGfcgAfca(L96) (vinu)sGfsucgCfugacuugGfaGfggcsascBD-12174 gscsccUfcCfAfAfgucaGfcgAfca(L96) (vinu)sGfsucgCfuGfAfcuugGfaGfggcsasc BD-12175 gscsccUfcCfAfAfgucaGfCfgaca(L96) (vinu)sGfsucgCfugacuugGfaGfggcsascBD-12176 gscsccUfcCfAfAfgucaGfCfgaca(L96) (vinu)sGfsucgCfuGfAfcuugGfaGfggcsasc BD-12177 gscsccUfcCfAfAfgucagcgaca(L96) (vinu)sGfsucgCfugacuugGfaGfggcsascBD-12178 gscsccucCfaAfGfUfcagcGfacLJfca(L96) (vinu)sGfsaguCfgcugacuUfgGfagggcsasc BD-12179 gscsccucCfaAfGfUfcagcGfacUfca(L96) (vinu)sGfsaguCfgCfUfgacuUfgGfagggcsasc BD-12180 gscsccucCfaAfGIUfcagcGfAfcuca(L96) (vinu)sGfsaguCfgcugacuUfgGfagggcsasc BD-12181 gscsccucCfaAfGfUfcagcGfAfcuca(L96) (vinu)sGfsaguCfgCfUfgacuUfgGfagggcsasc BD-12182 gscsccucCfaAfGfUfcagcgacuca(L96) (vinu)sGfsaguCfgcugacuUfgGfagggcsasc BD-12183 gscsccucCfaAfGfUfcagcgacuca(L96) (vinu)sGfsaguCfgCIUfgacuUfgGfagggcsasc BD-12184 gscsccUfcCfAfAfgucagcgaca(L96) (vinu)sGfsucgCfuGfAfcuugGfaGfggcsasc BD-12185 asasguCfaGfCfGfacucUfcuCfga(L96) (vinu)sCfsgagAfgagucgcUfgAfcuusgsgBD-12186 asasguCfaGfCfGfacucUfcuCfga(L96) (vinu)sCfsgagAfgAfGfucgcUfgAfcuusgsg BD-12187 asasguCfaGfCfGfacucUfCfucga(L96) (vinu)sCfsgagAfgagucgcUfgAfcuusgsgBD-12188 asasguCfaGfCfGfacucUfCfucga(L96) (vinu)sCfsgagAfgAfGfucgcUfgAfcuusgsg BD-12189 asasguCfaGfCfGfacucucucga(L96) (vinu)sCfsgagAfgagucgcUfgAfcuusgsgBD-12190 asasgucaGfcGfAfCfucucUfcgAfua(L96) (vinu)sAfsucgAfgagagucGfcUfgacuusgsg BD-12191 asasgucaGfcGfAfCfucucUfcgAfua(L96) (vinu)sAfsucgAfgAfGfagucGfcUfgacuusgsg BD-12192 asasgucaGfcGfAfCfucucUfCfgaua(L96) (vinu)sAfsucgAfgagagucGfcUfgacuusgsg BD-12193 asasgucaGfcGfAfCfucucUfCfgaua(L96) (vinu) s Af sucg Afg Af Gfaguc GfcU fgacuusgsg BD-12194 asasgucaGfcGfAfCfucucucgaua(L96) (vinu)sAfsucgAfgagagucGfcUfgacuusgsg BD-12195 asasgucaGfcGfAfCfucucucgaua(L96) (vinu) sAf sucg Afg Af Gfaguc GfcU fgacuusgsg BD-12196 asasguCfaGfCfGfacucucucga(L96) (vinu)sCfsgagAfgAfGfucgcUfgAfcuusgsg BD-12197 asgsucAfgCfGfAfcucuCfucGfaa(L96) (vinu)sUfscgaGfagagucgCfuGfacususgBD-12198 asgsucAfgCfGfAfcucuCfucGfaa(L96) (vinu)sUfscgaGfaGfAfgucgCfuGfacususg BD-12199 asgsucAfgCfGfAfcucuCIUfcgaa(L96) (vinu)sUfscgaGfagagucgCfuGfacususgBD-12200 asgsucAfgCfGfAfcucuCfUfcgaa(L96) (vinu)sUfscgaGfaGfAfgucgCfuGfacususg BD-12201 asgsucAfgCfGfAfcucucucgaa(L96) (vinu)sUfscgaGfagagucgCfuGfacususgBD-12202 asgsucagCfgAfCfUfcucuCfgaUfca(L96) (vinu)sGfsaucGfagagaguCfgCfugacususg BD-12203 asgsucagCfgAfCfUfcucuCfgaUfca(L96) (vinu)sGfsaucGfaGfAfgaguCfgCfugacususgBD-12204 asgsucagCfgAfCfUfcucuCfGfauca(L96) (vinu)sGfsaucGfagagaguCfgCfugacususg NAI-5008944785v1 Page 79 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-12205 asgsucagCfgAfCfUfcucuCfGfauca(L96) (vinu)sGfsaucGfaGfAfgaguCfgCfugacususg BD-12206 asgsucagCfgAfCfUfcucucgauca(L96) (vinu)sGfsaucGfagagaguCfgCfugacususg BD-12207 asgsucagCfgAfCfUfcucucgauca(L96) (vinu)sGfsaucGfaGfAfgaguCfgCfugacususg BD-12208 asgsucAfgCfGfAfcucucucgaa(L96) (vinu)sUfscgaGfaGfAfgucgCfuGfacususg BD-12209 gsascuCfuCfUfCfgaucAfgaGfca(L96) (vinu)sGfscucUfgaucgagAfgAfgucsgscBD-12210 gsascuCfuCfUfCfgaucAfgaGfca(L96) (vinu)sGfscucUfgAfUfcgagAfgAfgucsgsc BD-12211 gsascuCfuCfUfCfgaucAfGfagca(L96) (vinu)sGfscucUfgaucgagAfgAfgucsgscBD-12212 gsascuCfuCfUfCfgaucAfGfagca(L96) (vinu)sGfscucUfgAfUfcgagAfgAfgucsgsc BD-12213 gsascuCfuCfUfCfgaucagagca(L96) (vinu)sGfscucUfgaucgagAfgAfgucsgscBD-12214 gsascucuCfuCfGfAfucagAfgcGfca(L96) (vinu)sGfscgcUfcugaucgAfgAfgagucsgsc BD-12215 gsascucuCfuCfGfAfucagAfgcGfca(L96) (vinu)sGfscgcUfcUfGfaucgAfgAfgagucsgsc BD-12216 gsascucuCfuCfGfAfucagAfGfcgca(L96) (vinu)sGfscgcUfcugaucgAfgAfgagucsgsc BD-12217 gsascucuCfuCfGfAfucagAfGfcgca(L96) (vinu)sGfscgcUfcUfGfaucgAfgAfgagucsgsc BD-12218 gsascucuCfuCfGfAfucagagcgca(L96) (vinu)sGfscgcUfcugaucgAfgAfgagucsgsc BD-12219 gsascucuCfuCfGfAfucagagcgca(L96) (vinu)sGfscgcUfcUfGfaucgAfgAfgagucsgsc BD-12220 gsascuCfuCfUfCfgaucagagca(L96) (vinu)sGfscucUfgAfUfcgagAfgAfgucsgsc BD-12221 ascsucUfcUfCfGfaucaGfagCfga(L96) (vinu)sCfsgcuCfugaucgaGfaGfaguscsgBD-12222 ascsucUfcUfCfGfaucaGfagCfga(L96) (vinu)sCfsgcuCfuGfAfucgaGfaGfaguscsg BD-12223 ascsucUfcUfCfGfaucaGfAfgcga(L96) (vinu)sCfsgcuCfugaucgaGfaGfaguscsgBD-12224 ascsucUfcUfCfGfaucaGfAfgcga(L96) (vinu)sCfsgcuCfuGfAfucgaGfaGfaguscsg BD-12225 ascsucUfcUfCfGfaucagagcga(L96) (vinu)sCfsgcuCfugaucgaGfaGfaguscsgBD-12226 ascsucucUfcGfAfUfcagaGfcgCfaa(L96) (vinu)sUfsgcgCfucugaucGfaGfagaguscsg BD-12227 ascsucucUfcGfAfUfcagaGfcgCfaa(L96) (vinu)sUfsgcgCfuCfUfgaucGfaGfagaguscsg BD-12228 ascsucucUfcGfAfUfcagaGfCfgcaa(L96) (vinu)sUfsgcgCfucugaucGfaGfagaguscsg BD-12229 ascsucucUfcGfAfUfcagaGfCfgcaa(L96) (vinu)sUfsgcgCfuCfUfgaucGfaGfagaguscsg BD-12230 ascsucucUfcGfAfUfcagagcgcaa(L96) (vinu)sUfsgcgCfucugaucGfaGfagaguscsg BD-12231 ascsucucUfcGfAIUfcagagcgcaa(L96) (vinu)sUfsgcgCfuCfUfgaucGfaGfagaguscsg BD-12232 ascsucUfcUfCfGfaucagagcga(L96) (vinu)sCfsgcuCfuGfAfucgaGfaGfaguscsg BD-12233 csuscuCfuCfGfAfucagAfgcGfca(L96) (vinu)sGfscgcUfcugaucgAfgAfgagsuscBD-12234 csuscuCfuCfGfAfucagAfgcGfca(L96) (vinu)sGfscgcUfcUfGfaucgAfgAfgagsusc BD-12235 csuscuCfuCfGfAfucagAfGfcgca(L96) (vinu)sGfscgcUfcugaucgAfgAfgagsuscBD-12236 csuscuCfuCfGfAfucagAfGfcgca(L96) (vinu)sGfscgcUfcUfGfaucgAfgAfgagsusc BD-12237 csuscuCfuCfGfAfucagagcgca(L96) (vinu)sGfscgcUfcugaucgAfgAfgagsuscBD-12238 csuscucuCfgAfUfCfagagCfgcAfaa(L96) (vinu)sUfsugcGfcucugauCfgAfgagagsusc BD-12239 csuscucuCfgAfUfCfagagCfgcAfaa(L96) (vinu)sUfsugcGfcUfCfugauCfgAfgagagsusc BD-12240 csuscucuCfgAfUfCfagagCfGfcaaa(L96) (vinu)sUfsugcGfcucugauCfgAfgagagsusc BD-12241 csuscucuCfgAfUfCfagagCfGfcaaa(L96) (vinu)sUfsugcGfcUfCfugauCfgAfgagagsusc BD-12242 csuscucuCfgAfUfCfagagcgcaaa(L96) (vinu)sUfsugcGfcucugauCfgAfgagagsusc BD-12243 csuscucuCfgAfUfCfagagcgcaaa(L96) (vinu)sUfsugcGfcUfCfugauCfgAfgagagsusc BD-12244 csuscuCfuCfGfAfucagagcgca(L96) (vinu)sGfscgcUfcUfGfaucgAfgAfgagsusc BD-12245 asuscgUfcGfGfGfgagcUfauAfaa(L96) (vinu)sUfsuauAfgcuccccGfaCfgaususgBD-12246 asuscgUfcGfGfGfgagcUfauAfaa(L96) (vinu)sUfsuauAfgCfUfccccGfaCfgaususg BD-12247 asuscgUfcGfGfGfgagcUfAfuaaa(L96) (vinu)sUfsuauAfgcuccccGfaCfgaususgBD-12248 asuscgUfcGfGfGfgagcUfAfuaaa(L96) (vinu)sUfsuauAfgCfUfccccGfaCfgaususg BD-12249 asuscgUfcGfGfGfgagcuauaaa(L96) (vinu)sUfsuauAfgcuccccGfaCfgaususgBD-12250 asuscgucGfgGfGfAfgcuaUfaaCfca(L96) (vinu)sGfsguuAfuagcuccCfcGfacgaususg BD-12251 asuscgucGfgGfGfAfgcuaUfaaCfca(L96) (vinu)sGfsguuAfuAfGfcuccCfcGfacgaususg BD-12252 asuscgucGfgGfGfAfgcuaUfAfacca(L96) (vinu)sGfsguuAfuagcuccCfcGfacgaususg BD-12253 asuscgucGfgGfGfAfgcuaUfAfacca(L96) (vinu)sGfsguuAfuAfGfcuccCfcGfacgaususg BD-12254 asuscgucGfgGfGfAfgcuauaacca(L96) (vinu)sGfsguuAfuagcuccCfcGfacgaususgBD-12255 asuscgucGfgGfGfAfgcuauaacca(L96) (vinu)sGfsguuAfuAfGfcuccCfcGfacgaususg NAI-5008944785v1 Page 80 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-12256 asuscgUfcGfGfGfgagcuauaaa(L96) (vinu)sUfsuauAfgCfUfccccGfaCfgaususg BD-12257 uscsguCfgGfGfGfagcuAfuaAfca(L96) (vinu)sGfsuuaUfagcucccCfgAfcgasusuBD-12258 uscsguCfgGfGfGfagcuAfuaAfca(L96) (vinu)sGfsuuaUfaGfCfucccCfgAfcgasusu BD-12259 uscsguCfgGfGfGfagcuAfUfaaca(L96) (vinu)sGfsuuaUfagcucccCfgAfcgasusuBD-12260 uscsguCfgGfGfGfagcuAlUfaaca(L96) (vinu)sGfsuuaUfaGfCfucccCfgAfcgasusu BD-12261 uscsguCfgGfGfGfagcuauaaca(L96) (vinu)sGfsuuaUfagcucccCfgAfcgasusuBD-12262 uscsgucgGfgGfAfGfcuauAfacCfaa(L96) (vinu)sUfsgguUfauagcucCfcCfgacgasusu BD-12263 uscsgucgGfgGfAfGfcuauAfacCfaa(L96) (vinu)sUfsgguUfaUfAfgcucCfcCfgacgasusu BD-12264 uscsgucgGfgGfAfGfcuauAfAfccaa(L96) (vinu)sUfsgguUfauagcucCfcCfgacgasusu BD- 12265 uscsgucgGfgGfAfGfcuauAfAfccaa(L96) (vinu)sUfsgguUfaUfAfgcucCfcCfgacgasusu BD-12266 uscsgucgGfgGf AfGfcuauaaccaa(L96 ) (vinu)sUfsgguUfauagcucCfcCfgacgasusu BD-12267 uscsgucgGfgGfAfGfcuauaaccaa(L96) (vinu)sUfsgguUfaUfAfgcucCfcCfgacgasusu BD-12268 uscsguCfgGfGfGfagcuauaaca(L96) (vinu)sGfsuuaUfaGfCfucccCfgAfcgasusu BD-12269 csgsucGfgGfGfAfgcuaUfaaCfca(L96) (vinu)sGfsguuAfuagcuccCfcGfacgsasuBD- 12270 csgsucGfgGfGfAfgcuaUfaaCfca(L96) (vinu)sGfsguuAfuAfGfcuccCfcGfacgsasu BD-12271 csgsucGfgGfGfAfgcuaUfAfacca(L96) (vinu)sGfsguuAfuagcuccCfcGfacgsasuBD-12272 csgsucGfgGfGfAfgcuaUfAfacca(L96) (vinu)sGfsguuAfuAfGfcuccCfcGfacgsasu BD-12273 csgsucGfgGfGfAfgcuauaacca(L96) (vinu)sGfsguuAfuagcuccCfcGfacgsasuBD-12274 csgsucggGfgAfGfCfuauaAfccAfua(L96) (vinu)sAfsuggUfuauagcuCfcCfcgacgsasu BD-12275 csgsucggGfgAfGfCfuauaAfccAfua(L96) (vinu)sAfsuggUfuAfUfagcuCfcCfcgacgsasu BD-12276 csgsucggGfgAfGfCfuauaAfCfcaua(L96) (vinu)sAfsuggUfuauagcuCfcCfcgacgsasu BD-12277 csgsucggGfgAfGfCfuauaAfCfcaua(L96) (vinu)sAfsuggUfuAfUfagcuCfcCfcgacgsasu BD-12278 csgsucggGfgAfGfCfuauaaccaua(L96) (vinu)sAfsuggUfuauagcuCfcCfcgacgsasu BD-12279 csgsucggGfgAfGfCfuauaaccaua(L96) (vinu)sAfsuggUfuAfUfagcuCfcCfcgacgsasu BD-12280 csgsucGfgGfGfAfgcuauaacca(L96) (vinu)sGfsguuAfuAfGfcuccCfcGfacgsasu BD-12281 csgsggGfaGfCfUfauaaCfcaUfua(L96) (vinu)sAfsaugGfuuauagcUfcCfccgsascBD-12282 csgsggGfaGfCfUfauaaCfcaUfua(L96) (vinu)sAfsaugGfuUfAfuagcUfcCfccgsasc BD-12283 csgsggGfaGfCfUfauaaCfCfauua(L96) (vinu)sAfsaugGfuuauagcUfcCfccgsascBD-12284 csgsggGfaGfCfUfauaaCfCfauua(L96) (vinu)sAfsaugGfuUfAfuagcUfcCfccgsasc BD-12285 csgsggGfaGfCfUfauaaccauua(L96) (vinu)sAfsaugGfuuauagcUfcCfccgsascBD-12286 csgsgggaGfcUfAfUfaaccAfuuGfaa(L96) (vinu)sUfscaaUfgguuauaGfcUfccccgsasc BD-12287 csgsgggaGfcUfAfUfaaccAfuuGfaa(L96) (vinu)sUfscaaUfgGfUfuauaGfcUfccccgsasc BD-12288 csgsgggaGfcUfAfUfaaccAfUfugaa(L96) (vinu)sUfscaaUfgguuauaGfcUfccccgsasc BD-12289 csgsgggaGfcUfAfUfaaccAfUfugaa(L96) (vinu)sUfscaaUfgGfUfuauaGfcUfccccgsasc BD-12290 csgsgggaGfcUfAfUfaaccauugaa(L96) (vinu)sUfscaaUfgguuauaGfcUfccccgsasc BD-12291 csgsgggaGfcUfAfUfaaccauugaa(L96) (vinu)sUfscaaUfgGfUfuauaGfcUfccccgsasc BD-12292 csgsggGfaGfCfUfauaaccauua(L96) (vinu)sAfsaugGfuUfAfuagcUfcCfccgsasc BD-12293 gsgsggAfgCfUfAfuaacCfauUfga(L96) (vinu)sCfsaauGfguuauagCfuCfcccsgsaBD-12294 gsgsggAfgCfUfAfuaacCfauUfga(L96) (vinu)sCfsaauGfgUfUfauagCfuCfcccsgsa BD-12295 gsgsggAfgCfUfAfuaacCfAfuuga(L96) (vinu)sCfsaauGfguuauagCfuCfcccsgsaBD-12296 gsgsggAfgCfUfAfuaacCfAfiiuga(L96) (vinu)sCfsaauGfgUfUfauagCfuCfcccsgsa BD-12297 gsgsggAfgCfUfAfuaaccauuga(L96) (vinu)sCfsaauGfguuauagCfuCfcccsgsaBD-12298 gsgsggagCfuAfUfAfaccaUfugAfua(L96) (vinu)sAfsucaAfugguuauAfgCfuccccsgsa BD-12299 gsgsggagCfuAfUfAfaccaUfugAfua(L96) (vinu)sAfsucaAfuGfGfuuauAfgCfuccccsgsa BD-12300 gsgsggagCfuAfUfAfaccaUfUfgaua(L96) (vinu)sAfsucaAfugguuauAfgCfuccccsgsa BD-12301 gsgsggagCfuAfUfAfaccaUfUfgaua(L96) (vinu)sAfsucaAfuGfGfuuauAfgCfuccccsgsa BD-12302 gsgsggagCfuAfUfAfaccauugaua(L96) (vinu)sAfsucaAfugguuauAfgCfuccccsgsa BD-12303 gsgsggagCfuAfUfAfaccauugaua(L96) (vinu)sAfsucaAfuGfGfuuauAfgCfuccccsgsa BD-12304 gsgsggAfgCfUfAfuaaccauuga(L96) (vinu)sCfsaauGfgUfUfauagCfuCfcccsgsa BD-12305 gsgsgaGfcUfAfUfaaccAfuuGfaa(L96) (vinu)sUfscaaUfgguuauaGfcUfcccscsgBD-12306 gsgsgaGfcUfAfUfaaccAfuuGfaa(L96) (vinu)sUfscaaUfgGfUfuauaGfcUfcccscsg NAI-5008944785v1 Page 81 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-12307 gsgsgaGfcUfAfUfaaccAfUfugaa(L96) (vinu)sUfscaaUfgguuauaGfcUfcccscsgBD-12308 gsgsgaGfcUfAfUfaaccAfUfugaa(L96) (vinu)sUfscaaUfgGfUfuauaGfcUfcccscsg BD-12309 gsgsgaGfcUfAfUfaaccauugaa(L96) (vinu)sUfscaaUfgguuauaGfcUfcccscsgBD-12310 gsgsgagcUfaUfAfAfccauUfgaUfaa(L96) (vinu)sUfsaucAfaugguuaUfaGfcucccscsg BD-12311 gsgsgagcUfaUfAfAfccauUfgaUfaa(L96) (vinu)sUfsaucAfaUfGfguuaUfaGfcucccscsg BD-12312 gsgsgagcUfaUfAfAfccauUfGfauaa(L96) (vinu)sUfsaucAfaugguuaUfaGfcucccscsg BD-12313 gsgsgagcUfaUfAfAfccauUfGfauaa(L96) (vinu)sUfsaucAfaUfGfguuaUfaGfcucccscsg BD-12314 gsgsgagcUfaUfAfAfccauugauaa(L96) (vinu)sUfsaucAfaugguuaUfaGfcucccscsg BD-12315 gsgsgagcUfaUfAfAfccauugauaa(L96) (vinu)sUfsaucAfaUfGfguuaUfaGfcucccscsg BD-12316 gsgsgaGfcUfAfUfaaccauugaa(L96) (vinu)sUfscaaUfgGfUfuauaGfcUfcccscsg BD-12317 gsgsagCfuAfUfAfaccaUfugAfua(L96) (vinu)sAfsucaAfugguuauAfgCfuccscscBD-12318 gsgsagCfu AfU f AfaccaUfugAfua(L96) (vinu)sAfsucaAfuGfGfuuauAfgCfuccscsc BD-12319 gsgsagCfuAfUfAfaccaUfUfgaua(L96) (vinu)sAfsucaAfugguuauAfgCfuccscscBD-12320 gsgsagCfuAfUfAfaccaUfUfgaua(L96) (vinu)sAfsucaAfuGfGfuuauAfgCfuccscsc BD-12321 gsgsagCfuAfUfAfaccauugaua(L96) (vinu)sAfsucaAfugguuauAfgCfuccscscBD-12322 gsgsagcuAfuAfAfCfcauuGfauAfca(L96) (vinu)sGfsuauCfaaugguuAfuAfgcuccscsc BD-12323 gsgsagcuAfuAfAfCfcauuGfauAfca(L96) (vinu)sGfsuauCfaAfUfgguuAfuAfgcuccscsc BD-12324 gsgsagcuAfuAfAfCfcauuGfAfuaca(L96) (vinu)sGfsuauCfaaugguuAfuAfgcuccscsc BD-12325 gsgsagcuAfuAfAfCfcauuGfAfuaca(L96) (vinu)sGfsuauCfaAfUfgguuAfuAfgcuccscsc BD-12326 gsgsagcuAfuAfAfCfcauugauaca(L96) (vinu)sGfsuauCfaaugguuAfuAfgcuccscsc BD-12327 gsgsagcuAfuAfAfCfcauugauaca(L96) (vinu)sGfsuauCfaAfUfgguuAfuAfgcuccscsc BD-12328 gsgsagCfuAfUfAfaccauugaua(L96) (vinu)sAfsucaAfuGfGfuuauAfgCfuccscsc BD-12329 asgscuAfuAfAfCfcauuGfauAfca(L96) (vinu)sGfsuauCfaaugguuAfuAfgcuscscBD-12330 asgscuAfuAfAfCfcauuGfauAfca(L96) (vinu)sGfsuauCfaAfUfgguuAfuAfgcuscsc BD-12331 asgscuAfuAfAfCfcauuGfAfuaca(L96) (vinu)sGfsuauCfaaugguuAfuAfgcuscscBD-12332 asgscuAfuAfAfCfcauuGfAfuaca(L96) (vinu)sGfsuauCfaAfUfgguuAfuAfgcuscsc BD-12333 asgscuAfuAfAfCfcauugauaca(L96) (vinu)sGfsuauCfaaugguuAfuAfgcuscscBD-12334 asgscuauAfaCfCfAfuugaUfacUfga(L96) (vinu)sCfsaguAfucaauggUfuAfuagcuscsc BD-12335 asgscuauAfaCfCfAfuugaUfacUfga(L96) (vinu)sCfsaguAfuCfAfauggUfuAfuagcuscsc BD-12336 asgscuauAfaCfCfAfuugaUfAfcuga(L96) (vinu)sCfsaguAfucaauggUfuAfuagcuscsc BD-12337 asgscuauAfaCfCfAfuugaUfAfcuga(L96) (vinu)sCfsaguAfuCfAfauggUfuAfuagcuscsc BD-12338 asgscuauAfaCfCfAfuugauacuga(L96) (vinu)sCfsaguAfucaauggUfuAfuagcuscsc BD-12339 asgscuauAfaCfCfAfuugauacuga(L96) (vinu)sCfsaguAfuCfAfauggUfuAfuagcuscsc BD-12340 asgscuAfuAfAfCfcauugauaca(L96) (vinu)sGfsuauCfaAfUfgguuAfuAfgcuscsc BD-12341 csusauAfaCfCfAfuugaUfacUfga(L96) (vinu)sCfsaguAfucaauggUfuAfuagscsuBD-12342 csusauAfaCfCfAfuugaUfacUfga(L96) (vinu)sCfsaguAfuCfAfauggUfuAfuagscsu BD-12343 csusauAfaCfCfAfuugaUfAfcuga(L96) (vinu)sCfsaguAfucaauggUfuAfuagscsuBD-12344 csusauAfaCfCfAfuugaUfAfcuga(L96) (vinu)sCfsaguAfuCfAfauggUfuAfuagscsu BD-12345 csusauAfaCfCfAfuugauacuga(L96) (vinu)sCfsaguAfucaauggUfuAfuagscsuBD-12346 csusauaaCfcAfUfUfgauaCfugCfca(L96) (vinu)sGfsgcaGfuaucaauGfgUfuauagscsu BD-12347 csusauaaCfcAfUfUfgauaCfugCfca(L96) (vinu)sGfsgcaGfuAfUfcaauGfgUfuauagscsu BD-12348 csusauaaCfcAfUfUfgauaCfUfgcca(L96) (vinu)sGfsgcaGfuaucaauGfgUfuauagscsu BD-12349 csusauaaCfcAfUfUfgauaCfUfgcca(L96) (vinu)sGfsgcaGfuAfUfcaauGfgUfuauagscsu BD-12350 csusauaaCfcAfUfUfgauacugcca(L96) (vinu)sGfsgcaGfuaucaauGfgUfuauagscsu BD-12351 csusauaaCfcAfUfUfgauacugcca(L96) (vinu)sGfsgcaGfuAfUfcaauGfgUfuauagscsu BD-12352 csusauAfaCfCfAfuugauacuga(L96) (vinu)sCfsaguAfuCfAfauggUfuAfuagscsu BD-12353 usasuaAfcCfAfUfugauAfcuGfca(L96) (vinu)sGfscagUfaucaaugGfuUfauasgscBD-12354 usasuaAfcCfAfUfugauAfcuGfca(L96) (vinu)sGfscagUfaUfCfaaugGfuUfauasgsc BD-12355 usasuaAfcCfAfUfugauAfCfugca(L96) (vinu)sGfscagUfaucaaugGfuUfauasgscBD-12356 usasuaAfcCfAfUfugauAfCfugca(L96) (vinu)sGfscagUfaUfCfaaugGfuUfauasgscBD-12357 usasuaAfcCfAfUfugauacugca(L96) (vinu)sGfscagUfaucaaugGfuUfauasgscNAI-5008944785v1 Page 82 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-12358 usasuaacCfaUfUfGfauacUfgcCfaa(L96) (vinu)sUfsggcAfguaucaaUfgGfuuauasgsc BD-12359 usasuaacCfaUfUfGfauacUfgcCfaa(L96) (vinu)sUfsggcAfgUfAfucaaUfgGfuuauasgsc BD-12360 usasuaacCfaUfUfGfauacUfGfccaa(L96) (vinu)sUfsggcAfguaucaaUfgGfuuauasgsc BD-12361 usasuaacCfaUfUfGfauacUfGfccaa(L96) (vinu)sUfsggcAfgUfAfucaaUfgGfuuauasgsc BD-12362 usasuaacCfaUfUfGfauacugccaa(L96) (vinu)sUfsggcAfguaucaaUfgGfuuauasgsc BD-12363 usasuaacCfaUfUfGfauacugccaa(L96) (vinu)sUfsggcAfgUfAfucaaUfgGfuuauasgsc BD-12364 usasuaAfcCfAfUfugauacugca(L96) (vinu)sGfscagUfaUfCfaaugGfuUfauasgsc BD-12365 cscsauUfgAfUfAfcugcCfagAfca(L96) (vinu)sGfsucuGfgcaguauCfaAfuggsusuBD-12366 cscsauUfgAfUfAfcugcCfagAfca(L96) (vinu)sGfsucuGfgCfAfguauCfaAfuggsusu BD-12367 cscsauUfgAfUfAfcugcCfAfgaca(L96) (vinu)sGfsucuGfgcaguauCfaAfuggsusuBD-12368 cscsauUfgAfUfAfcugcCfAfgaca(L96) (vinu)sGfsucuGfgCfAfguauCfaAfuggsusu BD-12369 cscsauUfgAfUfAfcugccagaca(L96) (vinu)sGfsucuGfgcaguauCfaAfuggsusuBD-12370 cscsauugAfuAfCfUfgccaGfacGfga(L96) (vinu)sCfscguCfuggcaguAfuCfaauggsusu BD-12371 cscsauugAfuAfCfUfgccaGfacGfga(L96) (vinu)sCfscguCfuGfGfcaguAfuCfaauggsusu BD-12372 cscsauugAfuAfCfUfgccaGfAfcgga(L96) (vinu)sCfscguCfuggcaguAfuCfaauggsusu BD-12373 cscsauugAfuAfCfUfgccaGfAfcgga(L96) (vinu)sCfscguCfuGfGfcaguAfuCfaauggsusu BD-12374 cscsauugAfuAfCfUfgccagacgga(L96) (vinu)sCfscguCfuggcaguAfuCfaauggsusu BD-12375 cscsauugAfuAfCfUfgccagacgga(L96) (vinu)sCfscguCfuGfGfcaguAfuCfaauggsusu BD-12376 cscsauUfgAfUfAfcugccagaca(L96) (vinu)sGfsucuGfgCfAfguauCfaAfuggsusu BD-12377 csasuuGfaUfAfCfugccAfgaCfga(L96) (vinu)sCfsgucUfggcaguaUfcAfaugsgsuBD-12378 csasuuGfaUfAfCfugccAfgaCfga(L96) (vinu)sCfsgucUfgGfCfaguaUfcAfaugsgsu BD-12379 csasuuGfaUfAfCfugccAfGfacga(L96) (vinu)sCfsgucUfggcaguaUfcAfaugsgsuBD- 12380 csasuuGfaUfAfCfugccAfGfacga(L96) (vinu)sCfsgucUfgGfCfaguaUfcAfaugsgsu BD-12381 csasuuGfaUfAfCfugccagacga(L96) (vinu)sCfsgucUfggcaguaUfcAfaugsgsuBD-12382 csasuugaUfaCfUfGfccagAfcgGfca(L96) (vinu)sGfsccgUfcuggcagUfaUfcaaugsgsu BD-12383 csasuugaUfaCfUfGfccagAfcgGfca(L96) (vinu)sGfsccgUfcUfGfgcagUfaUfcaaugsgsu BD-12384 csasuugaUfaCfUfGfccagAfCfggca(L96) (vinu)sGfsccgUfcuggcagUfaUfcaaugsgsu BD-12385 csasuugaUfaCfUfGfccagAfCfggca(L96) (vinu)sGfsccgUfcUfGfgcagUfaUfcaaugsgsu BD-12386 csasuugaUfaCfUfGfccagacggca(L96) (vinu)sGfsccgUfcuggcagUfaUfcaaugsgsu BD-12387 csasuugaUfaCfUfGfccagacggca(L96) (vinu)sGfsccgUfcUfGfgcagUfaUfcaaugsgsu BD-12388 csasuuGfaUfAfCfugccagacga(L96) (vinu)sCfsgucUfgGfCfaguaUfcAfaugsgsu BD-12389 ususgaUfaCfUfGfccagAfcgGfca(L96) (vinu)sGfsccgUfcuggcagUfaUfcaasusgBD-12390 ususgaUfaCfUfGfccagAfcgGfca(L96) (vinu)sGfsccgUfcUfGfgcagUfaUfcaasusg BD-12391 ususgaUfaCfUfGfccagAfCfggca(L96) (vinu)sGfsccgUfcuggcagUfaUfcaasusgBD-12392 ususgaUfaCfUfGfccagAfCfggca(L96) (vinu)sGfsccgUfcUfGfgcagUfaUfcaasusg BD-12393 ususgaUfaCfUfGfccagacggca(L96) (vinu)sGfsccgUfcuggcagUfaUfcaasusgBD-12394 ususgauaCfuGfCfCfagacGfgcUfga(L96) (vinu)sCfsagcCfgucuggcAfgUfaucaasusg BD-12395 ususgauaCfuGfCfCfagacGfgcUfga(L96) (vinu)sCfsagcCfgUfCfuggcAfgUfaucaasusg BD-12396 ususgauaCfuGfCfCfagacGfGfcuga(L96) (vinu)sCfsagcCfgucuggcAfgUfaucaasusg BD-12397 ususgauaCfuGfCfCfagacGfGfcuga(L96) (vinu)sCfsagcCfgUfCfuggcAfgUfaucaasusg BD-12398 ususgauaCfuGfCfCfagacggcuga(L96) (vinu)sCfsagcCfgucuggcAfgUfaucaasusg BD-12399 ususgauaCfuGfCfCfagacggcuga(L96) (vinu)sCfsagcCfgUfCfuggcAfgUfaucaasusg BD-12400 ususgaUfaCfUfGfccagacggca(L96) (vinu)sGfsccgUfcUfGfgcagUfaUfcaasusg BD- 12401 gsasuaCfuGfCfCfagacGfgcUfga(L96) (vinu)sCfsagcCfgucuggcAfgUfaucsasaBD-12402 gsasuaCfuGfCfCfagacGfgcUfga(L96) (vinu)sCfsagcCfgUfCfuggcAfgUfaucsasa BD-12403 gsasuaCfuGfCfCfagacGfGfcuga(L96) (vinu)sCfsagcCfgucuggcAfgUfaucsasaBD- 12404 gsasuaCfuGfCfCfagacGfGfcuga(L96) (vinu)sCfsagcCfgUfCfuggcAfgUfaucsasa BD-12405 gsasuaCfuGfCfCfagacggcuga(L96) (vinu)sCfsagcCfgucuggcAfgUfaucsasaBD-12406 gsasuacuGfcCfAfGfacggCfugUfga(L96) (vinu)sCfsacaGfccgucugGfcAfguaucsasa BD-12407 gsasuacuGfcCfAfGfacggCfugUfga(L96) (vinu)sCfsacaGfcCfGfucugGfcAfguaucsasaBD-12408 gsasuacuGfcCfAfGfacggCfUfguga(L96) (vinu)sCfsacaGfccgucugGfcAfguaucsasa NAI-5008944785v1 Page 83 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-12409 gsasuacuGfcCfAfGfacggCfUfguga(L96) (vinu)sCfsacaGfcCfGfucugGfcAfguaucsasa BD-12410 gsasuacuGfcCfAfGfacggcuguga(L96) (vinu)sCfsacaGfccgucugGfcAfguaucsasa BD-12411 gsasuacuGfcCfAfGfacggcuguga(L96) (vinu)sCfsacaGfcCfGfucugGfcAfguaucsasa BD-12412 gsasuaCfuGfCfCfagacggcuga(L96) (vinu)sCfsagcCfgUfCfuggcAfgUfaucsasa BD-12413 uscscuGfuGfUfCfuuugAfugUfua(L96) (vinu)sAfsacaUfcaaagacAfcAfggasasuBD-12414 uscscuGfuGfUfCfuuugAfugUfua(L96) (vinu)sAfsacaUfcAfAfagacAfcAfggasasu BD-12415 uscscuGfuGfUfCfuuugAfUfguua(L96) (vinu)sAfsacaUfcaaagacAfcAfggasasuBD-12416 uscscuGfuGfUfCfuuugAfUfguua(L96) (vinu)sAfsacaUfcAfAfagacAfcAfggasasu BD-12417 uscscuGfuGfUfCfuuugauguua(L96) (vinu)sAfsacaUfcaaagacAfcAfggasasuBD-12418 uscscuguGfuCfUfUfugauGfuuUfua(L96) (vinu)sAfsaaaCfaucaaagAfcAfcaggasasu BD-12419 uscscuguGfuCfUfUfugauGfuuUfua(L96) (vinu)sAfsaaaCfaUfCfaaagAfcAfcaggasasu BD-12420 uscscuguGfuCfUfUfugauGfUfuuua(L96) (vinu)sAfsaaaCfaucaaagAfcAfcaggasasu BD-12421 uscscuguGfuCfUfUfugauGfUfuuua(L96) (vinu)sAfsaaaCfaUfCfaaagAfcAfcaggasasu BD-12422 uscscuguGfuCfUfUfugauguuuua(L96) (vinu)sAfsaaaCfaucaaagAfcAfcaggasasu BD-12423 uscscuguGfuCfUfUfugauguuuua(L96) (vinu)sAfsaaaCfaUfCfaaagAfcAfcaggasasu BD-12424 uscscuGfuGfUfCfuuugauguua(L96) (vinu)sAfsacaUfcAfAfagacAfcAfggasasu BD-12425 ususuaAfuUfUfCfugguGfauCfca(L96) (vinu)sGfsgauCfaccagaaAfuUfaaasascBD-12426 ususuaAfuUfUfCfugguGfauCfca(L96) (vinu)sGfsgauCfaCfCfagaaAfuUfaaasasc BD-12427 ususuaAfuUfUfCfugguGfAfucca(L96) (vinu)sGfsgauCfaccagaaAfuUfaaasascBD-12428 ususuaAfuUfUfCfugguGfAfucca(L96) (vinu)sGfsgauCfaCfCfagaaAfuUfaaasasc BD-12429 ususuaAfuUfUfCfuggugaucca(L96) (vinu)sGfsgauCfaccagaaAfuUfaaasascBD-12430 ususuaauUfuCfUfGfgugaUfccCfaa(L96) (vinu)sUfsgggAfucaccagAfaAfuuaaasasc BD-12431 ususuaauUfuCfUfGfgugaUfccCfaa(L96) (vinu)sUfsgggAfuCfAfccagAfaAfuuaaasasc BD-12432 ususuaauUfuCfUfGfgugaUfCfccaa(L96) (vinu)sUfsgggAfucaccagAfaAfuuaaasasc BD-12433 ususuaauUfuCfUfGfgugaUfCfccaa(L96) (vinu)sUfsgggAfuCfAfccagAfaAfuuaaasasc BD-12434 ususuaauUfuCfUfGfgugaucccaa(L96) (vinu)sUfsgggAfucaccagAfaAfuuaaasasc BD-12435 ususuaauUfuCfUfGfgugaucccaa(L96) (vinu)sUfsgggAfuCfAfccagAfaAfuuaaasasc BD-12436 ususuaAfuUfUfCfuggugaucca(L96) (vinu)sGfsgauCfaCfCfagaaAfuUfaaasasc BD-12437 asusuaCfuAfGfUfuuggAfaaUfga(L96) (vinu)sCfsauuUfccaaacuAfgUfaausgsgBD-12438 asusuaCfuAfGfUfuuggAfaaUfga(L96) (vinu)sCfsauuUfcCfAfaacuAfgUfaausgsg BD-12439 asusuaCfuAfGfUfuuggAfAfauga(L96) (vinu)sCfsauuUfccaaacuAfgUfaausgsgBD-12440 asusuaCfuAfGfUfuuggAfAfauga(L96) (vinu)sCfsauuUfcCfAfaacuAfgUfaausgsg BD-12441 asusuaCfuAfGfUfuuggaaauga(L96) (vinu)sCfsauuUfccaaacuAfgUfaausgsgBD-12442 asusuacuAfgUfUfUfggaaAfugAfua(L96) (vinu)sAfsucaUfuuccaaaCfuAfguaausgsg BD-12443 asusuacuAfgUfUfUfggaaAfugAfua(L96) (vinu)sAfsucaUfuUfCfcaaaCfuAfguaausgsg BD-12444 asusuacuAfgUfUfUfggaaAfUfgaua(L96) (vinu)sAfsucaUfuuccaaaCfuAfguaausgsg BD-12445 asusuacuAfgUfUfUfggaaAfUfgaua(L96) (vinu)sAfsucaUfuUfCfcaaaCfuAfguaausgsg BD-12446 asusuacuAfgUfUfUfggaaaugaua(L96) (vinu)sAfsucaUfuuccaaaCfuAfguaausgsg BD-12447 asusuacuAfgUfUfUfggaaaugaua(L96) (vinu)sAfsucaUfuUfCfcaaaCfuAfguaausgsg BD-12448 asusuaCfuAfGfUfuuggaaauga(L96) (vinu)sCfsauuUfcCfAfaacuAfgUfaausgsg BD-12449 asgsauUfgGfCfAfuagaAfgaAfua(L96) (vinu)sAfsuucUfucuaugcCfaAfucusgsuBD-12450 asgsauUfgGfCfAfuagaAfgaAfua(L96) (vinu)sAfsuucUfuCfUfaugcCfaAfucusgsu BD-12451 asgsauUfgGfCfAfuagaAfGfaaua(L96) (vinu)sAfsuucUfucuaugcCfaAfucusgsuBD-12452 asgsauUfgGfCfAfuagaAfGfaaua(L96) (vinu)sAfsuucUfuCfUfaugcCfaAfucusgsu BD-12453 asgsauUfgGfCfAfuagaagaaua(L96) (vinu)sAfsuucUfucuaugcCfaAfucusgsuBD-12454 asgsauugGfcAfUfAfgaagAfauGfua(L96) (vinu)sAfscauUfcuucuauGfcCfaaucusgsu BD-12455 asgsauugGfcAfUfAfgaagAfauGfua(L96) (vinu)sAfscauUfcUfUfcuauGfcCfaaucusgsu BD-12456 asgsauugGfcAfUfAfgaagAfAfugua(L96) (vinu)sAfscauUfcuucuauGfcCfaaucusgsu BD-12457 asgsauugGfcAfUfAfgaagAfAfugua(L96) (vinu)sAfscauUfcUfUfcuauGfcCfaaucusgsu BD-12458 asgsauugGfcAfUfAfgaagaaugua(L96) (vinu)sAfscauUfcuucuauGfcCfaaucusgsuBD-12459 asgsauugGfcAfUfAfgaagaaugua(L96) (vinu)sAfscauUfcUfUfcuauGfcCfaaucusgsu NAI-5008944785v1 Page 84 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-12460 asgsauUfgGfCfAfuagaagaaua(L96) (vinu)sAfsuucUfuCfUfaugcCfaAfucusgsu BD-12461 asgsaaUfaAfGfGfauucUfggGfca(L96) (vinu)sGfscccAfgaauccuUfaUfucusgsuBD-12462 asgsaaUfaAfGfGfauucUfggGfca(L96) (vinu)sGfscccAfgAfAfuccuUfaUfucusgsu BD-12463 asgsaaUfaAfGfGfauucUfGfggca(L96) (vinu)sGfscccAfgaauccuUfaUfucusgsuBD-12464 asgsaaUfaAfGfGfauucUfGfggca(L96) (vinu)sGfscccAfgAfAfuccuUfaUfucusgsu BD-12465 asgsaaUfaAfGfGfauucugggca(L96) (vinu)sGfscccAfgaauccuUfaUfucusgsuBD-12466 asgsaauaAfgGfAfUfucugGfgcAfaa(L96) (vinu)sUfsugcCfcagaaucCfuUfauucusgsu BD-12467 asgsaauaAfgGfAfUfucugGfgcAfaa(L96) (vinu)sUfsugcCfcAfGfaaucCfuUfauucusgsu BD-12468 asgsaauaAfgGfAfUfucugGfGfcaaa(L96) (vinu)sUfsugcCfcagaaucCfuUfauucusgsu BD-12469 asgsaauaAfgGfAfUfucugGfGfcaaa(L96) (vinu)sUfsugcCfcAfGfaaucCfuUfauucusgsu BD-12470 asgsaauaAfgGf AfUfucugggcaaa(L96 ) (vinu)sUfsugcCfcagaaucCfuUfauucusgsu BD-12471 asgsaauaAfgGfAfUfucugggcaaa(L96) (vinu)sUfsugcCfcAfGfaaucCfuUfauucusgsu BD-12472 asgsaaUfaAfGfGfauucugggca(L96) (vinu)sGfscccAfgAfAfuccuUfaUfucusgsu BD-12473 asgsguCfaUfGfAfagguUfuuAfaa(L96) (vinu)sUfsuaaAfaccuucaUfgAfccuscsuBD-12474 asgsguCfaUfGfAfagguUfuuAfaa(L96) (vinu)sUfsuaaAfaCfCfuucaUfgAfccuscsu BD-12475 asgsguCfaUfGfAfagguUfUfuaaa(L96) (vinu)sUfsuaaAfaccuucaUfgAfccuscsuBD-12476 asgsguCfaUfGfAfagguUfUfuaaa(L96) (vinu)sUfsuaaAfaCfCfuucaUfgAfccuscsu BD-12477 asgsguCfaUfGfAfagguuuuaaa(L96) (vinu)sUfsuaaAfaccuucaUfgAfccuscsuBD-12478 asgsgucaUfgAfAfGfguuuUfaaUfga(L96) (vinu)sCfsauuAfaaaccuuCfaUfgaccuscsu BD-12479 asgsgucaUfgAfAfGfguuuUfaaUfga(L96) (vinu)sCfsauuAfaAfAfccuuCfaUfgaccuscsu BD-12480 asgsgucaUfgAfAfGfguuuUfAfauga(L96) (vinu)sCfsauuAfaaaccuuCfaUfgaccuscsu BD-12481 asgsgucaUfgAfAfGfguuuUfAfauga(L96) (vinu)sCfsauuAfaAfAfccuuCfaUfgaccuscsu BD-12482 asgsgucaUfgAfAfGfguuuuaauga(L96) (vinu)sCfsauuAfaaaccuuCfaUfgaccuscsu BD-12483 asgsgucaUfgAfAfGfguuuuaauga(L96) (vinu)sCfsauuAfaAfAfccuuCfaUfgaccuscsu BD-12484 asgsguCfaUfGfAfagguuuuaaa(L96) (vinu)sUfsuaaAfaCfCfuucaUfgAfccuscsu BD-12485 ususaaGfaGfGfCfaagaGfcuGfaa(L96) (vinu)sUfscagCfucuugccUfcUfuaasasaBD-12486 ususaaGfaGfGfCfaagaGfcuGfaa(L96) (vinu)sUfscagCfuClUfugccUfcUfuaasasa BD-12487 ususaaGfaGfGfCfaagaGfCfugaa(L96) (vinu)sUfscagCfucuugccUfcUfuaasasaBD-12488 ususaaGfaGfGfCfaagaGfCfugaa(L96) (vinu)sUfscagCfuCfUfugccUfcUfuaasasa BD-12489 ususaaGfaGfGfCfaagagcugaa(L96) (vinu)sUfscagCfucuugccUfcUfuaasasaBD-12490 ususaagaGfgCfAfAfgagcUfgaAfaa(L96) (vinu)sUfsuucAfgcucuugCfcUfcuuaasasa BD-12491 ususaagaGfgCfAfAfgagcUfgaAfaa(L96) (vinu)sUfsuucAfgCfUfcuugCfcUfcuuaasasa BD-12492 ususaagaGfgCfAfAfgagcUfGfaaaa(L96) (vinu)sUfsuucAfgcucuugCfcUfcuuaasasa BD-12493 ususaagaGfgCfAfAfgagcUfGfaaaa(L96) (vinu)sUfsuucAfgCfUfcuugCfcUfcuuaasasa BD-12494 ususaagaGfgCfAfAfgagcugaaaa(L96) (vinu)sUfsuucAfgcucuugCfcUfcuuaasasa BD-12495 ususaagaGfgCfAfAfgagcugaaaa(L96) (vinu)sUfsuucAfgCfUfcuugCfcUfcuuaasasa BD-12496 ususaaGfaGfGfCfaagagcugaa(L96) (vinu)sUfscagCfuCfUfugccUfcUfuaasasa BD-12497 usgsauCfaUfUfAfgccaUfaaGfaa(L96) (vinu)sUfscuuAfuggcuaaUfgAfucasusgBD-12498 usgsauCfaUfUfAfgccaUfaaGfaa(L96) (vinu)sUfscuuAfuGfGfcuaaUfgAfucasusg BD-12499 usgsauCfaUfUfAfgccaUfAfagaa(L96) (vinu)sUfscuuAfuggcuaaUfgAfucasusgBD-12500 usgsauCfaUfUfAfgccaUfAfagaa(L96) (vinu)sUfscuuAfuGfGfcuaaUfgAfucasusg BD-12501 usgsauCfaUfUfAfgccauaagaa(L96) (vinu)sUfscuuAfuggcuaaUfgAfucasusgBD-12502 usgsaucaUfuAfGfCfcauaAfgaAfaa(L96) (vinu)sUfsuucUfuauggcuAfaUfgaucasusg BD-12503 usgsaucaUfuAfGfCfcauaAfgaAfaa(L96) (vinu)sUfsuucUfuAfUfggcuAfaUfgaucasusg BD-12504 usgsaucaUfuAfGfCfcauaAfGfaaaa(L96) (vinu)sUfsuucUfuauggcuAfaUfgaucasusg BD-12505 usgsaucaUfuAfGfCfcauaAfGfaaaa(L96) (vinu)sUfsuucUfuAfUfggcuAfaUfgaucasusg BD-12506 usgsaucaUfuAfGfCfcauaagaaaa(L96) (vinu)sUfsuucUfuauggcuAfaUfgaucasusg BD-12507 usgsaucaUfuAfGfCfcauaagaaaa(L96) (vinu)sUfsuucUfuAfUfggcuAfaUfgaucasusg BD-12508 usgsauCfaUfUfAfgccauaagaa(L96) (vinu)sUfscuuAfuGfGfcuaaUfgAfucasusg BD-12509 ususagGfgAfAfAfgaagUfcuAfua(L96) (vinu)sAfsuagAfcuucuuuCfcCfuaasusuBD-12510 ususagGfgAfAfAfgaagUfcuAfua(L96) (vinu)sAfsuagAfcUfUfcuuuCfcCfuaasusu NAI-5008944785v1 Page 85 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-12511 ususagGfgAfAfAfgaagUfCfuaua(L96) (vinu)sAfsuagAfcuucuuuCfcCfuaasusuBD-12512 ususagGfgAfAfAfgaagUfCfuaua(L96) (vinu)sAfsuagAfcUfUfcuuuCfcCfuaasusu BD-12513 ususagGfgAfAfAfgaagucuaua(L96) (vinu)sAfsuagAfcuucuuuCfcCfuaasusuBD-12514 ususagggAfaAfGfAfagucUfauUfua(L96) (vinu)sAfsaauAfgacuucuUfuCfccuaasusu BD-12515 ususagggAfaAfGfAfagucUfauUfua(L96) (vinu)sAfsaauAfgAfCfuucuUfuCfccuaasusu BD-12516 ususagggAfaAfGfAfagucUfAfuuua(L96) (vinu)sAfsaauAfgacuucuUfuCfccuaasusu BD-12517 ususagggAfaAfGfAfagucUfAfuuua(L96) (vinu)sAfsaauAfgAfCfuucuUfuCfccuaasusu BD-12518 ususagggAfaAfGfAfagucuauuua(L96) (vinu)sAfsaauAfgacuucuUfuCfccuaasusu BD-12519 ususagggAfaAfGfAfagucuauuua(L96) (vinu)sAfsaauAfgAfCfuucuUfuCfccuaasusu BD-12520 ususagGfgAfAfAfgaagucuaua(L96) (vinu)sAfsuagAfcUfUfcuuuCfcCfuaasusu BD-12521 usasggGfaAfAfGfaaguCfuaUfua(L96) (vinu)sAfsauaGfacuucuuUfcCfcuasasuBD-12522 usasggGfaAfAfGfaaguCfuaUfua(L96) (vinu)sAfsauaGfaCfUfucuuUfcCfcuasasu BD-12523 usasggGfaAfAfGfaaguCfUfauua(L96) (vinu)sAfsauaGfacuucuuUfcCfcuasasuBD-12524 usasggGfaAfAfGfaaguCfUfauua(L96) (vinu)sAfsauaGfaCfUfucuuUfcCfcuasasu BD-12525 usasggGfaAfAfGfaagucuauua(L96) (vinu)sAfsauaGfacuucuuUfcCfcuasasuBD-12526 usasgggaAfaGfAfAfgucuAfuuUfga(L96) (vinu)sCfsaaaUfagacuucUfuUfcccuasasu BD-12527 usasgggaAfaGfAfAfgucuAfuuUfga(L96) (vinu)sCfsaaaUfaGfAfcuucUfuUfcccuasasu BD-12528 usasgggaAfaGfAfAfgucuAfUfuuga(L96) (vinu)sCfsaaaUfagacuucUfuUfcccuasasu BD-12529 usasgggaAfaGfAfAfgucuAfUfuuga(L96) (vinu)sCfsaaaUfaGfAfcuucUfuUfcccuasasu BD-12530 usasgggaAfaGfAfAfgucuauuuga(L96) (vinu)sCfsaaaUfagacuucUfuUfcccuasasu BD-12531 usasgggaAfaGfAfAfgucuauuuga(L96) (vinu)sCfsaaaUfaGfAfcuucUfuUfcccuasasu BD-12532 usasggGfaAfAfGfaagucuauua(L96) (vinu)sAfsauaGfaCfUfucuuUfcCfcuasasu BD-12533 asasagAfaGfUfCfuauuUfgaUfga(L96) (vinu)sCfsaucAfaauagacUfuCfuuuscscBD-12534 asasagAfaGfUfCfuauuUfgaUfga(L96) (vinu)sCfsaucAfaAfUfagacUfuCfuuuscsc BD-12535 asasagAfaGfUfCfuauuUfGfauga(L96) (vinu)sCfsaucAfaauagacUfuCfuuuscscBD-12536 asasagAfaGfUfCfuauuUfGfauga(L96) (vinu)sCfsaucAfaAfUfagacUfuCfuuuscsc BD-12537 asasagAfaGfUfCfuauuugauga(L96) (vinu)sCfsaucAfaauagacUfuCfuuuscscBD-12538 asasagaaGfuCfUfAfuuugAfugAfaa(L96) (vinu)sUfsucaUfcaaauagAfcUfucuuuscsc BD-12539 asasagaaGfuCfUfAfuuugAfugAfaa(L96) (vinu)sUfsucaUfcAfAfauagAfcUfucuuuscsc BD-12540 asasagaaGfuCfUfAfuuugAfUfgaaa(L96) (vinu)sUfsucaUfcaaauagAfcUfucuuuscsc BD-12541 asasagaaGfuCfUfAfuuugAfUfgaaa(L96) (vinu)sUfsucaUfcAfAfauagAfcUfucuuuscsc BD-12542 asasagaaGfuCfUfAfuuugaugaaa(L96) (vinu)sUfsucaUfcaaauagAfcUfucuuuscsc BD-12543 asasagaaGfuCfUfAfuuugaugaaa(L96) (vinu)sUfsucaUfcAfAfauagAfcUfucuuuscsc BD-12544 asasagAfaGfUfCfuauuugauga(L96) (vinu)sCfsaucAfaAfUfagacUfuCfuuuscsc BD-12545 asasgaAfgUfCfUfauuuGfauGfaa(L96) (vinu)sUfscauCfaaauagaCfuUfcuususcBD-12546 asasgaAfgUfCfUfauuuGfauGfaa(L96) (vinu)sUfscauCfaAfAfuagaCfuUfcuususc BD-12547 asasgaAfgUfCfUfauuuGfAfugaa(L96) (vinu)sUfscauCfaaauagaCfuUfcuususcBD-12548 asasgaAfgUfCfUfauuuGfAfugaa(L96) (vinu)sUfscauCfaAfAfuagaCfuUfcuususc BD-12549 asasgaAfgUfCfUfauuugaugaa(L96) (vinu)sUfscauCfaaauagaCfuUfcuususcBD-12550 asasgaagUfcUfAfUfuugaUfgaAfua(L96) (vinu)sAfsuucAfucaaauaGfaCfuucuususc BD-12551 asasgaagUfcUfAfUfuugaUfgaAfua(L96) (vinu)sAfsuucAfuCfAfaauaGfaCfuucuususc BD-12552 asasgaagUfcUfAfUfuugaUfGfaaua(L96) (vinu)sAfsuucAfucaaauaGfaCfuucuususc BD-12553 asasgaagUfcUfAfUfuugaUfGfaaua(L96) (vinu)sAfsuucAfuCfAfaauaGfaCfuucuususc BD-12554 asasgaagUfcUfAfUfuugaugaaua(L96) (vinu)sAfsuucAfucaaauaGfaCfuucuususc BD-12555 asasgaagUfcUfAfUfuugaugaaua(L96) (vinu)sAfsuucAfuCfAfaauaGfaCfuucuususc BD-12556 asasgaAfgUfCfUfauuugaugaa(L96) (vinu)sUfscauCfaAfAfuagaCfuUfcuususc BD-12557 csuscuUfaGfGfUfgaagGfgaGfua(L96) (vinu)sAfscucCfcuucaccUfaAfgagscsuBD-12558 csuscuUfaGfGfUfgaagGfgaGfua(L96) (vinu)sAfscucCfcUfUfcaccUfaAfgagscsu BD-12559 csuscuUfaGfGfUfgaagGfGfagua(L96) (vinu)sAfscucCfcuucaccUfaAfgagscsuBD-12560 csuscuUfaGfGfUfgaagGfGfagua(L96) (vinu)sAfscucCfcUfUfcaccUfaAfgagscsuBD-12561 csuscuUfaGfGfUfgaagggagua(L96) (vinu)sAfscucCfcuucaccUfaAfgagscsuNAI-5008944785v1 Page 86 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-12562 csuscuuaGfgUfGfAfagggAfguCfua(L96) (vinu)sAfsgacUfcccuucaCfcUfaagagscsu BD-12563 csuscuuaGfgUfGfAfagggAfguCfua(L96) (vinu)sAfsgacUfcCfCfuucaCfcUfaagagscsu BD-12564 csuscuuaGfgUfGfAfagggAfGfucua(L96) (vinu)sAfsgacUfcccuucaCfcUfaagagscsu BD-12565 csuscuuaGfgUfGfAfagggAfGfucua(L96) (vinu)sAfsgacUfcCfCfuucaCfcUfaagagscsu BD-12566 csuscuuaGfgUfGfAfagggagucua(L96) (vinu)sAfsgacUfcccuucaCfcUfaagagscsu BD-12567 csuscuuaGfgUfGfAfagggagucua(L96) (vinu)sAfsgacUfcCfCfuucaCfcUfaagagscsu BD-12568 csuscuUfaGfGfUfgaagggagua(L96) (vinu)sAfscucCfcUfUfcaccUfaAfgagscsu BD-12569 gsusgaAfgGfGfAfgucuCfugCfua(L96) (vinu)sAfsgcaGfagacuccCfuUfcacscsuBD-12570 gsusgaAfgGfGfAfgucuCfugCfua(L96) (vinu)sAfsgcaGfaGfAfcuccCfuUfcacscsu BD-12571 gsusgaAfgGfGfAfgucuCfUfgcua(L96) (vinu)sAfsgcaGfagacuccCfuUfcacscsuBD-12572 gsusgaAfgGfGfAfgucuCfUfgcua(L96) (vinu)sAfsgcaGfaGfAfcuccCfuUfcacscsu BD-12573 gsusgaAfgGfGfAfgucucugcua(L96) (vinu)sAfsgcaGfagacuccCfuUfcacscsuBD-12574 gsusgaagGfgAfGfUfcucuGfcuUfua(L96) (vinu)sAfsaagCfagagacuCfcCfuucacscsu BD-12575 gsusgaagGfgAfGfUfcucuGfcuUfua(L96) (vinu)sAfsaagCfaGfAfgacuCfcCfuucacscsu BD-12576 gsusgaagGfgAfGfUfcucuGfCfuuua(L96) (vinu)sAfsaagCfagagacuCfcCfuucacscsu BD-12577 gsusgaagGfgAfGfUfcucuGfCfuuua(L96) (vinu)sAfsaagCfaGfAfgacuCfcCfuucacscsu BD-12578 gsusgaagGfgAfGfUfcucugcuuua(L96) (vinu)sAfsaagCfagagacuCfcCfuucacscsu BD-12579 gsusgaagGfgAfGfUfcucugcuuua(L96) (vinu)sAfsaagCfaGfAfgacuCfcCfuucacscsu BD-12580 gsusgaAfgGfGfAfgucucugcua(L96) (vinu)sAfsgcaGfaGfAfcuccCfuUfcacscsu BD-12581 usgsaaGfgGfAfGfucucUfgcUfua(L96) (vinu)sAfsagcAfgagacucCfcUfucascscBD- 12582 usgsaaGfgGfAfGfucucUfgcUfua(L96) (vinu)sAfsagcAfgAfGfacucCfcUfucascsc BD-12583 usgsaaGfgGfAfGfucucUfGfcuua(L96) (vinu)sAfsagcAfgagacucCfcUfucascscBD-12584 usgsaaGfgGfAfGfucucUfGfcuua(L96) (vinu)sAfsagcAfgAfGfacucCfcUfucascsc BD-12585 usgsaaGfgGfAfGfucucugcuua(L96) (vinu)sAfsagcAfgagacucCfcUfucascscBD-12586 usgsaaggGfaGfUfCfucugCfuuUfua(L96) (vinu)sAfsaaaGfcagagacUfcCfcuucascsc BD-12587 usgsaaggGfaGfUfCfucugCfuuUfua(L96) (vinu)sAfsaaaGfcAfGfagacUfcCfcuucascsc BD-12588 usgsaaggGfaGfUfCfucugCfUfuuua(L96) (vinu)sAfsaaaGfcagagacUfcCfcuucascsc BD-12589 usgsaaggGfaGfUfCfucugCfUfuuua(L96) (vinu)sAfsaaaGfcAfGfagacUfcCfcuucascsc BD- 12590 usgsaaggGfaGfUfCfucugcuuuua(L96) (vinu)sAfsaaaGfcagagacUfcCfcuucascsc BD-12591 usgsaaggGfaGfUfCfucugcuuuua(L96) (vinu)sAfsaaaGfcAfGfagacUfcCfcuucascsc BD-12592 usgsaaGfgGfAfGfucucugcuua(L96) (vinu)sAfsagcAfgAfGfacucCfcUfucascsc BD-12593 asgsguAfgGfAfCfagaaGfuaUfca(L96) (vinu)sGfsauaCfuucugucCfuAfccusgsuBD-12594 asgsguAfgGfAfCfagaaGfuaUfca(L96) (vinu)sGfsauaCfuUfCfugucCfuAfccusgsu BD-12595 asgsguAfgGfAfCfagaaGfUfauca(L96) (vinu)sGfsauaCfuucugucCfuAfccusgsuBD-12596 asgsguAfgGfAfCfagaaGfUfauca(L96) (vinu)sGfsauaCfuUfCfugucCfuAfccusgsu BD-12597 asgsguAfgGfAfCfagaaguauca(L96) (vinu)sGfsauaCfuucugucCfuAfccusgsuBD-12598 asgsguagGfaCfAfGfaaguAfucAfua(L96) (vinu)sAfsugaUfacuucugUfcCfuaccusgsu BD-12599 asgsguagGfaCfAfGfaaguAfucAfua(L96) (vinu)sAfsugaUfaCfUfucugUfcCfuaccusgsu BD-12600 asgsguagGfaCfAfGfaaguAfUfcaua(L96) (vinu)sAfsugaUfacuucugUfcCfuaccusgsu BD-12601 asgsguagGfaCfAfGfaaguAfUfcaua(L96) (vinu)sAfsugaUfaCfUfucugUfcCfuaccusgsu BD-12602 asgsguagGfaCfAfGfaaguaucaua(L96) (vinu)sAfsugaUfacuucugUfcCfuaccusgsu BD-12603 asgsguagGfaCfAfGfaaguaucaua(L96) (vinu)sAfsugaUfaCfUfucugUfcCfuaccusgsu BD-12604 asgsguAfgGfAfCfagaaguauca(L96) (vinu)sGfsauaCfuUfCfugucCfuAfccusgsu BD-12605 gsgsuaGfgAfCfAfgaagUfauCfaa(L96) (vinu)sUfsgauAfcuucuguCfcUfaccsusgBD-12606 gsgsuaGfgAfCfAfgaagUfauCfaa(L96) (vinu)sUfsgauAfcUfUfcuguCfcUfaccsusg BD-12607 gsgsuaGfgAfCfAfgaagUfAfucaa(L96) (vinu)sUfsgauAfcuucuguCfcUfaccsusgBD-12608 gsgsuaGfgAfCfAfgaagUfAfucaa(L96) (vinu)sUfsgauAfcUfUfcuguCfcUfaccsusg BD-12609 gsgsuaGfgAfCfAfgaaguaucaa(L96) (vinu)sUfsgauAfcuucuguCfcUfaccsusgBD-12610 gsgsuaggAfcAfGfAfaguaUfcaUfca(L96) (vinu)sGfsaugAfuacuucuGfuCfcuaccsusg BD-12611 gsgsuaggAfcAfGfAfaguaUfcaUfca(L96) (vinu)sGfsaugAfuAfCfuucuGfuCfcuaccsusgBD-12612 gsgsuaggAfcAfGfAfaguaUfCfauca(L96) (vinu) sGf saug AfuacuucuGfuCfcuacc susg NAI-5008944785v1 Page 87 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-12613 gsgsuaggAfcAfGfAfaguaUfCfauca(L96) (vinu)sGfsaugAfuAfCfuucuGfuCfcuaccsusg BD-12614 gsgsuaggAfcAfGfAfaguaucauca(L96) (vinu)sGfsaugAfuacuucuGfuCfcuaccsusg BD-12615 gsgsuaggAfcAfGfAfaguaucauca(L96) (vinu)sGfsaugAfuAfCfuucuGfuCfcuaccsusg BD-12616 gsgsuaGfgAfCfAfgaaguaucaa(L96) (vinu)sUfsgauAfcUfUfcuguCfcUfaccsusg BD-12617 gsusagGfaCfAfGfaaguAfucAfua(L96) (vinu)sAfsugaUfacuucugUfcCfuacscsuBD-12618 gsusagGfaCfAfGfaaguAfucAfua(L96) (vinu)sAfsugaUfaCfUfucugUfcCfuacscsu BD-12619 gsusagGfaCfAfGfaaguAfUfcaua(L96) (vinu)sAfsugaUfacuucugUfcCfuacscsuBD-12620 gsusagGfaCfAfGfaaguAfUfcaua(L96) (vinu)sAfsugaUfaCfUfucugUfcCfuacscsu BD-12621 gsusagGfaCfAfGfaaguaucaua(L96) (vinu)sAfsugaUfacuucugUfcCfuacscsuBD-12622 gsusaggaCfaGfAfAfguauCfauCfca(L96) (vinu)sGfsgauGfauacuucUfgUfccuacscsu BD-12623 gsusaggaCfaGfAfAfguauCfauCfca(L96) (vinu)sGfsgauGfaUfAfcuucUfgUfccuacscsu BD-12624 gsusaggaCfaGfAfAfguauCfAfucca(L96) (vinu)sGfsgauGfauacuucUfgUfccuacscsu BD-12625 gsusaggaCfaGfAfAfguauCfAfucca(L96) (vinu)sGfsgauGfaUfAfcuucUfgUfccuacscsu BD-12626 gsusaggaCfaGfAfAfguaucaucca(L96) (vinu)sGfsgauGfauacuucUfgUfccuacscsu BD-12627 gsusaggaCfaGfAfAfguaucaucca(L96) (vinu)sGfsgauGfaUfAfcuucUfgUfccuacscsu BD-12628 gsusagGfaCfAfGfaaguaucaua(L96) (vinu)sAfsugaUfaCfUfucugUfcCfuacscsu BD-12629 asgsgaCfaGfAfAfguauCfauCfca(L96) (vinu)sGfsgauGfauacuucUfgUfccusascBD-12630 asgsgaCfaGfAfAfguauCfauCfca(L96) (vinu)sGfsgauGfaUfAfcuucUfgUfccusasc BD-12631 asgsgaCfaGfAfAfguauCfAfucca(L96) (vinu)sGfsgauGfauacuucUfgUfccusascBD-12632 asgsgaCfaGfAfAfguauCfAfucca(L96) (vinu)sGfsgauGfaUfAfcuucUfgUfccusasc BD-12633 asgsgaCfaGfAfAfguaucaucca(L96) (vinu)sGfsgauGfauacuucUfgUfccusascBD-12634 asgsgacaGfaAfGfUfaucaUfccCfua(L96) (vinu)sAfsgggAfugauacuUfcUfguccusasc BD-12635 asgsgacaGfaAfGfUfaucaUfccCfua(L96) (vinu)sAfsgggAfuGfAfuacuUfcUfguccusasc BD-12636 asgsgacaGfaAfGfUfaucaUfCfccua(L96) (vinu)sAfsgggAfugauacuUfcUfguccusasc BD-12637 asgsgacaGfaAfGfUfaucaUfCfccua(L96) (vinu)sAfsgggAfuGfAfuacuUfcUfguccusasc BD-12638 asgsgacaGfaAfGfUfaucaucccua(L96) (vinu)sAfsgggAfugauacuUfcUfguccusasc BD-12639 asgsgacaGfaAfGfUfaucaucccua(L96) (vinu)sAfsgggAfuGfAfuacuUfcUfguccusasc BD-12640 asgsgaCfaGfAfAfguaucaucca(L96) (vinu)sGfsgauGfaUfAfcuucUfgUfccusasc BD- 12641 gsgsacAfgAfAfGfuaucAfucCfca(L96) (vinu)sGfsggaUfgauacuuCfuGfuccsusaBD-12642 gsgsacAfgAfAfGfuaucAfucCfca(L96) (vinu)sGfsggaUfgAfUfacuuCfuGfuccsusa BD-12643 gsgsacAfgAfAfGfuaucAfUfccca(L96) (vinu)sGfsggaUfgauacuuCfuGfuccsusaBD-12644 gsgsacAfgAfAfGfuaucAfUfccca(L96) (vinu)sGfsggaUfgAfUfacuuCfuGfuccsusa BD-12645 gsgsacAfgAfAfGfuaucauccca(L96) (vinu)sGfsggaUfgauacuuCfuGfuccsusaBD-12646 gsgsacagAfaGfUfAfucauCfccUfaa(L96) (vinu)sUfsaggGfaugauacUfuCfuguccsusa BD-12647 gsgsacagAfaGfUfAfucauCfccUfaa(L96) (vinu)sUfsaggGfaUfGfauacUfuCfuguccsusa BD-12648 gsgsacagAfaGfUfAfucauCfCfcuaa(L96) (vinu)sUfsaggGfaugauacUfuCfuguccsusa BD-12649 gsgsacagAfaGfUfAfucauCfCfcuaa(L96) (vinu)sUfsaggGfaUfGfauacUfuCfuguccsusa BD-12650 gsgsacagAfaGfUfAfucaucccuaa(L96) (vinu)sUfsaggGfaugauacUfuCfuguccsusa BD-12651 gsgsacagAfaGfUfAfucaucccuaa(L96) (vinu)sUfsaggGfaUfGfauacUfuCfuguccsusa BD-12652 gsgsacAfgAfAfGfuaucauccca(L96) (vinu)sGfsggaUfgAfUfacuuCfuGfuccsusa BD-12653 asgsaaGfuAfUfCfauccCfuaCfca(L96) (vinu)sGfsguaGfggaugauAfcUfucusgsuBD-12654 asgsaaGfuAfUfCfauccCfuaCfca(L96) (vinu)sGfsguaGfgGfAfugauAfcUfucusgsu BD-12655 asgsaaGfuAfUfCfauccCfUfacca(L96) (vinu)sGfsguaGfggaugauAfcUfucusgsuBD-12656 asgsaaGfuAfUfCfauccCfUfacca(L96) (vinu)sGfsguaGfgGfAfugauAfcUfucusgsu BD-12657 asgsaaGfuAfUfCfaucccuacca(L96) (vinu)sGfsguaGfggaugauAfcUfucusgsuBD-12658 asgsaaguAfuCfAfUfcccuAfccCfca(L96) (vinu)sGfsgggUfagggaugAfuAfcuucusgsu BD-12659 asgsaaguAfuCfAfUfcccuAfccCfca(L96) (vinu)sGfsgggUfaGfGfgaugAfuAfcuucusgsu BD-12660 asgsaaguAfuCfAfUfcccuAfCfccca(L96) (vinu)sGfsgggUfagggaugAfuAfcuucusgsu BD-12661 asgsaaguAfuCfAfUfcccuAfCfccca(L96) (vinu)sGfsgggUfaGfGfgaugAfuAfcuucusgsu BD-12662 asgsaaguAfuCfAfUfcccuacccca(L96) (vinu)sGfsgggUfagggaugAfuAfcuucusgsuBD-12663 asgsaaguAfuCfAfUfcccuacccca(L96) (vinu)sGfsgggUfaGfGfgaugAfuAfcuucusgsu NAI-5008944785v1 Page 88 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID Sense (5 ‘-3’) Antisense (5 ‘-3’)BD-12664 asgsaaGfuAfUfCfaucccuacca(L96) (vinu)sGfsguaGfgGfAfugauAfcUfucusgsu BD- 12665 usasuuAfaAfGfCfuacaAfauUfca(L96) (vinu)sGfsaauUfuguagcuUfuAfauasascBD-12666 usasuuAfaAfGfCfuacaAfauUfca(L96) (vinu)sGfsaauUfuGfUfagcuUfuAfauasasc BD-12667 usasuuAfaAfGfCfuacaAfAfuuca(L96) (vinu)sGfsaauUfuguagcuUfuAfauasascBD-12668 usasuuAfaAfGfCfuacaAfAfuuca(L96) (vinu)sGfsaauUfuGfUfagcuUfuAfauasasc BD-12669 usasuuAfaAfGfCfuacaaauuca(L96) (vinu)sGfsaauUfuguagcuUfuAfauasascBD- 12670 usasuuaaAfgCfUfAfcaaaUfucUfua(L96) (vinu)sAfsagaAfuuuguagCfuUfuaauasasc BD-12671 usasuuaaAfgCfUfAfcaaaUfucUfua(L96) (vinu)sAfsagaAfuUfUfguagCfuUfuaauasasc BD- 12672 usasuuaaAfgCfUfAfcaaaUfUfcuua(L96) (vinu)sAfsagaAfuuuguagCfuUfuaauasasc BD-12673 usasuuaaAfgCfUfAfcaaaUfUfcuua(L96) (vinu)sAfsagaAfuUfUfguagCfuUfuaauasasc BD-12674 usasuuaaAfgCfUfAfcaaauucuua(L96) (vinu)sAfsagaAfuuuguagCfuUfuaauasasc BD-12675 usasuuaaAfgCfUfAfcaaauucuua(L96) (vinu)sAfsagaAfuUfUfguagCfuUfuaauasasc BD-12676 usasuuAfaAfGfCfuacaaauuca(L96) (vinu)sGfsaauUfuGfUfagcuUfuAfauasasc BD-12677 gscsuaCfaAfAfUfucuuCfacAfca(L96) (vinu)sGfsuguGfaagaauuUfgUfagcsusuBD-12678 gscsuaCfaAfAfUfucuuCfacAfca(L96) (vinu)sGfsuguGfaAfGfaauuUfgUfagcsusu BD-12679 gscsuaCfaAfAfUfucuuCfAfcaca(L96) (vinu)sGfsuguGfaagaauuUfgUfagcsusuBD-12680 gscsuaCfaAfAfUfucuuCfAfcaca(L96) (vinu)sGfsuguGfaAfGfaauuUfgUfagcsusu BD-12681 gscsuaCfaAfAfUfucuucacaca(L96) (vinu)sGfsuguGfaagaauuUfgUfagcsusuBD-12682 gscsuacaAfaUfUfCfuucaCfacCfaa(L96) (vinu)sAfsgguGfugaagaaUfuUfguagcsusu BD-12683 gscsuacaAfaUfUfCfuucaCfacCfaa(L96) (vinu)sAfsgguGfuGfAfagaaUfuUfguagcsusu BD-12684 gscsuacaAfaUfUfCfuucaCfAfccaa(L96) (vinu)sAfsgguGfugaagaaUfuUfguagcsusu BD-12685 gscsuacaAfaUfUfCfuucaCfAfccaa(L96) (vinu)sAfsgguGfuGfAfagaaUfuUfguagcsusu BD-12686 gscsuacaAfaUfUfCfuucacaccaa(L96) (vinu)sAfsgguGfugaagaaUfuUfguagcsusu BD-12687 gscsuacaAfaUfUfCfuucacaccaa(L96) (vinu)sAfsgguGfuGfAfagaaUfuUfguagcsusuBD-12688 gscsuaCfaAfAfUfucuucacaca(L96) (vinu)sGfsuguGfaAfGfaauuUfgUfagcsusuNAI-5008944785v1 Page 89 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Table 5. siRNAs screened in Hep3B for HFE2 knockdownDuplex ID HFE2 KD (%) at 10 nM HFE2 KD (%) at 0.1 nM(n=4) (n=4)Mean SD Mean SDBD-10628 66.6 2.83 68 1.76BD-10640 65.1 14.3 23.4 8.06BD-10652 65.2 6.06 42.8 8.21BD- 10664 78.7 3.51 61.7 4.06BD-10676 72.4 24.9 55.1 18.6BD-10712 43.8 14.8 11.4 11.4BD-10724 55.1 20.3 29.8 10.1BD-10736 76.9 4.02 59.7 9.39BD-10748 61.2 10.7 30.3 9.13BD-10760 25.5 31.7 <10BD-10772 80.2 1.9 60.5 2.21BD-10784 46.7 8.96 25.8 4.07BD-10796 58.9 7.47 46.1 3.92BD-10808 57.1 12.3 52.7 6.91BD-10820 14.9 22 <10BD-10832 39.5 13.2 <10BD-10844 43.2 7.99 <10BD-10856 66.4 19.1 17.6 6.46BD-10868 <10 <10BD-10880 64 2.58 27.9 6.04BD-10892 <10 <10BD-10904 19.2 23.6 <10BD-10916 37.1 2.81 <10BD-10928 32.1 8.3 <10BD-10940 33.7 12.2 <10BD- 10952 53.6 4.94 20.7 9.41BD-10964 56.5 11.9 48.6 4.11BD-10976 28.4 16.2 42.3 6.93BD-10988 28.7 26.1 11.7 11.6BD-11000 74.7 6.81 35.8 4.75BD-11036 71 1.07 36.8 5.16BD-11048 48.8 14.7 21.8 4.96BD-11060 47 7.56 36.7 5.86BD-11072 64.1 4.27 47.8 4.52BD-11084 55.6 8.62 43.7 9.28BD-11096 80.5 3.04 43 10BD-11108 53.2 18.4 41.6 6.18BD-11120 68.2 2.07 32.3 8.77BD-11132 42.5 1.72 33.7 3.89BD-11144 48.1 8.18 <10BD-11156 65 4.97 61.3 3.73NAI-5008944785v1 Page 90 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID HFE2 KD (%) at 10 nM HFE2 KD (%) at 0.1 nM(n=4) (n=4)BD-11168 <10 10.6 13.5BD-11180 <10 <10BD-11192 17.1 2.42 <10BD-11204 53.1 3.59 14.7 10.2BD-11216 46.3 12.1 11.8 7.68BD-11228 61.5 6.37 57.3 6.28BD-11240 60.6 3.62 58.5 3.86BD-11252 25.6 16 20.2 9.67BD-11264 84 3.49 47.2 8.24BD-11276 60 24.5 50.5 7.46BD-11288 83.6 3.15 53.8 5.86BD-11312 52.7 13.6 18.7 4.41BD-11324 67 6.23 52.5 8.02BD-11336 62.8 3.63 57 2.13BD-11348 49.6 13.2 <10BD-11360 58.1 4.06 13.5 9.34BD-11372 17.3 4.15 <10BD-11384 50.5 6.88 12.2 4.94BD-11396 <10 <10BD-11408 33.2 3.44 <10BD-11420 29.3 20 <10BD-11432 79.9 2.97 20.6 13.6BD-11444 <10 <10BD-11456 36.7 3.03 <10BD-11468 14.1 6.53 10.1 7.27BD-11480 44.5 18.6 <10BD-11492 34.1 10.3 38.8 5.03BD- 11504 16.6 7.61 <10BD-11516 83 4.47 63.9 4.66BD-11528 75.7 11.5 65.3 6.42BD- 11540 49.1 3.37 26.2 9.95BD- 11552 84.8 1.46 71.3 3.99BD- 11564 69.4 2.08 60.8 1.64BD- 11576 88.5 1.25 49.4 2.68BD-11588 74 4.49 53.8 3.74BD-11600 26.1 4.46 11.4 2.83BD-11624 44.5 9.14 <10BD-11636 62.6 6.27 <10BD-11660 39.9 18.5 25.5 21.3BD-11672 72.1 4.19 46.5 5.43BD-11696 87.2 1.24 67.3 2.73BD-11732 <10 <10BD-11744 61.3 6.07 31.3 2.5NAI-5008944785v1 Page 91 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID HFE2 KD (%) at 10 nM HFE2 KD (%) at 0.1 nM(n=4) (n=4)BD-11756 87.9 2.8 28.3 14.6BD-11768 73.6 2.99 19.3 2.82BD-11780 58.7 13.8 10.8 17.3BD-11792 34.4 10.4 <10BD- 11804 60.3 9.76 29.1 4.9BD-11816 80 3.35 41.1 9.63BD-11828 82.1 1.48 <10BD-11840 15.7 9.97 <10BD-11852 73 2.83 <10BD-11864 74.6 5.78 13.1 11.8BD-11876 89.7 2.58 17.5 14.4BD-11888 87.9 1.33 17.9 5.36BD-11900 89 1.4 22.6 7.97BD-11912 66.3 6.53 <10BD- 11924 44.1 7 <10BD-11936 79.4 4.96 31.8 10.4BD-11948 58.4 8.77 16 11.5BD-11960 44.1 10.2 <10BD-11972 83.4 1.04 36.6 3.92BD-11984 92.2 1.4 50.4 5.96BD-11996 86.2 2.7 35.8 6.55BD-12008 80.8 2.07 54.6 6.19BD-12020 75.4 5.3 48.3 5.43BD-12032 77.5 5.83 38.7 7.74BD-12044 92.2 1.51 72.4 2.8BD-12056 77.2 3.12 46.7 5.74BD-12068 80 3.59 26.1 10.4BD-12080 41.5 6.92 <10BD-12092 78.3 5.99 33.6 10.8BD-12104 80.9 6.07 18 8.66BD-12116 71.3 9.01 29.5 2.43BD-12128 73 3.45 59.6 8.08BD-12140 75.3 4.06 58.7 7.12BD-12152 61.9 5.52 <10BD-12164 42.1 17.9 <10BD-12176 67.5 7.36 <10BD-12188 63.1 8.54 21.7 3.57BD- 12200 72.2 3.23 25.4 10.8BD-12212 84.3 2.55 29 9.1BD-12224 82 2.57 34.3 8.29BD-12236 82.9 2.18 25.4 8.98BD-12248 65.6 6.28 <10BD-12260 83.9 4.14 61.9 5.18NAI-5008944785v1 Page 92 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Duplex ID HFE2 KD (%) at 10 nM HFE2 KD (%) at 0.1 nM(n=4) (n=4)BD-12284 65.6 7.65 50.4 9.99BD-12296 92 1.31 57.5 8.73BD-12308 85.8 0.995 30.7 3.86BD-12320 86.2 1.01 24.2 10.2BD-12332 81 1.91 <10BD-12344 61.3 14.9 <10BD-12368 72.8 7.16 64.1 6.76BD-12380 88.6 4.22 29.9 7.92BD-12392 70.8 10.2 60.9 3.75BD-12404 63.5 7.61 43.3 4.49BD-12416 74.8 2.84 51 2.92BD-12428 91 1.21 59.3 5.75BD-12476 77.6 2.3 72.2 5.44BD-12500 37.2 21.9 <10BD-12512 77.8 6.89 43.4 9.14BD-12536 83.2 9.38 74.2 5.8BD-12560 80.1 7.49 69.8 1.86BD-12572 89 1.21 56.6 3.8BD-12584 79.9 1.13 36.5 2.62BD-12596 90 2.5 32.3 5.35BD-12620 78.6 1.33 50.9 4.47NAI-5008944785v1 Page 93 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Table 6: Dose response of selected siRNAs in Hep3B cellsDuplex ID IC50 (nM) Maximum measuredknockdown (%)HFE2 HFE2BD-10676 0.094 97.6BD-11264 0.019 83.0BD-11288 0.033 84.5BD-11516 0.062 82.8BD-11528 0.045 90.6BD-11552 0.012 80.9BD-11576 0.206 83.6BD-11756 0.075 91.5BD-11888 0.097 88.5BD-11900 0.091 90.2BD-11984 0.017 87.4BD-12044 0.019 92.0BD-12212 0.096 90.2BD-12296 0.136 89.3BD-12308 0.186 89.4BD-12320 0.024 61.8BD-12380 0.078 92.7BD-12572 0.140 87.4BD-12596 0.128 92.0Table 7: Dose response of selective siRNAs in Hep3B cells (with sequences that originate from 12 gene start sites)Gene Start Duplex ID IC50 (nM) Maximum measuredposition knockdown (%)HFE2 HFE2575 BD-11281 0.055 68.4BD-11280 0.028 76.4BD-11279 0.025 70.5BD-11278 0.028 76.2BD-11277 0.132 71.9722 BD-11509 0.021 91.1BD-11508 0.131 61.3BD-11507 0.027 81.4BD-11506 0.105 91.8734 BD-11569 0.057 76.0BD-11568 0.068 82.2NAI-5008944785v1 Page 94 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Gene Start Duplex ID IC50 (nM) Maximum measuredposition knockdown (%)HFE2 HFE2BD-11567 0.038 77.8BD-11566 0.052 91.9BD-11565 0.140 83.51027 BD-11881 0.060 88.1BD-11880 0.103 88.0BD-11879 0.307 41.4BD-11878 0.130 87.4BD-11877 0.138 91.51028 BD-11893 0.168 91.5BD-11892 0.081 90.8BD-11891 0.319 57.7BD-11890 0.117 76.7BD-11889 0.122 82.41072 BD-11977 0.053 95.4BD-11976 0.039 91.4BD-11975 0.060 75.8BD-11974 0.033 96.2BD-11973 0.056 89.01086 BD-12037 0.011 89.2BD-12036 0.020 89.4BD-12035 0.010 86.4BD-12034 0.012 88.0BD-12033 0.010 88.51238 BD-12205 0.043 92.8BD-12204 0.122 93.6BD-12203 0.122 83.1BD-12202 0.129 95.2BD-12201 0.101 54.11249 BD-12289 0.027 92.0BD-12288 0.016 90.2BD-12287 0.023 93.1BD-12286 0.019 92.2BD-12285 0.017 89.21536 BD-12373 0.493 86.5BD-12372 0.150 90.2BD-12371 0.440 88.8BD-12370 0.149 93.7BD-12369 0.242 77.32062 BD-12565 0.151 88.2BD-12564 0.092 89.0BD-12563 0.135 86.3NAI-5008944785v1 Page 95 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO Gene Start Duplex ID IC50 (nM) Maximum measuredposition knockdown (%)HFE2 HFE2BD-12562 0.083 91.3BD-12561 0.139 76.62067 BD-12589 0.095 89.5BD-12588 0.144 81.6BD-12587 0.127 74.7BD-12586 0.195 75.2BD-12585 0.195 45.7Table 8: Dose response of selective siRNA in primary human hepatocytesDuplex ID PHH Donor Free Uptake Maximum measuredICso (nM) knockdown (%)HFE2 HFE2BD-11900 Donor U 0.739 48.6BD-11984 Donor U 0.971 56.2BD-12044 Donor U 0.255 82.0Donor R 0.174 87.2Donor W 0.886 83.7Donor X 0.157 86.7BD-12212 Donor U 0.407 44.5BD-12296 Donor U 0.455 65.6Donor P 1.321 91.1BD-12380 Donor U 3.430 54.9BD-12572 Donor U 0.974 51.9BD-12596 Donor U 0.442 39.0EQUIVALENTS AND SCOPE

[0156] Although for purposes of clarity of understanding the foregoing embodiments are described in some detail byway of illustration and example, it will be readily apparent to those skilled in the art that certain changes and modifications may made thereto without departing from the spirit or scope of the appended claims. Only such limitations as appear in the appended claims should be placed on any claimed invention.NAI-5008944785v1 Page 96 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO

[0157] All publications, patents, and patent applications cited in this specification are herein incorporated by reference as if each publication, patent, or patent application were specifically and individually indicated to be incorporated by reference.NAI-5008944785v1 Page 97 of 100

Claims

Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO CLAIMS1. An isolated small interfering RNA (siRNA) comprising a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 2 and modified versions thereof.

2. An isolated small interfering RNA (siRNA) comprising a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 3 and modified versions thereof.

3. An isolated small interfering RNA (siRNA) comprising a sense strand and an antisense strand, wherein the sense strand and antisense strand form a duplex selected from the group consisting of duplexes listed in TABLE 4.

4. The isolated siRNA of claim 4, wherein the siRNA is selected from the group consisting of BD-11900, BD-11984, BD-12044, BD-12212, BD-12296, BD-12380, BD- 12572 and BD-12596.

5. The isolated siRNA of claim 4, wherein the siRNA is selected from the group consisting of BD-12044, BD-12212, BD-12296 and BD-12596.

6. The isolated siRNA of claim 4, wherein the siRNA is selected from the group consisting of BD-12044 and BD-12296.

7. The isolated siRNA of claim 4, wherein the siRNA is BD-12044.

8. The isolated siRNA of claim 4, wherein the siRNA is BD-12296.

9. A pharmaceutical composition comprising the siRNA of any one of claims 1 to 8, and a pharmaceutically acceptable excipient, carrier or delivery vehicle.

10. The pharmaceutical composition of claim 9, wherein the composition is in the form of a lipid nanoparticle.NAI-5008944785v1 Page 98 of 100Attorney Docket No.: 14874-001-228Brii Ref. No.: BRB0023WO 11. A method of reducing expression of HFE2 in a cell comprising contacting the cell with the siRNA of any one of claims 1 to 8.

12. A method of reducing hepcidin serum concentration in a subject comprising administeringto the subject a therapeutically effective amount of the siRNA of any one of claims 1 to 8.

13. A method to boost erythropoiesis in a subject having an anemia, the method comprising administeringto the subject a therapeutically effective amount of the siRNA of any one of claims 1 to 8.

14. A method of treating a disorder associated with elevated serum hepcidin concentration in a subject, comprising administering to the subject with a disorder associated with elevated serum hepcidin concentration a therapeutically effective amount of the siRNA of any one of claims 1 to 8.

15. A method of treating (i) an anemia associated with elevated hepcidin; (ii) an iron refractory iron deficiency anemia; (iii) a hepcidin-producing adenoma; or (iv) an anemia of inflammation (“Al”) in a subject in need thereof, the method comprising administeringto the subject a therapeutically effective amount of the siRNA of any one of claims 1 to 8.

16. The method of claim 15, wherein the subject has Al.

17. The method of claim 16, wherein the subject has a chronic infection, an autoimmune disease, chronic kidney disease, an anemia of the elderly, an advanced cancer, graft versus host disease, congestive heart failure, myelofibrosis, irritable bowel syndrome, rheumatoid arthritis, sepsis, or chronic obstructive pulmonary disease.

18. The method of any one of claims 14 to 17, wherein the method further comprises administering a therapeutically effective amount of a second therapeutic agent useful in the treatment of the disease, disorder or condition.NAI-5008944785v1 Page 99 of 100

Images